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Patients with Acute Myeloid Leukaemia (AML) present with the signs and symptoms of 
bone marrow failure. This finding spans the genetic and phenotypic diversity of the disease. 
The mechanism which underlies it is poorly understood.   
This thesis explores the effect of AML on the normal haematopoietic stem cell (HSC) 
population, using primary human diagnostic bone marrow samples. Previous work from our 
group suggested that AML induces a state of quiescence in HSCs, producing a 
differentiation block responsible for the observed cytopenias1. Reversal of this process 
might offer an alternative to the current treatment of patients with palliative transfusions.   
I have developed a flow cytometry-based technique to differentiate normal HSCs from 
leukaemia cells, selecting cells with the CD34+38-ALDHhighCLL1- expression signature. 
Validation of this technique by assessment of sorted cells by FISH and PCR, suggests it is 
successful in 73% of AML samples. In a further 25% of samples, it selects for a population 
significantly enriched for normal HSCs.  
We used this panel to investigate the concentration of HSCs at AML diagnosis, compared to 
controls. We show that there is no significant difference between HSC concentration at 
AML diagnosis (n=38, median [HSC] 2.5 cells/µl) and controls (n=24, median [HSC] 2.4 
cells/µl). HSC concentration was not significantly affected by AML karyotype, patient age or 
gender.  
However, those patients presenting with a low HSC concentration at diagnosis (<0.1 
HSC/µl) were found to have a significantly worse outcome both in terms of overall and 
relapse-free survival, an effect apparently independent of age, gender and underlying 
karyotype. HSC concentration at diagnosis with AML may therefore represent a new 
independent prognostic marker.  
We then studied CD33 expression patterns on HSCs within Core Binding Factor mutated 
AML (n=37) at diagnosis, and found its expression to be significantly lower than on HSCs 
within controls (n=9) (17% versus 58%, p=0.005). CD33 expression on HSCs from AML 
samples rose significantly from diagnosis to remission (n=16) (17% to 58%, p=0.0001). This 
mirrors previous findings from our group using CD34low AML samples, and is, we believe, 
the first time that the antigenic signature of normal HSCs has been shown to be modified 
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by the presence of AML. However, an in vitro assay to test the significance of these changes 
in terms of the cytotoxicity of GO towards normal HSCs did not demonstrate a significant 
difference between HSC subgroups.  
Finally, we attempted to investigate the mechanism by which AML might induce HSC 
quiescence by studying the comparative transcriptomes of HSCs from CD34low AML (n=6) 
and controls (n=6) by RNA-Seq, using direct cell to cDNA synthesis, followed by 
amplification. A first attempt resulted in poor quality data, with a significant proportion of 
reads mapping to non-coding DNA regions. A repeat approach, using utilising immediate 
RNA extraction post sorting resulted in significantly better quality data Bioinformatics 
analysis revealed differential expression of 6 genes between the 2 datasets (GNPDA1, 
ADGRG3, MIAT, WDR31, RP11-244H3.1 and RXFP1). GO enrichment studies using David 
highlighted a number of pathways including the TNF signalling pathway (p=0.003; after 
Benjamini-Hochberg correction p=0.51). Validation of these findings by independent qPCR, 
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Chapter 1 Introduction 
1.1 Background 
Normal haematopoiesis is the process by which the blood cells needed for survival are made in 
the bone marrow. In many haematological disorders, but AML in particular, the process of 
normal haematopoiesis is disrupted. The mechanism by which this occurs is poorly 
understood. Patients presenting with AML normally present with the problems resultant from 
a failure of normal blood production: overwhelming sepsis, bleeding or anaemia-driven fatigue 
and shortness of breath.     
Visual inspection at the time of diagnosis normally shows the healthy bone marrow 
architecture to be completely effaced with a mass of malignant blast cells. However, that the 
capacity for normal haematopoiesis persists is shown by the fact that the majority of patients, 
once remission is obtained, regain normal blood counts three to four weeks after the 
completion of chemotherapy.  
With some notable exceptions (acute promyelocytic leukaemia or APML providing the prime 
example2), survival rates for AML have shown only modest improvements over the last few 
decades in younger patients3, with little change in the figures in patients presenting over the 
age of 604. Much of the improvement noted is credited to the improvements seen in 
supportive care given to patients undergoing intensive chemotherapy5. The backbone of 
treatment for the majority of patients remains similar to that used in the 1970s. There is a 
need for new approaches (and effective new drug therapies) to improve prognosis.        
If the mechanism by which haematopoietic failure in AML is better understood, this might give 
a new therapeutic approach to treating patient with indolent disease, with the aim of reducing 
their transfusion requirements and improving their quality of life.  
1.2 Normal Haematopoiesis  
 Introduction 1.2.1
In the human adult, normal haematopoiesis occurs in the bone marrow in a tightly controlled 
homeostatic process, derived to maintain normal levels of blood cells for function. Steady 
state requires the production of approximately 1011 to 1012 new cells daily. Normal cell 
numbers found in the peripheral blood in health are given in Table 1-1. 
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Table 1-1 Normal peripheral blood parameters for adult males and females. Modified from Bain, Blood Cells (2008)
6
 
 Site of Haematopoiesis 1.2.2
In embryonic development, primitive blood formation occurs in aggregates of blood cells in the 
yolk sac, called blood islands7. As development progresses, haematopoiesis migrates to 
the spleen, liver and lymph nodes. As bone marrow forms, it eventually assumes the task of 
forming most of the blood cells for the entire organism. However, maturation, activation, and 
some proliferation of lymphoid cells occur in secondary lymphoid organs (spleen, thymus, and 
lymph nodes)8. In children, haematopoiesis occurs in the marrow of the long bones such as the 
femur and tibia, but by adulthood, the areas responsible for active haematopoiesis have 
shrunk to comprise mainly the pelvis, cranium, vertebrae, and sternum9. In some disease 
states, the liver, thymus, and spleen may resume their haematopoietic function 
(extramedullary haematopoiesis), causing these organs to increase in size substantially10. 
Occasionally, for example in patients with thalassemia major and intermedia, haematopoietic 
development may occur even in areas where the resultant tissue disrupts the surrounding 
organs11,12.  
 The hierarchy of haematopoietic development 1.2.3
The current paradigm for haematopoietic development describes a pluripotent 
haematopoietic stem cell (HSC), maintained in small numbers, capable of differentiating into 
all of the different mature blood cell lineages required for normal life. Estimates of murine HSC 
frequency have been generated by testing the ability of limiting dilutions of murine bone 
marrow cells to rescue haematopoiesis in lethally irradiated murine recipients. This work 
suggests the frequency of long term repopulating stem cells in mice is around 1 in 10,00013,14. 
Anecdotally, human HSC frequency is thought to be much lower, but is probably 
underestimated by xenograft transplant models (D Taussig, personal communication). 
Haematopoietic stem cells are thought to reside within a hypoxic marrow niche, maintained in 
an undifferentiated and largely quiescent state, partly due to interactions with the surrounding 
PARAMETER MALE FEMALE 
HAEMOGLOBIN (g/dL) 13.5-18.0 11.5-16.0 
PLATELETS (x10
9
/L) 150-400 150-400 
WBC (x10
9
/L) 4.00-11.0 4.0-11.0 
NEUTROPHILS (x10
9
/L) 2.0-7.5 2.0-7.5 
LYMPHOCYTES (x10
9
/L) 1.0-4.5 1.0-4.5 
MONOCYTES (x10
9
/L) 0.2-0.8 0.2-0.8 
EOSINOPHILS (x10
9
/L) 0.04-0.4 0.04-0.4 
BASOPHILS (x10
9
/L) <0.1 <0.1 
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stromal cells15. However, HSCs retain the ability to leave their bone marrow niche and mobilise 
via peripheral blood, as part of normal homeostasis. These cells maintain their levels in bone 
marrow by largely asymmetric divisions16. The pool of stem cells is heterogeneous, and is 
comprised of long term cells which multiply infrequently, and short term renewing cells, which 
replicate much more frequently17. Their daughter progeny begin a pathway of differentiation 
to myeloid-erythroid and lymphoid progenitors (the so called Common Myeloid Erythroid 
Progenitor (CMP)18 and Common Lymphoid Progenitor (CLP)19 subtypes), but begin to lose the 
ability to self-renew20-22. The influence of further cytokines and growth factors in the bone 
marrow are thought to lead to further cell differentiation, as shown in Figure 1-1  
   
Figure 1-1 Key cytokines in haematopoietic development. From Robb, Oncogene, 2008
23
 
These different commitment stages can be identified genetically by sequential expression of 
different transcription factors, and phenotypically by changes in surface antigen expression. 
However, the idea of step-wise progression towards fate determination has recently been 
challenges by advances in the world of single cell transcriptomics. Recent papers, involving 
massively parallel sequencing of bone marrow progenitor cells, suggests commitment to fate-
determining transcriptional programs occurs at the very earliest stages of differentiation24,25. 
During haematopoietic development, precursor cells migrate from the subendosteal region of 
bone marrow, towards a more central location. The resultant mature blood cells exit the bone 
marrow environment through a dense network of vascular sinuses. The average cellular 
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lifespan varies significantly between cell types from five to ten days (platelets26 and 
neutrophils27), to three months (erythrocytes28) to many years (memory lymphocytes29). 
Senescent blood cells are removed from the circulating blood volume as they pass through the 
spleen. 
1.3 The Haematopoietic Stem Cell 
 The HSC concept 1.3.1
Over 40 years ago, Till and McCulloch demonstrated that a single precursor cell exists in bone 
marrow that is capable of both extensive self-renewal and multi-lineage differentiation30. The 
HSC pool has been characterised phenotypically and is separable into distinct subpopulations 
based on both phenotype and function22. Long term reconstituting HSCs (LT-HSC) have the 
greatest self-renewal capacity, and give rise to all the haematopoietic lineages throughout life. 
The immediate progeny of LT-HSC are short term HSCs, which also are capable of generating 
all lineages of blood cells, but do so for a period of only 8 to 12 weeks. The proportions of HSCs 
that are LT-HSC vary with the site and age of the individual under investigation31,32.    
 Physical location of HSCs 1.3.2
1.3.2.1 The Stem Cell niche concept   
HSCs appear to circulate freely, but have little function outside specific anatomically defined 
locations.  The concept of a niche as a specialised microenvironment housing stem cells was 
first proposed by Schofield over 30 years ago33. As the site of haematopoiesis changes during 
vertebrate development, the nature of this stem cell niche must also change34. The adult bone 
marrow niche has received most attention. As summarised in an excellent review of the area, 
there exists experimental evidence for key roles for both osteoblasts and vascular endothelial 
cells in the formation of the HSC niche34. The key experiments which led to these conclusions 
are summarised below.  
1.3.2.2 The role of the osteoblast in the stem cell niche 
The physical location of HSCs close to the bone surface was first demonstrated in 197535. 
Morphological evidence for the presence of HSC niches in close association with the 
endosteum was provided more recently when cells with HSC and progenitor activity and/or 
phenotype were shown to localize close to the endosteal lining of bone-marrow cavities in 
trabecular regions of long bones, whereas more differentiated haematopoietic progenitors 
were found mainly in the central bone-marrow region36,37. 
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The ability of osteoblastic cells to support HSC populations was first demonstrated by 
osteoblastic cell lines, which were shown to secrete cytokines capable of supporting HSCs38. 
Osteoblast activity is in part regulated by parathyroid hormone (PTH) or locally produced PTH-
related protein (PTHrP), acting via the PTH/PTHrP receptor. Calvi et al developed a transgenic 
mouse model with a constitutively active PTH/PTHrP receptor, which resulted in upregulation 
of both osteoblast and HSC numbers39.  
In a second study, using a transgenic murine model with conditional  inactivation of the BMP 
receptor type IA, which is normally expressed on osteoblasts lining the endosteum, Zhang et al 
demonstrated a simultaneous increase in the number of both osteoblasts and repopulating 
HSCs. The same study used histological examination of bone structure and staining for N-
cadherin expression, to reveal a small subset of spindle shaped osteoblasts, which appeared 
architecturally in close contact with HSCs. A small subset of HSCs was shown to express N-
cadherin asymmetrically on the surface which abutted the osteoblasts. As the cadherin family 
had already been shown to have a role in ovarian stem cell niche formation by knock-out 
experiments in Drosophila, this led to the hypothesis that N-cadherin mediated interactions 
between a subset of osteoblasts and HSCs might play a similar function in mammals37.  
1.3.2.3 The role of the vascular endothelial cell in the stem cell niche 
A second school of thought proposes a key role for vascular endothelial cells in the formation 
of the HSC niche. Histological studies of murine bone marrow showed a large proportion of 
CD150+ HSCs to be attached to the fenestrated endothelium of bone-marrow sinusoids36. 
Although vascular endothelial cells that are isolated from various adult non-haematopoietic 
organs have little or no ability to maintain HSCs in vitro, bone marrow sinusoidal endothelial 
cells (BMECs) are functionally and phenotypically distinct40. Indeed BMECs constitutively 
express cytokines such as CXC-chemokine ligand 12 (CXCL12) (also known as Stromal Derived 
factor 1 (SDF1))41,42, the ligand for the CXCR4 receptor, and adhesion molecules such as 
endothelial-cell (E)-selectin43 and vascular cell-adhesion molecule 1 (VCAM1) that are 
important for HSC mobilisation, homing and engraftment.  
These two distinct niches may prove not to be mutually exclusive, but indeed may co-exist. By 
the use of label retaining studies (involving pulsed bromodeoxyuridine (BrdU)), those HSCs 
located in the endosteal niche have been shown to divide infrequently, and therefore may 
represent the most dormant subtype of HSCs44. Those cells that are found in contact with 
vascular endothelial cells comprise a more mixed distribution of cell types, including some that 
divide relatively frequently. Theoretically, the location of these CD150+ murine HSCs, in close 
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proximity to sinusoids, would enable them to be constantly sensitive to blood-borne hormone 
levels, a position that would enable a rapid response to haematological stress.  
 Regulation of Stem Cell Behaviour  1.3.3
1.3.3.1 Maintenance of a quiescent population of stem cells is vital for long term 
haematopoietic survival  
Multiple studies of cell cycle kinetics have identified the co-existence of pools of HSCs with 
distinct behavioural patterns: highly quiescent stem cells that remain metabolically inactive 
with little transcriptional activity; and those which divide more frequently, and are responsible 
for replenishing the pool of haematopoietic progenitor cells by division and differentiation into 
mature blood cells20.  
Relative quiescence is thought to have a protective role in ensuring the longevity of the HSC 
pool, perhaps by  minimising stresses of cellular metabolism and genome replication45. 
Amongst other adaptations, HSCs appear to have developed a distinct response mechanism to 
DNA damage, possibly rendering them more tolerant to insults, but also more susceptible to 
mutational change. Double stranded DNA breaks occurring at the Go stage of the cell cycle are 
subject to immediate repair by non-homologous end joining, which is more error prone than 
the response of other cell types to the same insult46,47.  
Experimentally induced defects in HSC dormancy by murine conditional knock-out experiments 
(see Section 1.3.3.1.1), frequently result in defects in stem cell self-renewal and stem cell pool 
exhaustion. Serial transplantation experiments in mice are eventually limited by 
haematopoietic failure, suggesting a requirement for repeated repopulation is unsustainable48.    
The factors which modulate the balance in these two distinct behaviour patterns have been 
the subject of a number of excellent reviews49. Experimental data suggest there are numerous 
factors which control HSC divisional status: as well as those intrinsic to stem cells themselves, 
signalling through cell-cell interactions within the niche, as well as secreted cytokines, may 
play key roles. 
Murine studies suggest that the proportion of HSCs in cycle changes dramatically over the 
lifetime of an organism, presumably in response to its immediate haematopoietic needs. 
During foetal development, 95 to 100% of the HSCs located in the liver are in cycle at any one 
time point; by four weeks after birth, the proportion of those cycling in the bone marrow has 
fallen dramatically to less than 5%32. These cells cycle extremely infrequently (every 145 
days)50.   
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 Genes identified as key regulators in HSC quiescence  1.3.3.1.1
Studies from murine knock-out models have suggested a key role for a number of genes in the 
maintenance of HSC quiescence. Knock-out of the p2151, Gfi152, Pten53 and Foxo genes54 all 
resulted in an early expansion of the cycling pool of HSCs, followed by subsequent exhaustion 
of the population, as illustrated by serial transplantation assays. The same techniques have 
identified negative regulators of quiescence, such as the Myeloid EL1-like gene (ELF4), whose 
knock-out results in an increase in stem cell quiescence, expansion of the HSC pool and 
increased resistance to fluorouracil (5-FU) 55. The majority of these genes are thought to exert 
their effects by controlling the rate of HSC entry into the cell cycle.  
Wilson et al demonstrated a potentially key role for c-myc in the regulation of HSC number. 
Using a murine conditional c-myc knock-out model, they noted that reduced expression of the 
gene was associated with quiescence of the progenitor population, but a ten-fold increase in 
HSC numbers. Forced overexpression had the opposite effect. As c-myc has a role in the 
regulation of a variety of cell adhesion molecules, a potential pathway for its effect has been 
described56.  
 Signalling interactions between stem cells and their microenvironment  1.3.3.1.2
Signalling interactions between HSCs and their immediate microenvironment have also been 
shown to have a vital role in the regulation of HSC behaviour. Arai et al demonstrated the 
importance of the Tie2-Angiopoietin-1 signalling axis in the maintenance of stem cell 
quiescence. The ligand Angiopoietin-1 is thought to be produced by niche osteoblasts, whilst 
HSCs positive for its receptor, Tie2, were found to be relatively quiescent. In vitro work 
involving the exogenous application of Angiopoietin-1 to HSC populations resulted in enhanced 
HSC adhesion, maintenance of an immature phenotype and maintained BM repopulating 
ability57.  
Other interactions thought to be important for HSC maintenance include that between c-mpl 
(expressed on HSCs) and thrombopoietin (TPO). Murine knock-out experiments resulting in 
reduced c-mpl expression resulted in a reduction in HSC function58,59.  
 Metabolic adaptations and quiescence   1.3.3.1.3
HSCs are known to have a distinct metabolism, in part adapted to the hypoxia observed in the 
BM niche. Quiescent cells are more dependent on anaerobic respiration to meet their 
metabolic needs; as cells divide and mature, mitochondrial aerobic respiration becomes more 
important. While such relative hypoxia is thought to have a protective effect on the longevity 
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of HSCs, it may also have a role in the regulation of stem cell behaviour through signalling via 
the Hif pathway60,61.  
Ito et al described a key role for metabolism in the control of stem cell quiescence and 
differentiation, in studies of the promyelocytic leukaemia-peroxisome proliferator activator-
receptor δ (PML-PPAR-δ) pathway, which controls fatty acid oxidation (FAO). Knockout of key 
components of the PML-PPAR-δ pathway, or drug-based inhibition of FAO, led to loss of HSC 
maintenance. FAO also appears to have a role in the determination of cell fate after HSC 
division: its inhibition resulted in the symmetrical commitment of daughter cells, in 
comparison to PPAR-δ activation which led to asymmetrical division62.  
 Stem Cell Mobilisation and Homing  1.3.4
1.3.4.1 Normal HSC mobilisation in health and disease  
Although the vast majority of HSCs are located in the bone marrow in a state of shielded 
quiescence, as part of normal homeostasis, small numbers mobilise and migrate throughout 
the body in peripheral blood. This process has been shown to follow a circadian rhythm63, 
possibly modulated by the action of the sympathetic nervous system nerve endings, located in 
close proximity to the putative HSC niche within bone marrow64. 
No definitive reason why stem cells mobilise in this manner has been proven, though one can 
postulate it may represent an evolutionary adaption to ensure HSC survival in the case of 
inadequate bone marrow stromal support or localised damage. HSC circulation has also been 
noted to increase in times of physiological stress, such as illness or pregnancy. In work with a 
particular relevance for this thesis, Ailles et al have shown that normal HSCs are easily 
detectable in the peripheral blood of patients newly diagnosed with AML. In experiments 
designed to identify the presence of leukaemia stem cells (LSCs) in peripheral blood samples of 
patients with AML of abnormal karyotype, the authors found the number of LTC-IC cells 
generating colonies of normal karyotype (presumed to be normal HSCs) was ten-fold higher 
than those seen in controls65.  
1.3.4.2 Regulation of HSC homing to bone marrow  
One of the key characteristics of HSCs is an ability to recognise and return to their bone 
marrow niche. This is the case in normal physiology, but is also clearly demonstrated both in 
xenograft transplant experiments, and clinically during autologous or allogeneic bone marrow 
transplantation.  
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Key pathways thought to regulate the homing process include the CXCR4/CXCL12 interaction. 
CXCR4 (CD184) is an alpha-chemokine receptor expressed on the surface of HSCs, known to 
bind to the ligand CXCL12 or SDF1. CXCL12 is highly expressed on bone marrow niche cells, and 
as such as been shown to be a potent chemokine directing HSC homing. A secondary 
regulatory pathway is provided by interplay between cKit and Stem Cell Factor (SCF or Kit 
ligand). cKit (also known as CD117) is a cell surface receptor universally expressed on HSCs66, 
whose ligand SCF is highly expressed in BM stromal tissue. Roles for this interaction in stem 
cell homing and adhesion within the niche have been put forward67.  
1.3.4.3 Regulation of HSC mobilisation  
Study of the factors responsible for stem cell mobilisation has revealed roles for a variety of 
cytokines, including granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage 
colony stimulating factor (GM-CSF), thrombopoietin (TPO), Kit and Flt3 ligand. As well as being 
of biological interest, this has allowed the development of drugs to promote HSC egress from 
bone marrow, prior to stem cell collection procedures for human transplantation.   
The mechanism of action of G-CSF has been the most investigated to date. It appears able to 
suppress the activity of mature osteoblasts, as well as suppressing CXCL12 expression in 
mesenchymal stromal and endothelial cells. As such, it interferes with one of the main 
signalling axes responsible for HSC retention in the BM68. Experiments involving conditional 
knockouts of CXCR4 in the BM suggest this is the key mechanism responsible for the action of 
G-CSF69.   
Increased understanding of this process has resulted in significant clinical impact over the last 
decade, as peripheral blood based collection of HSCs by leucophoresis has overtaken the 
traditional bone marrow harvest as the preferred source of HSC collection for autologous and 
allogeneic bone marrow transplantation. Excess G-CSF mobilised peripheral blood (GMPB) 
collected in this manner also provides an excellent source of enriched human HSCs for 
laboratory work.   
In addition to G-CSF, other drugs used clinically to enhance HSC mobilisation prior to stem cell 
collection include Plerixafor, a partial CXCR4 agonist which antagonises the binding of SDF-1 to 
its cognate receptor. A number of clinical trials have demonstrated its effectiveness when 
given in combination with G-CSF in mobilising HSCs70. 
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 Methodology for studying stem cells  1.3.5
1.3.5.1 Identification using flow cytometry  
Identification of HSCs in bone marrow samples is complex for a number of reasons. They are 
rare cells, of rather indistinct morphological appearance. HSCs share a common appearance 
with lymphocytes, being small cells with a high nuclear to cytoplasmic ratio and an agranular 
cytoplasm.   
One of the most commonly utilised techniques for stem cell identification in bone marrow and 
blood samples is based on flow cytometric analysis, which enables the simultaneous 
interrogation of large numbers of cells, thus rendering it an excellent technique for studying 
cells of a rare subtype. 
HSCs are known to have a low forward (FSC) and side scatter (SSC) profile (see Section 2.4). 
Further phenotyping has identified a number of cell surface markers commonly associated 
with cells that exhibit stem cell behaviour. For human HSCs, these include 
CD34, CD38, CD90, CD133, CD105, CD45, and c-kit71,72. HSCs should be negative for the 
markers that are used for detection of lineage commitment (Lin-). Negative selection using a 
cocktail of lineage-specific markers can be used to enrich a sample for stem cells (see Section 
2.2.3.1). 
The field (and literature) is complicated by the fact that there exists cross-species variation in 
antigen expression on HSCs. Table 1-2 summarises some of the main difference in cell surface 
phenotype between human and murine HSCs73.    
Table 1-2 summarising the different antigen expression patterns seen on human and murine HSCs 
The experimental work within my PhD has solely involved human samples. Henceforth, unless 
clearly stated otherwise, further discussion of stem cell phenotype will be limited solely to that 
of the human HSC.  
Flow-based sorting experiments of different fractions of cord blood, followed by 
transplantation assays into mice, have shown the CD34+ fraction of cells to be highly enriched 
ANTIGEN HUMAN HSC MURINE HSC 
CD34 POSITIVE LOW/NEGATIVE 
SCA1 NO HUMAN HOMOLOG POSITIVE 
THY 1.1 POSITIVE POSITIVE/LOW 
CD38 LOW POSITIVE 
C-KIT POSITIVE POSITIVE 
LIN NEGATIVE NEGATIVE 
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for stem cells, and the CD34+38- fraction even more so. Some cells capable of long term 
repopulation of murine models exist within the CD34+38+ fractions, but the bulk of these cells 
are more mature progenitors74. Indeed, functional stem cells are not solely limited to cells that 
express CD34. The Bonnet group recently published a study of CD34- cells, showing them to 
contain a subset of extremely primitive stem cells75.      
We, along with most groups in the field, accept the approximation that the CD34+38- group of 
cells comprises a population highly enriched for HSC behaviour. However, it must be stressed 
that the cells that share this phenotype are by no means homogenous, but contain cells at a 
variety of stages of maturity and early lineage commitment21,76.  
1.3.5.2 Assays for Stem Cell Function 
Flow cytometry helps us to identify cells likely to be enriched for stem cell behaviour, but the 
best tests of stem cell nature, as defined by the abilities of long-term survival, differentiation 
and repopulation, are provided by a series of in vitro and in vivo assays. These are described in 
brief below, along with a summary of their strengths and weaknesses.  
 Short Term in vitro Culture Assays 1.3.5.2.1
Short term in vitro assays are semi-solid assays, which can identify and quantify lineage-
restricted progenitors in standardised conditions. Their immobilised progeny accumulate in 
tight colonies with specific characteristics of composition, size and colour. Several types of 
progenitors (erythroid, granulocytic, macrophagic and megakaryocytic) can differentiate 
simultaneously in a given culture77. Within a given lineage, progenitors with different levels of 
maturity can be identified dependent on sensitivity to cytokines, time to generate 
differentiated cells and colony size78. The growth media utilised in such assays is unable to 
support cell growth for greater than three weeks, and therefore these assays are not 
appropriate for testing for the presence of immature stem cells, as these have to undergo a 
much higher number of divisions (>15) over a longer period (>5 weeks) before producing the 
differentiated progeny this assay is designed to detect76.      
 Long Term in vitro Culture Assays 1.3.5.2.2
A long term in vitro assay describes a system designed to identify immature progenitors, with 
an assay period extending beyond four weeks. This allows immature progenitors to complete 
differentiation, and rules out any contribution from lineage-committed cells present at the 
start of the assay. A common feature in these assays is the presence of a feeder layer of 
stromal cells, designed to secrete a source of regulatory factors, mimicking the complexity of 
the bone marrow stromal microenvironment79. Spontaneously immortalised murine bone 
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marrow derived stromal cell lines (such as MS-5, S17 and AFT024) are popular, because they 
support both myeloid and lymphoid development80. The presence of LTC-IC in the wells is 
identified retrospectively by the output of colony forming cells in the culture at five to eight 
weeks81. An initial stem cell concentration can be estimated by a serial dilution assay. One of 
the main issues with this assay is its lack of reproducibility between laboratories, due in part to 
variations in stromal cell lines and growth media utilised76.  
 In vivo Murine Transplant Model   1.3.5.2.3
The use of a mouse transplant model allows the identification of long term repopulating stem 
cells, identified by their ability to reconstitute haematopoiesis in mice over a period of months, 
rather than simply weeks. To survive, transplanted stem cells also have to exhibit the key 
ability of homing, from the site of injection into the mouse tail, to the host bone marrow 
microenvironment.  
Murine experimentation has identified three types of HSC behaviour in the transplant model:  
short lived Colony Forming Unit-Spleen (CFU-S) cells home to the spleen, and start producing 
cells by day twelve82; the Marrow Repopulating Activity (MRA) cells83; and finally the long term 
reconstituting cells, which produce differentiated myeloid and lymphoid lineages months after 
transplantation.  
The first immunodeficient mouse model, sufficiently tolerant to allow engraftment of human 
HSCs, was described by Kamel-Reid and Dick in 198884. However, the haematopoietic 
development observed in this first model was not normal- NOD SCID mice are strikingly more 
permissive to the development of B cells, with a noticeable absence of T and NK cells derived 
from the transplanted HSCs. Genetic manipulation of these models (such as the NOD SCID β2-
microglobulin-null murine strain)85 have led to increased permissiveness towards T and NK 
cellular differentiation. 
1.4 Acute Myeloid Leukaemia  
 Introduction 1.4.1
Acute myeloid leukaemia is a rare, aggressive cancer, characterised by overproliferation of 
myeloblasts in the bone marrow leading to a failure of normal haematopoiesis.86 The clinical 
features were first described two centuries ago by the French physician Alfred-Armand-Louis-
Marie VelpeauIt, but it was the development of the light microscope by Virchow in the middle 
of the last century that meant its pathology could begin to be understood. Today, although the 
diagnosis of AML can still be made just by the examination of a stained blood film, additional 
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information is routinely gained by the use of immunological, cytogenetic and molecular 
analysis of bone marrow samples. 
 Incidence  1.4.2
Acute Myeloid Leukaemia is a rare cancer. 2013 figures from The Office of National Statistics 
suggest that it represents 0.8% of all new cancer cases in the UK, and 34% of all of all new 
leukaemia diagnoses. This translates to approximately 3000 new cases annually in the UK, with 
a male: female incidence ratio of 12:1087.  
Paediatric AML cases are rare. The incidence increases with age in adulthood, most markedly 
after the age of 6088,89.   
 Predisposing Factors to Disease Development 1.4.3
For the majority of patients with AML, no predisposing factors are identified. There is a clear 
association between myeloid disorders such as myelodysplasia (MDS) and myeloproliferative 
disorders (MPD), and later progression to AML. Prior drug exposure to chemotherapy, 
especially the alkylating agents and anthracyclines, is associated with the development of 
therapy-related leukaemias several years later, often with characteristic genetic 
rearrangements90. Likewise, exposure to ionising radiation, such as that observed post-
Chernobyl, is associated with an increased incidence of AML91.  
Rarely, germline mutations in RUNX1 and CEBPA can lead to a familial predisposition to 
MDS/AML92, as can more profound karyotypic abnormalities such as Down’s syndrome, which 
is associated with a ten to eighteen fold increased lifetime risk of AML93.  
 Clinical Presentation 1.4.4
Patients with AML almost always present with the signs and symptoms of an abnormal blood 
count: fatigue or shortness of breath due to anaemia; overt bleeding or skin petechiae due to a 
reduced platelet count and/or disseminated intravascular coagulation; or overwhelming 
infection due to a lack of functional neutrophils.  
Rarely, presentation can be precipitated by the symptoms of leucostasis driven by an elevated 
white cell count: namely headache, blurred vision, cerebrovascular events or shortness of 
breath from pulmonary infiltration.  
Very occasionally, patients can develop symptoms or signs from extramedullary blast 
infiltration: skin rashes, gingival hypertrophy or chloromas.  




Blood tests are generally highly abnormal, with suppressed levels of normal blood cells, and 
either a low or a high WCC. A blood film stained with May-Grünwald-Giemsa (MGG) may be 
diagnostic if it reveals the presence of circulating blasts. A bone marrow aspirate plus or minus 
trephine biopsy is normally performed to confirm the diagnosis. Morphological examination of 
the marrow contents will show a predominance of immature blast-like cells, characterised by a 
nucleus with open chromatin, a high nuclear-cytoplasmic ratio and (dependent on the subtype 
of AML) granular cytoplasm. Further classification can be made if other cellular subtypes are 
visible in excess, or show signs of dysplasia. 
The blast percentage and assessment of degree of maturation and dysplastic abnormalities in 
the neoplastic cells should be determined, if possible, from a 200-cell leukocyte differential 
performed on a peripheral blood smear, and a 500-cell differential performed on marrow 
aspirate smears stained with Wright Giemsa or MGG.  
In the past, further classification of an AML sample, and confident distinction from acute 
lymphoblastic leukaemia (ALL) was done with the use of cytochemical stains such 
as myeloperoxidase, Sudan black and nonspecific esterase stain; however nowadays, these 
have largely been superseded by the use of flow cytometry.  
1.4.5.2 Flow cytometry  
Although not part of the World Health Organisation (WHO) diagnostic criteria94, flow 
cytometry in the clinical setting is a crucial tool in the diagnosis of AML95. Immediate analysis 
of bone marrow and blood samples can facilitate distinction between AML and ALL samples in 
those cases of morphological uncertainty, as well as further subtyping AML dependant on the 
myeloid maturation markers co-expressed on the blasts. In recent years, with the development 
of multicolour flow panels, it can also be used to identify aberrant blast antigen expression 
patterns, which can then be used for assessment of Minimal Residual Disease (MRD) in 
subsequent post-therapeutic samples96.  
Standard diagnostic flow laboratories identify the presence of blasts based on expression of 
CD45, CD34, CD117 and HLA-DR, as well as basic FSC and SSC characteristics. Myeloid blasts 
may typically co-express myeloid maturation markers such as CD33 and CD13, but be free of 
those associated with the lymphoid lineage.    
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1.4.5.3 Cytogenetic Abnormalities 
The trail-blazing work of Janet Rowley and colleagues in the 1970s resulted in the identification 
of recurrent karyotypic changes in AML samples. Nowadays, bone marrow samples at 
diagnosis are routinely sent for G banding and fluorescence in situ hybridisation (FISH) studies 
for the commonest chromosomal translocations associated with AML97. Cytogenetic 
abnormalities carry key prognostic information for patients: the t(15;17) translocation, 
associated with the formation of the PML RARA fusion protein, carries an extremely good 
prognosis; but is now treated very differently to other AML subtypes98. Translocations of 8;21 
and inversion 16 are commonly seen, and also are associated with improved five year survival 
and superior response to certain drugs, such as anti-CD33 therapy3,99. AMLs associated with 
multiple different cytogenetic changes are associated with older age and preceding MDS, and 
carry a significantly poorer prognosis100  
The MRC 2010 classification system for AMLs, based on presentation cytogenetics into good, 
intermediate and poor risk subgroups is summarised below in Table 1-3101. This has been used 
throughout this thesis, whenever cytogenetics-based risk stratification has been required 
during analysis  
Table 1-3 The MRC 2010 Modified Cytogenetic classification of AML, based on the clinical outcome data from the 
MRC AML trials. Adapted from Grimwade et al
101
 





INTERMEDIATE Everything else 
POOR 
abn(3q) [excluding t(3;5)(q21∼25;q31∼35)] 
inv(3)(q21q26)/t(3;3)(q21;q26) 




t(11q23) [excluding t(9;11)(p21∼22;q23) and t(11;19)(q23;p13)] 
t(9;22)(q34;q11), 
−17/abn(17p), 
Complex (≥ 4 unrelated abnormalities) 
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1.4.5.4 Genetic abnormalities  
AML is a disorder associated by the acquisition of multiple, complex genetic mutations. The 
seminal Cancer Genome Atlas consortium study sequenced 200 AML genomes covering the 
cytogenetic spectrum of the disease. These samples each harboured on average more than ten 
mutations, with in excess of 200 genes being identified as recurrent targets102. Clinical practise 
often lags behind laboratory research, but screening for common genetic mutations known to 
have prognostic significance appears to be growing in importance as a method for risk 
stratifying patients with normal cytogenetics. Many clinical laboratories will routinely screen 
for the presence of the NPM1 mutation103 and the FLT3 internal duplication104. Characteristics 
associated with these mutations are discussed in more depth below. Other genes found 
commonly mutated in AML samples include CEBPA, KIT, N-RAS, MLL, WT1, IDH1&2, TET2 and 
DNTMT3A102.  
 NPM1 Mutations   1.4.5.4.1
The nucleophosmin (NPM1) gene encodes for a multifunctional nucleo-cytoplasmic shuttling 
protein, which is normally localized in the nucleolus. Mutated NPM1 protein locates aberrantly 
to the cytoplasm of leukaemia; hence the term NPM-cytoplasmic positive AML105. 
NPM1 mutations occur in 25 to 35% of all AML patients, but are seen much more frequently 
(50 to 60%) in samples of normal karyotype.  Mutations are strongly associated with de novo 
AML, and are rarely seen in AML associated with previous chemotherapy exposure, 
myelodysplasia or myeloproliferative disorders.  
The mutation is characteristically heterozygous, with preservation of the wild-type allele. 
Although multiple gene mutations have been described, the vast majority affect Exon 12. Type 
A mutations represent a duplication of a TCTG tetranucleotide at positions 956 to 959 of the 
reference sequence, and account for 75 to 80% of cases. Mutations B and D are responsible for 
10% and 5% of cases respectively; other mutations are very rare106. 
Evidence from recent papers which involve sequencing for early mutations in pre-leukaemic 
HSCs (see section 1.5.4) suggest that NPM1 mutations are not seen in this population of cells, 
which are more often characterised by alterations in genes such as DNMT3A107,108. However, 
the acquisition of NPM1 mutation appears to be a key, later, transformational step in towards 
the leukaemia phenotype. Once acquired, its expression remains remarkably stable over the 
disease course109,110. Such persistence and stability in a mutation makes it an excellent 
candidate for MRD assessment111.  
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NPM1 mutant AML was a provisional entity in WHO 2008 classification of myeloid disease112 
and now in the recent 2016 reclassification is a distinct entity113.  
 FLT3 mutations  1.4.5.4.2
Fms-like tyrosine kinase 3 (FLT3), also known as CD135, is a receptor tyrosine kinase expressed 
on the surface of early haematopoietic cells. Normal signalling through the FLT3 receptor is 
thought to be important in the development of stem and progenitor cells.  
Mutations in the FLT3 gene are seen in some 25 to 30% of newly diagnosed adult AML 
cases104,114. Two patterns of mutation are observed: internal tandem duplications (FLT3/ITD 
mutations) in or near to the juxtamembrane domain, and point mutations resulting in single 
amino acid substitutions with the tyrosine kinase domain (FLT3/TKD). Both cause constitutive 
activation of the receptor115.  
Patients with FLT3/ITD mutated AML often present with a similar phenotype, namely a high 
peripheral WCC and a hyperproliferative bone marrow appearance on morphology116. Whilst 
sensitivity to induction chemotherapy is comparable to other AML patients, FLT3-ITD mutation 
is associated with an increased relapse rate and short remission times115. The FLT3-TKD 
mutation is less common and does not share the same clinical phenotype117.        
In comparison to NPM1 mutations, alterations in the FLT3 gene are generally viewed as later 
events in the evolution of AML. When the Majeti lab studied FLT3-mutated AML samples for 
the presence of pre-leukaemic stem cells, the FLT3 mutation was universally absent, 
suggesting this is not an initiating mutation118. Similarly, in a study of paired diagnosis and 
relapse samples, the mutated FLT3 allelic burden varied significantly, suggesting a degree of 
instability in the mutation119.   
In addition to their prognostic significance, FLT3 mutations are of interest in the world of 
precision medicine, as they offer a potential therapeutic drug target. A number of FLT3 
inhibitors exist and have been used in the clinical trial setting. The first generation FLT3 
inhibitors (examples include sunitinib, midostaurin, and lestaurtinib) were initially designed for 
use in other solid organ malignancies, and despite promising in vitro activity against AML 
samples, have largely been disappointing both in terms of efficacy and tolerability when given 
to patients115. However, second-generation FLT3 inhibitors have begun to emerge, such as 
quizartinib (AC-220), crenolanib (CP-868596), and PLX3397. These have a greater specificity for 
FLT3 receptor, and as such offer the promise of potentially greater efficacy and fewer off 
target side defects120. 
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The MRC-sponsored, UK based AML trials have included the investigation of several FLT3 
inhibitors in recent years (from which formal data remain unpublished at this time). AML-17 
involved randomisation of those patients found to have FLT3 mutations to receive CEP701121; 
AML-18 involved randomisation to receive the second generation FLT3 inhibitor AC220, either 
over three courses or as a year-long maintenance therapy122, and finally, AML-19 includes the 
Phase II pilot study of Ponatinib for those with FLT3 mutations123.  
 Classification Systems for AML 1.4.6
AML is a highly heterogeneous disorder, with individual samples showing a wide range of 
morphological, cytogenetic and molecular aberrances. Developing a classification that 
recognises these differences has been an importance goal for more informative clinical 
research and patient prognostication. The most recent classification system was issued by the 
WHO in 2008, and relies heavily on cytogenetic information to group samples with similar 
disease evolution and prognosis112. Previously, classification was based on the morphological 
and cytochemical appearance of blasts, using the French-American-British (FAB) system124.  
 Current Therapy and Clinical Trials 1.4.7
The backbone of treatment given with curative intent remains chemotherapy. For those 
patients fit enough to receive it, intensive chemotherapy is given in blocks. An initial induction 
block aims to achieve morphological remission, followed by two to three consecutive 
consolidation blocks, attempting to remove any residual leukaemia cells There exist global 
variations in favoured induction regimens, but in the UK, most patients will receive a 
combination of daunorubicin and cytarabine (plus or minus etoposide) as a first therapy.  
Chemotherapy given with curative intent comes with significant side effects. These include 
further myelosuppression, alopecia, infertility, nausea and anthracyline-induced cardiotoxicity.  
Typically, 75% of patients will achieve a morphological remission after a first induction course, 
and will regain the ability for normal haematopoiesis four to five weeks after the initiation of 
chemotherapy101. Dependant on age, transplant availability and pre and post treatment 
prognostic indicators, patients will either proceed with further consolidation chemotherapy, or 
an allogeneic bone marrow transplant.    
The intensity of side effects seen with standard chemotherapy, combined with its relative lack 
of efficacy in certain disease subtypes, mean that for frailer patients, it is not an appropriate 
therapeutic option. Thus many patients presenting with AML may be offered a palliative 
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approach with early treatment of infections and regular blood and/or platelet infusions, in 
combination with the use of historically well tolerated drugs such as hydroxyurea to limit the 
speed of disease progression.  In more recent years, attempts have been made by the MRC to 
improve treatment options available to this group, including wide scale testing of novel 
agents4,122.  
It is worth noting that APML, characterised by a distinct morphological appearance and 
associated with the t(15;17) cytogenetic abnormality, is now approached very differently to 
other AMLs. When recognised and treated promptly, and the bleeding disorders often 
observed at diagnosis due to disseminated intravascular coagulation (DIC) are corrected, these 
leukaemias are associated with an excellent prognosis98. This relatively pathologically-
homogenous group of leukaemias respond extremely well to non-standard chemotherapy with 
ATRA125 and Arsenic trioxide, which are much better tolerated than standard cytotoxics.  
In the UK and parts of the Commonwealth, the majority of new patients diagnosed with AML 
are recruited into the current age-appropriate MRC trial. In the past, these trials have been 
designed to try and answer a number of key treatment decisions: the best induction regimen; 
the most appropriate number of consolidation courses of chemotherapy; which patients 
should receive an allograft in first remission. They have been used for rapid assessment of the 
efficacy of a number of drugs which showed laboratory promise: Mylotarg, Everolimus, and 
Zarnestra being a few examples. More recently, samples gathered have also been used to 
assess the feasibility of flow cytometry and molecular genetics as means of rapid MRD 
assessment of patient responses to therapy121,122,126.  
In Europe, similar national trial conglomerates include GIMENA (Italy), PETHEMA (Spain) and 
the HOVON group (Netherlands). In the US, the CALGB (Cancer and Leukaemia Group B) and 
the SWOG (South Western Oncology Groups) cooperatives run similar trials.  
 Prognosis  1.4.8
The following are currently viewed as important prognostic markers at the time of disease 
diagnosis: age, presenting WCC, the presence of particular cytogenetic abnormalities, 
development of secondary AML, and the mutational status of FLT3, NPM1, CEBPA and 
IDH1&297. Predictors of overall outcome after therapy include the blast count after induction 
chemotherapy and the absence of minimal residual disease (MRD)96,111.   
Current estimates of five year survival for all patients at diagnosis with AML are between 40 
and 50%, but with significant variation dependent upon age and disease characteristics at 
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presentation. Study of the long term survival data from sequential MRC AML trials between 
1978 and 2009 would suggest that 5 year survival has improved significantly during this period 
for those patients under the age of 603, but with much more modest improvements for those 
aged 60 and over4. Improvements in supportive care and aggressive treatment of sepsis have 
improved treatment-induced mortality. Sequential multinational studies have led to the 
honing of cytotoxic chemotherapy regimens, but with the notable exception of APML, the 
backbone of chemotherapy for AML remains the same as it was three decades ago5.   
 The Leukaemia Stem Cell Model 1.4.9
1.4.9.1 The LSC Concept 
The idea that a cancer stem cell exists which shares some of the characteristics of a normal 
stem cell has been postulated for some time, but the first experimental evidence for its 
existence came from the study of leukaemia samples. In 1997, Bonnet and Dick transplanted 
CD34+38- cells from leukaemic samples into NOD SCID mice, and showed that these fractions 
were capable of developing into leukaemia blasts and self-propagating127. Furthermore, these 
cells can go on to produce the disease in a secondary mouse transplant experiment, indicating 
the ability of self-renewal in the primary recipient. These cells were described as leukaemia 
stem cells (LSCs).    
In a parallel to normal haematopoiesis, AML is often described as a loose hierarchy, in which a 
small number of self-renewing LSCs give rise to a large population of more mature blasts, 
which lack self-renewal capacity. LSCs are thought to also share the characteristics of 
quiescence and apoptotic resistance with normal HSCs. 
One reason for the frequent failure of conventional chemotherapy to prevent relapse may be 
that the infrequently dividing LSCs are more chemoresistant than the majority of the blast 
population.   
Although the LSC is thought to maintain the reservoir of disease, confer chemoresistance and 
be the cell type responsible for delayed relapse, we cannot assume that all leukaemia initiating 
mutations occur in the normal healthy HSC fraction of haematopoietic cells. Indeed, a 
mutation event in a partially committed progenitor cell may re-confer self-renewal abilities. 
Alternatively, although an initial mutation may occur in a stem cell, and persist indefinitely in 
this pool, development to blast crisis may only occur with the addition of further mutations, as 
appears to be the case in CML128.  
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1.4.9.2 Phenotypic Identification of the LSC 
Improved efficiency of the initial xenograft transplant model (use of the NSG murine strain, or 
intrafemoral injection of transplanted cells), allowed experimental work which showed that 
LSC cells exist not just within the CD34+38- fraction of bone marrow, but can share the 
phenotype of a more committed cell129. LSC phenotype can also vary dependant on the 
phenotypic appearance of the leukaemia: for example, in AML samples characterised by low 
expression of CD34, LSC activity is restricted to the CD34- compartment, whereas in CD34+ AML 
samples, LSCs are found in both CD34+ and 34- fractions130.  
A number of other antigens commonly expressed on LSCs have been reported. These are of 
interest both for the experimental identification of LSCs and also their therapeutic 
targeting131,132. The most valuable targets are those which are differentially expressed on LSCs 
and normal HSCs. 
1.5 Why does the development of AML lead to a failure of normal 
haematopoiesis?  
 Introduction  1.5.1
Many acquired haematological disorders, malignant and non-malignant, present with the 
symptoms resultant from disruption in normal haematopoietic development, but the 
mechanism or mechanisms by which these diseases disrupt haematopoiesis are in general 
poorly understood. Both haematological and non-haematological malignancies such as 
metastatic breast carcinoma or melanoma presenting with heavy bone marrow infiltration can 
result in abnormal blood counts: any clinician should be fully aware that this is not an 
association solely seen with AML. However, the extent of bone marrow infiltration with 
abnormal disease alone is not predictive for the effect on a patients’ blood count: for example, 
many patients with CLL will present with a marrow effaced with lymphocytes, and yet maintain 
normal haematopoiesis.  
Personal observation of presentation bone marrows with AML suggests that even with fairly 
limited disease bulk (i.e. 20 to 30% blasts), myelopoiesis is much more profoundly affected 
than it would be from a comparable disorder.  
The recent literature in this area is sparse and therefore open to conjecture. As AML is a 
disease of the developing myeloid lineage, it could be argued that healthy myeloid cells and 
blasts are more likely to be competing for resources (such as niche space, nutrients, 
appropriate cytokine signalling), than if the diseased cell was derived from another lineage. 
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Are the healthy myeloid cells sensitive to negative feedback signalling from the blast 
population which might impede their growth? Might exosome secretion from blast cells affect 
the normal haematopoietic population? Or is the effect a grosser one, such as a change in pH 
within the stromal milieu to which the normal tissue is sensitive?  Or is it that, in bone 
marrows which have developed AML, even the “normal” cells are aberrant (see Section 1.5.4).  
Secondary questions include the following. Where in the pathway of normal haematopoiesis 
do these effects take place? Are all cells along the haematopoietic pathway of development 
sensitive to the effect of AML, or are some more sensitive than others? The fact that patients 
commonly present with trilineage haematopoietic failure might suggest that those cells at the 
top of the hierarchy are most likely affected, but this does not mean subsidiary effects are not 
seen on partially committed progenitors as well.  
Indeed, there may be more than one or indeed multiple mechanisms concurrently responsible 
for the observed failure of haematopoiesis in any one patient. AML is an incredibly 
heterogeneous disorder, as described above, but a strongly recurrent theme across almost all 
patients is the bone marrow failure associated with it. Are the mechanism or mechanisms by 
which this occurs universal across the diversity of cytogenetic and genetic abnormities 
associated with the development of the disease?   
Clinical observation suggests that the effect of AML on normal haematopoiesis is generally 
reversible. Assuming a patient enters clinical remission after induction chemotherapy, normal 
bone marrow function is generally regained three to four weeks after the completion of 
therapy.  
 The interaction between HSCs and AML: summary of previous work by the 1.5.2
group which led to the hypothesis that acute myeloid leukemia does not deplete 
normal haematopoietic stem cells but induces cytopenias by impeding their 
differentiation 
As early as 30 years ago, it was observed that AML cells had the ability to disrupt growth of 
haematopoietic colonies by the secretion of an apparently diffusible substance133,134. Although 
we recognise that inhibition of normal haematopoiesis by AML may occur at many steps along 
the cellular development hierarchy, our laboratory to date has focussed on the interaction 
between AML and normal HSCs. Our work has used both a murine xenograft model of AML 
engraftment, and the study of primary human bone marrow samples1.  
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1.5.2.1 Murine experiments 
111 unirradiated NSG mice were transplanted with 10 human AML samples to determine the 
effect of AML engraftment on the mouse CD45+ cells. The mice were sacrificed at different 
time-points post transplantation to study the effect of the developing AML on their 
haematopoiesis. As the AML engrafted, there were three phases of haematopoietic activity 
observed in the mouse bone marrow, termed early, mid and late. By the midphase of AML 
engraftment, progenitor cell numbers had fallen in the mouse bone marrow (p<0.0001) in 
comparison to controls, whilst HSC levels were maintained. In the late phase of engraftment, 
both progenitor and HSC numbers had fallen significantly. Figure 1-2A summarizes this data. 
Assays of HSC function were also performed on the murine CD45+ cells extracted from bone 
marrow at the midphase, to back up the immunophenotyping data. Colony-formation and 
repopulation assays, as well as xenograft secondary engraftment studies suggested that the 
murine CD45+ fraction is enriched with long term repopulating cells at this time-point.   
HSC cycling at the midphase was tested by BrdU incorporation assay. In the two samples 
tested, murine stem cells showed significantly reduced BrdU incorporation (p=0.007 and p= 
0.04), suggesting reduced cycling. 
These findings are consistent with a hypothesis that AML induces BM failure by impeding 
differentiation at the HSC-progenitor transition. 
The ten samples used in this study had all previously been shown to be capable of engrafting in 
a mouse xenograft model, and represented a range of cytogenetic abnormalities. All had a 
similar effect on murine haematopoiesis, which gives weight to the idea of a universal theory 
of bone marrow suppression by AML. However, the use of an interspecies transplant model is 
open to a number of significant criticisms. Any observed changes in stem cell behaviour might 
be due simply to the transplantation process, rather than the interaction between AML cells 
and murine HSCs.  
1.5.2.2 Primary Human Samples  
Human correlation of these observations from mouse based studies was provided by studies of 
HSC and progenitor numbers in the bone marrows of 16 patients with a rare subtype of AML. 
The term CD34low AML is here used to describe a rare subtype of AML, where the blasts are 
characterized by low expression of CD34. Diagnostic clinical laboratories will typically describe 
a CD34- AML as one where less than 20% of the blast cells express CD34. This phenotype is 
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highly associated with the presence of the NPM1 mutation105. However, our group has 
previously subclassified this group into three groups defined by the phenotypic flow 
appearances (see Figure 1-2B). Subgroup A contains a much more restricted CD34+ population 
(<0.5% of all cells). Previous transplantation studies have shown this region to be free of LSCs, 
and enriched for normal stem cell activity130,135. Quite why normal karyotype NPM1-mutated 
AMLs exhibit such a range of phenotypes is not clear, but the Subtype A group was notably 
free of associated mutations in genes such as FLT3, which were more commonly observed in 
samples with higher CD34 expression. 
The subtype A group of AML samples (henceforth referred to as CD34low) encompasses 40% of 
NPM1 mutant normal karyotype AMLs, and a small proportion of NPM1 wild type AMLs as 
well. Because both the CD34+38- HSC subset and the CD34+38+ progenitor subset have 
previously been shown to be clear of leukaemic cells, they represent an excellent sample 
group to study the effect of AML on normal HSCs135.  
In 16 patients with CD34low leukaemias, the HSC (CD34+38-) and progenitor (CD34+38+) 
populations were quantified at diagnosis and compared to controls. Whilst the progenitor 
numbers were significantly reduced in AML samples, the number of normal HSCs was not 
statistically different between AML and control samples. Assessment of cycling status of the 
HSCs was determined by Ki67 staining. A lower percentage of HSCs from AML BM were in cycle 
in comparison to controls (p=0.002), a finding mirrored by the murine xenograft study. LTC 
assays and murine engraftment tests showed the CD34+ fraction within the AML samples to be 
more enriched in LTC-IC and repopulating cells than controls. These findings are summarised in 
Figure 1-2 C and D.  
The combination of this murine xenograft and human data led the group to develop the 
hypothesis that acute myeloid leukaemia does not deplete normal haematopoietic stem cells 
numbersbut induces cytopenias by impeding their differentiation. The mechanism by which 
this inhibition occurs remains unknown.  
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Figure 1-2A The effect of AML on mouse haematopoietic populations in a xenograft model showing number of 
CD45
+
 cells, progenitors and HSCs in mice with AML as a percentage of values in controls. The grey line represents 
controls. Adapted from Miraki-Moud et al, PNAS, 2013
1
. B: Classification of 8 NPM1 mutated AML samples based on 
CD34 and CD38 expression. Subtype A samples have <0.5% of cells which express CD34. Subtype B samples have 











 populations. Subtype C samples are more heterogeneous. The CD34
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 fraction is greater than 0.5%, but there 




 population. Diagram from Taussig et al, 2010. C: Assessment of normal residual 
haematopoiesis in humans with CD34
low
 AML. Numbers of phenotypically defined HSPCs are preserved (p=0.6) in 
the BM of 16 patients with subtype A AML, whereas progenitors are reduced in comparison with 42 controls 
(p<0.0001). D: The percentage of HSPCs in cell cycle was lower in subtype A (n=7) AMLs than controls (n=9) 
(p=0.002). Adapted from Miraki-Moud et al, PNAS, 2013
1
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1.5.2.3 Corroborative data  
Since this paper was published, encouraging corroborative findings have been published by an 
unrelated group. Cheng et al developed a non-irradiated murine model of AML, by retroviral-
mediated introduction of the MLL-AF9 fusion gene into B6-Ly5.2 (CD45.2) mice. The resultant 
leukaemia cells were harvested, and introduced into B6-Ly5.1 (CD45.1) mouse recipients, 
which subsequently developed AML within 21 days. Flow-based analysis of the CD45.1 normal 
haematopoietic populations showed relative preservation of LT-HSC numbers in comparison to 
more committed progenitors, until the last stages of AML development. BRDU incorporation 
studies suggested that these HSCs are more quiescent than those extracted from 
untransplanted mice.  
Gene expression analysis of the murine HSC populations performed at Days 7 and 14 showed 
differential expression of a number of quiescence-associated genes, including the transcription 
factor Egr3, which was overexpressed in murine stem cells exposed to AML, relative to 
controls136. Members of the Egr family are transcription factors, whose previously described 
roles include the control of HSC137 and lymphocye proliferation138,139.   
Further evidence was presented for a potential role for Egr3 expression in mediating the effect 
of AML on HSCs. Retrovirally induced overexpression of Egr3 in murine stem cells led to a 
quiescent phenotype both in vitro and in a murine transplant model. The reverse effects 
where observed when Egr3 expression was reduced in murine stem cells by shRNA knock-
down.  
 The interaction between AML and stromal cells may affect the niche and 1.5.3
therefore HSC development indirectly 
An alternative, but by no means mutually exclusive theory to explain the changes seen in 
haematopoiesis in AML is that, rather than solely directly inhibiting normal HSCs, AML cells 
might induce changes in the microenvironment and bone marrow niche such that it is no 
longer able to support normal haematopoietic development.  
Support for this concept is provided by recent work looking at the effect of AML on 
mesenchymal stromal cells isolated from human AML diagnostic BM samples. The growth of 
these cells, as assessed in vitro by colony-forming unit fibroblast activity and population 
doubling time, was significantly lower than controls. The cells also exhibited reduced 
osteogeneic differentiation, and differential DNA methylation. Importantly, mesenchymal 
stromal cells also showed a reduced ability to support normal haematopoietic development as 
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evidence by reduced growth of normal CD34+ cells in a 7 week culture assay140,141. Similar 
findings have also been described in murine models142,143.    
More radically, some sources have suggested that acquired mutations within stromal cells 
might themselves be a driver for leukaemia development. In a murine model, selective 
deletion of the miRNA processing endonuclease Dicer1 in mesenchymal osteoprogenitors 
resulted in abnormal haematopoietic development, characterised by MDS-like changes and 
AML development144. Blau et al investigated the genetic makeup of MSCs on 96 AML samples 
and 36 controls. They found chromosomal changes within the MSCs of patients who had 
developed leukaemia to be significantly more common than within controls, and particularly 
associated with the development of poor risk AMLs. However, the actual patterns of 
chromosomal aberrations seen in AML and stromal cells were different. Whether there exists a 
causal relationship between these findings is not clear145. 
1.5.3.1 Potential mechanisms for signalling between AML and HSCs: do exosomes play a 
role? 
Our previous work described observed changes in HSC and progenitor behaviour in the context 
of AML development, but did not include an explanation for how these changes might be 
brought about, or what signalling mechanisms might be important. As detailed above, others 
have subsequently proposed a role for Egr3 in mediating the observed HSC quiescence136.  
An interesting hypothesis is that exosome secretion from AML blasts might prove a means of 
modulating HSC and/or stromal cell behaviour that does not require direct cell-cell contact133.  
Exosomes are tiny (30 to 100nm diameter), cell-derived vesicles, which contain protein, RNA 
and miRNA. They were first identified in reticulocytes, but have since been associated with a 
range of different cell types146. Exosomes have been found in the plasma, bone marrow and 
urine in healthy humans147. 
Exosomes are produced either by the fusion of vesicular bodies with the cell surface 
membrane, or by budding of the plasma membrane itself. Whilst the normal physiological 
functions of exosomes are still being explored, it is clear that the vesicles retain the ability to 
fuse with other cells, deposit their contents into the recipient cell, and as a result, modulate 
cell behaviour.   
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However, exosome secretion is not simply observed in normal cells, but also by a range of 
malignant cells. It has been hypothesized that exosome secretion is one way in which cancer 
cells can modulate their microenvironment to a more permissive state.  
The presence of exosomes in fluid surrounding both AML primary samples and cell lines has 
been demonstrated by density-gradient centrifugation of culture medium and subsequent 
transmission electron microscopy studies. The transfer of membrane proteins in real time was 
visualized by staining AML cells with N-Rh-PE, which was imaged localizing to the cell 
membrane before subsequent budding-off. Fusion of these exosomes with stromal cells was 
illustrated by exposure of murine stromal cells to PKH26-labelled exosomes from the HL-60 
AML line. Subsequent RNA analysis of the murine cells after 48 hours showed the presence of 
human derived CXCR4 transcripts within the cells148. The transfer of exosome contents to 
stromal cells has been shown to reduce their expression of SCF and CXCL12. The same paper 
also identified a number of exosome-induced changes seen directly in HSCs including CXCR4 
and cKit downregulation, as well as repression of transcription factors such as c-Myb and 
CEBP-β. Whether it is via the loss of supporting signals from stromal cells, or direct changes 
induced in normal HSCs, the secretion of exosomes may be one way in which AML induces 
quiescence in normal HSCs.   
Other authors have reported similar changes in stromal cell behaviour induced by exosomes, 
as well as the abrogation of these effects when extravesicular transport was inhibited. One 
paper identified a particular role for MiR-7977 secretion within exosomes in the induction of 
HSC quiescence149. 
 Caveat: How normal are the “normal” HSCs in acute myeloid leukaemia 1.5.4
samples? The pre-leukaemic stem cell concept 
There have been a number of excellent recent papers examining the HSC fraction within AML 
samples for the presence of early, leukaemia associated mutations. Evidence for the existence 
of a pre-leukaemic stem cell population dates back to clinical observation of one patient, in 
remission from t(8;21) associated AML. Lin−CD34+CD38−CD90+ HSCs isolated from the patient 
up to 150 months after therapy, produced normal myeloid colonies in methylcellulose in vitro 
clonal progenitor cell assays, yet contained detectable AML1-ETO transcripts 150.  
The Majeti group from Stanford separated Lin-CD34+38-TIM3- cells from six patients with 
normal karyotype FLT3-mutated AML. Having identified genetic mutations in AML by exome 
sequencing, they went on to study the separated HSCs and their progeny (derived from 
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subsequent murine transplantation) for the presence of the same mutations by targeted 
sequencing.  In five of these samples, 32 of a total of 51 mutations found in the leukaemia cells 
were also found to be present in the residual HSCs. Moreover, 7 of 13 mutations in genes 
recurrently mutated in AML were also present in the residual HSC population, with the notable 
absence of FLT3-ITD in all five cases151.  
A similar study was performed by John Dick’s laboratory, using NPM1/DNTMT3A mutated AML 
samples. In this case, HSCs, common myeloid progenitors (CMPs) and mature lymphocytes 
were flow sorted from the leukaemia sample and the resultant cell fractions sequenced for the 
presence of mutations. DNTMT3A mutations were commonly found in all normal cellular 
fractions, whereas the NPM1 mutation was found only in the blast populations. The authors 
highlight the fact that the DNTMT3A mutated HSCs appear at a competitive advantage in serial 
transplantation assays over non-mutated cells107. 
Clinical data supporting the idea of pre-malignant HSC mutations come from Jaiswal et al, who 
performed whole exome sequencing on blood samples from 17182 people (previously 
recruited into a national Type II Diabetes surveillance study and therefore unselected for 
haematological disease), looking for the presence of mutations within 160 genes recurrently 
identified in haematological malignancy108. Mutations were common (most commonly in 
DNTMT3A, TET2 and ASXL1), with an increase in incidence with rising age. 9.5% of patients 
aged 70 to 79 were found to have one or more mutations in the studied gene set. Moreover, in 
long term follow up studies, the presence of a somatic mutation was associated with a 
significantly increased risk of developing a haematological malignancy (hazard ratio 11.1). For 
those patients who had serial samples available, sequential studies revealed persistence of the 
mutations over time. Similar findings have been made by others152, and have led to the 
concept of clonal haematopoiesis of indeterminate potential (CHIP)153.   
. 
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Chapter 2 Materials and Methods 
2.1 Samples and Ethics  
Samples of peripheral blood and bone marrow from patients with AML and controls (obtained 
pre-treatment from patients with Stage I and II lymphoma and normal blood counts) were 
obtained by the Tissue Bank maintained by the Centre for Haemato-Oncology at Bart’s Cancer 
Institute. This tissue bank is maintained according to the Human Tissue Act 2004 (Licence no. 
12199). All patients had to sign consent forms to allow storage of specimens for research 
purposes after appropriate counselling, in accordance with the Declaration of Helsinki.  
Both cord blood and G-CSF mobilised peripheral blood (GMPB) were used as sources of 
enriched stem cells for optimisation of experimental techniques, controls where stated, and 
for the source of stem cells within the AML Co-Culture assay. GMPB was obtained with consent 
from the excess donations of healthy donors and patients undergoing primed stem cell 
collection at Bart’s Hospital. Cord cells were derived from donated umbilical cord samples 
from the Delivery Suite at the Royal London Hospital.  
This project was approved by the East London and City HA local research ethics committee 2 
with REC reference 06/Q0604/100 titled “Characterisation of leukaemia stem cells and their 
interactions with normal bone marrow cells”. 
2.2 Sample Handling Techniques 
 Collection of Fresh Bone Marrow Aliquots for Immediate Analysis 2.2.1
A standard operating procedure was used to ensure that the BM samples used for 
quantification of HSCs were obtained from the first pull of the aspirate and in a small volume 
(less than 0.5ml) to reduce haemodilution. Samples were decanted into eppendorfs containing 
100µl Anticoagulant Citrate Dextrose Solution (Haemonetics, Cat: 426C). Samples with visible 
clots at the time of analysis were discarded. 200µl of fresh BM was mixed with 4ml ammonium 
chloride solution (Stem Cell Technologies, Cat:  07850), and incubated at 4oC for 10 minutes to 
induce red cell lysis. 1ml FCS was added and the sample pelleted (1500rpm, 5 minutes). The 
cells were re-suspended in 50 µl 2% HAG, mixed well and incubated for 20 minutes at 4oC. 5µl 
of CD34-PerCP (BD, Cat: 345803 (clone 8G12)) and CD38-Pecy7 (BD, Cat: 335825 (clone HB7) 
were added, and the sample incubated for 30 minutes at 4oC. The sample was then washed in 
4ml 2% PBS, and re-suspended in 300µl 2% PBS/DAPI/DNase. Cell counting was facilitated by 
the addition of 50µl CountBright™ Absolute Counting Beads (Life Technologies, Cat: C36950). 
Analysis was performed using a BD Biosciences LSR Fortessa.  
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 Tissue Bank Processing of Samples for Delayed Analysis 2.2.2
Bone marrow aspirate samples were collected into EDTA collecting tubes (from multiple 
suppliers) at Bart's Hospital. On arrival in the Tissue Bank, extraction of mononuclear cells was 
performed following the Departmental SOP. In brief, samples were layered on top of 4ml 
LymphoprepTM (Stem Cell Technologies, Cat: 07851) in a 15ml Falcon tube, and centrifuged 
with brakes off (1500rpm, 25 minutes). The resultant mononuclear cell layer was removed 
using a pipette, and added to a Falcon tube containing 9ml of RPMI Medium (Sigma, Cat: 
R8758). Cell count and viability was assessed using the Beckmann Coulter Vicell XR Cell 
Viability Counter.  
The sample was then centrifuged (1300rpm, 10 minutes), and the resultant pellet resuspended 
in 1ml freeze mix (7 parts RPMI; 1 part DMSO; 2 parts FCS), before gradual freezing to -198oC.   
 Processing of G-CSF mobilised peripheral blood and cord blood 2.2.3
Excess aliquots of leucophoresis blood obtained from patients or donors undergoing G-CSF 
mobilised peripheral blood harvests at St Bartholomew’s Hospital, London, were obtained 
after obtaining written informed consent. Alternatively, samples of cord blood were obtained 
post-delivery at the Royal London Hospital, after written informed parental consent.  
These samples were diluted 1:4 with PBS, and overlaid onto LymphoprepTM (Fresnius, Cat 
2015-06). The samples were centrifuged with breaks off (1550rpm, 30 minutes) at room 
temperature, to produce separation of red cells and a layer enriched in mononuclear cells. 
After removal of the mononuclear layer using a pipette, the cells were washed in PBS and re-
pelleted. Pelleted cells were re-suspended in 10ml ammonium chloride (Stem Cell 
Technologies Cat 07850) and incubated at 4oC for 10 minutes to induce red cell lysis. Lysis was 
terminated with the addition of 1ml FBS, the sample pelleted and re-suspended in 10ml 2% 
PBS. Cell number was counted and viability assessed using the Beckmann Coulter Vicell XR Cell 
Viability Counter.  
If cells were frozen at this juncture, a freezing mix was made, consisting of 95% FBS to 5% 
DMSO. Cells were frozen to a maximum concentration of 100x106 cells/ml. 
2.2.3.1 Lineage Depletion of GMPB or cord samples to enrich for the presence of HSCs  
Samples of cord or GMPB can be enriched for the presence of immature cells using negative 
selection for cells expressing lineage specific antigens (Lin depletion). This technique utilises 
the EasySep Human Progenitor Cell Enrichment Kit (Stem Cell Technologies; Cat: 19056) and 
the EasySep magnet (Stem Cell Technologies; Cat: 18000).  
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Unselected mononuclear cells were pelleted and resuspended at a concentration of 100x106 
cells/ml in 2% PBS, to a maximum volume of 2ml in 5ml polystyrene tubes (BD Falcon, Cat: 
352052). EasySep Human Progenitor Cell Enrichment Cocktail (Stem Cell Technologies, Cat: 
19056) was added at a concentration of 50µl/ml; the suspension was mixed and incubated (15 
minutes, room temperature). EasySep Magnetic Nanoparticles (Stem Cell Technologies, Cat: 
19056) were left at room temperature for at least 15 minutes, and mixed thoroughly to ensure 
even distribution. The nanoparticles were then added at a concentration of 50µl/ml to the 
tube, mixed and left to incubate (15 minutes, room temperature).  
2% PBS was then added to the polystyrene tube to bring the total tube volume to 2.5 ml, and 
the tube gently mixed. The tube (without cap) was placed in the EasySep Magnet (Stem Cell 
Technologies, Cat: 18000), and left for 10 minutes at room temperature. Leaving the tube in 
the magnet, the contents of the tube were then decanted into a 50ml tube. The magnetic 
beads, bound to unwanted, Lin-expressing cells, remained in the polystyrene tube.  
The yield of Lin-negative immature cells was increased as follows. The 5ml polystyrene tube 
was removed from the magnet, and the cells and beads re-suspended by adding 2.5ml 2% PBS. 
The tube was replaced in the magnet, incubated for 10 minutes at room temperature, and 
contents decanted into a 50ml Falcon tube. This was repeated twice.  
Cell number and viability was then assessed using the Beckmann Coulter Vicell XR Cell Viability 
Counter.       
 Tissue Bank storage of bone marrow serum samples 2.2.4
Bone marrow samples were collected into SST tubes (multiple manufacturers) and centrifuged 
(3000rpm, 3 minutes). The resultant serum supernatant was aliquoted off, and frozen at -20oC.  
 Cell Thawing 2.2.5
On removal from liquid nitrogen storage, cells were rapidly thawed at 37oC in a water bath for 
one to two minutes. In order to minimise cell loss through cellular clumping, 500μl DNase was 
added immediately post-thawing, and the vial left for 2 minutes at room temperature. The vial 
contents were immediately diluted in 20ml 2% PBS, to limit the toxicity from DMSO. The cell 
suspension was then centrifuged (1500rpm, 5 minutes) and re-suspended to the required 
volume.  
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2.3 Cell Counting 
 Automated Assessment of Cell Numbers  2.3.1
Automated assessment of cell number and viability was performed using the Beckmann 
Coulter Vicell XR Cell Viability Counter. This is a video imaging system, which automates 
assessment of the ability of live cells to extrude trypan blue dye. The cell numbers in 30 fields 
were assessed, and an average calculated. The machine is calibrated to assess cell numbers 
most accurately at concentrations between 0.5x106 and 100x106 cells/ml, so samples were 
diluted appropriately before analysis. 
 Manual Counting of Cell Numbers  2.3.2
For low cellular concentrations, below the resolution of automated counting, manual 
assessment of cell concentration using a haemocytometer was performed. A 10μl aliquot of 
cells was added to 90μl trypan blue (P2100102, Cell Viability Inc), and mixed well, to produce a 
1:10 dilution. 10μl of this mixture was injected into the top of a 1/400 mm2 haemocytometer 
(Weber Scientific, Cat: 3048-12), under a coverslip. Using a microscope, cell numbers were 
counted in each of the four large corner squares of the haemocytometer and a mean taken. A 
mean cell number of α calculated using this technique, gives a cellular concentration (post-
dilution) of αx104 cells/ml; and therefore pre-dilution with trypan blue, a cellular concentration 
of αx105 cells/ml. 
2.4 Flow Cytometry 
 Background 2.4.1
Flow cytometry is a technique designed to measure the characteristics of single cells flowing 
through a detector system. Fluorescent antibodies are used to identify the expression of 
specific cell surface or internal glycoproteins. Single cell suspensions are introduced to the 
cytometer in a cell-free buffer called the sheath fluid, which flows towards a laser. Laminar 
flow of the sheath fluid forces the cells to line up in single file as they approach the laser. The 
bound antibody-fluorophore absorbs the laser energy and subsequently releases it in the form 
of a specific wavelength of light as cells pass through the laser. The emitted light is detected by 
an optical system sensitive to various wavelengths, allowing information on multiple surface 
markers to be read simultaneously. The specificity of detection is controlled by optical filters, 
which block certain wavelengths while transmitting others. Photodetectors convert the light 
signal into a current, whose voltage has an amplitude proportional to the total amount of light 
received. These data are then plotted graphically.    
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Basic information on cell size is represented by the forward scatter parameter (FSC), 
quantifying light scattered at a small angle and detected by a sensor on the opposite side of 
the 488-nm blue laser. Light that scatters off the cell at a 90o angle is called side-scatter (SSC), 
and reflects cell granularity.  
Fluorochromes are dyes, which accept light energy at a given wavelength (in this case from a 
laser) and re-emit it at a longer wavelength, processes called excitation and emission. At a 
basic level, a good fluorochrome will absorb and emit light at significantly different 
wavelengths, a phenomenon known as the Stokes shift, which will enable the machine to 
clearly differentiate emitted light, from the unabsorbed light emitted by the laser itself.    
A variety of fluorochromes are commercially available that individually emit light of specific 
different wavelengths, whilst absorbing light of the same wavelength. This enables us to study 
a number of different parameters simultaneously, which is a key principle of the work in 
Chapters 4 and 5. An ideal fluorochrome has an extremely narrow emission spectrum, read by 
only one detector, but in practise, this does not occur in a system adapted for multi-colour 
analysis. Because the emission spectra of fluorochromes overlap to different degrees, a single 
detector may see fluorescence originating from more than one fluorochrome; this spill-over of 
readings from other fluorochromes in the detectors not assigned to them is removed using an 
algorithm called compensation.  Cells stained with a single fluorochrome are run through the 
detector separately, and the signal detected in the channels not assigned to them is noted and 
removed from the final analysis.  
 Fluorescence Activated Cell Sorting (FACS)  2.4.2
Fluorescence Activated Cell Sorting (FACS) uses the principles of flow-cytometric based cell 
labelling to separate cells of different types.   
Labelled single cell suspensions are introduced to the FACS machine, and laminar flow of the 
sheath fluid ensures the cells approach the lasers individually. After cells are interrogated by 
the laser in the flow chamber, the single cell stream is broken accurately into tiny droplets by a 
fine nozzle vibrating at ultrasonic frequency. The scatter and fluorescence signal is compared 
to the sort criteria set on the instrument. If the particle matches the selection criteria, the fluid 
stream is charged as it exits the nozzle of the fluidics system.  
The speed of flow sorting depends on several factors including particle size and the rate of 
droplet formation.  
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 Specific Uses of Flow Cytometry in this Thesis 2.4.3
Flow cytometry has been used heavily in this project for several purposes: to quantify HSCs in 
diagnostic AML samples; to characterise the expression of a variety of antigens both on the 
surface and cytoplasm of stem cells; to identify stem cells prior to sorting, and to identify 
erythroid progenitors in bone marrow samples.  
The number of cells stained varied dependant on the individual experiment, and the rarity of 
the cell type under investigation. In general, when working with valuable bone marrow 
samples, all available thawed cells were stained, and the whole sample analysed.   
All flow cytometry analysis was performed on a BD LSR Fortessa, equipped with 405, 488, 561 
and 641 nm lasers.  
 Fluorochrome Panel Selection  2.4.4
Combinations of fluorochromes were always optimised before performing multicolour flow 
cytometry. Up to seven colours were used simultaneously in some experiments. The particular 
combinations utilised in this study were chosen based on local experience of best 
discrimination of the rare stem cell phenotype, in combination with knowledge of the optimal 
stains for the machine which we use in the lab. We attempted to pick the brightest colours for 
rarely expressed antigens, and to minimise spill-over between important discriminating 
antigens. For commonly studied antigens (i.e. CD34), a range of fluorochromes were 
commercially available to select from, whereas others presented a more restricted selection 
(i.e. ALDH activity, as assayed by the AldefluorTM reagent kit, can only be assessed in the FITC 
channel).      
 Specific Techniques  2.4.5
2.4.5.1 Surface Staining 
All staining procedures on live cells were undertaken at 2 to 8oC to avoid antibody capping and 
internalisation. For any staining procedure involving more than one antibody, the cells were 
pre-stained with a solution of human γ globulin (at a concentration of 50µl 2% HAG/1.5x106 
cells) for 20 minutes at 4oC to reduce non-specific binding of antibodies. Each antibody was 
optimised to determine the best volume for surface staining, which ranged from 1 to 20μl/106 
cells. The samples were then incubated for 30 minutes in the dark. The cells were then washed 
in 4ml 2% PBS and re-suspended in 300μl 2% PBS/DAPI to allow for live/dead cellular 
discrimination. Cells were kept in the dark until analysis to reduce fluorochrome bleaching.  
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2.4.5.2 Intracellular Assessment of Aldehyde Dehydrogenase (ALDH) Activity 
Internal ALDH activity was assessed by the AldefluorTM reagent kit. The activated reagent is a 
fluorescent substrate for ALDH, which freely diffuses into viable cells. In the presence of ALDH, 
the reagent is converted into a substrate which is internalised within cells. The amount of 
fluorescence produced is proportional to the ALDH activity within cells and is measurable in 
the FITC channel of a cytometer. Active efflux of the reaction product is inhibited by an efflux 
inhibitor in the AldefluorTM assay buffer. Cell staining was optimised at a concentration of 5µl 
AldefluorTM reagent per 1x106 cells, prior to incubation for 60 minutes at 37oC in a water bath. 
To minimise efflux, all further handling of cells was performed at 4oC, and analysis was 
undertaken as rapidly as possible (normally within two hours of AldefluorTM staining). Further 
washing and suspension of cells was undertaken in AldefluorTM buffer rather than PBS, for the 
same reason. Similarly, when using HAG to minimise non-specific antibody binding, 
optimisation experiments showed that the cells remained ALDHbright if HAG diluted in 
AldefluorTM buffer was used, rather than with 2% PBS as standard.  
2.4.5.3 Intracytoplasmic Staining 
Any intracellular staining technique involves membrane permeabilisation to allow the 
antibodies to pass into the cytoplasm. In this context, DAPI cannot be used for live/dead 
discrimination of cells, as it normally stains dead cells by passing through non-intact 
membranes, and binding AT rich portions of DNA. Live/dead discrimination is therefore 
performed using a fixed viability dye (Fixed Viability Dye eFluor 780 (E Biosciences, Cat: 65-
0865)), before surface staining.   
For 1x106 cells, cells were re-suspended in 1ml of diluted Fixed Viability Dye (1µl Fixed Viability 
Dye, premixed with 1 ml PBS), left to incubate at 4oC for 30 minutes, and then washed in 2% 
PBS.  
Cell fixation and permeabilisation was then undertaken using the BD Fixation/Permeabilization 
Solution Kit (BD, Cat: 554714). Cells were resuspended and membranes permeabilized by the 
addition of 100µl Cytofix/Cytoperm per 1x106 cells, followed by incubation for 15 minutes at 
room temperature. All subsequent washing of cells was performed using 1ml PermWash 
buffer per 1x106 cells.  
Internal blockade of non-specific binding was performed by the addition of a goat 
serum/glycine mix (50μl per 1x106 cells of 10% normal goat serum, 0.3M glycine) to cells for 20 
minutes at 4oC. Internal primary and secondary antibody staining was performed at room 
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temperature, with incubation for 30 minutes, followed by careful washing to remove unbound 
antibody.  
Extracellular surface antigen staining was performed after the completion of internal staining 
as previously described, albeit with the continued use of PermWash buffer for the wash steps.   
2.4.5.4 Controls  
Unstained controls were used to set the voltages in the flow cytometer. Isotype controls were 
used in experiments where there was not expected to be a significant population of target 
antigen negative cells. Fluorescence minus one (FMO) controls were also used for certain 
experimental conditions.  
Compensation was set using single stained controls, where the cells were known to express 
the target antigens. For experiments utilising fixed cells, the compensation cells also 
underwent fixation before staining.   
2.4.5.5 FACS 
All cell sorting for these experiments were performed on a BD FACSAria IITM, supplied with 405, 
488, 561 and 641 nm lasers. Sorting tiny numbers of cells from large samples involves a 
number of challenges to optimise sort purity. 
Live cells were stained as described, and resuspended in a stock solution of 2% 
PBS/DAPI/DNase at a concentration of 8x106 cells/ml. This concentration had previously been 
optimised by our group as appropriate for sorting out cells of rare phenotype from AML 
samples. DNase was added to the pre-sort suspension to reduce cellular clumping, and for the 
same reason cells were filtered immediately prior to sorting to remove cellular debris (Cell 
Strainer Cap, BD Falcon, Cat: 352235), to reduce the chance of nozzle blockage. An 85µm 
nozzle was used for all sorts, and a slow flow rate of between 10 to 30µL/minute was used at 
all times.     
To increase cell survival, cells were sorted into polypropylene tubes (BD Falcon, Cat 352063) 
containing 2% PBS, in order to remove the electrostatic charge from the sorted droplets prior 
to further processing.  
Cells stained with ALDH reagent were sorted into ALDH buffer media to reduce ALDH efflux 
prior to purity assessment.  
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The purity of the sorted population was always checked immediately post sort, irrespective of 
cell numbers collected. Between sorting and purity checked, the machine was flushed for a 
minimum of five minutes to reduce cellular debris. If the purity of the sorted population was 
found to be below 90%, resorting was undertaken.    
Sorted cells were then pelleted (1500rpm, 10 minutes) and the supernatant removed using a 
Gilson Safe Aspiration Centre.  
2.4.5.6 Flow Cytometric Analysis  
All analysis was performed using the FlowJo v 10 package. Figure 2-1 illustrates the gating 
strategy applied to the test samples. A first gate defined live cells from debris on the basis of 
FSC and SSC. A second gate excluded doublets from the analysis, on the basis of SSC-A and SSC-
width. A third gate was applied on the basis of DAPI/fixed viability dye and SSC-A to exclude 
dead cells from the analysis. Therefore all subsequent analysis of fluorochrome intensity was 
performed on compensated, live-singlet cells.  
 
Figure 2-1 Illustrating the successive flow gating strategy used to select single, live cells 
2.5 Tissue Culture Methods 
 MS5 Culture 2.5.1
Unless otherwise stated, all liquids were pre-warmed to 37oC in a water bath prior to cell 
contact. To reduce the chances of cell-line infection, antibiotics were added to all media to a 
concentration of 1% (Streptomycin/Penicillin (Sigma, Cat: P4333)).  
Cells from the MS-5 cell line (DSMZ, Cat ACC-441) were initially thawed, washed and 
resuspended in 20ml of 10% IMDM. Cells were pipetted into a flask (75cm2 Cell Culture Flask, 
Coning Cat: 430720U), and incubated at 37oC, 5% CO2. MS-5 cells are surface-adherent, and 
therefore flasks were placed flat in the incubator. Flasks were inspected daily for cellular 
appearance, and split before a confluence of 80% was reached. To split cells, the adherent cell 
layer was washed with PBS twice, to remove traces of FBS. 3ml of trypsin-EDTA (Sigma, Cat: 
 Chapter 2: Materials & Methods 
62 
T4299) was added to the flask, and left to incubate at 37oC for 4 minutes. Flask contents were 
visually inspected to confirm loosening of the adherent stromal cells, and further activity of the 
trypsin inactivated by the addition of 10ml 10% IMDM. Cells were centrifuged (1300rpm, 5 
minutes), resuspended in 10% IMDM, and split into the required number of flasks for ongoing 
culture.   
MS-5 cells were kept in culture for a minimum of 2 weeks from thawing prior to their use as a 
feeder layer in the LTC-IC assay. Cell lines were not passaged indefinitely: after two months in 
continuous culture, cells were discarded, as local experience had shown their effectiveness as 
a feeder line to be reduced over repeated passaging (personal communication, Dr Anjos-
Afonso).    
If required, cells were frozen to a concentration of 5x106 cells/ml in freeze vials in a mixture of 
19 parts FCS to 1 part DMSO. 
2.6 In vitro assays of stem cell function  
 Methylcellulose Assay (for the presence of CFU) 2.6.1
Bone marrow samples were thawed, counted, stained and sorted (under sterile conditions) as 
described above. Cells were centrifuged (1500rpm, 10 minutes), and the supernatant aspirated 
using the Gilson Safe Aspirator Station, leaving a small volume (approximately 50µl) of residual 
fluid in the tube. The pelleted cells were resuspended, and transferred to a tube containing 
4ml Methylcellulose (MethoCult H4435 enriched, Stem Cell Technologies, Cat: 04435). Cells 
were carefully mixed throughout the methylcellulose using a standardised technique with a 
1ml pipette and a 16G blunt hub needle (Monoject Blunt Needle, Kendall, Cat: 8881202322), 
and left to settle for 2 minutes. 1ml of the cells and methylcellulose mixture was transferred 
using the same syringe and needle to a small culture dish (Culture Dishes for Optimal Colony 
Growth in Methylcellulose Based Assay, Stem Cell Technologies, Cat: 27150), trying to avoid 
the introduction of bubbles. Plates were set up in triplicate for each experimental condition. 
Into one, larger 10cm diameter tissue culture dish were placed two small culture dishes 
containing methylcellulose, along with one open small culture dish containing 6ml sterile 
water to maintain an appropriate humidity. The plates were then incubated at 37oC, 5% CO2 
for two weeks.  
After two weeks, the myeloid and erythroid colonies visible under the microscope were 
counted using a graticule. Plates with visible colonies were then re-plated to assess growth 
over a further two weeks. For test conditions which had produced more than five colonies per 
 Chapter 2: Materials & Methods 
63 
plate, one of the three available replicated plates was used. If there were five or less colonies 
per plate, colonies from all three plates were pooled. Using a 1ml pipette and 16G blunt 
needle, cells and methylcellulose were removed, and placed into a 50ml Falcon tube. The plate 
was washed with 1ml 2% PBS, and the washings added to the Falcon tube. This was repeated a 
further two times. The Falcon tube was topped up to a volume of 50ml with 2% PBS, 
centrifuged for 1500rpm for 5 minutes, and the supernatant discarded. The pelleted cells were 
washed again with 50ml 2% PBS, pelleted and re-suspended in 500µl PBS and counted using a 
Haemocytometer. 40,000 cells were then added to a tube containing 4ml methylcellulose, 
mixed well and re-plated as described above. The re-plated colonies were then incubated for a 
further two weeks.  
At the end of two further weeks culture, cell colony numbers were assessed. Cells were 
removed from the culture medium and washed as described, prior to placing onto slides for 
FISH based analysis.  
 Long Term Culture Initiating Cell Assay  2.6.2
A 96 well flat bottom cell culture plate (Costar, Cat: 3598) was coated with collagen using the 
following method. 50µl of Collagen Solution (Stem Cell Technologies, Cat: 04902) was added to 
each well, and left to dry for two minutes before the excess collagen was removed. The plate 
was left open under a hood to dry for at least an hour. Subsequently, each well was washed 
with 100µl PBS.  
Meanwhile, MS-5 cells were prepared at a concentration of 1x106 cells/ml in IMDM/10%FCS, 
and placed in a 50ml Falcon Tube. The cells were irradiated at a dose of 70Gy (RadSource 
2000, X-ray emitter). Cell viability 1 hour post-irradiation was assessed using a Beckmann 
Coulter Vicell XR Cell Viability Counter. Cells were pelleted, and re-suspended in MyeloCultTM 
H5100 (Stem Cell Technologies, Cat: 05100) to a concentration of 125,000 cells/ml. 100µl of 
cell/H5100 suspension was added to 60 wells per plate, having filled each of the outside wells 
with 100µl water.  
The following day, HSCs were sorted as previously described. Cells were pelleted (1500rpm, 10 
minutes), diluted and distributed at different concentrations between wells in triplicate. 
The plates were then placed in a long term incubator at 37oC, 5% CO2. Weekly, for five weeks 
of culture, the media was changed as followed. Taking care to not disturb the bottom of each 
well, 65µl of media was removed from the top of each well using a multichannel pipette. This 
was replaced with 75µl of MyeloCultTM H5100. 
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At the end of week 5 of culture, the media was removed from each well, using a Gilson Safe 
Aspiration Station, having taken care not to disturb the 10 to 20µl at the bottom of each well 
containing cells. Using a Gilson Distriman pipette, 100µl of MethoCult H4435 enriched 
Methylcellulose medium was added to each well, and the plates returned to the incubator. 
After a further two weeks culture at 37oC, each individual well was examined for the presence 
of myeloid and erythroid colonies and their numbers recorded. If growth was noted, cells were 
removed, washed and placed on slides for FISH analysis as described in Section 2.7.1 
2.7 Histological techniques  
 Preparation of Slides  2.7.1
If greater than 5000 cells were collected, slides were made as follows. Cells were pelleted and 
re-suspended in 150 to 600µl 2% PBS, dependant on the number of slides required. Cell 
numbers did not exceed 500,000 per slide, to prevent overcrowding. Using a clean glass slide 
clipped into a slide holder, 150µl of 2% PBS/cell suspension was added to the well. Slides were 
spun (8500rpm, 6 minutes) using a Stat Spin Cytofuge 2. Excess liquid was removed using a 
Gilson Safe Aspirator Station, and the slides allowed to air-dry.  
If handling less than 5000 cells, the cells were resuspended after initial centrifugation in 50µl 
2% PBS. This was removed using a pipette, and transferred onto a dry slide. The slides were 
air-dried without spinning.  
 Immunocytochemistry and Microscopy 2.7.2
2.7.2.1 Background 
Immunocytochemistry involves the use of fluorescent antibodies to identify the presence and 
location of particular antigens in a cell, when studied using a laser microscope designed to 
detect the fluorescence. There are two forms of immunocytochemistry: direct and indirect. 
Only indirect methods, which involve consecutive antibody staining were used in this project, 
and so will be described below.  
A primary antibody specific to the antigen of interest is applied to a specimen. After binding, 
its presence is revealed by staining with a secondary antibody against the immunoglobulin of 
the species used for primary antibody production. Primary antibodies are generally unlabelled, 
whereas secondary antibodies contain a tag for detection. The use of a preliminary blocking 
step prevents non-specific binding of antibodies. The choice of blocking buffer is based on the 
secondary antibody used. Dissolving the blocking agent in saponin increases the cells’ 
permeability. 
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2.7.2.2 Methodology 
After drying, slides were fixed and permeabilized. 50µl Cytofix/Cytoperm Buffer (BD, Cat: 
554722) was applied to the slide, and left to incubate in a damp box for 30 minutes. Slides 
were rinsed in PBST (0.1% Tween-20 (Sigma P1379) in PBS). 
Slides were then blocked with donkey serum (Sigma, Cat: D9663) (0.1% saponin, 5% donkey 
serum in PBS). 50µl of 5% donkey serum was added to slides, which were left to incubate for 
30 minutes in a damp box. Slides were then rinsed in PBST.  
Primary antibody concentration was optimised, based on manufacturers’ instructions. 50µl of 
antibody was applied to slides, which were then incubated for 1 hour. Slides were washed 
twice, in between 5 minute agitation periods on a Stuart Scientific Platform shaker STR6.  
Secondary antibody staining was performed using a labelled monoclonal antibody against the 
species used in the primary antibody. Secondary antibody concentration was also optimised 
for each experimental set up. 50µl of secondary antibody was added to slides, which were left 
to incubate for 1 hour in a damp box. Slides were then washed three times with PBST as 
described above. The slides were covered during the washing process to reduce light exposure.  
Slides were then mounted with 1 drop of Vectashield HardsetTM Mounting Medium in Dapi 
(Vector, Cat: 1500), and a coverslip added. Examination was performed using the Confocal 
Zeiss Laser Scanning Microscope SM 5100.      
 FISH Staining 2.7.3
I am extremely grateful for the assistance of Marianne Grantham of the Cytogenetics 
department, Royal London, who performed all the FISH based staining and analysis detailed in 
this thesis. Her technical expertise was invaluable, as was her assistance in probe selection to 
detect less common karyotypic abnormalities. Her patience in dealing with the considerable 
challenges of FISH staining of small numbers of cells was also much appreciated.   
FISH (Fluorescence In Situ Hybridisation) describes a technique where fluorescent probes bind 
to complementary sequences of DNA or RNA within cells. Subsequent examination with 
fluorescent microscopy can then be used to detect the presence of the probes. FISH based 
analysis of bone marrow, using probes specific for commonly found translocations or 
mutations, is part of the routine AML diagnostic process.    
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In brief, probes are added to cells fixed onto slides, and are left to hybridise for 12 hours, 
before the removal of unbound probe by washing. For DNA binding probes to anneal to 
complimentary sequences, the chromosomal material inside the cells has to be accessible 
(cells either in interphase or metaphase).  
Table 2-1 FISH probes used in this thesis with expected signal patterns in normal and mutated cells 
A variety of different probe designs exist. Fusion probes detect translocations which bring two 
genes of interest together. They normally involve the use of two different coloured probes, 
which when brought together in close physical proximity, produce a third colour visible by eye. 
Break-apart probes are designed to bind sequences which under normal circumstances are 
found close together. If a translocation separates the two regions, the probes produce two 
distinct colours.  
Table 2-1 details the probes used in this study, as well as the specific changes they were used 
to detect and the expected signal patterns in normal and mutated cells. Some probes were 
used for their standard commercial purpose i.e. the Cytocell CBFB-MYH11 probe for the 
detection of inv(16). Imaginative use of other probes allowed identification of other, rarer 
abnormalities. For example, the MLL break-apart probe, which normally binds to chromosome 
11, was in this case used not to detect mutations within the MLL gene specifically, but trisomy 



































2 FUSION, 1 RED, 
1 GREEN 







2 FUSION, 1 RED, 
1 GREEN 





2 FUSION 3 FUSION 
Cytocell Del(7q) 
(LPH 025) 
Del(7) DUAL COLOUR 
2 RED, 
2 GREEN 









3 RED, 3 AQUA 
 Chapter 2: Materials & Methods 
67 
2.8 Genetic Techniques 
  DNA Extraction modified for small cell numbers   2.8.1
DNA extraction from small populations of cells was performed using the QIAamp DNA Blood 
Mini Kit (Qiagen, Cat: 51104), designed for purification of up to 12µg DNA. All components 
listed below are included within this kit.  
After washing, and pelleting of cells (1500rpm, 10 minutes), the supernatant was removed 
using the Gilson Safe aspiration centre. Cells were gently resuspended in 100µl PBS and 100µl 
AL lysis buffer (Cat: 1014594), and transferred into a 1.5ml Eppendorf tube. After vortexing for 
30 seconds, 40µl Proteinase K (0.1mg/ml) (Cat: 1045166) was added, the tube briefly vortexed 
and then put to incubate for 10 minutes at 70oC. 210µl of 100% Ethanol (Sigma, Cat: E7023) 
was then added, the tube vortexed and 500µl of the solution added to the spin column. The 
column was spun (8000rpm, 1 minute), and the supernatant discarded. The spin column was 
placed in a clean collection tube, and 500µl of wash buffer AW1 (Cat: 1014790) added, before 
centrifugation (8000rpm, 1 minute). The collection tube was again replaced, and a further 
500µl of wash buffer AW2 (Cat: 1014592) added, prior to centrifugation (14000rpm, 3 
minutes).  
The spin column was then placed in a clean 1.5ml eppendorf tube, and between 20 and 50µl of 
AE (Cat:1014574), pre warmed to 45oC, was added (volume added is dependent on initial cell 
numbers collected: for samples of between 100 to 5000 cells, 20µl of AE was added; for 
samples up to 50,000 cells, 50µl of AE was added). The tube was then left to incubate at room 
temperature for 5 minutes, and then centrifuged (8000rpm, 1 minute). The resultant DNA 
concentration was measured using the Nanodrop ND-1000 Spectrophotometer, prior to PCR.  
 RNA extraction modified for small cell numbers  2.8.2
Cells for RNA extraction were pelleted (3000rpm, 10 minutes, 4oC), and the excess supernatant 
removed using the Gilson Safe Aspirator Station. Cells were kept on ice during RNA extraction, 
which was performed under a hood to reduce contamination of samples. RNA extraction was 
performed using the RNeasy MicroKit, designed for extraction of up to 45µg RNA (Qiagen, Cat: 
74004).  
To each sample, 75µl of buffer RLT (Cat: 1015750) (premixed in a ratio of 100:1 with 6-
Mercaptoethanol (Sigma, Cat: M6250)), was added and the mixture vortexed. The liquid was 
then added to a QIAshredder spin column (Qiagen Cat: 79654), and centrifuged (13,000rpm, 2 
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minutes). An additional 75µl of RLT/6-Mercaptoethanol was added to the spin column and 
centrifugation repeated.  
150µl of 70% Ethanol was then added to the filtrate, before transfer to an RNeasy MinElute 
spin column (Cat: 1026497), and repeat centrifugation (8000rpm, 15 seconds). The flow-
through was then discarded. 350µl of buffer RW1 (Cat: 1014567) was then added to the 
column, centrifuged (13,000rpm, 15 seconds) and the flow-through discarded. This step was 
repeated to reduce 280nm contamination. A mixture of 10µl DNase I stock Solution and 70µl 
Buffer RDD (Cat: 1023460) was added to the top of the column, and left to incubate (room 
temp, 15 minutes). 350µl of buffer RW1 was then added to the column, before centrifugation 
(13000rpm, 15 seconds). The spin column was then placed in a fresh 2ml collection tube, and 
500µl of buffer RPE (Cat: 1017974) added to the column, before centrifugation (13,000rpm, 15 
seconds). The flow-through was discarded, before the addition of 80% ethanol to the spin 
column, which was then centrifuged (13,000rpm, 2 minutes). The spin column was then placed 
in a clean, dry collection tube, and centrifuged (13,000 rpm, 5 minutes) with the lid open. The 
spin column was then placed in a 1.5ml collection tube, 14µl of RNase free water (Cat: 
1017979) warmed to 45oC was added to the spin membrane, and incubated at room 
temperature for two to three minutes. Elution of the RNA was then performed by 
centrifugation (13,000rpm, 1 minute). The resultant RNA was then stored at -80oC before 
subsequent use.     
 DNA sequencing (for the NPM1 gene) 2.8.3
2.8.3.1 PCR for NPM1 Exon 12 
Cells for sequencing were pelleted and DNA extracted as described in Section 2.8.1. The 
resultant DNA concentration was measured using the Nanodrop ND-1000 Spectrophotometer, 
prior to PCR.  
Standard PCR for the NPM1 gene Exon 12 was performed as follows. DNA was diluted to a 
concentration of 100ng/µl with AE solution. Forward and reverse primers with the following 
sequences were ordered from Sigma- NPM1 Forward (F) Primer:  5’ 
cttaaccacatttctttttttttttttccag 3’; NPM1 Reverse (R) Primer: 5’ ggacaacatttatcaaacacggtag 3’.  
Master mix was made up in the following proportions for each sample: 20µl Reddy mix PCR 
MasterMix (ThermoScientific, Cat: AB-0575/LD/A); 1µl F Primer (10µM); 1µl R primer (10µM); 
2µl Water. 1µl of DNA (100ng/µl) was added to 24µl of master mix, and the sample mixed by 
pipetting.         
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A negative control was also made up containing Forward and Reverse primers, ReddyMix and 
3µl water. The DNA and master mix solution was placed into small PCR tube, and run on the 
following PCR cycle (using MJ Research PTC 225 Peltier Thermal Cycler): 95oC for 5 minutes; 
94oC for 30 seconds, 62oC for 30 seconds, 72oC for 1 minute for a total of 40 cycles; 72oC for 
10 minutes; hold at 12oC.   
2.8.3.2 Confirming the Production of a PCR Product 
The PCR product was run on an agarose gel to check for the presence of a band prior to 
sequencing. A 2% agarose gel was first made up as follows. 1g agarose (UltrapureTM Agarose, 
Invitrogen, Cat: 15510-027) was dissolved in 50ml TBE buffer by heating in a microwave for 6 
minutes until completely dissolved. 5µl of Gel Red Nucleic Acid Stain (Biotium, Cat: 41003-1) 
was added to the gel, which was then poured into the plate mould. Bubbles were removed, 
and a comb inserted into the liquid gel, which is then allowed to set at room temperature.      
When dry, the plate was placed in a horizontal electrophoresis gel tray, and TBE was added 
until the gel was completely covered with buffer. The comb was removed, and 5µl of samples 
were added to the wells. 5µl of a DNA ladder (ExatGene 100bp PCR DNA ladder (Fisher 
Scientific, Cat: BP2571100)) was added to either end of the gel. The gel plate voltage was set to 
95V, and the plate left for 30 minutes at room temperature. The presence of a band around 
the 198bp weight suggested a positive PCR reaction, and allowed us to proceed to DNA 
purification and sequencing.  
2.8.3.3 DNA Purification 
DNA purification was performed using the Montage PCR Centrifuge Filter Device (Merck 
Millipore, Cat: P36461). 350µl of Millidrop purified water was added to the device column, 
followed by the PCR product to be purified. The column was centrifuged (1000g, 15 minutes) 
at room temperature. 20µl of water was then added to the column membrane; the column 
was inverted and placed into a clean eppendorf tube, which was then centrifuged (1000g, 2 
minutes). The resultant DNA concentration in the eppendorf was measured using the 
Nanodrop ND-1000 Spectrophotometer, and the DNA stored at -20oC. 
2.8.3.4 Preparation for sequencing (addition of sequencing primer)  
Sequencing of the purified product was then performed as follows, having diluted the DNA 
product to a concentration of 10ng/µl.   
A master mix was produced by mixing the following in the given proportions (sufficient for 12 
samples): 6μl BigDye Terminator v3.1 (Applied Biosystems, Cat: 4337454); 45μl Big Dye 
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terminator Buffer (x5) (Applied Biosystems, Cat: 4337454); 2μl NPM1 Reverse primer 
(sequence as in Section 2.8.3.1); 175μl Water.  
For each sample, 1µl of DNA was mixed with 19µl master mix, before running the following 
PCR cycle:  96oC for 1 minute; 96oC for 30 seconds, 50oC for 15 seconds, 60oC for 4 minutes for 
a total of 25 cycles; hold at 12oC.   
2.8.3.5 Sequencing  
The amplified PCR product was then taken to Sequencing Laboratory at the London Research 
Institute for sequencing by capillary electrophoresis. The protocol for sample processing 
followed there is described in brief below.   
The PCR product was loaded onto a 96 well plate, and cleaned in an automated process, 
performed on a Beckman Coulter Biomek FX machine. PCR products were positively selected 
for by adherence onto charged magnetic beads (Chemagic SEQ Pure Kit).  The beads were then 
washed twice in buffer, and the cleaned DNA eluted off the beads by washing in Millipore 
water.   
The plates were then transferred to a 96-capillary Applied Biosystem 3730XL DNA Analyser, 
where the DNA strands were sequenced by capillary electrophoresis overnight.  
2.8.3.6 Analysis 
Software analysis was performed using the BioEdit Sequence Alignment Editor. Commonly 
found mutations in the NPM1 gene are detailed in Section 1.4.5.4.1.  
 Quantitative Real Time Polymerase Chain Reaction (qPCR) 2.8.4
2.8.4.1 Background  
The real-time polymerase chain reaction is a laboratory technique based on the polymerase 
chain reaction (PCR), which is used to amplify and simultaneously detect or quantify a targeted 
DNA molecule. For assessment of gene expression as measured by mRNA transcript numbers, 
an RNA sample is first reverse-transcribed to complementary DNA (cDNA) with reverse 
transcriptase, before qPCR is undertaken.  
There exist two common methods for the detection of products in quantitative PCR: non-
specific fluorescent dyes that intercalate with any double-stranded DNA; and sequence-
specific DNA probes, consisting of oligonucleotides that are labelled with a fluorescent 
reporter, which permits detection only after hybridization of the probe with its 
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complementary sequence to quantify messenger RNA (mRNA) and non-coding RNA in cells or 
tissues. Both have been utilised in different experiments in this thesis. 
DNA-binding dyes (such as SYBR Green) bind to all double-stranded (ds) DNA in a PCR reaction, 
causing fluorescence of the dye. An increase in DNA product during PCR therefore leads to an 
increase in fluorescence intensity, which is measured at each PCR cycle. By nature of their 
design, these probes will also bind to non-specific PCR products (such as primer-dimers), which 
can potentially interfere with accurate quantification of the intended target sequence.  
The fluorescent reporter probe method uses a DNA-based probe with a fluorescent reporter at 
one end and a quencher of fluorescence at the opposite end of the probe. The close proximity 
of the reporter to the quencher prevents detection of its fluorescence; breakdown of the 
probe by the 5' to 3' exonuclease activity of the Taq polymerase breaks the reporter-quencher 
proximity and thus allows unquenched emission of fluorescence, which can be detected after 
excitation with a laser. An increase in the product targeted by the reporter probe at each PCR 
cycle therefore causes a proportional increase in fluorescence due to the breakdown of the 
probe and release of the reporter.  
Fluorescent reporter probes detect only the DNA containing the probe sequence; therefore 
significantly increasing detection specificity, and enabling target quantification even in the 
presence of non-specific DNA amplification. Fluorescent probes can be used in multiplex 
assays, based on specific probes with different-coloured labels, provided that all targeted 
genes are amplified with similar efficiency. The specificity of fluorescent reporter probes also 
prevents interference of measurements caused by primer-dimers. However, fluorescent 
reporter probes do not prevent the inhibitory effect of the primer-dimers, which may depress 
accumulation of the desired products in the reaction. 
2.8.4.2 SYBR Green analysis  
qPCR reactions using SYBR green regents were set up as follows. A master mix was made to a 
total volume of 9μl per well as follows: 6μl Sso Advanced Universal SYBR Green Supermix 
(BioRad, Cat: 7725274); 0.125μl F primer (10μM); 0.125μl R primer (10μM); 2.75μl H2O. 9μl of 
master mix was added to each well, followed by 1μl of cDNA, to a total well volume of 10μl. 
Reactions were set up in triplicate, along with appropriate negative controls. 384 well, clear 
white wells (BioRad HSP 3805) were used and sealed with compatible seals (Microseal B Seals, 
BioRad MSB1001). After sealing, the plate was centrifuged (1500rpm, 1 minute). 
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The following analysis cycle was run on the BioRad C1000 Touch Thermal Cycler: 95oC for 2 
minutes; 95oC for 5 seconds, 60oC for 30 seconds for a total of 40 cycles; melt curve 65oC to 
95oC, with 0.5oC increments every 5 seconds.  
2.8.4.3 Taqman assays  
qPCR reactions using commercially available Taqman probe and primer sets were set up as 
follows.  
A master mix was made up in the following proportions for each sample: 1µl 20xProbe/Primer 
set; 10µl Taqman 2xPCR Master mix (Thermofisher, Cat: 4304437) and 7µl H2O. 18µl master 
mix and 2µl cDNA were added to a 96 well PCR plate (MicroAmp Fast Optical 96 Well Plate, 
Applied Biosystems, Cat: 4346906), to a total well volume of 20µl. Each sample was set up in 
triplicate, along with appropriate negative controls. Plates were sealed and centrifuged at 
1500rpm for one minute.   
Samples were run on a AB StepOne Plus analyser on the following cycle: 50oC for 2 minutes; 
95oC for 10 minutes; 95oC for 15 seconds, 60oC for 1 minute, for a total of 40 cycles.  
2.8.4.4 Analysis  
Data from the qRT-PCR reaction were converted into relative quantities (RQ). This allowed 
comparison of mRNA quantities between samples without the requirement to set up a 
standard curve.  
The cycle threshold (CT) for each target gene and an endogenous control gene (in most cases, 
GAPDH) was recorded for each sample under investigation. This is the cycle at which the 
exponential phase of the PCR reaction crosses a user defined threshold, which was 
standardised across all plates run. Triplicate CT values for each gene were averaged. Any 
replicate reactions with a CT standard deviation of >0.5 were discarded from further analysis.  
The difference between the average CT of a target gene and the endogenous control gene was 
calculated by the formula:  
                                    
This step normalises the gene expression values. Expression was then compared to that of a 
user-defined calibrator sample, by the following calculation:  
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In most of the work found within this thesis, the calibrator sample was derived from the 
average of all of the control samples’ ΔCT values.  
The logarithm base 2 scaled data are then converted into a linear scale by the formula:  
                                    
The significance of differences in gene expression between two groups of samples were then 
be assessed by a t-test (for parametric data), or Mann-Whitney test (for non-parametric data).   
2.8.4.5 Purity Assessment of Sorted HSCs from AML samples with sequenced NPM1 
Mutations 
This method uses qPCR to assess the proportion of DNA, and therefore cells, within a given 
sample which carry a known mutation of the NPM1 gene. This allows us to assess the 
percentage purity of a sorted, “normal” population within an appropriately selected AML 
sample. The relative sensitivity of this method means it is ideally suited to assessing the purity 
of small sorted population of cells, as results can reliably be obtained for cell numbers as low 
as 750.     
 Preparation of a Standard curve 2.8.4.5.1
Standards were produced using stock DNA samples known to have the same point mutation as 
the sample for which purity was being assessed. A stock solution with a concentration of 
60ng/µl was made up. Using the assumption that one cell contains 6x10-3ng DNA, this allowed 
the production of the standards as detailed in Table 2-2.  
Table 2-2 showing the production of standards for NPM1 assessment assay  
 Sample preparation 2.8.4.5.2
The cells whose purity was assessed were pelleted (3800rpm, 5 minutes), washed with 4ml 2% 















2 6 20µl STANDARD 1 180 5000 
3 1.2 30µl STANDARD 2 120 1000 
4 0.12 20µl STANDARD 3 180 100 
5 0.012 20µl STANDARD 4 180 10 
6 0.006 50µl STANDARD 5 50 5 
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51104), as described in Section 2.8.1. Samples were diluted to a DNA concentration that fell 
below that of the highest standard concentration (i.e. less than 60ng/µl).  
 PCR Reaction 2.8.4.5.3
The following probes and primers were ordered from Applied Biosystems, via the Assay-by-
Design Service.  
Forward primer (common for all NPM1 mutations) 5’ gtgttgtggttccttaaccacat 3’; Reverse 
primer (mutation specific) for the NPM1 mutation A TCTG 5’ tcctccactgccagacagag 3’; Probe 
(Taqman MGB probe, FAM dye-labelled) 5’ ttttccaggctattcaagat 3’.  
Master mix was made up in the following proportions for each sample: 10μl 2xTaqMan 
Universal Master Mix (Applied Biosystems, Cat: 4304437); 1μl Forward Primer (10µM); 1μl 
Reverse Primer (10µM); 2.5μl Probe (2µM); 0.5μl H2O. Master mix for the control Albumin was 
made up in the following proportions for each sample: 10μl 2xTaqMan Universal MasterMix; 
1μl Albumin Probe and Primer Mix (x20) (Applied Biosystems, Cat: 4351372); 4μl H2O.   
All samples were run in triplicate. Both master mix and DNA samples were vortexed before 
addition to the PCR plate (MicroAmp Fast Optical 96 Well Plate, Applied Biosystems, Cat: 
4346906).  
15µl of appropriate master mix was added to each well, followed by 5µl of DNA solution. The 
plate was centrifuged to 1500rpm briefly to remove air bubbles, and analysed on an Applied 
Biosciences 7900HT Fast Real Time PCR System, using the following program: 50oC for 2 
minutes; 95oC for 10 minutes; 95oC for 15 seconds, 60oC for 1 minute, for a total of 40 cycles.  
 Analysis 2.8.4.5.4
Results were calculated as the percentage of DNA and therefore by extrapolation, percentage 
of cells, within the sample which were NPM1 mutant positive. This was calculated by using the 
average CT of triplicate readings, and then using this result to read from the standard curve 
the number of cells this CT represents. The same process was undertaken for both NPM1 
mutated DNA, and Albumin.   
The results are then expressed as   
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Chapter 3 Study of patients with AML who present without 
trilineage haematopoietic failure 
3.1 Introduction 
 Mechanisms of presentation with AML  3.1.1
The vast majority of patients with AML present with the signs or symptoms of bone marrow 
failure. These include shortness of breath and fatigue resultant from anaemia; bleeding or 
bruising resultant from a low platelet count, and sepsis resultant from reduced or 
dysfunctional neutrophils.  
Whilst other haematological malignancies can present in a fashion attributable to bone 
marrow failure (this is by no means a mechanism specific to AML), they also commonly present 
via very different mechanisms. Some leukaemias, including ALL, are detected during incidental 
blood tests. ALL can often cause systemic malaise or neurological manifestations, rather than 
simply overt cytopenias.  
 Summary of previous work suggesting bone marrow failure in AML is due to 3.1.2
induced HSC quiescence 
In Section 1.5.2 of this thesis, I summarise previous work from our group investigating the 
mechanism by which AML appears to impede normal haematopoiesis. Our group has chosen 
to focus on the interaction between AML blasts and normal HSCs. Studies of human samples 
and xenograft models have suggested that, whilst absolute numbers of normal HSCs appear 
preserved in AML diagnosis samples in comparison to controls, their behaviour is modulated to 
a state of induced quiescence.  In contrast, the number of downstream progenitor cells is 
significantly lower than in controls. These observations led to the theory that haematopoietic 
failure in AML is due to the induction of quiescence in normal HSC populations, leading to a 
block in further differentiation1. This is summarised pictorially in Figure 3-1.  
AML is an extremely heterogeneous disease, characterised by a diversity of cytogenetic and 
genetic abnormalities between patients, and observed blast phenotypes. The hypothesis put 
forward above is potentially a universal explanation that could encompass the bone marrow 
failure observed across this wide diversity of samples. 
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Figure 3-1 A hypothesis of induced differentiation block in HSCs in AML. HSC- haematopoietic stem cell; HPC- 
haematopoietic progenitor cell; CMP- common myeloid progenitor; MEP- megakaryocyte-erythroid progenitor cell; 
GMP- granulocyte-macrophage progenitor cell; CLP- common lymphoid progenitor  
3.1.2.1 Do AMLs which present with haematopoietic lineage preservation invalidate this 
hypothesis?   
One potential flaw in a hypothesis that seeks to explain AML-associated bone marrow failure 
solely by an observed effect on the HSC population is that the pattern of cytopenia 
development is not universal across all patients. Although most present with suppression of 
normal red cells, platelets and neutrophils (henceforth referred to as trilineage failure), we 
have also diagnosed patients with preservation of one or more of these lineages. If AML causes 
only HSC quiescence in all samples, theoretically, one might expect to observe the same 
pattern and time course of haematopoietic failure across all subjects. A parallel situation is 
provided by patients who receive myeloablative chemotherapy or radiotherapy during bone 
marrow transplantation conditioning, who universally drop their normal counts in a highly 
predictable fashion.     
In looking for parallels in other diseases associated with HSC failure, it is clear that trilineage 
haematopoietic failure at diagnosis is not always observed, although the reasons for this are 
murky. Myelodysplasia (MDS) and acquired aplastic anaemia (AAA) are bone marrow failure 
syndromes thought to be due to HSC failure. However, the diagnosis of aplastic anaemia only 
requires the suppression of two of the three haematopoietic lineages154. Similarly, trilineage 
cytopenias are often not seen in MDS (an excellent example being that of MDS associated with 
5q- deletion, associated with refractory anaemia, a preserved platelet count and the presence 
of dysplastic megakaryocytes in the bone marrow)155,156.      
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Below, I have summarised a number of potential explanations for the differential lineage 
failure sometimes observed in AML. This is a novel area, with little published literature to 
guide conjecture. 
 Interaction with different diseases 3.1.2.1.1
Not all patients who develop AML might do so on the background of an entirely normal 
haematopoietic system, a fact which might affect their time to presentation, as well as their 
full blood count at the time they seek medical assistance.  Examples include patients with pre-
existent anaemia, due to iron deficiency or haemoglobinopathies, who might present with 
markedly low haemoglobin with relative preservation of platelets if HSC quiescence was 
induced by AML.  
In a similar fashion, the association between myeloproliferative disorders and subsequent 
development of AML is well known157,158. Patients with JAK-2 positive thrombocytosis who 
develop AML might maintain a normal or even elevated platelet count, whilst their red cell and 
neutrophils plummet. Those with Polycythaemia Rubra Vera may demonstrate a similar 
pattern with respect to red cell levels.      
 Do some AMLs retain the ability to differentiate into apparently normal functional 3.1.2.1.2
cells?  
A very different possibility is that some AML LSCs might retain the ability to differentiate into 
cells of similar morphological appearances to at least some of the terminally differentiated 
cells required for normal bone marrow function.   
Certain leukaemia subtypes are associated with the preservation or proliferation of certain 
mature cell subtypes. Obvious examples include AML M4Eo, highly associated with inv(16) and 
eosinophilia159; or AMLs with inv(3), t(3;3) and balanced t(3q21) rearrangements, which have 
been shown to present with higher platelet counts than other AMLs160.  
Information on lineage involvement of mature cells in AML is scarce, and published work 
normally involves small series of patients161,162.  
FISH staining on fresh bone marrow samples of patients with t(8;21)163 and inv(16)164, 
concurrent with morphological identification of cells, has occasionally shown the development 
of cells from a leukaemic clone into eosinophils of mature appearances. Using the same 
methodology, AMLs with inv(3) have been shown to differentiate into a variety of different 
mature cell forms165. Falini’s team used laser-dissection techniques on bone marrow samples 
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of AML patients with known NPM1 mutations to dissect out visible megakaryocytes and 
perform single cell mutational analysis. This revealed the presence of the mutated gene in 
megakaryocytes of three patients166.   
 Is bone marrow failure in AML not solely due to induced quiescence on the HSC 3.1.2.1.3
population?  
Our group has focussed on the interaction between AML and the activity of the normal HSC 
within the bone marrow. However, it is perfectly possible that this is not the only step in the 
pathway of normal haematopoiesis that is affected by the presence of malignant blasts in the 
marrow. This concept is illustrated pictorially in Figure 3-2 .  
 
Figure 3-2 Pathway showing a proposed theory of haematopoietic suppression at multiple steps of the 
haematopoietic pathway by AML blasts 
This hypothesis suggests that AML might inhibit either differentiation or division at multiple 
steps in normal development, by competition for niche space, resources, or appropriate 
cytokine signalling. These effects might not be consistent across all AML subtypes: dependant 
on the AML phenotype, different lineages might be differentially altered. For example, might 
an AML M7 have more impact on normal platelet production than other leukaemias? Might 
the interference on normal erythropoiesis be more marked from an AML of M6 subtype?   
Again, this hypothesis is not mutually exclusive with the observations made by our group with 
regard to the effect of AML on normal HSCs, but might explain the non-uniform patterns in 
count suppression we observe clinically.     
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 Normal erythroid development  3.1.3
3.1.3.1 Morphologically described maturation 
Morphological examination of the bone marrow has identified a number of discrete, 
sequential steps in erythroid development. The first stage to be clearly identifiable is the 
pronormoblast; followed by the appearance of early, intermediate and late normoblasts (or 
erythroblasts); reticulocytes; and finally mature red cells, which are extruded into the blood 
stream. During this process of maturation, the cells shrink in size, and assume a biconcave disc 
shape, which facilitates efficient oxygen transfer. The nucleus is also extruded: an evolutionary 
adaptation thought to contribute to gas transfer ability and to improve cell mobility6. 
The use of flow cytometry has identified a series of surface antigens expressed on maturing 
cells belonging to the erythroid lineage. Commonly utilised markers in clinical practice include 
CD71 (transferrin receptor), which is reported to be expressed throughout development, but is 
downregulated as cells mature to erythrocytes167, and CD235a (glycophorin A) whose 
expression increases during maturation168,169. 
3.1.3.2 In vitro assessment of red cell maturation 
In the in vitro setting, the earliest committed erythroid progenitors are the Burst-Forming Unit-
Erythroid (BFU-E) cells, which divide relatively slowly, and mature into the more rapidly 
proliferative Colony Forming Unit-Erythroid (CFU-E) cells. Over a period of two to three days, 
these cells divide and differentiate to assume the form of mature erythrocytes.      
3.1.3.3 Homeostatic control of erythropoiesis 
The process of normal erythropoiesis is under tight homeostatic control and is exquisitely 
sensitive to the effect of the hormone erythropoietin, produced in the kidney. Erythropoietin 
appears to particularly affect CFU-E cells, promoting their proliferation and terminal 
differentiation. However, in an acute setting, the response to erythropoietin is limited by the 
fact that each CFU-E can only undergo a further four to five divisions170. Therefore, under 
conditions of extreme stress, upstream activation also has to be initiated by inducing division 
of the BFU-E, which is an erythropoietin-independent process171. Work on rodent models 
suggests that in this context of “stress-haematopoiesis”, BFU-E mobilise to the spleen, where 
their proliferation is enhanced172. Hormonal signals which appears to have a role in promoting 
this process include glucocorticoids such as cortisol173, SCF (Kit ligand) 174 and BMP4175. The key 
steps in erythropoiesis, including cytokines and transcription factors with defined roles, are 
summarised in Figure 3-3. 
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Figure 3-3 Summary of erythroid development from Hattangadi, Blood 2011
170 
 Normal platelet development pathway  3.1.4
Like erythropoiesis, normal platelet production occurs in the bone marrow under tight 
homeostatic control. CMP or MEP cells can differentiate to form megakaryocytes: rare, large 
(50 to 100μm diameter) cells of distinct morphological appearances, responsible for the 
production of platelets. The bone marrow osteoblastic niche is thought to attract immature 
precursor cells and promote megakaryocyte formation. This area is rich in collagen, which has 
been shown, through α2β1 integrin binding, to promote differentiation towards the 
megakaryocytic fate whilst preventing the formation of proplatelet projections required for 
platelet release176,177. In this location, cells become polyploid via the process of endomitosis178. 
This is thought to be promoted by the action of thrombopoietin (TPO), and may represent an 
adaptation to the need to produce significant amounts of mRNA and protein for platelet 
production, without the need to undergo mitosis179. 
These partially mature megakaryocyte precursors are subsequently drawn to a separate 
perivascular niche location via expression of SDF1 and upregulation of the receptor CXCR4. 
This area seems to provide an environment conducive to late stage megakaryocytic 
development41. In this site, megakaryocytes extend long branching processes called 
proplatelets into the sinusoidal blood vessels of the bone marrow. The formation of these 
extensions requires the coordinated assembly of β1-tubulin180, myosin181 and F-actin182, which 
not only act as structural supports, but also shuttle organelles and proteins to the developing 
platelets at the end of the projections.  
Mature platelets bud off from the end of these branched processes. These are enucleate, small 
cells (1 to 3µm diameter). It is estimated that the process of megakaryocyte development from 
polyploidisation to the release of mature platelets takes two or three days in rats183, and 
double that time in humans.  
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3.1.4.1 Phenotypic identification of cells of megakaryocytic lineage  
Surface markers commonly used to identify cells of the megakaryocytic pathway include CD41 
(αIIβ integrin, also known as platelet GPIIb) and CD61 (β3 integrin, also known as platelet 
GPIIIa)184,185. Both of these markers remain highly expressed on mature platelets as well as 
immature bone marrow forms. It is also worth highlighting that these markers are not 
absolutely restricted to this lineage186.   
 Homeostatic control of platelet production     3.1.4.1.1
The influence of TPO is key to the formation of megakaryocytes. Its activity has been linked to 
a number of roles in megakaryocyte development and maturation, and as a result, it 
represents a key component of in vitro culture systems for megakaryocyte studies187. TPO 
receptor agonists such as romiplostin and eltrombopag have demonstrated clinical efficacy in 
restoring platelet counts in the setting of refractory ITP188,189. However, there is clearly 
redundancy within this control system, as murine knock-outs of the TPO receptor, c-mpl, have 
demonstrated the ability to maintain normal platelet counts190.    
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3.2 Aims and Objectives 
The first aim of this chapter was to determine the extent of clinical bone marrow failure in 
patients with AML. We hoped to determine if all patients present with the same pattern of 
bone marrow failure, and if there are differences, identify any obvious associations.  
This aim was met by the construction and subsequent interrogation of a database comprising 
clinical information on all de novo AML patients presenting to St Bartholomew’s Hospital in the 
15 years. As the cancer referral centre for the largest NHS trust in the country, and the current 
highest recruiter of patients into the national MRC AML trials, this represents an extremely 
valuable local resource.  
The second aim of this chapter was to determine how some patients present with AML with 
preserved levels of either red cells or platelets. For this cohort of patients, I wished to 
determine if these cells were derived from the leukaemia itself, or normal unmutated 
haematopoietic cells. Levels of neutrophils at presentation were not included, due to 
documented difficulties in distinguishing neutrophils from leukaemic cells on an automated 
blood count.  
This aim was met by the development of a flow-based method for separation of nucleated red 
cell and platelet precursors from bone marrow samples. Subsequent examination of FACS 
sorted precursor cells was performed either using PCR or FISH based techniques to look for the 
presence of the leukaemia associated mutation.   
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3.3 Specific Methods 
 Database analysis  3.3.1
I am very grateful for the work of Janet Matthews, Haematology Data Manager, in compiling a 
database of all patients newly diagnosed with AML at Bart’s Hospital between January 1997 
and September 2012. The data for this table was retrieved from the Bart’s Clinical Cancer 
Database.  
The following were recorded for all patients where data were available: age at diagnosis; sex; 
karyotype and FAB classification of AML; presenting haemoglobin (g/dL), WCC (x109/L) and 
platelet count (x109/L). Clinical survival data and relapse/remission status were recorded 
where available. Final censoring of patients was performed in June 2016.  
Presenting FBC parameters were measured from peripheral blood using a Sysmex analyser, as 
is standard clinical practise in Bart’s. Haemoglobin (g/dL) and platelet count (x109/L) were 
logged for each patient. Other parameters generated as standard by a Sysmex included a total 
white cell count, as well as a full leucocyte differential. However, in the presence of blasts, 
these parameters often do not accurately represent the blood film appearances, and therefore 
a decision was made not to include measurement of neutrophil levels within this dataset. 
Some of these patients had records of manually differentiated blood films, but again, my own 
clinical experience suggests distinguishing malignant and non-malignant cells in this setting is a 
non-exact science.   
FAB classification was made after morphological examination of the bone marrow by the 
Haematopathology team. Karyotypic information was provided by cytogenetic and FISH based 
analysis of samples run as part of routine clinical practise at the Royal London Hospital.  
All data were anonymised in keeping with University-wide data protection regulations.   
3.3.1.1 Statistical analysis  
The majority of statistical analysis was performed using the Prism software package.  
All data sets were tested for normality of distribution by the D’Agostino & Pearson Omnibus 
Normality Test. For parametric datasets, means and standard deviations are quoted. In the 
determination of statistical significance between two data sets, a Student’s t-test was applied. 
If data were not normally distributed, medians and interquartile ranges are quoted. In the 
determination of statistical significance between two non-parametric data sets, a Mann-
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Whitney t-test was applied. If the differences in the averages of more than two groups were 
being compared, either an ANOVA test (for parametric datasets with equal variance) or a 
Kruskal-Wallis test (for non-parametric data) was applied.   
 Patients and samples  3.3.2
Diagnostic bone marrow samples from selected AML patients were obtained from the tissue 
bank maintained by the Department of Haemato-Oncology at St Bartholomew’s Hospital. 
Written informed consent was obtained in accordance with the Declaration of Helsinki. These 
were used for both FACS sorting and subsequent genetic analysis of erythroid precursors, as 
well as flow based-identification and enumeration of erythroid precursor and stem cell 
populations.   
Flow and immunohistochemical techniques were optimised on control bone marrows. Control 
marrows were defined as those obtained during the work-up of newly diagnosed Stage I-III 
lymphoma patients with not only a full blood count within normal parameters, but also an 
unaffected bone marrow as confirmed by aspirate, flow cytometry and trephine 
histopathology.    
Bone marrow trephine slides previously stained in H&E were examined for megakaryocyte 
numbers for both AML patients and controls were selected from an Institute bank comprising 
of bone marrow trephine samples collected between 2005 and 2011.  
 Flow Cytometry 3.3.3
3.3.3.1 Staining for Erythroblasts 
As detailed in Section 3.1.3, mature red cells extrude their nuclei before entering the 
circulation. Therefore, when attempting to determine the clonality of red cells in AML samples 
which had presented with a relatively preserved haemoglobin level, I attempted to distinguish 
erythroblast precursors at as late a stage of maturity as possible, before the loss of their nuclei. 
A flow-based strategy was adopted which identified erythroblasts (CD235a+71+ cells), but 
aimed to exclude mature erythrocytes (which have lower CD71 expression levels). Co-
expression of these markers by leukaemia blasts themselves is rare (with the exception of 
AMLs of the M6 subtype)191. 
Bone marrow vials were thawed, counted and incubated with 2% HAG as described in Section 
2.4.5.1. Cells were incubated with 2.5µl/1.5x106 cells CD235a PE (Biolegend, Cat: 349105 
(Clone HI264)), 5µl/1.5x106 cells CD71-APC (Biolegend, Cat: 334107 (Clone CY1G4)) and CD3-
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FITC (BD, Cat: 555332 (Clone UCHT1)). After incubation, cells were washed and resuspended in 
DAPI/2% PBS as previously described, and sorted using a BD FACSAria IITM.  
The CD235a+CD71+CD3-DAPI- population of cells was selected using the gating strategy 
illustrated in Figure 3-4, and sorted into 2% PBS. Sort purity was checked, and if this fell below 
90%, resorting was undertaken.  
Subsequent analysis was performed using the FlowJo Version 10 software.  
Sorted cells were made into slides as described in Section 2.7.1, for MGG staining, 
immunocytochemical staining for haemoglobin and FISH analysis.     
 
Figure 3-4 showing the flow gating strategy used to identify erythroid precursors from bone marrow samples 
3.3.3.2 Analysis of previously analysed samples for erythroid precursor populations and stem 
cell concentrations 
Chapter 5 details work on fresh BM samples designed to calculate the concentrations of 
normal HSCs at diagnosis with AML. In brief, AML and control bone marrow samples were 
analysed fresh using CountBeads, stained with CD34 and CD38, and the concentration of CD34+ 
cells in each fresh sample (cells/µl) was calculated. At a later date, a frozen sample of the same 
bone marrow was thawed, and using staining with CD34, CD38, ALDH and CLL1, the 
concentration of CD34+38-ALDHhighCLL1- cells at diagnosis was calculated. Full methodological 
details are given in Sections 5.3.1 and 5.3.2.  
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For 20 of these AML samples and 7 control samples, at the time of thawing and staining with 
CD34, CD38, ALDH and CLL1 for HSC numbers, a separate aliquot was used to identify and 
quantify erythroid precursors.  
Thawing, enumeration and staining of BM samples for the HSC population was performed as 
described in Section 5.3.2. 3x106 cells were pelleted and resuspended in 2% HAG at a 
concentration of 50µl 2% HAG/1.5x106 cells. Cells were incubated at 4oC for 20 minutes. 
Antibodies to CD34-PerCP, CD235a-PE and CD71-APC were then added at a concentration of 
5µl/1.5 x106 cells, and left to incubate for 30 minutes at 4oC. The cells were then washed with 
4ml 2% PBS, and pelleted.  
Cells were re-suspended in 300µl of a stock solution of 2% PBS/DAPI/DNase and filtered before 
analysis on a BD Fortessa.  
 Analysis of the frozen sample 3.3.3.2.1
Erythroid precursor numbers in the frozen sample were determined by sequential gating for 
live, CD235a+CD71+ cells. CD34+ cell numbers in the same sample were also recorded.  
The ratio of CD235a+CD71+ cells to CD34+ cells within the same, thawed sample was calculated. 
The original concentration of CD235a+CD71+ erythroid precursor cells (cells/µl) at diagnosis 
was calculated as shown below. 
[            ]  
[          ]                   {
                  
           
}                    
The concentrations of CD34+38-ALDHhighCLL1- stem cells in the same sample were calculated as 
shown in Section 5.3.2.2.  
3.3.3.3 Staining for megakaryocytes  
Bone marrow vials were thawed, counted and incubated with 2% HAG as previously described. 
Cells were then incubated with CD45-APCy7 (BD, Cat: 557833 (Clone 2D1)) and CD41a-APC 
(BD, Cat: 561852 (Clone HIP8)) at concentrations of 5µl/1.5x106 cells for CD45-ApcCy7, and 
10µl/1.5x106 cells for CD41a-APC. After incubation, cells were washed and resuspended in 
DAPI/2% PBS as previously described, and sorted on a BD FACSAria IITM.  
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 Morphological Techniques 3.3.4
3.3.4.1 MGG staining of slides prior to morphological assessment  
Slides were transferred to the Haematology Laboratory at St Bartholomew’s Hospital, and 
underwent automated staining with May-Grunwald-Giemsa stain. Slides were air-dried, and 
mounted in oil, prior to examination under the microscope.  
3.3.4.2 Immunostaining for the presence of haemoglobin  
Slides were fixed, dried, and permeabilised as previously described.  
Slides were then blocked with donkey serum (Sigma, Cat: D9663)(0.1% saponin, 5% donkey 
serum in PBS).  
Primary antibody staining was performed using a mouse monoclonal IgG1 anti-Haemoglobin 
antibody (AbCam, Cat: ab55081) at a concentration of 2µg/ml.  
Secondary antibody staining was performed using Alexafluor 546 Donkey anti-mouse IgG (Life 
Technologies, Cat: A10036) at a 1:100 dilution (in donkey serum).   
 Genetic Analysis of samples for clonality identification  3.3.5
3.3.5.1 FISH based assessment of sorted cells  
FISH staining and analysis was performed by Marianne Grantham at the Cytogenetics 
Department, Royal London Hospital, on slides prepared as described in Section 2.7.1. The 
following probes were used: Vysis RUNX1/RUNX1T1 DF Fish Probe Kit (Abbott Molecular, Cat: 
08L70-020), CBFB t(16;16) inv 16 Break Probe (Kreatech, Cat: KBI-10304) and DEK/NUP 214 
t(6;9) Fusion Probe (Kreatech, Cat: KBI-10306). 
3.3.5.2 Confirmation of clonality of sorted cells by assessment for the presence of the NPM1 
mutation  
For those samples with a previously identified and sequenced NPM1 mutation, sorted 
CD235a+71+ populations were assessed for the proportion of cells containing the NPM1 
mutation by the method described in Section 2.8.4.5.    
 Megakaryocyte Enumeration by Trephine Analysis  3.3.6
Within the Bart’s Tissue Bank, there exists a small collection of bone marrow trephine samples 
taken at diagnosis from patients with AML.  
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Samples were obtained by the use of a trephine needle placed into the posterior iliac crest to 
remove a solid core of cortex and marrow of at least 2cm length. Samples underwent fixation 
with formalin, decalcification, and wax embedding prior to sectioning and staining with 
haematoxylin and eosin (H&E).  
Selected, anonymised slides were then scanned onto the Pannoramic Viewing software for 
analysis. Sample quality was ensured by the analysis of trephines of a length of greater than 
1cm, with an absence of artefact or significant clot.  
Slides were studied at a uniform magnification of x20. Megakaryocytes were identified by their 
morphological appearance by one observer (KH) and tagged. The stromal area examined 
(excluding bony cortex) was mapped out and its size calculated by the Pannoramic system in 
mm2.    
Megakaryocyte concentrations were expressed as the number of megakaryocytes present per 
mm2 of marrow stroma.  
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3.4 Results 
 Database analysis results 3.4.1
Data were collated on new patients presenting with AML to Bart’s Hospital between January 
1997 and August 2012. In this period of 15 years, 529 new cases of AML were identified where 
the full blood count (FBC) at diagnosis was documented.   
3.4.1.1 Patient characteristics  
The basic clinical profile of these 529 patients are summarised below.  
The incidence of AML with age does not follow a normal distribution, a finding which mirrors 
previously reported series. Median age at diagnosis is 56, with a range of 16 to 86 years.  
There is a slight predominance of males in this cohort, with a calculated male:female ratio of 
1.2:1 (288/529 (54%) are male and 241/529 (46%) are female). This is also consistent with 
previously published epidemiological studies of AML incidence192. 
Karyotypic information was available for 489 of the 529 patients (92%) diagnosed between 
1997 and 2012. In the cases where data were not available, this was either because 
cytogenetic analysis on diagnostic samples had not been requested, or because standard 
analysis assays had failed. Of these 489 patients, 100 (20.4%) had cytogenetic profiles 
consistent with good risk disease, 270 (55.2%) were classified intermediate risk and 119 
(24.3%) were of poor risk. The frequency of these cytogenetic abnormalities is broadly in 
keeping with published datasets101,193.   
Morphological classification of samples according to the FAB classification system was 
recorded in 448/529 cases (85%). Cases were split across the different morphological 
categories as follows: 28 (6.2%) patients were of FAB M0 appearance; 82 (18.3%) patients 
were FAB M1; 99 (22.1%) patients were FAB M2; 68 (15.2%) patients were FAB M3; 87 (19.4%) 
patients were FAB M4; 63 (14.1%) patients were FAB M5; 12 (2.7%) patients were FAB M6, and 
9 (2.0%) FAB M7. Again, these figures are in keeping with previously published data series124. 
3.4.1.2 Haemoglobin levels at diagnosis with AML  
 Haemoglobin levels are lower than expected normal range at diagnosis in the vast 3.4.1.2.1
proportion of patients  
Haemoglobin levels at diagnosis, are, unsurprisingly, substantially lower than the expected 
values for normal healthy individuals. Figure 3-5 A illustrates the range of haemoglobin levels 
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seen at diagnosis with AML across the whole cohort. Interestingly, this follows a normal 
distribution pattern, as do haemoglobin levels within a healthy population.  
The mean haemoglobin level at diagnosis across the cohort is 9.2g/dL, with a standard 
deviation of 2.1. The range of observed haemoglobin levels is wide (between 3.4 to 15g/dL).  
 Age  3.4.1.2.2
The effect of age on presenting haemoglobin was explored. This was on the basis that older 
patients might have a lower tolerance to anaemia, due to co-morbidity: a factor which might 
precipitate their earlier presentation to medical attention. 
In fact, analysis of the relationship between age and haemoglobin levels at diagnosis using 
Spearman’s rank order correlation gave a non-significant Spearman’s correlation coefficient of 
0.035 (p=0.42). The relationship between age and presentation haemoglobin is shown 
graphically in Figure 3-5 B.  
 Gender 3.4.1.2.3
Gender is known to influence haemoglobin levels in health (see Table 1-1), with the normal 
range for men (13.0 to 18.0g/dL) being slightly higher than that seen in women (11.5 to 
16.0g/dL). Given these differences, presenting haemoglobin patterns for men and women 
were independently assessed. The median haemoglobin at presentation for men is 9.4g/dL 
(interquartile range 7.9 to 10.6g/dL), and for women 9.3g/dL (interquartile range 7.9 to 
10.4g/dL). There is no statistical difference between these two results (Mann-Whitney t-test, 
p=0.35).   
However, it is worth noting that the level of haemoglobin at diagnosis was not abnormal for all 
patients within this dataset. Allowing for gender-based differences in the lower limit of the 
normal range, 32/529 (6.0%) of all patients had a normal haemoglobin at diagnosis. 10/288 
(3.4%) of male patients had a haemoglobin of greater than 13.0g/dL, whilst a higher 
proportion of women (22/219 (10.0%)) had a haemoglobin greater than 11.5g/dL.  
 Cytogenetic abnormalities do not have an effect on haemoglobin levels at 3.4.1.2.4
presentation 
Samples were grouped into good, intermediate or poor risk cohorts based on their 
cytogenetics. Within these groups, there were very slight differences in mean presenting 
haemoglobin levels only: 9.1g/dL for good risk patients (standard deviation 2.2, n=100); 
9.3g/dL for intermediate risk patients (standard deviation 2.1, n=270); 9.3g/dL for poor risk 
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patients (standard deviation 2.0, n=119). There is no statistical significant difference between 
the means of these three groups (One way ANOVA, p=0.81).  
To ensure I had not missed the haemoglobin-preserving (or depleting) effect of a particular 
translocation by pooling samples together into three cytogenetic risk groups, samples were 
subdivided into 19 categories with known prognostic impact, and the median haemoglobin 
levels for each were determined. These results are shown in Figure 3-5 C.    
There is no significant difference observed between the median haemoglobins at presentation 
of these different cytogenetic risk categories (Kruskal-Wallis, p=0.89).  
 There are insufficient data available for this cohort of patients on the status of genes 3.4.1.2.5
commonly mutated in AML to assess their impact on presentation haemoglobin 
Ideally, one would analyse this dataset for the impact of common gene mutations found in 
AML on presentation haemoglobin. These would include NPM1, FLT3, CEBPA, KIT, N-RAS, MLL, 
WT1, IDH1/2, TET2 and DNTMT3A, but also in this context it would also be interesting to know 
the study the effects of mutation within the JAK2 gene.  
Unfortunately, this dataset comprises of patients diagnosed between 1997 and 2012, the 
majority of which predate even the introduction of routine NPM1 and FLT3 screening at 
diagnosis (see Section 3.5.5 for further discussion of this area). We did not have sufficient 
funds to enable the targeted sequencing of these samples for the listed mutations.   
However, clinical notes were obtainable for 22 of 32 patients who presented with a 
haemoglobin within normal limits for gender. None of these patients had a prior diagnosis of 
PRV or MPD before presentation with AML.   
 Does presentation haemoglobin have a prognostic impact?  3.4.1.2.6
Survival data were obtained for 528 patients within this cohort. Analysing patients as two 
cohorts (low haemoglobin at diagnosis corrected for gender (<11.5g/L for females, <13.5g/dL 
for men, n=497) and normal haemoglobin at diagnosis corrected for gender (≥11.5g/dL for 
females, ≥13.5g/dL for men, n=31)), there was no significant difference in overall survival 
observed by Kaplan-Meier analysis (log rank test, Chi Square 1.4, p=0.23).  This is illustrated in 




Figure 3-5 A: Histogram illustrating presentation Hb levels for 529 patients with AML; B: Histogram illustrating the relationship between presentation Hb level and age at diagnosis. Mean Hb and SD 
are plotted for each age range; C: Bar chart showing effect of 19 different AML cytogenetic abnormalities on Hb level at diagnosis, following the classification by Grimwade et al (2010). Good risk 
subcategories shown are t(8;21) n=23, inv(16) n=14, t(15;17) n=63; intermediate risk subcategories shown are normal cytogenetics n=19, abnormalities not otherwise classified or NOS n=58, t(11;19) 
n=2, t(9;11) n=8, t(3;5) n=1, t(6;9) n=4; poor risk subcategories shown are abn(3q) n=3, inv(3) n=2, abn(5) n=8, abn(7) n=24, t(6;11) n=1, t(10;11) n=4, t(11q23) n=14, t(9;22) n=5, abn(17) n=2, complex 
n=48. If a sample contained two or three cytogenetic abnormalities which meant its grouping was not clear (for example, coexistent deletion 5 and 7), it was excluded from analysis. Those with 4 or 
more abnormalities were placed in the complex cytogenetics cohort. Median Hb and IQR are plotted for all samples; D: Kaplan-Meier curve showing the effect of gender-adjusted Hb at diagnosis with 
AML on overall survival (normal Hb for males >13.0g/dL, and >11.5 for females) 
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3.4.1.3 Platelet levels at diagnosis with AML 
 Platelet levels are lower than the expected normal range in the majority of patients 3.4.1.3.1
with AML, but they do not follow a normal distribution  
Analysis of the 529 patients within the Bart’s cohort showed, as expected, platelet levels in 
patients at diagnosis are substantially lower for the majority of individuals than the normal 
range in health. The median platelet count at diagnosis is 52x109/L (interquartile range of 27-
99). The range of observed counts is wide (3 to 567x109/L).  
However, in contrast to the pattern seen with haemoglobin levels, platelet levels in this cohort 
of AML patients do not follow a normal distribution pattern, as illustrated in Figure 3-6 A. The 
proportion of patients presenting with a normal platelet count is higher than the 
corresponding figure for haemoglobin levels. 75/529 (14.2%) of all patients have a platelet 
count greater than 150x109/L. 
Although 150x109/L is widely considered the lower limit of the normal range for platelets, 
symptomatic bleeding is extremely rare at this level. A platelet count of 100x109/L is taken as 
indicative of full count recovery in clinical trials, and within this cohort, 131/529 (24.6%) have 
levels greater than this.  
 Age  3.4.1.3.2
The effect of age on presenting platelet count was explored. This was based on the hypothesis 
that older patients might have a lower tolerance to thrombocytopenia, and possibly present 
earlier with bleeding manifestations, due to diverse factors such as increased tissue fragility 
and falls risk.  
However, in a reflection of the pattern seen with haemoglobin levels and age, there appears to 
be no correlation between age and platelet count at diagnosis. Spearman’s rank order 
correlation gave a non-significant coefficient of 0.049 (p=0.26). These data are shown 
graphically in Figure 3-6 B.  
 Gender 3.4.1.3.3
Unlike haemoglobin, the normal ranges in health for platelet levels are identical between men 
and women. The platelet levels at diagnosis with AML were also examined for any effect of 
gender. The median platelet count for men was 48.5x109/L (interquartile range 26 to 83; range 
6 to 567x109/L). The median platelet count for women was 56x109/L (interquartile range 29 to 
111; range 3-385x109/L). The difference between these two results just fails to reach 
significance by Mann-Whitney t-test (p=0.07). 
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 Patients with good risk cytogenetics have a lower platelet count at diagnosis than 3.4.1.3.4
other groups 
As in Section 3.4.1.2.4, samples were placed into good, intermediate and poor cytogenetic risk 
groups; and subsequently analysed for the effect of this classification on platelet levels at 
diagnosis. The median platelet level of good risk samples was 37.5x109/L (interquartile range 
16.5-61; range 6-226); of intermediate risk samples was 59x109/L (interquartile range 31-106; 
range 7-567); and of poor risk samples was 51x109/L (interquartile range 29-103; range 4-426). 
Kruskal-Wallis testing suggests the differences in platelet level between these groups are 
highly significant (p=0.0001). Sub-analysis using Dunn’s Multiple Comparison Test suggests that 
the observed differences in platelet level between the good and intermediate risk groups, and 
between good and poor risk groups are highly significant.  
3.4.1.3.4.1 Subgroup analysis suggests this may be due to the effect of t(15;17) 
The effect of individual cytogenetic abnormalities on platelet count was explored, to ensure 
the effect of a particular translocation was not lost in pooling samples into three clinical risk 
groups. Samples were subdivided as described in Section 3.4.1.2.4, and median platelet count 
calculated for each category. Results are illustrated in Figure 3-6 C.  
Kruskal-Wallis testing of these datasets suggest cytogenetic subclassification has a significant 
effect on platelet count at diagnosis (p=0.0002). However, further analysis using Dunn’s 
Multiple Comparison Test reveals that it is only the difference in platelet counts between 
patients with t(15;17) (with a median platelet count of 22x109/L) and those with normal 
cytogenetics (with a median platelet count of 66x109/L) that reaches independent significance.  
However, it is worth noting that the small numbers of samples which contain abnormalities of 
the long arm of chromosome 3 (t(3;5), inv(3) and abn (3q)) (n=6)) do appear to have relatively 
preserved platelet counts at diagnosis, in keeping with published data, even if the sample size 
here is too small to achieve statistical significance194.  
 Preservation of platelet counts at diagnosis with AML does not appear to be due to 3.4.1.3.5
pre-existing myeloproliferative disease. 
As explained in Section 3.4.1.2.5, unfortunately, there were minimal data available for the 
patients within this cohort regarding the status of commonly mutated genes in AML.  
However, given the potential effect of a prior diagnosis of essential thrombocytopenia (ET) on 
platelet counts, I attempted to review the clinical records of the 75 patients with platelet 
counts preserved above 150 at diagnosis. Notes were accessible for 44 of these.  One patient 
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had a previous diagnosis of ET, and one a recent diagnosis of CMML. Therefore only 5% of 




Figure 3-6 A: Histogram illustrating platelet counts for 529 patients at diagnosis with AML; B: Histogram showing the relationship between presentation platelet count and age at diagnosis. Median 
platelet counts and IQR are plotted for each age range; C: Bar chart showing effect of 19 different AML cytogenetic abnormalities on platelet level at diagnosis, following the classification by 
Grimwade et al (2010). Good risk subcategories shown are t(8;21) n=23, inv(16) n=14, t(15;17) n=63; intermediate risk subcategories shown are normal cytogenetics n=19, abnormalities not 
otherwise classified or NOS n=58, t(11;19) n=2, t(9;11) n=8, t(3;5) n=1, t(6;9) n=4; poor risk subcategories shown are abn(3q) n=3, inv(3) n=2, abn(5) n=8, abn(7) n=24, t(6;11) n=1, t(10;11) n=4, 
t(11q23) n=14, t(9;22) n=5, abn(17) n=2, complex n=48. If a sample contained two or three cytogenetic abnormalities which meant its grouping was not clear (for example, coexistent deletion 5 and 
7), it was excluded from analysis. Those with 4 or more abnormalities were placed in the complex cytogenetics cohort. Median platelet count and IQR are plotted for all samples; D: Kaplan-Meier 
survival curve showing the effect of platelet count at diagnosis with AML on overall survival 
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 Platelet count at diagnosis with AML does not have a prognostic impact on overall 3.4.1.3.6
survival  
Survival data were obtainable for 528 patients within this cohort. Analysing patients as two 
cohorts (low platelets at diagnosis (<150x109/L, n=454) and normal platelets at diagnosis 
(≥150x109/L, n=74)), there was no significant difference in overall survival observed by Kaplan-
Meier analysis (log rank test, Chi Square 0.09, p=0.76). These data are illustrated graphically in 
Figure 3-6 D.  
3.4.1.4 Is there a relationship between preservation of haemoglobin and platelet levels at 
diagnosis with AML?    
We have identified patient cohorts with preserved haemoglobins and platelets independently. 
Table 3-1 highlights the interrelation between these parameters, and identifies an extremely 
small cohort of patients (1%) who present with both haemoglobin and platelet counts entirely 
within the normal range.  
Table 3-1 illustrating the relationship between normal platelet levels and haemoglobin at diagnosis 
In the absence of obvious bone marrow failure (at least with regard to red cell and platelet 
lineages), how did these patients actually present? Clinical notes were accessible for four out 
of five of these patients. In three cases, patients presented with persistent and recurrent 
infections, presumably due to dysfunctional neutrophil populations. In the final case, 
presentation was prompted by abdominal pain from a chloroma.    
3.4.1.5 Summary of results from clinical data  
Study of presentation counts from this large series of patients does confirm that patients 
present with AML with evidence of bone marrow failure, given that 99% of patients identified 
within these cohorts presented with either or both an abnormally low haemoglobin or platelet 
count. However, as Table 3-1 shows, the pattern in which these parameters fall is not 
universal. This is illustrated by the fact that 5% of patients presented with normal haemoglobin 












HAEMOGLOBIN NORMAL (FOR 
GENDER) 
5 (1%) 26 (5%) 31 (6%) 
HAEMOGLOBIN LOW 
(FOR GENDER) 
70 (13%) 428 (81%) 498 (94%) 
TOTAL 75 (14%) 454 (86%) 529 
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Whilst haemoglobin levels in these patients fall at diagnosis with AML, but maintain a normal 
distribution within the cohort, platelet levels follow a different pattern, with a small and 
possibly distinct number of patients who appear to be able to maintain platelet production.  
Examination of factors such as age, gender and cytogenetics has not been able to further 
identify potential drivers which might explain these patterns. The one exception to this is the 
confirmation in this dataset that the t(15;17) translocation is associated with significantly 
lower platelet levels at diagnosis. However, this observation may be due to increased 
peripheral consumption of platelets due to the DIC associated with this AML subtype, rather 
than relatively reduced marrow production.  
 Erythroid precursor lineage identification and quantification  3.4.2
3.4.2.1 Confirmation of red cell lineage in patients with preserved haemoglobin levels 
 Dual staining for CD235a and CD71 positivity reveals a population of erythroid 3.4.2.1.1
precursor cells within normal bone marrow samples  
Staining of normal control bone marrow samples with CD235 and CD71 produced a clear 
population of dual positive cells, which represented an average of 3% of all viable cells sorted 
(see Figure 3-4). Published flow based data would suggest this population contains nucleated 
erythroblasts, before extrusion of their nuclei and the final transformation to mature red cells 
(processes associated with CD71 expression downregulation).  
 






 cells. A: cytospin stained with MGG showing 
classic erythroid cells on the background of significant background staining presumably from cell lysis in cytospin 












 cells (negative control) 
The technique was validated by morphological examination of slides of these cells stained with 
MGG. Whilst slides consistently contained high artefact of cells lysed by the cytospin process, 
the nucleated cells in the slides had the morphological appearance of red cell precursors (as 
shown in Figure 3-7 A). 
 Chapter 3: Patients without trilineage haematopoietic failure  
99 
Secondary evidence of the erythroid nature of the sorted cells was obtained by staining the 
cells for the presence of intracellular haemoglobin, which is present even in nucleated red 
blood cell precursors. As with the MGG staining, there was consistently high background 
staining on the slides (presumably due to cell lysis during the cytospin process depositing free 
haemoglobin on the slides). However, intact nucleated cells had high uptake of the 
haemoglobin stain, suggesting an erythroid origin (Figure 3-7 B). 
 CD235a+71+ cells exist within AML samples, and appear cytogenetically normal 3.4.2.1.2
Having optimised and validated a flow based technique to sort CD235a+71+ erythroblasts from 
normal bone marrow samples, we then used the same technique to identify residual 
erythroblast populations within diagnostic AML samples. 
Samples with a haemoglobin level of greater than 10g/dL, a known detectable leukaemia 
associated genetic lesion and a diagnostic bone marrow sample available in the Bart’s Tissue 
Bank were identified and underwent sorting as described in Section 3.3.3.1. Ten samples were 
studied in total. Their clinical characteristics are detailed in Table 3-2. Seven had karyotypic 
abnormalities, and three had a normal karyotype but a mutation in the NPM1 gene. Those 
samples with karyotypic abnormalities underwent sorting, with the resultant sorted cells 
undergoing fixation and FISH staining with relevant probes. The three NPM1 mutated samples 
underwent immediate DNA extraction of sorted populations of cells and quantitative PCR for 
the presence of the NPM1 mutation as detailed in Section 2.8.4.5.  
Table 3-2 Clinical and genetic characteristics of 10 patients with preserved haemoglobin at diagnosis which 
underwent sorting and clonality assessment of their erythroblast populations 
PATIENT DETAILS GENETICS 
PATIENT ID AGE SEX KARYOTYPE NPM1 STATUS 
6318 33 F NORMAL TYPE A 
6580 59 M NORMAL TYPE A 
7033 55 F NORMAL TYPE A 
6317 22 M t(8;21)  
8750 47 M t(8;21) 
 
9220 55 F t(8;21) 
 
6988 55 M INV(16)  
7036 70 F INV(16)  
7248 27 F INV(16)  
7696 32 F INV(16)  
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3.4.2.1.2.1 The CD235a+71+ cells within NPM1 mutated samples are genetically normal and 
not part of the leukaemia clone   
Assessment of the clonality of the sorted CD235a+71+ cells derived from the three AML 
samples with preserved haemoglobin levels at diagnosis and known NPM1 mutation was 
performed. Results are shown in Table 3-3. Percentages of cells within the CD235a+71+ 
population containing NPM1 mutated DNA were extremely low (1 to 15%), comparable with 
the sorted negative lymphocyte controls, and compatible with accepting a sort purity of 
greater than 90%. CD235a-71-3- cells (likely blasts) were separated as a positive control for 
each sample; CD235a-71-3+ lymphocytes were separated concurrently as a negative control.  
We conclude from these figures that the CD235a+71+ population of erythroblasts from these 
NPM1 mutated AMLs does not contain the mutation at significant levels, and therefore that 
the resultant mature erythrocyte population has not been derived from the malignant blast 
clone.   
Table 3-3 Percentage of NPM1 mutated cells within sorted erythroid, lymphoid and blast populations from NPM1 
mutated AML samples 
3.4.2.1.2.2 The CD235a+71+ cells within CBF mutated samples are genetically normal and not 
part of the leukaemia clone  
Seven AML samples with identified karyotypic abnormalities underwent sorting for their 
CD235a+71+ erythroblast populations. Of these, four had inv(16) and three t(8;21). The results 
of FISH analysis of the sorted populations (and also concurrent analysis of the CD235a-71-3- 
population of presumed blasts which acted as a positive control) are shown in Table 3-4.    
In six samples, slide quality was sufficient and enough cells present to make FISH analysis 
possible. In all cases, sorted CD235a+71+ cells were free of the clonal translocation which 
characterised the leukaemic cell population, and therefore it is assumed that their mature red 
cell populations were also derived from cells of normal karyotype rather than the leukaemia 
clone.  
PATIENT ID 



























6580 15 87 5 
7033 10 114 1 
6318 1 79 40 
 Chapter 3: Patients without trilineage haematopoietic failure  
101 




 cells from AML samples with known karyotypic abnormalities 
3.4.2.2 There is no relationship between haematopoietic stem cell concentration and 
haemoglobin levels at presentation 
Chapter 5 details a large body of work identifying HSC concentrations in bone marrow samples 
at diagnosis with AML. To summarise the main findings, there was no statistically significant 
difference found between the concentration of HSCs in AML diagnostic BM samples (with a 
range of presenting blood counts) and controls (all of whom had normal blood counts). 
Nevertheless, the same patient series did identify that very low stem cell concentrations at 
diagnosis (<0.1 HSCs/µl) identified a subgroup of AML patients with a significantly worse 
overall survival.  
Within this cohort of 38 patients, and using the same categorisation of samples into low stem 
cells at diagnosis ([HSC]<0.1/µl)(n=8) and high stem cells at diagnosis ([HSC]>0.1µl)(n=30), 
there is no significant difference found between these groups in observed haemoglobin levels 
at diagnosis (t test, p=0.8). This result is shown in Figure 3-8 A. 
3.4.2.3 Does the concentration of CD235a+71+ erythroblasts at diagnosis with AML have 
clinical significance?   
20 diagnostic AML samples and 7 control samples, which had been analysed whilst fresh and 
their CD34+ concentration quantified, were subsequently analysed concurrently for their 
concentrations of CD34+38-ALDHhighCLL1- stem cells and CD235a+71+ erythroid precursors. 
Patient clinical details, including presenting full blood counts, calculated [CD34+] in fresh 
sample, [CD34+38-ALDHhighCLL1-] and [CD235a+CD71+] are shown in Table 3-5 (AML samples) 
and Table 3-6 (Control samples).  














6988 INV(16) Cytocell CBFB-MYH11 0/100 74/100 
7036 INV(16/0 Cytocell CBFB-MYH11 0/100 50/100 
7248 INV(16) Cytocell CBFB-MYH11 0/100 80/100 
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 erythroblasts at diagnosis with AML   
AML samples were divided, as described in Chapter 5, between those with low concentrations 
of HSCs at diagnosis (<0.1 cells/μl) and relatively high concentrations of HSCs at diagnosis (>0.1 
cell/μl). Those with a low HSC concentration had a significantly lower number of erythroid 
precursors present at diagnosis (median 0.7 cells/μl, n=4), compared to those with relatively 
high HSC levels (median 174 cells/μl, n=20)(p=0.04, Mann Whitney t-test).   
 There is no relationship between the concentrations of CD235a+71+ erythroblasts in 3.4.2.3.2
the bone marrow and haemoglobin levels at diagnosis with AML  
Spearman’s correlation test was used to analyse these datasets for a possible relationship 
between erythroblast concentration at diagnosis with AML and presentation haemoglobin 
level. No significant correlation was found (Spearman's r correlation coefficient 0.14, p=0.56).  
 There is no difference in erythroblast concentrations between AML samples and 3.4.2.3.3
controls  
In the group’s previously published work into the effect of AML on the haematopoietic 
hierarchy in CD34low AMLs, whilst HSC concentrations were preserved between controls and 
AML samples, levels of precursor cells (CD34+38+ cells) were significantly lower in AML samples 
than controls (see Section 1.5.2 )1. 
Although CD34 is expressed on many erythroblasts at the start of their maturation, its 
expression wanes as that of CD235a increases, and therefore we would not expect all 
erythroblasts to fall within the CD34+38+ subset. Nevertheless, as a precursor population, one 
might expect the erythroblast population to fall in a manner consistent with the hypothesised 
differentiation block.  
In fact, in this dataset of 20 patients, whilst there is no significant difference in HSC 
concentration at diagnosis between AML and control samples ([HSC] AML samples median 2.4 
cells/μl (n=20), [HSC] control samples median 2.3 cells/μl (n=7) (p=0.72, Mann Whitney t test)), 
there is also no significant difference observed between erythroblast concentrations 
([erythroblast] AML samples median 3.7 cells/μl (n=20); [erythroblast] control samples, median 
89.6 cells/μl)(p=0.79, Mann Whitney t test). These data are shown graphically in Figure 3-8 B.    
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 Attempts to study megakaryocyte lineage and concentration at diagnosis with 3.4.3
AML    
3.4.3.1 FACS based separation of megakaryocytes from bone marrow samples previously 
stored in Bart's Tissue Bank by Standard Methodology is not possible   
Previous published work describing the separation of megakaryocytes from bone marrow 
samples suggests these cells are a rare, FSChighCD41+61+ population in the bone marrow.  
Repeated attempts to develop a methodology capable of separation of intact megakaryocytes 
from control bone marrows by FACS based sorting proved unsuccessful. FACS staining of 
normal control bone marrows revealed a population of cells of FSChighCD41a+ cells in small 
numbers (300 to 400 sorted cells per approximately every 10x106 nucleated bone marrow 
cells). However, after sorting, slide preparation and MGG staining, the morphology of the cells 
examined did not correlate with the distinctive appearance of megakaryocytes. This was not a 
surprise given the previously published literature on this area.  
Review of the available literature on megakaryocyte separation frequently describes technical 
difficulties attributed to cell rarity, fragility and tendency to aggregate185. Groups which have 
published on FACS analysis of megakaryocytes collect and process bone marrow in specific 
buffers designed to reduce megakaryocyte aggregation; followed by density gradient 
centrifugation designed to enrich for the megakaryocyte population185. As all the BM samples 
identified for this study have been pre-frozen by our standard Tissue Bank technique (Section 
2.2.2), and new cases are of sufficient rarity to preclude analysis of bone marrows before 
freezing, we have come to the conclusion that we are unable to separate megakaryocytes 
successfully from the BM samples which we have stored in this patient subgroup by flow based 
sorting techniques. An additional factor which added to concerns over FACS sorting accuracy 
was the documented adherence of platelets (also CD41a+) to blast cells195. As a result, further 
attempts to utilise FACS to identify the lineage of platelet production in these patients were 
postponed.    
3.4.3.2 Examination of diagnostic bone marrow trephine samples suggests that 
megakaryocyte concentration in AML are significantly reduced compared to controls  
17 trephines taken from AML patients at diagnosis and 9 control bone marrows were studied 
for megakaryocyte numbers as described in Section 3.3.6 using the Pannoramic system. The 
median platelet count of the AML samples was 100x109/L, with a range of between 13 to 
169x109/L. 9 of the AML samples were derived from patients with intermediate risk 
cytogenetics and 8 represented patients with poor risk cytogenetics.  
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Calculated megakaryocyte concentrations were significantly lower in AML bone marrow 
trephines than in control samples (AML samples, median [megakaryocyte] 2.9/mm2 versus 
control samples, median [megakaryocyte] 13.8/mm2; p=0.0014 by Mann-Whitney t-test). 
There was no statistically significant difference observed between the megakaryocyte 
concentrations of different cytogenetic risk group samples (intermediate risk, median 
[megakaryocyte] 3.6/mm2 versus poor risk [megakaryocyte] 2.8/mm2; p=0.44 by Mann-
Whitney t-test)  
 There is no relationship between the concentrations of megakaryocytes in the bone 3.4.3.2.1
marrow and platelet levels at diagnosis with AML  
Spearman’s correlation test was used to analyse this dataset for a possible relationship 
between megakaryocyte concentration at diagnosis with AML and presentation platelet levels. 
No significant correlation was found (Spearman's r correlation coefficient 0.07, p=0.78).  
 There is no relationship between haematopoietic stem cell concentration and platelet 3.4.3.2.2
count levels at diagnosis  
In a parallel with Section 3.4.2.2, the potential relationship between HSC concentration and 
platelet levels at diagnosis with AML was explored. The same cohort of 38 patients, whose HSC 
concentration at diagnosis was identified by the work performed in Chapter 5 were examined, 
and the same separation of the cohort into samples with HSC concentrations above and below 
0.1 HSC/µl was used. As was the case with haemoglobin levels, HSC concentration at diagnosis 
does not appear to have a significant effect on platelet level at diagnosis (Mann-Whitney t test 




Figure 3-8 A: Bar-chart showing the relationship between HSC concentration & Hb at diagnosis. [HSC]<0.1/µl, n=8, mean Hb 8.5g/dL; [HSC]>0.1/µl, n=30, mean Hb 8.7g/dL. Mean and SD are plotted; 
B: Bar chart showing the relationship between HSC and erythroblast concentrations at diagnosis in AML and control samples C: Bar chart showing trephine megakaryocyte concentration at diagnosis 
with AML and controls. Median and IQR are plotted; D: Bar chart showing the relationship between HSC concentration and platelet count at diagnosis. [HSC]<0.1/µl, n=8, median platelets 37x10
9
/L; 
[HSC]>0.1/µl, n=30, median platelets 57x10
9
/L. Median platelet count and IQR are shown 
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Table 3-5 illustrating clinical characteristics, diagnosis blood counts and calculated  stem cell and erythroblast concentrations in 20 AML diagnosis samples 
PAT ID AGE SEX 
GENETICS DIAGNOSIS BLOOD COUNT FRESH SAMPLE FROZEN SAMPLE 































7774 62 M NORMAL TCTG 
 
8.1 0 37 9.5 0.08 1.42 
7793 56 F 13 TCTG 
 
11.1 4 10 15.7 0.01 0.06 
7916 62 F NORMAL WT 
 
6.3 38 76 18.0 4.26 242.95 
7955 61 M NORMAL WT 
 
9.3 14 19 2943.6 8.31 3.48 
7967 67 F NORMAL CCTG 
 
10 2 18 328.5 2.06 3.93 
8169 27 F t(11;19) WT 
 
9.7 0 110 420.4 1.09 1382.02 
8199 45 F NORMAL TCTG 
 
6.6 22 41 31.8 1.29 157.99 
8429 48 M NORMAL TCTG FLT3-TKD 6.1 3 39 20.1 0.03 2.98 
8452 27 M t(11;17) WT WT 8.6 6 75 28.6 8.27 190.10 
8791 59 M COMPLEX WT 
 
7.4 31 43 797.6 5.36 2.93 
8932 43 M t(8;21) WT WT 7.2 3 54 67997.4 1.57 1.91 
9067 67 M NORMAL CTTG WT 7.4 143 172 18.6 0.04 0.02 
9154 63 M COMPLEX WT WT 10.3 4 129 46787.9 10.38 0.00 
9669 41 M INV(16) WT WT 11.1 12 70 21448.1 2.45 291.04 
9672 61 M DEL(7q) WT 
 
6.9 45 20 35640.0 2.41 0.00 
9815 42 M NORMAL WT WT 7.7 5 105 37365.7 71.81 1432.54 
9900 61 F NORMAL WT WT 9.1 1 239 3004.1 6.65 899.22 
9963 63 F COMPLEX WT WT 10.8 5 57 17705.4 17.17 1096.20 
9964 24 1 NORMAL TCTG FLT3-ITD 13.9 77 80 14867.1 6.72 3.01 








Table 3-6 showing clinical characteristics, diagnosis blood counts and calculated stem cell and erythroblast concentrations at staging in 7 control samples 
PAT ID Age Sex 
DIAGNOSIS BLOOD COUNT FRESH SAMPLE ANALYSIS FROZEN SAMPLE ANALYSIS 
























7926 42 M 11.2 527 14.3 59.54 2.37 89.62 
7957 63 M 12.5 295 5.2 1.58 0.03 2.60 
8066 27 F 13.5 316 7.5 141.09 1.36 0.36 
8115 42 M 16.5 318 8.1 353.99 13.80 1006.11 
8510 21 F 13.1 587 7.4 232.21 3.07 192.17 
TEMP1735 30 M 14.6 252 12.7 4.50 0.01 1.75 
10115 50 M 15 294 12.6 1368.94 7.33 3174.38 
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3.5 Discussion 
In the first chapter of this PhD, I have attempted to investigate a subset of AML samples which 
do not fit the pattern of trilineage haematopoietic failure classically associated with this 
disease. The existence of these patients presents a challenge to the previous hypothesis put 
forward by our group, namely that haematopoietic failure in AML is due to induced quiescence 
and differentiation block of the HSC population1. If such a universal pattern were the case, one 
would naively expect the same pattern of count deterioration to be observed in all patients at 
diagnosis. 
 Summary of database analysis 3.5.1
Analysis of the blood counts presenting counts at the time of diagnosis with AML for over 500 
patients presenting to Bart’s Hospital would suggest that trilineage failure is very strongly the 
normal pattern, with 81% of patients presenting with both haemoglobin and platelet levels 
below normal for age. Only 1% of patients were diagnosed with AML whilst maintaining a 
normal haemoglobin and platelet level.  
Perhaps surprisingly, age and gender had no bearing on the levels of these parameters at 
presentation.  
Detailed cytogenetic subanalysis showed no effect of different cytogenetic risk groups or 
specific translocations on haemoglobin levels at presentation.  
The patterns of platelet count at diagnosis were more interesting, with a definite skewing of 
platelet counts (rather than preservation of a normal distribution), and a suggestion there is a 
substantial, and possibly separate, population of patients (15%) who present with a normal 
platelet count at diagnosis. However, I was unable to identify a clear cause for these patterns. 
Cytogenetic subanalysis identified only that patients with good risk disease were more likely to 
have a lower platelet count at diagnosis than those with intermediate and poor risk disease. 
Unsurprisingly, subgroup analysis showed this effect is largely due to the inclusion of patients 
with t(15;17). As these patients often present with DIC, it is impossible to determine if the 
lower platelet counts observed in this cohort are due to inefficient production or peripheral 
consumption.  
No cytogenetic abnormalities were significantly associated with preservation of platelet counts 
in this cohort, although note is made of the patients with t(3;5), with a platelet count of 
385x109/L, and the 2 patients with inv(3) with platelets of 192 and 263x109/L at diagnosis. Such 
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preservation of counts is keeping with small previous dataseries associating AML with 
abnormalities of 3q and relative thromobocytosis, although the small numbers of patients with 
these abnormalities in this cohort prevent these results from acheiving statistical 
significance194.  . 
Analysis of survival data for this group shows that neither gender-adjusted haemoglobin nor 
platelet level at diagnosis appears to have a significant effect on overall survival.  
 Clonality studies of erythroid precursors suggests red cells are derived from 3.5.2
normal precursors and not from the leukaemic clone (in NPM1 and CBF 
mutated AML samples), but were not possible with megakaryocytes 
FACS based sorting of nucleated erythroid precursors was performed in AML samples with 
relative preservation of their red cell levels and known genetic mutations, to identify the 
clonality of the maturing red cell precursors. In all cases, these appeared to be of normal 
karyotype, and were therefore assumed not to be part of the leukaemic clone. In these 
patients with preserved haemoglobin levels at diagnosis, we have no evidence to suggest that 
normal counts are maintained by terminal differentiation of blasts.  
However, although erythroblasts do not appear to contain NPM1 or CBF mutations in the ten 
samples studied, these findings do not absolutely exclude the possibility of other AMLs 
carrying alternative cytogenetic or genetic mutations maturing into red cells of normal 
appearances. In order to confirm this, it would be worth performing FACS separation and 
analysis of erythroblasts from AMLs representing a wider range of genetic anomalies. 
We attempted the same technique to study the genotype of megakaryocytes in bone marrow, 
in these patients with preserved platelet counts at diagnosis. Frustratingly, FACS based 
attempts to separate megakaryocytes proved unsuccessful, due we believe to their large size, 
and the need for specialist handling of bone marrow samples from the time of receipt (see 
Section 3.4.3.1). Other factors which might make FACS based separation of nucleated platelet-
lineage precursors from AML BM difficult include the observed adherence of CD41+ platelets to 
blasts, which would make confident distinguishing of megakaryocytes from blasts practically 
impossible195. Reassuringly (?!), similar difficulties of using flow based sorting techniques to 
separate intact megakaryocytes have been well documented by other groups185.  
Given the failure to adequately separate megakaryocytes from bone marrow samples by FACS 
sorting, a number of alternative approaches were considered.  
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By virtue of their distinct morphology, megakaryocytes are clearly identifiable in trephine 
sections. A significant number of AML patients diagnosed at Bart’s Hospital have had bone 
marrow trephines taken at diagnosis, some of which are held for research purposes. 
Genetic investigation of megakaryocytes located within trephine sections has been undertaken 
apparently successfully in the past: as referenced in Section 3.1.2.1.2, Falini’s group reported 
laser dissection of megakaryocytes from diagnostic AML bone marrow trephines, which 
subsequently tested positive for the NPM1 mutation. However, it is worth noting that no other 
group has been able to replicate this approach. The same group also have utilised staining for 
the presence of cytoplasmic NPM1 protein, as a surrogate marker for the presence of the 
NPM1 mutated gene in studies of bone marrow sections166. However, using 
immunohistochemical techniques to identify the clonality of individual cells is not a widely 
available technique, and the antibodies are not commercially available.  
In conjunction with Marianne Grantham in the Cytogenetics Department of the Royal London 
Hospital, we did attempt to see if we could utilise chromogenic in situ hybridisation (CISH) 
staining of bone marrow trephine sections of patients with known karyotypic abnormalities to 
identify whether megakaryocytes stain positive for the leukaemia associated mutations. On a 
first attempt staining AML bone marrow samples with the t(6;9) translocation, using the 
Kreatech DEK/NUP 214 t(6;9) Fusion Probe, probe binding was rendered inefficient by the fact 
that trephine sections processed at Bart's Hospital are universally fixed in formalin, with 
resultant DNA denaturation. This makes any attempt to identify clonality in these fixed 
samples by genetic means extremely difficult. 
One approach we have not attempted would involve the sorting of platelets, followed by RNA 
extraction, reverse transcription, and interrogation of the resultant cDNA for mutations in 
genes such as NPM1. Issues with this could include documented difficulties relating to platelet 
adherence to other cell types, as well as generalised low transcription levels in platelets 
(indeed as the NPM1 protein is thought to be involved in nuclear-cytoplasmic shuttling, one 
wonders whether it has a function in enucleate platelets).  
 Studies of erythroid precursor levels  3.5.3
Having established that erythroblasts in AML appear to be derived from normal 
haematopoietic cells (at least in the cases of CBF and NPM1 mutated samples), we then 
proceeded to calculate their concentration at diagnosis. 
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There was a wide variation in observed concentrations of erythroblasts between samples, but 
this did not correlate with presentation haemoglobin. Similarly, due possibly to the wide range 
of results, there was no significant difference observed between erythroblast concentration in 
AML and control samples. There was, however, a significant relationship between HSC 
concentration at presentation with AML and erythroblast levels (those with very low levels of 
HSCs had significantly lower erythroblast concentrations).   
Perhaps it is unsurprising that we fail to observe a very clearly defined pattern between these 
parameters. Is it possible that under conditions of stress haematopoiesis, the more mature 
erythroblast forms (BFU-E) might retain the ability to move to extramedullary sites for the final 
stages in replication as we observe in rodent models?172,173 The cells marked out as CD235a+71+ 
represent a range of stages in erythroblast maturation: it is possible that within these cohorts, 
certain populations are preserved or able to expand, and others are more affected. Could the 
final stages in red cell development such as nuclei extrusion and release into the bone marrow 
also be blocked by the presence of AML, therefore resulting in a failure to maintain peripheral 
counts?  
One experimental concern on review of the data is whether the use of CD235a and CD71 by 
themselves is sufficient to exclude mature red cells from analysis. As mature red cells are 
present in very high relative concentrations in bone marrow samples, this would certainly 
significantly reduce the quality of the generated data. In the initial design of these 
experiments, I had hoped that the initial processing of the bone marrow samples (by density 
gradient centrifugation using FicollTM, followed by freezing- see Section 2.2.2) would be 
sufficient to remove the vast majority of mature red cells. Secondarily, CD71 expression is 
reported to be downregulated on mature erythroid cells, and therefore I had hoped that 
selection of the CD235a+71+ dual positive population would be sufficient. In retrospect, the 
flow-based differentiation of erythroblasts would be improved by the addition of a step 
requiring the positive selection of cells with an intact nucleus.  
 Studies of platelet precursor levels  3.5.4
As megakaryocytes are easily identifiable in bone marrow trephine sections, I attempted to 
enumerate megakaryocytes in AML samples and compared these to controls. This approach 
suggested that megakaryocyte levels were significantly lower in AML patients than trephines 
taken from normal controls (2.9 versus 13.8 megakaryocytes/mm2, p=0.001). This is in contrast 
to numbers of erythroid precursors, which did not appear to show significant reduction in their 
levels in bone marrow aspirates from AML patients when compared to controls.  
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In a parallel to the work with erythroid precursors, I attempted to analyse the different 
patterns observed in different cytogenetic risk groups. Here, I had no NPM1 mutated or CBF 
samples: all the samples were either of intermediate or poor prognoses. There was no 
significant difference found between the megakaryocyte concentrations within these two risk 
groups, and insufficient samples were available to further subcategorise.  
Again, in a situation analogous to the erythroid data, there is not a significant correlation 
between platelet count at diagnosis and megakaryocyte number in the bone marrow at 
diagnosis. Could this imply that platelet levels lag behind changes in megakaryocytes? Or could 
megakaryocytes similarly enter a state of induced quiescence similar to that observed in stem 
cells? Or are the initial changes in peripheral platelet count observed in AML more due to 
peripheral destruction initially than a failure in bone marrow production? 
 Further experimental work  3.5.5
Given unlimited time and resources, there are a number of further experiments I would wish 
to perform.  
Whilst we failed to find an association between cytogenetic risk groups of AML and lineage 
preservation, in the current era of genomic sequencing, it would certainly be interesting to 
screen this cohort for commonly associated mutations in AML. This would allow us to identify 
if any of these mutations have a bearing on presentation blood counts, either because of 
leukaemia cells retaining the ability to differentiate into mature cells, or conferring variable 
inhibitory ability of the blasts on the development of cells of different lineages. However, it is 
noteworthy that the recently published study of 1540 patients from three German AML trials 
did not mention any observed association between particular genetic mutations and 
presentation counts196.   
Other alternative approaches could include the study of the blasts’ ability to produce cytokines 
with known roles in lineage differentiation. This could be performed either at a transcriptional 
level, or by ELISA based assays of the bone marrow stromal milieu. Do, for example, those 
AMLs which present with a preserved platelet count secrete TPO themselves, or influence 
surrounding stromal cells to increase local production?   
 Summary  3.5.6
In conclusion, this chapter has confirmed the dominant pattern of bone marrow failure in the 
vast majority of AML patients. However, it is clear the patterns of lineage deterioration do vary 
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between patients, and the reasons for this are not clear. Evidence presented in this chapter 
would suggest this is not due to leukaemia differentiation, or intrinsic properties of the AML 
linked to its cytogenetic abnormalities.  
However, I do not believe that the work presented in this chapter invalidates the group’s 
hypothesis that the dominant mechanism of bone marrow failure seen in AML is that of 
induced quiescence of the stem cell population. However, I would argue that it is possible that 
different AML samples may well induce blocks on differentiation and maturation at a number 
of different stages in development, and the variable extent to which these occur may affect 
the fashion in which blood counts fall at presentation.   
Further experimental work would be required to try and address these questions as detailed in 
Section 3.5.5 above. However, due to time and financial limitations in this work, we made the 
decision to focus on the interaction between HSCs and AML: work which is detailed in the 
following chapters.  
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Chapter 4 Developing a methodology for the identification of 
normal stem cells within AML Samples 
4.1 Introduction  
Our group historically has been interested in the fate of normal HSCs during the development 
of AML, and how any disruption in their behaviour may affect downstream haematopoiesis. 
Key to this work is the accurate identification of normal stem cells from within AML samples, 
and their differentiation from cells belonging to the leukaemic clone. 
 The identification of normal stem cells and progenitors within CD34low 4.1.1
expressing AML samples  
Previous work from our group summarized in Chapter 1.5.2.2 involved the identification of 
normal CD34+38- stem cells from human primary bone marrow samples of the rare CD34low 
phenotype AML1. Separation of these HSCs from the leukaemia clone was facilitated by the 
fact that in this rare subtype of AML (highly associated with a normal karyotype, NPM1 gene 
mutations and an absence of concurrent FLT3 mutation), the CD34+ cells found in the marrow 
are free of the leukaemia-associated mutation130,135. When the normal HSC concentration at 
diagnosis was calculated in these samples, it was found to be unchanged when compared to 
controls. In contrast, the number of CD34+38+ progenitor cells (also free of the NPM1 
mutation) was significantly reduced. Moreover, assessment of the cycling status of cells within 
the CD34+38- bone marrow fraction suggested these cells are quiescent in comparison to 
controls1. These observations led to the development of our group’s theory that AML induces a 
differentiation block in normal haematopoietic development between the HSC and progenitor 
stage.  
 Difficulties in identifying normal stem cells within AML samples  4.1.2
Identification of HSCs in bone marrow in health is made difficult because of their relative 
rarity. There is a lack of a universally agreed panel of markers to identify human HSCs, 
although it is widely accepted that the CD34+38- fraction of bone marrow is the most enriched 
for cells with long term repopulating potential. However, there is considerable heterogeneity 
within this fraction, which contains not just cells with long term repopulating potential, but 
also short-term repopulating cells, and even cells beginning the pathway to differentiation.    
This situation is complicated considerably when attempting to identify normal stem cells from 
AML samples, due to the overlap in phenotypes between the HSC and the leukaemia stem cell 
(LSC). In AML samples, many downstream blasts lacking LSC properties may also fall into the 
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CD34+38- fraction, and due to the hyperproliferative nature of the disease, will constitute the 
vast bulk of cells seen at diagnosis.  
A final consideration in the identification of normal HSCs is the possibility that exposure to 
AML may directly modulate their normal surface antigen expression. Such a shifting phenotype 
is not a widely-documented phenomenon, although a changing surface phenotype of long 
term repopulating cells after 5-FU chemotherapy has been documented in mice197. However, 
in Chapter 6 of this thesis, we demonstrate that CD33 expression within the normal HSC 
fraction of AMLs with t(8;21) and inv(16) mutations is temporarily down-regulated at 
diagnosis, returning to normal levels in remission. It is therefore possible that the expression of 
other key antigenic identifiers of cells with long-term repopulating ability may be similarly 
altered.     
 Antigenic markers reported to show differential expression between normal stem 4.1.3
and leukaemic cells 
There is considerable interest in isolating phenotypic markers which are differentially 
expressed between HSC and leukaemic blasts or LSCs. Not only do these markers represent a 
useful research tool, but they also present a target for antibody therapy, if relatively 
overexpressed on LSCs131,198-200. Given the diversity of AML samples, reflected in their varying 
phenotypic appearances, it is not surprising that there is no single, universal marker reported 
to distinguish normal HSCs from blasts in all cases.  
A number of methods have been used to identify differentially expressed markers in HSCs and 
blasts: these include bulk gene expression profiling198, which helps to identify differential 
expression of known extracellular antigens, phage display technology201 and the signal 
sequence trap strategy methodology which identifies mRNAs coding for cell surface proteins 
by virtue of their ability to redirect a constitutively active version of c-mpl to the cell surface202.  
Irrespective of the manner of their identification, the biological function of many of these 
markers is often poorly understood. Therefore the reasons for the differential expression 
patterns remain unclear. 
A summary of the best characterised extra and intracellular markers for separating HSCs and 
blasts is found below.  
 Chapter 4: Identification of normal HSCs  
116 
4.1.3.1 Aldehyde Dehydrogenase 
 Aldehyde dehydrogenase (ALDH) is a cytosolic enzyme responsible for the oxidization of a 
variety of aldehydes, including Vitamin A. In healthy bone marrow, it is expressed at high levels 
in CD34+38- HSCs and is thought to be responsible for their observed resistance to alkylating 
agents, such as cyclophosphamide203. An assay system designed to measure ALDH activity by 
the generation of a fluorescent substrate was developed and described first in 1999204. 
Utilising this system, approximately 80% of the CD34+38- fraction stain ALDHhigh 205. As cells 
mature (and thus CD38 expression increases), ALDH activity reduces205,206.   
In a key paper for this thesis, Gerber et al described the study of ALDH activity levels in 20 
patients with newly diagnosed AML (the majority with inv(16) or t(8;21) karyotypes)207. The 
CD34+38- compartments within these bone marrow samples were shown to have three sub-
populations of cells based on ALDH activity: ALDHhigh, ALDHint and ALDHlow. These staining 
patterns are illustrated in Figure 4-1. In 16 of the 20 patients studied, the following pattern 
was seen. The CD34+38-ALDHhigh populations were small, devoid of the leukaemia-associated 
mutation by FISH, and capable of reconstituting normal haematopoiesis when transplanted 
into mice. FISH analysis of the CD34+38-ALDHint and ALDHlow populations showed these to 
contain cells of leukaemic origin. Transplantation of the CD34+38-ALDHint cells showed these to 
be capable of leukaemic engraftment of mice, suggesting this population might include LSCs.  
 
Figure 4-1 Representative flow plots showing ALDH activity against side scatter for a normal donor and 3 AML 
samples. A: normal donor; B: a patient with t(8;21) AML; C: a patient with inv(16) AML and D: a patient with AML 
with normal cytogenetics. Figure from Gerber et al, 2012
207
.  
Of the other four patients, two (one with normal karyotype and FLT3-ITD mutation; one with 
complex cytogenetics) did not contain a separate, small CD34+38-ALDHhigh population: most of 
the CD34+38- cells had high ALDH activity (see below). The other two patients showed the 
phenotypic appearances we would describe as CD34low, and therefore the diagnostic 
leukaemia marker was only found in the CD34- cells130.   
This paper went on to look at the clinical follow-up data available on 13 of the initial cohort, to 
see if ALDH expression could be used as an MRD marker. In this group, all of whom achieved a 
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morphological remission, the presence of a persistent CD34+38-ALDHint population in follow up 
samples was highly predictive for early relapse.   
Further validation for this approach was provided by Schuurhuis et al, who tested ALDH 
expression patterns using a range of AML samples (although with a high proportion of CD34low 
AMLs)205. In this paper, they also make the observation that high expression of ALDH is often 
associated with the absence of CLL1 expression (see Section 4.4.1.3).    
Schuurhuis et al went on to look at mRNA expression levels of the different isoforms of ALDH 
within CD34+38- cells from normal bone marrow and AML samples. Normal stem cells showed 
significantly higher levels of the ALDH1A1 isoform than putative leukaemia stem cells (as 
defined in this paper by FSC/SSChigh, CLL1+)205.    
As already mentioned, 2 of the 20 patients in the Gerber series did not have a distinct 
population of ALDHhigh cells within the CD34+38- subgroup, due to overlap with a blast 
population with a similarly high ALDH expression. It has been noted in several studies that high 
ALDH expression within AML samples is associated with a poorer prognosis. Cheung et al 
studied 43 AML samples, and found the majority (29 samples) to have undetectable or rare 
cells (<5%, which should encompass all normal stem cells) within the SSClowALDHhigh gate. 
However, in 14 cases, a much larger SSClowALDHhigh population of cells was observed (median 
15%, range 6 to 48%). Amongst other clinical variables, high ALDH expression of AML samples 
was significantly associated with poor risk cytogenetics208.      
Similar findings were reported by Ran et al, who studied ALDH expression within 68 AML 
samples. They reported that the frequency of ALDHhigh expressing cells within the samples was 
significantly associated with reduced survival (p=0.025) and also poor risk cytogenetics 
(p<0.05)209.    
4.1.3.2 CD33 
CD33 is a transmembrane receptor frequently, but not exclusively, expressed on myeloid cells. 
It is known to be a member of the sialic acid binding family of receptors, although its 
physiological function in myeloid cells remains undetermined. The extracellular component 
comprises of two immunoglobulin domains, and the intracellular compartment contains 
immunoreceptor tyrosine-based inhibitory motifs that are implicated in inhibition of cellular 
activity210. 
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CD33 is highly expressed in 90 to 95% of AML samples211,212. Over ten years ago, cross linking 
of the receptor with antibodies was shown to cause significant apoptosis in AML samples213. 
Increasing interest in the development of targeted molecular therapies led to the production 
of Gemtuzumab Ozogamicin (GO) (marketed in the UK as Mylotarg by Wyeth): an anti-CD33 
antibody, conjugated to calicheamicin. 
Although CD33 expression is classically associated with maturing myeloid cells, it has also been 
shown to be expressed at low intensity on normal, undifferentiated stem cells214. However, as 
we demonstrate in Chapter 6 of this thesis, CD33 expression appears to be downregulated on 
normal stem cells at diagnosis with AML (illustrated by studies of both CD34low and core 
binding factor-mutated AML), and therefore is a candidate marker for use in separation of 
HSCs and blasts.    
4.1.3.3 CD47 
CD47 is an immunoglobulin-like cell surface marker that interacts with the SIRPα receptor on 
macrophages to inhibit phagocytosis. CD47 has been implicated in a variety of different 
functions across cell types, including neutrophil migration and T cell co-stimulation. In a paper 
exploring the role of CD47 on mobilized stem cells, Jaiswal et al showed CD47 expression on 
mobilized cells in human cord and G-CSF mobilized cells to be significantly higher than normal 
controls215. Administration of G-CSF to mice led to a 4 fold increase in CD47 expression on 
murine HSC cKit+ cells.  
Observations from a CD47 knockout murine mouse model had previously described a 
protective role for CD47 in preventing macrophage-mediated removal of red cells and 
platelets. Using mice transplanted with murine HSCs heterozygous for the CD47 knockout- IAP 
+/-, Jaiswal et al showed that the transplanted mice tended to lose their donor granulocyte 
chimerism over time, suggesting the same protective role may also be the case for HSCs.     
The same group simultaneously reported flow data on CD47 expression from 13 cases of AML 
(11 with normal cytogenetics; 1 inv(16) and 1 complex), and found the CD47 expression to be 
higher within the CD34+38-90+Lin- fraction of AML samples than controls131. Gene expression 
data from 285 AML samples suggest that levels of CD47 expression are similar between 
different subsets of AML, apart from patients with the t(8;21) translocation, which are 
associated with lower expression levels. Higher CD47 expression is strongly associated with 
mutations within the FLT3 gene. This paper described the FACS sorting of one AML sample 
(FLT3 mutated) to Lin-CD34+38-CD47low and CD47high subsets. The CD47low subset was capable 
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of reconstituting normal haematopoiesis when transplanted into mice, with the resultant cells 
being free of the FLT3 mutation, which was present in the CD47high cells.  
4.1.3.4 CD99  
CD99 (also known as MIC2) is an O-glycosylated transmembrane protein. It is expressed across 
all leucocyte subsets, but is also found in endothelial cells and fibroblasts. In oncology, its 
expression is best characterized in Ewing’s sarcoma and ALL.    
Zhang et al studied the CD99 expression patterns on a variety of myeloid derived tumours, 
including AML, MDS and chloromas. Using immunostaining of bone marrow trephines from 30 
patients with AML, the authors found 13 of these to be positive for CD99 expression216. More 
recently, a group from the Memorial-Sloan Hospital studied CD99 expression in 78 AML bone 
marrow samples by flow cytometry, and found 81% of these to be positive200. Limiting dilution 
xenotransplant experiments of the CD34+38-90-45RA+99high and CD34+38-90-45RA+99low cells of 
AML samples suggest that cells with LSC function reside in the CD99high expressing subset. It is 
interesting that study of a larger patient cohort (309 patients recruited to the ECOG 1900 
study) suggested that CD99 transcript expression positively correlated with overall survival 
(p=0.001). Neither of these papers described the CD99 expression patterns within the 
CD34+38- fraction of normal bone marrow.   
In their key 2012 paper, describing the evolution of the pre-leukaemic stem cell, Jan et al used 
a flow panel which included CD99 to separate out normal stem cells from 6 patient samples 
with FLT3 mutated AML. The CD34+38-TIM3-99- cell population was sorted out from these 
(presumably highly selected) samples, and the resultant cells found to be clear of the 
leukaemia defining FLT3 mutation151.    
4.1.3.5 CD300 
CD300 (also known as IREM-1) is a type I transmembrane protein first identified in dendritic 
cells217. Work by Korver et al resulted in the production of a monoclonal antibody against the 
extracellular portion of CD300, which enabled a full exploration of its expression on blood and 
bone marrow cells. CD300 appears to be expressed on blood cells of the myeloid lineage, but 
not on lymphocytes or erythroid precursors. Of 54 diverse AML samples, 39/54 (72%) were 
found to be positive for IREM-1 expression by flow cytometry analysis. In 24 AML samples, 
where the IREM expression of the CD34+38- subfraction was studied, 13/24 (54%) were found 
to be positive. In contrast, in 11 normal bone marrow samples, all CD34+38- subfractions were 
negative for IREM1 expression. The paper then goes on to investigate the utility of IREM-
targeted mAbs for the treatment of AML218.  
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4.1.3.6 CLL1  
C-type lectin-like molecule-1 or CLL1 (also known as Clec12A) was first identified in 2004 by 
members of the Schuurhuis laboratory, searching for novel AML surface targets for antibody 
therapy201.   
They used Phage Display technology to identify single chain Fv fragments from a large naive 
library capable of reacting with a panel of AML cells. Subsequent expression cloning identified 
the antigen recognized by the antibody as CLL1, a previously uncharacterized transmembrane 
glycoprotein. The function of CLL1 is still not known, but structural analysis suggested a 
possible role as a signalling receptor, based on an intracellular domain containing both 
immunotyrosine-based inhibition and YXXM motifs.   
In the same paper, the group describe the subsequent production of a human anti-CLL1 IgG1 
monoclonal antibody, generated from the single chain Fv fragment. A conjugated form of this 
antibody was then used to investigate the expression pattern of CLL1 across haematopoietic 
tissues. CLL1 expression appears to be restricted to the cells of the myeloid lineage. It is absent 
on CD34+38- stem cell fractions of bone marrow, but increasingly expressed on more mature 
subsets such as CD34+38+ progenitors. 68 of 74 AML samples assayed for CLL1 were positive 
for its expression.      
The same group went onto publish details of CLL1 expression within the CD34+38- fraction of 
both AML and normal bone marrow samples219. Using a large cohort of AML samples, they 
found the CD34+38- fraction to be positive for CLL1 expression in the vast majority (77 of 89). 
The CD34+38- fraction of normal bone marrow samples was universally negative for CLL1 
expression. They proposed a role for CLL1 as an MRD marker, having found that the 
persistence of a CD34+38-CLL+ population after the completion of chemotherapy was 
associated with an increased relapse rate.  Other groups have proposed a similar role after 
corroborative studies220.   
4.1.3.7 TIM3  
T-cell Immunoglobulin Mucin 3 was originally found as a surface marker on CD4+Th1 
lymphocytes in mice, and is known to be an importance regulator in Th1 cell immunity and 
tolerance induction221.  
Kikushige et al198 separated out the CD34+38- cell fractions of 12 patients with AML and 5 
controls, and performed cDNA microarray analysis looking for differential expression of genes, 
with the aim of identifying surface markers expressed more strongly on AML than normal 
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HSCs. Genes coding for surface markers with a greater than eight fold difference in their 
expression between the two test groups included CLL1, CD96 and TIM3.   
Expression of TIM3 in 33 AML samples, crucially representing all FAB subtypes, was then 
assayed by flow cytometry. Within the CD34+38- cells in these AML samples, TIM3 expression 
was high in M0, M1, M2 and M4 subtypes. TIM3 expression was low in M3 AMLs, and more 
variable in the M5 and M7 cases studied. Transplant experiments of sorted cells into mice from 
4 AML samples suggest that the LSC activity (as measured by the ability to produce AML in 
mice), resides in the CD34+38-TIM3+ rather than CD34+38-TIM3- fraction.  
The Weissman laboratory has also investigated TIM3 expression in AML. Jan et al tested TIM3 
expression on 22 patient AML samples, representing a range of diagnostic karyotypes222. They 
found the TIM3 expression within the Lin-CD34+38-90+ cells to be significantly higher in AML-
derived samples than controls. Transplantation of human HSCs, separated by their TIM3 
expression status, into an immunodeficient murine model, revealed preferential engraftment 
from the TIM3low fraction, suggesting that this is this fraction that is relatively enriched for the 
presence of long term repopulating cells.   
Analysis of the Weissman AML gene expression data suggested that although TIM3 expression 
was raised across all AML subtypes, it was significantly higher in AML samples with mutations 
in the core binding factors, and CEBPA gene.  
Crucially, they also went on to test the ability of TIM3 expression to differentiate between 
normal HSCs and LSCS. In this paper, they describe the selection of 8 primary AML samples. 6 
of these samples were sorted into Lin-34+ fractions and then subdivided into TIM3+ and TIM3– 
subgroups. The purity of these populations was then tested as follows. 3 of 6 samples were 
cultured in methylcellulose, and the resultant colonies tested for the presence of the 
leukaemia-associated mutation (FLT3 or inv(16)). In all 3 cases, at the end of the culture 
period, the molecular mutation was not detected in the TIM3- fraction progeny.  The other 3 
samples (2 with FLT3-ITD; one with MLL rearrangement) were transplanted into mice, and the 
resultant human haematopoietic populations studied. Studies of the progeny cells from the 
TIM3- fractions showed one to be free of the FLT3 mutation, one contain a mixture of FLT3-ITD 
and wild type cells, and one to contain a significant proportion of cells still positive for the MLL 
translocation. 
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4.1.3.8 Summary of reported attempts to use  differential surface antigen expression in the 
separation of normal HSCs and AML cells 
None of the authors of these papers, recognizing the heterogeneity of AML samples, argue 
that their antigenic marker of preference will distinguish HSCs from AML cells in all cases. Each 
group within the field tends to use their own preferred antigen or combination of antigens, 
based on local experience. For example, our laboratory has to date favoured the use of CD34 
and CD38 expression to identify normal HSCs from the CD34low subset of AMLs. The 
Majeti/Weissman group in Stanford, who have published extensively in this area and have 
produced some of the seminal papers in this field, have variously used a combination of CD34, 
38, in combination with CD90, CD47 and TIM3 to differentiate normal HSCs from AML blasts in 
a variety of leukaemia subtypes. 
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4.2 Aims and Objectives  
The primary aim of the work described in this chapter was to identify a methodology to 
separate normal HSCs from AML cells across all disease subtypes. 
The first objective was to test a range of the antigenic markers previously reported to be able 
to distinguish HSCs and LSCs, and assess if we could reproduce these findings in our laboratory.   
The secondary objective was to combine the most promising of these markers together to 
construct a panel of antigenic markers, capable of differentiating HSCs and LSCs in as many 
unselected samples as possible.  
The final objective was to validate this approach using a cohort of AML samples, chosen to 
reflect the genetic and phenotypic diversity of the disease.  
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4.3 Chapter specific methods  
 Flow Based Analysis of Stem Cell Marker Expression  4.3.1
Diagnostic bone marrow and peripheral blood samples from patients diagnosed with CD34high 
and CD34low AML were obtained from the Bart’s Tissue Bank with prior patient consent.  
Samples were thawed at 37oC in a water bath for 2 minutes. 500µl DNase was then added to 
each tube to reduce cell clumping, and cells incubated at room temperature for 2 minutes. 
Samples were washed with 20ml 2% PBS. Cells were centrifuged (1500 rpm, 5 minutes) and re-
suspended in 2ml 2% PBS. Cell counting was performed using the Beckmann Coulter Vicell XR 
Cell Viability Counter.   
2x106 cells were pelleted and re-suspended in AldefluorTM Assay Buffer (Stem Cell 
Technologies, Cat: 01702) to a concentration of 1x106 cells/ml. Activated AldefluorTM reagent 
(Stem Cell Technologies, Cat: 01703) was added at a concentration of 5µl reagent/ml. The 
suspension was mixed well, and incubated for 60 minutes at 37oC in a pre-warmed water bath. 
Samples were pelleted and re-suspended in 2% HAG pre-diluted in AldefluorTM Assay Buffer at 
a concentration of 50µl 2% HAG/1.5x106 cells. Cells were incubated at 4oC for 20 minutes. 
CD34-PerCP and CD38-Pecy7 were added to all samples, plus varying combinations of the 
following antibodies under investigation: CD33-FITC (BD, Cat: 555625 (Clone HIM 3-4)), CD33-
APC (BD, Cat: 551378 (Clone WM53)), CLL1-PE (BD, Cat: 562566 (Clone 50C1)), CD300-PE 
(Biolegend, Cat: 340604 (Clone UP-DZ)), CD47-FITC (BD, Cat: 556045 (Clone B6H12)), TIM3-APC 
(R&D Systems, Cat: FAB2365A (Clone 344823)) and CD99-PE (BD, Cat: 555689 (Clone TÜ12)). 
Antibodies were added at a concentration of 5µl/1x106 cells, with the exception of CD47, CD99 
and CD300, which were added at 20µl/1x106 cells. All were left to incubate for 30 minutes at 
4oC. The cells were then washed with 4ml AldefluorTM Assay Buffer, and pelleted.  
Cells were re-suspended pre-analysis into 300µl stock solution of AldefluorTM Assay 
Buffer/DAPI, and the sample analysed using a BD Biosciences LSR.   
 FACS Sorting 4.3.2
4.3.2.1 Standard Method 
Samples were thawed at 37oC in a water bath for 2 minutes, and 500µl DNase added to each 
tube to reduce cell clumping, and incubated at room temperature for 2 minutes. Samples were 
washed with 20ml 2% PBS. Cells were centrifuged (1500rpm, 5 minutes) and re-suspended in 
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2ml 2% PBS. Cell counting and viability assessment was performed using the Beckmann Coulter 
Vicell XR Cell Viability Counter.   
Cells were then pelleted and re-suspended in 2% HAG at a concentration of 50µl 2% 
HAG/1.5x106 cells. Cells were incubated at 4oC for 20 minutes.  
CD34-PerCP and CD38-Pecy7 were added at a concentration of 5µl/1.5 x106 cells, and left to 
incubate for 30 minutes at 4oC. The cells were washed with 20ml 2% PBS, and pelleted.  
Cells were re-suspended in a stock solution of 2% PBS/DAPI/DNase (to distinguish live and 
dead cells) at a concentration of 8x106 cells/ml, and filtered immediately pre-sort to reduced 
machine blockages.   
Cell sorting was performed on a BD Biosciences Aria 2. Cells were sorted into 2ml 2% PBS in 
polypropylene tubes (BD Falcon, Cat: 352063). Purity was assessed by centrifuging and re-
suspending cells in 2% PBS/DAPI/DNase prior to re-analysis. If sort purity was assessed as less 
than 90%, resorting was performed.           
Sorted cells were then pelleted (3000rpm, 10 minutes) and the supernatant removed using a 
Gilson Safe Aspiration Centre.   
4.3.2.2 Sorted Cells (ALDH Method)  
Samples were thawed, washed, and viable cells counted as described above.  
Cells were pelleted and re-suspended in AldefluorTM Assay Buffer to a concentration of 1x106 
cells/ml. Activated AldefluorTM reagent was added at a concentration of 5µl reagent/ml. The 
suspension was mixed well, and incubated for 60 minutes at 37oC in a pre-warmed water bath. 
Samples were pelleted and re-suspended in 2% HAG pre-diluted in AldefluorTM Assay Buffer at 
a concentration of 50µl 2% HAG/1.5x106 cells. Cells were incubated at 4oC for 20 minutes. 
Antibodies to CD34-PerCP, CD38-Pecy7 and CLL1 were then added at a concentration of 
5µl/1.5x106 cells, and left to incubate for 30 minutes at 4oC. The cells were then washed with 
10ml AldefluorTM Assay Buffer, and pelleted.  
Cells were resuspended pre-sort into a stock solution of AldefluorTM Assay Buffer/DAPI/DNase 
to a concentration of 8x106 cells/ml, and filtered immediately pre-sort to reduced machine 
blockages.   
 Chapter 4: Identification of normal HSCs  
126 
Sorting, purity assessment and pelleting were performed as described above: the only 
exception being that cells were sorted into AldefluorTM Assay Buffer rather than 2% PBS.  
 In vitro assays of stem cell function  4.3.3
4.3.3.1 Methylcellulose assay for 2 and 4 week culture   
Please see Section 2.6.1. 
4.3.3.2 Long term Culture Initiating Cell Assay  
Please see Section 2.6.2.  
 Assays to test for the presence of leukaemia associated mutations   4.3.4
4.3.4.1 FISH  
Slides were made as previously described and transported to the RLH for staining and analysis 
by Marianne Grantham, head of the Cytogenetics Department. The technique used for FISH 
staining is described in Methods 2.7.3.  
The following probes were used for analysis of sorted populations of cells in this chapter: 
Cytocell CBFB-MYH11 Probe (Cat: LPH 022) for detection of inv(16); Cytocell PML-RARA Probe 
(Cat: LPH 023) for detection of t(15;17); Cytocell AML1/ETO (RUNX1/RUNX1T1) Probe (Cat: LPH 
026) for the detection of t(8;21); Kreatech DEK/NUP 214 t(6;9) Probe for the detection of 
t(6;9); Cytocell Del(7q) Probe (Cat: LPH 025) for the detection of del(7); Cytocell MLL (KMT2A) 
Probe (Cat: LPH 013) for the detection of trisomy 11 and Cytocell BCR/ABL/ASS1 (Cat: LPH 038) 
for the detection of Trisomy 9q34.  
Table 2-1 contains a full description of the expected signal patterns seen with the FISH probes 
used within this thesis. 
4.3.4.2 PCR based assays  
 qPCR Based Assay for the presence of NPM1 mutation  4.3.4.2.1
Please see Section 2.8.4.5. for full methodology.  
 Assay for FLT3-TKD mutation 4.3.4.2.2
This assay is performed as part of the Molecular Genetics screen performed on all patients 
with newly diagnosed normal karyotype AML at Bart’s Hospital. The methodology follows that 
described by Huang et al, and facilitates the simultaneous detection of mutations within the 
NPM1 and FLT3 genes 223.   
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As this test was only required for assessment of one patient’s sorted cells, DNA was extracted 
as described in Section 2.8.1, and the sample processed as per the Hospital’s SOP by Suzanne 
McElwaine, Head of the Molecular Genetics Department at the RLH.  
In brief, a duplex assay was set up using two sets of fluorochrome-tagged primers in the same 
tube: one primer being specific for the juxtamembrane coding sequence involved in the ITD 
mutations, and one for the kinase domain sequence. After amplification, the fragments were 
separated by capillary gel electrophoresis and the fluorochrome signals analysed using a 
software program such as GeneScan. Subsequent EcoRV digestion of the PCR products would 
cleave the kinase domain fragment unless a TKD mutation at D835 (or I836) is present.  
 Clinical data  4.3.5
Data pertaining to treatment details, time to count recovery and clinical outcome were 
obtained by reference to hospital records. Final censoring of patients for survival analysis took 
place in April 2016.  
Full data tables showing treatment and outcome for all relevant samples are to be found in 
Chapter 5 (Table 5-3 and Table 5-5). 
 Statistical analysis  4.3.6
The majority of statistical analysis was performed using the Prism software package. All data 
sets were tested for normality of distribution by the D’Agostino & Pearson omnibus normality 
test. If data were not normally distributed, a Mann-Whitney t-test was applied in the 
determination of statistical significance.   
Clinical outcome data analysis was performed using the SPSS statistical package. Overall 
survival and relapse-free survival data were displayed graphically using Kaplan-Meier curves, 
and differences in outcome analysed by the log-rank assay.  
Due to small sample size, multivariate analysis of clinical outcome data was not undertaken. 
The distribution of samples within categories of variables of known significance was analysed 
by the Fisher’s Exact Test (for 2x2 contingency table), or the Freeman-Halton extension of the 
Fisher’s Exact Test (for 3x2 contingency tables).   
 Chapter 4: Identification of normal HSCs  
128 
4.4  Results 
 Antigenic panel design for stem cell identification 4.4.1
4.4.1.1 Sample Information 
AML diagnostic samples from 52 different patients were used to test a potential panel of 7 
antigenic markers. These samples were a mixture of leucophoresis aliquots, bone marrow and 
peripheral blood. They represented samples from good, intermediate and poor risk karyotype 
AMLs, as shown in Table 4-1. Of these, 37/52 (71%) were from patients with CD34+ AML, and 
15/52 (29%) from patients with CD34low AML. The relative overrepresentation of CD34low AML 
samples in this group reflects the ease of accessing samples from a bank of leucophoresis 
samples from CD34low AML patients maintained by the group.  
All samples were obtained from the Bart’s Tissue Bank, with consent for their use having been 
previously obtained in accordance with the Declaration of Helsinki.  





 fraction of a range of AML samples  
All results are summarised in Table 4-1. The results pertaining to individual antigens are 
considered below.  
 ALDH expression 4.4.1.2.1
49 AML samples were tested for ALDH expression. Of these, 31/49 (63%) contained a small, 
discrete ALDHhigh population (of putative stem cells) within the CD34+38- subfraction. In 12/49 
samples (25%), the leukaemia sample itself showed high ALDH expression, therefore negating 
the potential usefulness of ALDH expression as a mechanism of detecting stem cells. In the 
remaining 6/49 samples (12%), although the CD34+38- cells within the leukaemia were of 
either low or intermediate ALDH expression, there were no cells visible in the ALDHhigh gate, 
despite successful positive controls within the same ALDH staining batch. This might suggest 
an absence of stem cells within these samples. Examples of all three staining patterns are 
given in Figure 4-2. 
Subanalysis focusing on the CD34+ AML samples tested was then performed. These are the 
samples of the most interest to us, being the ones where CD34 and CD38 expression alone are 
insufficient to identify normal HSCs. 19/35 (54%) of CD34+ AML samples contained a small, 
discrete ALDHhigh population within the CD34+38- population. 11/35 (31%) of the leukaemia 
samples showed high ALDH expression, and 5/35 showed no cells with ALDHhigh expression.  
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 populations. Key: + 




 population; -: antibody does not separate out 




 population; Blank: not tested 
SAMPLE INFORMATION ANTIGEN 
ID CD34 STATUS CYTOGENETICS ALDH TIM3 CLL1 CD33 CD99 CD300 CD47 








+ - + + 
   
3978 POS 
 




NO CELLS - + + + - 
 
6217 POS t(6;11) LEUK HIGH 
 
- + 






   
6753 POS 
 
NO CELLS + + - + - - 
6796 POS t(15;16) LEUK HIGH - + + - 
  
7033 NEG NORMAL + + + + + - - 
7192 POS DEL 7q + + + - - 
  
7522 POS t(5;15) LEUK HIGH - - - - 
  
7620 NEG NORMAL + + 
     




+ - + - 
   
7820 POS t(9;22) + + + - + - 
 
7828 POS COMPLEX LEUK HIGH - - - 
  
- 
7829 POS +13 + + + + + - - 




+ - + + 






   
7882 POS INV(16) + - 
     
7913 POS DEL 7q NO CELLS 
 
+ 
   
- 
7967 POS NORMAL LEUK HIGH - + 
   
- 
7968 NEG NORMAL LEUK HIGH - - - 
   
8145 POS t(15;16) + - 
    
- 
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SAMPLE INFO ANTIGEN 
ID CD34 STATUS KARYOTYPE ALDH TIM3 CLL1 CD33 CD99 CD300 CD47 
8148 POS +13 + - + - + - 
 




8361 POS t(6;9) + - + + 
  
- 
8458 NEG NORMAL + - - + 
   
8492 POS t(8;21) 






NO CELLS - 
     
9066 POS t(9;22) LEUK HIGH - 
    
- 
9068 POS DEL 7 + - + + 
   
9332 POS NORMAL NO CELLS - + - 
   
9346 NEG +21 + + + + 
   
9552 POS 
 




+ + + + - - 
 
9584 POS DEL 5q + - + - 
   
9653 POS DEL 1q + + + + 
   
9668 POS NORMAL + - + - - 
 
- 
9669 POS INV(16) + - + - 
   
9672 POS DEL 7q 
 
- 
     
9713 NEG NORMAL + + + + + 
 
- 
9716 NEG NORMAL + + + + 
   
9717 POS DEL 7 and +21 + + + - 
   
9718 POS 
 
+ - + + 
   
9719 NEG 
 
+ + + - + - 
 
9725 NEG NORMAL + + + + 
   
9815 POS NORMAL + - + - 
   
TEMP 0580 POS 
 
LEUK HIGH - + - 
   
TEMP 1497 NEG 
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Figure 4-2 Flow plots illustrating the three patterns of ALDH expression within AML samples. Sample 9669 is an 
inv(16) AML sample where there is a clear, separate ALDH
high
 population of putative stem cells. Sample 9332 is an 
AML sample of normal karyotype where there are no apparent cells in the ALDH
high
 gate. Sample 7847 is a poor risk 
karyotype AML with hyperdiploidy, where the leukaemia cells are ALDH
high
 
It is interesting to observe the patterns of ALDH expression within the CD34+38- fraction of 
CD34low AMLs. As we might expect, in these samples, the majority of the CD34+38- cells stain 
ALDHhigh. This was the case in 12/14 samples studied. In 1/14 samples, all of the CD34+38- cells 
were ALDHhigh. In 1/14 samples, there were no cells seen in the ALDHhigh gate of the CD34+38  
subfraction.  
 CLL1 4.4.1.2.2
44 samples were tested for CLL1 expression. 38/45 (84%) of the samples showed differential 
CLL1 expression within the CD34+38- populations, which generally separated into two discrete 
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populations separated by one or two logs of staining intensity. Example plots are shown in 
Figure 4-3. 
Subanalysis of the CD34+ AML samples showed that in 26/31 (84%) of the samples tested, the 
CD34+38- cells separated into two populations. In the CD34low AML samples, 12/14 (86%) 
showed a range of expression.  
 
Figure 4-3 Flow plots illustrating typical patterns of CLL1 expression within a CD34
+
 AML (ID 7843) and a CD34
low
 
AML sample (Temp 1497) 
 TIM3 4.4.1.2.3
46 samples were tested for TIM3 expression. Of these, 17/47 (36%) of AMLs demonstrated a 
range of TIM3 expression within their CD34+38- subpopulations, which might be utilised to 
separate the cells into separate groups dependent on isotype gating. However, in only two 
cases did TIM3 staining mark separate populations of cells separated by greater than one log 
of intensity of staining. Both these staining patterns are illustrated in Figure 4-4. 
Subanalysis of the CD34+ AML samples showed that in 7/32 (22%) of the AML samples tested, 
the CD34+38- cells showed a spread of TIM3 expression. In the CD34low AML samples, 10/15 
(67%) showed a range of expression.  
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Figure 4-4 Flow plots showing characteristic patterns of TIM3 expression. Sample 7828 represents the most 




 subfraction of cells. Patient 9717 is a 




 cells of a 
CD34
+
 AML.  
 CD33  4.4.1.2.4
43 AML samples were tested for CD33 expression. Of these, 20/43 (47%) of the AML samples 
of the showed a range of CD33 expression within the CD34+38- cells, which might be utilised to 
separate out the population into separate groups. Differences between positive and negative 
staining cells were not as clearly defined as with CLL1 or ALDH expression (see Figure 4-5).  
Subanalysis of the CD34+ AML samples showed 10/30 (33%) to have differential expression of  
Figure 4-5 Flow plots showing CD33 expression within an AML sample. Here, CD33 defines a possible separation 




 population  
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CD33 within the CD34+38- subpopulation. Within the CD34low AML samples tested, 10/13 
samples (77%) showed differential expression. 
 CD99 4.4.1.2.5
19 AML samples were tested for CD99 expression. Of these, 9/19 (47%) showed distinct 
populations of CD99 positive and negative cells within the CD34+38- fraction.  
13 samples of CD34+ AML were tested, and of these, 4/13 (31%) showed differential CD99 
expression within the CD34+38- cells. Within the CD34low AML samples, 5/6 (83%) showed the 
same pattern. Typical flow appearances are shown in Figure 4-6. 
 
Figure 4-6 Flow plots showing typical CD99 expression patterns within two AML samples. ID 2069 is a CD34
+
 AML 




 cells. ID 7192 is a CD34
low
 
sample, where a more stringent separation is observed 
 CD300 4.4.1.2.6
CD300 expression was tested in 15 samples (8 of CD34+ AML, and 7 of CD34low AML). CD300 
did not appear to show a range of expression within the CD34+38- fraction of any of these 
samples (see Figure 4-7). 
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 AML sample 
 CD47 4.4.1.2.7
CD47 expression patterns were tested in 12 samples (ten with CD34+ AML and two with 
CD34low AML). As with CD300, CD47 failed to show a range of expression in the CD34+38- 
subfractions in any of these samples (see Figure 4-8).  
 





population within a CD34
+
 AML  
 What makes a useful marker?  4.4.1.2.8
The potential usefulness of an individual antigen in helping to separate out normal stem cells 
from the CD34+38- fraction of AML samples was assessed by two criteria. One is the number 
and diversity of samples in which it appears to separate out cells of different staining intensity. 
CLL1 and ALDH appeared to be the most effective with regarding to this effect, marking out 
putative populations in 84% and 54% of CD34+ AML samples respectively. CD33 and CD99 also 
appeared to have some utility, marking out populations in 33% and 31% of samples 
respectively.  
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In addition, the best antigenic markers stain populations of cells with clearly different 
intensities of staining (ideally at least one log difference between positive and negative 
populations). This allows for unequivocal gating of populations, which is especially important 
for this panel, as it was designed to help us to identify and enumerate normal HSCs in 
diagnostic samples (see Chapter 5). By this criteria, ALDH and CLL1 are again the most valuable 
markers, consistently marking out populations of cells within the CD34+38- subfraction of 
CD34+ AMLs, with clear differential intensity in staining between positive and negative 
fractions. CD33 and CD99 also identified differential expression of staining in approximately a 
third of all CD34+ samples, but in both cases, this staining represented more of continuum, 
rather than distinct populations. The same was also true for TIM3.  
Staining with CD47 and CD300 did not help to further define the cells within the CD34+38- 
fraction of AML samples, regardless of subtype.  
4.4.1.3 Combining ALDH and CLL1 staining leads to a more clearly defined population of 
putative stem cells in CD34
high
 samples 
Could simultaneous staining with more than one antigen help to resolve a putative stem cell 
population within the CD34+38- fraction of a greater proportion of CD34+ AML samples?  As 
ALDH expression and CLL1 appeared to be the most promising antigenic markers based on 
their single staining characteristics, analysis of co-stained samples was then undertaken. When 
CLL1 is used in combination with ALDH staining, a clear CD34+CD38-ALDHhighCLL1- population 
was identifiable in 100% of the 19 samples where the leukaemia was ALDHlow, but also in 5 of 
the 11 samples where the AML showed high ALDH expression. Thus the addition of CLL1 to 
ALDH enables us to identify a putative stem cell fraction in 24/35 (69%) of all CD34+ AML 
sample (see Figure 4-9).  
 
Figure 4-9 Flow plots illustrating how combining staining with ALDH and CLL1 can further define a putative stem cell 
population in a CD34
+
 AML 
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These flow plots help us to select markers which may identify a discrete stem cell population, 
but does not prove the cells we predict are normal genuinely are. However, it is encouraging to 
note that when we study the expression patterns seen within the CD34+38- fraction of CD34low 
AML samples, which we known to be enriched in stem cell activity and free of leukaemia-
associated genetic mutations, that the vast majority of these cells are ALDHhigh and CLL1 
negative.   
4.4.1.4 Final Panel Selection  
As a result of the data shown above, we constructed a panel to identify normal stem cells from 
AML samples comprising fluorochromes staining for expression of CD34, CD38, ALDH and CLL1. 
In single antigen studies, CD33 also appeared to show differential expression across the 
CD34+38- subfraction (in 33% of CD34+ AMLs). However, as we demonstrate in Chapter 6, the 
intensity of CD33 expression appears to fluctuate in the CD34+38- cell subfraction in AML 
samples between diagnosis and remission. As we were constructing a panel to stain and then 
count stem cells (comparing between AML samples and controls), gating would have to be 
consistent across all samples. Thus the inclusion of a marker that may vary in intensity 
between the two groups may make unbiased interpretation of results difficult.  
CD99 was another candidate marker for inclusion in the panel. As one might expect, the 
CD34+38- stem cells within CD34low AMLs were CD99 negative in 5/6 samples tested.  The 
CD34+38- cells within CD34+ AML samples showed differential CD99 expression in  4/13 (30%) 
of cases tested. However, at the time of panel construction, CD99 was only commercially 
available conjugated to the PE fluorochrome. This was also the case for CLL1, which appeared 
to be the superior marker for distinguishing putative stem cells in a wider range of samples, 
and hence CD99 was excluded.  
 Validation of the Stem Cell Panel: Early optimisation  4.4.2
4.4.2.1 Early attempts to assess the purity of putative stem cell fractions by FISH show 
encouraging results 
The purity of the putative stem cell fractions identified by the above technique was assayed, 
having selected two different AMLs with known karyotypic abnormalities to which FISH probes 
were commercially available.  
Patient 7013 had AML with associated inv(16). Bone marrow staining and subsequent sorting 
generated 7292 CD34+38-ALDHhigh cells, which were subsequently fixed onto slides. Using the 
Cytocell CBFB-MYH11 Probe (Cat: LPH 022) for detection of inv(16), 0/50 cells examined 
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contained the fusion product; a positive control slide made from unsorted bone marrow cells 
from the same patient showed the fusion signal in 10/10 cells. In this patient, as predicted by 
Gerber et al207, the use of ALDH expression alone is sufficient to separate out normal cells from 
the leukaemic clone within the CD34+38- subfraction.  
Patient 8361 was known to have developed AML with a t(6;9) translocation. Staining and 
subsequent sorting generated 2109 CD34+CD38-ALDHhighCLL1- cells. FISH staining using the 
Kreatech DEK/NUP 214 Probe for the detection of t(6;9), showed that 10/10 of the sorted cells 
gave a normal signal pattern. Analysis of the blast population (CD34+CD38-ALDHint) cells 
revealed 10/10 cells who all gave the same positive signal indicating the presence of t(6;9). 
This would suggest in patient 8361, this flow based method of sorting led to successful 
separation of normal cells from the leukaemic population.   
Technically, using FISH to analyse the purity of sorted populations of stem cells in this manner 
is a significant challenge, even for the most skilled practitioners. Even using the technique 
described in Section 2.7.1 to generate fixed slides from small numbers of sorted cells, FISH 
analysis becomes difficult when cell numbers fall below 2000 per slide. Numbers of 100,000 
per slide are preferred for optimal confidence in reporting. Thus samples which yield very 
small numbers (less than 1000) of CD34+38-ALDHhighCLL1- cells cannot be confidently analysed 
using this method.  
4.4.2.2 Testing the stem cell nature of sorted CD34+38-ALDHhighCLL1- cells by prolonged in 
vitro culture 
The next step in validating the sorting approach described above was to test the stem cell 
nature of the sorted cell fraction, as determined by the cells’ ability to survive in vitro culture 
conditions and generate colonies of normal karyotype. This approach has a secondary benefit: 
assuming cells grow in culture, the resultant amplified colonies can be tested for the presence 
of the leukaemia-specific mutation at the end of the culture period.  
This was first attempted by short term culture of sorted cells in methylcellulose for two weeks, 
and subsequently over a longer 7 week culture period, as detailed below.  
 Methylcellulose Assay 4.4.2.2.1
4.4.2.2.1.1 Optimisation of the Methylcellulose 2 week Cell Culture Assay  
Sensitivity of the methylcellulose assay in my hands was tested by sorting CD34+CD38-
ALDHhighCLL1- cells from GMPB, and growing these in culture for 2 weeks. After 2 weeks, having 
added 200 cells per plate in triplicate, a mean of 43 myeloid and 21 erythroid colonies were 
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noted. After replating of these cells, and culture for a further 2 weeks, means of 11 myeloid 
and 0.2 erythroid colonies were calculated.  
4.4.2.2.1.2 Methylcellulose Culture on HSCs sorted from AML samples- a 2 week culture 
period may not be sufficient to demonstrate colony production from quiescent stem 
cells   
Three different AMLs were then stained and sorted as described in Section 4.3.2.2. The 
number of CD34+38-ALDHhighCLL1- cells collected from each sample are shown below in Table 
4-2.  








 cells and grown in 2 week methylcellulose 
culture 
After 2 weeks of culture, no growth was visible on any of the plates from all 3 different AML 
samples. The plates were left unaltered at 37oC, and examined each week for the presence of 
colonies. At 5 weeks, colonies were visible on the plates containing cells from patient 8361. At 
an initial concentration of 100 CD34+38-ALDHhighCLL1- cells per plate; a mean of 1 myeloid and 
1 erythroid colony was seen per plate. At an initial concentration of 200 cells per plate, a mean 
of 4 myeloid and 1 erythroid colonies were counted. Subsequent FISH analysis for the t(6;9) 
translocation showed a normal signal, with no evidence of the translocation within these 
populations. No growth was observed on the plates from patients 8458 or 9068. 
This delayed growth of colonies is fascinating, as it is in marked contrast to the behaviour of 
the same CD34+38-ALDHhighCLL1- population from GMPB, which generated multiple colonies 
within two weeks. This observation gives further credence to the idea that the stem cells from 
within AML samples are in a state of induced quiescence.    
 7 week Long Term Culture on HSCs sorted from AML samples- assay optimisation   4.4.2.2.2
The results from the above experiment led us to hypothesise that a two to four week culture 
period may be inadequate to test the true stem cell nature of HSCs that have been induced 
into a state of quiescence by previous exposure to AML. The methylcellulose assay is not really 
designed to support the growth of any stem cells for a period greater than two weeks, as they 
generally require the cytokines released by supporting stromal cells to support a more 
prolonged culture period. Therefore a 7-week Long Term Culture Assay was set up to assess 








 CELLS SORTED CELLS PER PLATE 
8361 t(6;9) WT 2556 100 and 200 
9068 DEL 7 WT 168 42 
8458 NORMAL MUT 559 126 
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the growth and purity of cells sorted from three different AML samples, one control bone 
marrow and one GMPB sample (Table 4-3). As well as plating the putative sorted stem cell 
fraction of CD34+38-ALDHhighCLL1- cells, for the three AML samples, 1000 cells from each of the 
blast populations were also collected and plated to assess their behaviour in long term culture.  








 cells prior to 7 week LTC-IC assay 
After 7 weeks, no colonies were seen in any wells, including those containing the positive 
control cells. The absence of growth from any section of the culture, including the positive 
controls of GMPB or control bone marrow, pointed to a technical issue with the assay as the 
cause of this result.  
Therefore, a repeat LTC assay was set up using HSCs derived from normal bone marrow to test 
a number of variables which might have led to this assay failure. Any potential deleterious 
effect on cell viability by staining for ALDH expression was tested for by the simultaneous 
staining and sorting of the samples for CD34 and CD38 only (as detailed in Section 4.3.2.1), as 
well as concurrently for CD34, CD38, ALDH and CLL1 (as detailed in Section 4.3.2.2).  
My own inexperience in LTC-IC assays was tested as another variable. Two of 96 well plates 
were set up by an experienced operator (F Miraki-Moud), who also provided all the required 
weekly media changes. A further two plates were set up by myself in duplicate. 
Finally, the effect of different irradiation sources for MS5 preparation was also investigated. 
Two 96 well-plates were plated with MS5 cells irradiated at our newly installed irradiator at 
the BCI. A further two 96 well plates were plated using cells treated at the London Research 
Institute irradiator. The same dose of 70Gy was used for both conditions.  
Once again, at the end of 7 weeks’ culture period in a dedicated incubator, there was no 

















7820 AML t(9;22) 
 
1055 50, 100, 200 
9584 AML MONOSOMY 5 
 
528 10, 50, 100 






393 33, 100 
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Given this result, a third Long-Term Culture-Initiating Cell Assay was set up having ordered 
replacement stocks of fresh Collagen and H5100 MyelocultTM media. This time, GMPB was 
used as an enriched source of stem cells. CD34+ cells were sorted as per Section 4.3.2.1 (with 
no CD38 antibody added to reduce any potential inhibitory effect of residual CD38 antibody on 
stem cell viability)224. Cells were distributed in triplicate between wells in a range of 
concentrations. At the end of the culture period, a few, scattered colonies were visible (see 
Table 4-4).  
Table 4-4 LTC-IC attempt 3 results 
The growth of even a few scattered haematopoietic colonies was promising. However, these 
results show a very poor degree of concordance between technical replicates, and also a much 
lower sensitivity than was expected. As described in a recent publication, we had previously 
been able to generate to generate colony growth reliably from plating a mere five cells per 
well1.  
Our final hypothesis to explain the failure of the LTC assay was that the MS5 cells (used as a 
source of stromal-induced cytokines to support the growth of stem cells over the 7 week 
period) had become ineffective with age and repeated passaging (D Taussig: personal 
communication). Mycoplasma testing of our stocks of the cell line had been repeatedly 
negative. Fresh replacement stocks were ordered from the same supplier (DSMZ, Cat: 
ACC441), and the assay repeated. Lineage-depleted GMPB was sorted for CD34+ cells, which 
were plated in a range of concentrations as demonstrated in Table 4-5 .  
The universally positive growth as expected at the end of a 7 week culture period, from a 
source of enriched stem cells, suggested strongly that the previous failure of our LTC assay had 
been due to an issue with the MS5 stromal feeder line.  
NUMBER OF CD34
+
 CELLS PER WELL 
PRESENCE OF COLONIES IN WELLS 
WELL 1 WELL 2 WELL 3 
18233 + 0 0 
9116 + 0 0 
4558 0 + + 
1367 0 0 0 
911 0 0 0 
456 0 + 0 
230 0 0 0 
138 0 0 0 
46 0 0 0 
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Table 4-5 LTC-IC attempt 4 using new MS5 stocks 
Management of the feeder line throughout these experiments had been as described in 
Section 2.5.1. Once the cells reached 70 to 80% confluence in the culture flasks, cells were 
split. However, once thawed, cells on occasion been continually grown for periods of greater 
than two months, and therefore had undergone serial passaging. Other groups limit the 
number of serial passages to five or six to avoid an “exhaustion phenotype” (personal 
communication: F Anjos-Afonso). From this point on, we adopted a similar policy. All 
subsequent LTC assays were performed using our new replacement stocks. Given the technical 
difficulties this had led to, all subsequent LTC-IC assays were performed with the presence of a 
positive control of CD34+ sorted cells from either Lin depleted GMPB or cord cells.  
 Validation of the Stem Cell Panel: testing on AML bone marrow samples  4.4.3
Having optimised the 7 week LTC-IC assay in our laboratory, we were then finally able to 
proceed to test a range of diagnostic bone marrow AML samples by sorting their CD34+38-
ALDHhighCLL1- cells, attempting to amplify them in LTC and then testing the resultant 
populations of cells for the presence of leukaemia-specific mutations. This approach enabled 
us both to prove the stem cell nature of the fractions, as well as the testing the validity of the 
proposition that these antigens separate out “normal” stem cells from the AML bulk 
population.  
4.4.3.1 Identification of appropriate AML samples for sorting 
A cohort of AML patients with diagnosis BM samples stored in the tissue bank was identified. 
For all samples, hospital records were analysed for the recorded cytogenetic karyotype at 
diagnosis, as well as any molecular genetic analysis performed. Samples were selected if one 
could potentially differentiate the normal population from the AML cells based on a detectable 
leukaemia-specific mutation.  
NUMBER OF CD34
+
 CELLS PER WELL 
PRESENCE OF COLONIES IN WELLS 
WELL 1 WELL 2 WELL 3 
12705 + + + 
6352 + + + 
3176 + + + 
1588 + + + 
635 + + + 
423 + + + 
211 + + + 
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 Cytogenetic abnormalities   4.4.3.1.1
Samples associated with common cytogenetic abnormalities, detectable by FISH probes 
routinely used by the RLH Cytogenetic laboratory, were preferentially chosen. In a few 
instances, probes (such as the Kreatech DEK/NUP 214 t(6;9) Probe) were specifically purchased 
and optimised for use in this project by Marianne Grantham.  
For patients with multiple cytogenetic abnormalities, FISH probes were chosen which would 
recognise the dominant clone, as this seemed the most sensitive method of screening for the 
presence of blasts.  
 Molecular Genetic Mutations  4.4.3.1.2
As discussed at length in Section 1.4.5.4.1, assessment of the constitution of the CD34+38-
ALDHhighCLL1- population by PCR based analysis for a leukaemia-associated mutation was 
assumed to be the optimal technique available. This is in part because the sensitivity of this 
test to low input cell numbers meant pre-test amplification of the sorted CD34+38-
ALDHhighCLL1- cell populations was not required. In addition, in the case of the NPM1 mutation, 
the fact that this mutation occurs early in leukaemogenesis, tends to be stable throughout 
disease evolution111, and therefore present in the vast majority of leukaemia cells, makes it an 
excellent candidate for assessing sort purity (in comparison to a secondary mutation which 
might only be detected within one clone)106. Finally, an assay for assessing the purity of an 
NPM1 sorted sample had already been developed (see Section 2.8.4.5) and was therefore 
possible to perform in-house. As a result of these factors, strenuous efforts were made to 
detect all samples carrying the NPM1 mutation.     
Hospital records were searched for previous clinical assessment of NPM1 and FLT3 status for a 
large cohort of AML samples known to be stored in the tissue bank.   
The methodology adopted by the RLH Molecular Genetics department for clinical screening of 
samples for NPM1 mutation (as detailed in Section 4.3.4.2.2)223 detects the presence of an 4 
base pair insertion within Exon 12 of the NPM1 gene, but does not involve sequencing the 
actual mutation (knowledge which is required for the primer selection during the qPCR assay 
described in Section 2.8.4.5).  
Therefore, we undertook independent screening of 37 samples for NPM1 mutation within our 
laboratory by the Methodology detailed in Section 2.8.3, both sequencing those samples which 
had been detected as having an NPM1 mutation by the hospital lab (n=24), as well as assaying 
samples which no result was available (n=13).  
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Typical traces showing the normal sequence within NPM1 Exon 12, Type A and Type D 
mutations are shown in Figure 4-10. 
 
Figure 4-10 Typical Sanger Sequencing traces showing A: normal Exon 12; B: Type A mutation- an insertion of a 
TCTG tetranucleotide; C: Type D mutation- an insertion of a CCTG tetranucleotide 
Of 24 samples assayed by both methodologies, concordant results were found in 22 of 24 
patients. In two (Patient ID 9713 and 10203), results were found to be positive by the RLH 
assay, but subsequent local sequencing failed to reveal a mutation. The reason for this 
discrepancy is not obvious, given the general view that NPM1 mutations are early events that 
are found within the vast majority of leukaemic cells, and therefore both tests should be 
sufficiently sensitive to pick up a mutation if present.   
Results of screening, and comparison with hospital records for the 35 samples used for 
validation are shown in Table 4-6.  
4.4.3.2 Selected AML sample details  
In total, 35 AML samples were sorted in an attempt to validate if the CD34+38-ALDHhighCLL1- 
compartment consisted solely of normal HSCs. The number tested was restricted by sample 
availability and processing costs. All of these AML samples were associated with mutations 
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(either karyotypic abnormalities, or mutations of NPM1 and/or FLT3), which meant we could 
attempt to assess the “normality” of the sorted stem cells. Of these samples, 4 were of good 
risk cytogenetics, 21 intermediate and 10 poor. Biological parameters pertaining to these 
samples are shown in Table 4-6. 
Subsequent analysis is organised with reference to the karyotypic risk group of the underlying 
AML samples. A summary of the results of sorting, growth in LTC and purity assessment of the 
resultant populations is shown in Table 4-7. Examples of the variety of phenotypic 
appearances shown by the AML samples sorted are illustrated in the FACS plots in Figure 4-11 
and Figure 4-12.  
4.4.3.3 Good risk AML samples 
 CD34+38-ALDHhighCLL1- cells are normal and free of the leukaemia-associated 4.4.3.3.1
mutation in all cases studied  
In all 4 good risk patients, colonies were observed after 7 weeks LTC of sorted CD34+38-
ALDHhighCLL1- cell fraction. This supports the hypothesis that these cells retain a stem cell 
phenotype.  
FISH based analysis of the resultant colonies found these to be clear of the leukaemia 
associated mutation in all cases. These results are shown in Figure 4-13 and Table 4-8. 
4.4.3.4 Intermediate risk AML samples 
 Sample processing  4.4.3.4.1
21 samples with intermediate risk AML were analysed. This is a complex collection of results to 
explain for two reasons. Firstly, some of the samples with known NPM1 mutations were 
analysed immediately after undergoing sorting. This was to increase the number of samples it 
was possible to process (due to the costs and the labour-intensive nature of the 7 week LTC), 
and was possible due to the sensitivity of the NPM1 PCR assay. Secondarily, the intermediate 
cytogenetic risk group encompasses a range of cytogenetic and molecular mutations, and thus 












 populations- sample information 
PATIENT DETAILS DIAGNOSIS BLOOD COUNT 






(% of LIVE CELLS 
CD34
+







NPM1 FLT3 ITD FLT3 TKD NPM1 
7774 62 M 8.1 0 37 NORMAL 
   
Y-TCTG 1.6 
7777 39 M 8.9 15 83 NORMAL 
   
Y-TCTG 1.4 
7793 56 F 11.1 4 10 ADD 13 
   
Y-TCTG 56.2 
7820 66 M 12.6 9 52 t(9;22) BIPHENOTYPIC 
    
85.4 
7829 22 M 11.1 5 82 +13; t(3;14) 
   
Y-TCTG 82.9 
7912 72 F 7.3 3 19 NORMAL 
   
Y-TCTG 0.2 
7968 51 F 12.0 13 180 +13 
   
Y-TCTG 2.6 
8199 45 F 6.6 22 41 NORMAL 
   
Y-TCTG 0.1 
8361 38 F 9.5 41 53 t(6;9) WT MUT WT 
 
42.5 
8429 48 M 6.1 3 39 NORMAL MUT WT MUT Y-TCTG 0.0 
8458 49 F 11.2 ? 35 NORMAL MUT WT MUT Y-TCTG 0.0 
8613 28 M 10.7 52 53 +12 WT WT WT 
  
8618 51 M 10.5 19 
 
NORMAL 
   
Y-TCTG 0.1 
8791 59 M 7.4 31 43 COMPLEX 
    
0.5 
8932 43 M 7.2 3 54 t(8;21) WT WT WT 
 
67.1 
8993 83 M 6.5 45 25 TRISOMY 11 
    
8.5 
9066 59 F 6.8 12 84 DEL 5 WT WT WT WT 63.2 
9067 67 M 7.4 142.6 172 NORMAL MUT WT WT Y-CTTG 9.3 
9154 63 M 10.3 4 129 COMPLEX WT WT WT WT 2.6 
 
147 
PATIENT DETAILS DIAGNOSIS BLOOD COUNT 






(% of LIVE CELLS 
CD34
+







NPM1 FLT3 ITD FLT3 TKD NPM1 
9583 44 M 8.3 7.6 9 HYPERDIPLOID WT WT WT WT 0.9 
9584 84 F 5.5 1.9 71 DEL5Q;HYPERDIP WT WT WT WT 42.0 
9669 41 M 11.1 12 70 INV(16) WT WT WT WT 15.6 
9672 61 M 6.9 45 20 DEL 7q 
   
WT 49.8 
9713 36 M 5.5 19 100 NORMAL MUT WT MUT WT 0.4 
9717 24 F 7.4 1.5 23 -7 AND +21 
    
12.8 
9719 61 M 8.9 6 123 NORMAL MUT MUT WT Y-TCTG 0.1 
9850 59 M 8.3 56 101 NORMAL MUT MUT WT Y-TCTG 0.8 
9878 48 M 11.8 73 47 NORMAL MUT MUT WT Y-TCTG 0.0 
9962 66 F 7.0 230 40 NORMAL 
   
Y-TCTG 0.6 
9963 69 F 10.8 5 57 DIF CLONES INC. DEL 7Q AND 11 WT WT WT WT 0.8 
9964 24 M 13.9 77 80 NORMAL MUT MUT WT Y-TCTG 0.2 
10139 22 M 8.1 10.5 23 t(15;17) WT MUT WT WT 82.9 
10147 36 F 5.4 2.3 54 COMPLEX WITH 5Q 
    
21.3 
10192 57 M 7.0 56 121 11P DEL MUT MUT WT Y-TCTG 0.3 
10212 30 F 10.7 9.8 52 t(15;17) WT MUT WT WT 7.2 




Figure 4-11 Sorting FACS plots for 4 primary AML samples, illustrating key steps of consecutive gating strategy ID 
10139 is a good risk sample with t(15;17); Samples 7774 and 7793  both are intermediate risk samples illustrating 
the different phenotypic appearances of NPM1 mutated AML; Sample 7829 has t(3;14) and add13 but is NPM1 WT 
 




Figure 4-12 FACS sorting plots illustrating the diverse appearances of 4 poor risk samples. ID 7820 is a biphenotypic 












 populations, LTC results and assessment of sorted populations for AML-associated mutations 
SAMPLE INFO ASSESSMENT OF STEM CELL FUNCTION OF CD34+38-ALDHhighCLL1- CELLS ASSESSMENT OF CD34+38-ALDHhighCLL1- CELLS FOR AML ASSOCIATED MUTATION 





















TIMING OF ASSESSMENT 






10212 t(15;17) GOOD Y Y 546 2 2 Y Y 
 
+ FISH PURE 
10139 t(15;17) GOOD Y Y 371 2 2 Y Y 
 
+ FISH PURE 
8932 t(8;21) GOOD Y Y 462 3 3 Y Y 
 
+ FISH PURE 
9669 INV(16) GOOD Y Y 947 3 3 Y Y 
 
+ FISH PURE 
7793 +13 INT Y Y 2417 3 3 N Y 
 
+ NPM PCR PURE 
10192 DEL 11P INT Y Y 1000 3 0 Y Y + UNABLE NPM PCR PURE 
9962 NORMAL INT Y Y 1153 2 2 N Y 
 
+ NPM PCR PURE 
8458 NORMAL INT Y Y 141 2 2 Y Y 
 
+ NPM PCR PURE 
7968 NORMAL INT Y Y 9000 4 4 Y Y + + NPM PCR DIRTY 
9850 NORMAL INT Y Y 1000 3 3 Y Y + + NPM PCR ENRICHED 






8993 +11 INT Y Y 1080 3 3 Y Y 
 
+ FISH PURE 







7829 +13; t(3;14) INT Y N 
         
7774 NORMAL INT N 
     
Y + 
 
NPM PCR PURE 
7912 NORMAL INT N 
     
Y + 
 
NPM PCR ENRICHED 
8429 NORMAL INT N 
     
Y + 
 
NPM PCR PURE 
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SAMPLE INFO ASSESSMENT OF STEM CELL FUNCTION OF CD34+38-ALDHhighCLL1- CELLS ASSESSMENT OF CD34+38-ALDHhighCLL1- CELLS FOR AML ASSOCIATED MUTATION 





















TIMING OF ASSESSMENT 






8618 NORMAL INT N 
     
Y + 
 
NPM PCR PURE 
9719 NORMAL INT N 
     
Y + 
 
NPM PCR ENRICHED 
7777 NORMAL INT N 
     
Y + 
 
NPM PCR ENRICHED 
9964 NORMAL INT N 
     
Y + 
 
NPM PCR PURE 
9878 NORMAL INT N 
     
Y + 
 
NPM PCR ENRICHED 
8199 NORMAL INT N 
     
Y + 
 
RNA SEQ PURE 
9067 NORMAL INT N 
     
Y + 
 
RNA SEQ PURE 
8361 t(6;9) INT N 




9717 -7 and +21 POOR Y Y 1637 2 2 N Y 
 
+ FISH ENRICHED 
9963 
3 CLONES INC 
DEL 7q & 11q+ 
POOR Y Y 1003 3 3 Y Y 
 
+ FISH PURE 
8791 COMPLEX POOR Y Y 1211 3 3 Y Y 
 
+ FISH PURE 
9066 DEL 5 POOR Y Y 589 2 0 Y N     
9583 HYPERDIPLOID POOR Y Y 1074 3 0 N N 
    
9672 DEL 7q POOR Y Y 15 3 0 N N 
    
9154 COMPLEX POOR Y Y 16 2 0 Y N 




POOR Y N 
    
N 
    
7820 t(9;22) POOR Y N 
    
N 
    
10147 COMPLEX POOR N Y 8 NP 
  
N 
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cells after LTC ii. Unsorted blasts 
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CD34+38-ALDHhighCLL1- CELLS MADE 
INTO SLIDES IMMEDIATELY 
UNSORTED CELLS MADE INTO SLIDES 
IMMEDIATELY 
COLONIES FROM CD34+38-ALDHhighCLL1- 
CELLS AFTER LTC 






















9669 INV(16) GOOD 
Cytocell 
CBFB-MYH11   
79484 90 OF 100 175000 0 OF 100 16000 NA 
10212 t(15;17) GOOD 
Cytocell PML-
RARA   
150000 100 OF 100 250000 0 OF 100 90000 3 OF 100 
10139 t(15;17) GOOD 
Cytocell PML-
RARA   
NOT MADE 
FROM DIAGNOSTIC 
REPORT 95 OF 100 
NOT RECORDED 0 OF 100 NOT RECORDED 5 OF 100 
8932 t(8;21) GOOD 
Cytocell 
AML1/ETO   
250000 94 OF 100 196000 0 OF 100 21000 NA 
8613 TRISOMY 12 INT 
ATTEMPTED 
G BANDING     
NOT RECORDED ASSAY FAIL NOT RECORDED ASSAY FAIL 
8993 TRISOMY 11 INT 
Cytocell MLL 
(KMT2A)   
100000 100 OF 100 50000 0 OF 10 25000 NA 
8361 t(6;9) INT 
Kreatech 
DEK/NUP214 
2070 0 OF 10 9635 10 OF 10 










250000 18 OF 100 144000 0 OF 100 24500 NA 
9963 
COMPLEX 
INC DEL 7q 
POOR 
Cytocell 
Del(7q)   
250000 33 OF 100 34000 0 OF 100 110295 NA 
9717 
COMPLEX 




Del(7q)   
NOT MADE 
FROM DIAGNOSTIC 
REPORT 10 OF 10 
NOT RECORDED 21 OF 100 NO GROWTH 
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In summary, 10/21 samples underwent LTC of the sorted CD34+38-ALDHhighCLL1- fraction. The 
other eleven underwent immediate DNA extraction and analysis following FACS separation.  
Of the ten samples which underwent LTC after sorting, eight of the samples grew successfully 
in 7 week LTC. One failed to grow (10192), and for one (7829) the entire assay, including 
positive controls, failed to grow (see Section 4.4.2.2.2), therefore precluding further analysis.  
Of the eight samples which grew successfully, seven were tested successfully for the presence 
of the leukaemia-associated mutation (five for an NPM1 mutation, one for FLT3-TKD mutation 
and one by FISH for AML-associated trisomy 11). The final sample underwent G banding to 
look for the presence of AML-associated Trisomy 12 (in the absence of a relevant FISH probe), 
which was technically unsuccessful (in that the cells failed to grow in pre-banding culture in 
the RLH Cytogenetics lab). 
Eleven further samples underwent immediate analysis of their sorted CD34+38-ALDHhighCLL1- 
populations, rather than further culture. Of these, eight underwent PCR-based assessment for 
the presence of a leukaemia-associated NPM1 mutation, two underwent RNA-Seq analysis, 
and their transcriptomes were subsequently analysed for reads mapping to the NPM1 gene 
(see Chapter 7). One underwent FISH for the AML-associated t(6;9) translocation. In addition, 
three of the samples which underwent LTC (10192, 7968 and 9850) had sorted sufficient 
CD34+38-ALDHhighCLL1- cells to allow not just LTC, but also parallel immediate analysis.  
 Analysis of NPM1 mutated samples 4.4.3.4.2
In total, 16 samples were analysed. 8/16 samples were sorted, with the resultant CD34+38-
ALDHhighCLL1- populations undergoing immediate DNA extraction and analysis. In 2/16 
samples, the sorted CD34+38-ALDHhighCLL1- populations underwent RNA extraction 
immediately, followed by RNA-Seq analysis. A further 6/15 samples were sorted, with the 
sorted populations then undergoing 7 week LTC-IC assay. 5 of these samples grew colonies and 
were analysed. For 3/6 of these samples which underwent LTC-IC, sufficient cells were also 
sorted at the time of plating to facilitate parallel immediate qPCR analysis.  
Of these 16 samples, 15/16 had Type A mutations. Sample 9067 had a Type D mutation.  
4.4.3.4.2.1 qPCR based assessment of CD34+38-ALDHhighCLL1- populations from AMLs with 
known NPM1 mutation  
Results of purity analysis and the number of cells processed for each sample which underwent 
qPCR based analysis are summarised in Table 4-9. 
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Table 4-9 illustrating the sorted cell numbers and results for samples undergoing purity analysis by qPCR for NPM1 mutation status Key: * no growth of unsorted cells in LTC, so DNA for positive 
control obtained from tissue bank stores. ** number of cells not recorded.  
ID 
SORTED CELLS FOR DNA EXTRACTION % CELLS CONTANING NPM1 MUTATION 




















































7968 9000 15000 410000 160000 81 73 35 109 






50000 155000 175000 
 
81 0 44 








9850 1000 300000 5000 70000 18 39 6 97 
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Of the 14 samples tested by qPCR by this methodology, 8/14 of the CD34+38-ALDHhighCLL1- 
populations were entirely free of the leukaemia-associated NPM1 mutation. Of the remaining 
six samples, in five cases (7777, 7912, 9719, 9850 and 9878), the CD34+38-ALDHhighCLL1- cells 
contained a significantly lower proportion of the NPM1-associated mutation than the unsorted 
AML cells. In only one case (7968), the sorted CD34+38-ALDHhighCLL1- populations contained 
the same proportion of mutated cells as the unsorted population.   
4.4.3.4.2.2 RNA-Seq based assessment of CD34+38-ALDHhighCLL1- populations from AMLs 
with known NPM1 mutation  
In Chapter 7, I describe the sorting of CD34+38-ALDHhighCLL1- populations from six AML 
samples, RNA extraction and subsequent transcriptome profiling. Two of these samples (ID 
8199 and 9067) had mutations within the NPM1 gene. Detailed analysis of the sequence of the 
RNA-Seq reads mapping to Exon 12 of the NPM1 gene suggested no evidence of the mutation, 
and therefore we concluded that these sorted populations were free of the leukaemia-
associated mutation. 
 Analysis of FLT3-TKD mutated samples 4.4.3.4.3
Although several of the intermediate risk samples contained either a FLT3-ITD or TKD mutation 
(or both) in conjunction with a mutation in the NPM1 gene, only one sample contained an 
isolated mutation in the FLT3 gene as the sole AML-associated mutation. Patient 9713 
developed an AML associated with FLT3-TKD mutation, detected on clinical screening at 
diagnosis.   
DNA was extracted from the resultant colonies from both sorted CD34+38-ALDHhighCLL1- and 
unsorted cells after 7 weeks LTC, as well as unsorted AML cells at the time of FACS separation. 
After initial PCR for the FLT3 gene, the resultant DNA was then incubated with the EcoRV 
restriction enzyme, which normally will cleave the FLT3 gene within the TKD domain (see 
Section 4.3.4.2.2).  
Figure 4-14 shows the resultant PCR gel after sample processing. The presence of a slow band 
suggests the co-presence of the TKD mutation, which prevents protein cleavage.  However the 
presence of one, fast band in the DNA extracted from the colonies derived from the sorted 
CD34+38-ALDHhighCLL1- cells suggests that these cells are free from the leukaemia-associated 
mutation.  
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Figure 4-14 Results of PCR gel after digestion for TKD mutation. The presence of 2 bands represents a point 








 stem cells after 7 weeks in 
culture; 2: DNA extracted from unsorted AML sample, uncultured; 3: DNA from unsorted AML, grown in culture for 
7 weeks; 4: negative control; 5: positive control 
 Analysis of samples with karyotypic abnormalities by FISH 4.4.3.4.4
Three samples containing karyotypic abnormalities associated with intermediate risk AML (but 
NPM1 and FLT3 WT) were sorted and their CD34+38-ALDHhighCLL1- cell populations analysed. 
One (ID 8361) was analysed immediately; in the other two cases, amplification of the sorted 
cells via 7 week LTC was attempted. The results are summarised in Table 4-8.  
In cases 8361 and 8993, the CD34+38-ALDHhighCLL1- cell population was free of the AML-
associated mutation. Sample 8613 contains an AML with trisomy 12 as its only identifiable 
genetic lesion. As no appropriate FISH probe was available to test for this, the resultant cells 
were extracted after 7 week culture, placed in Cytogenetic media and sent for standard 
Cytogenetic analysis by G banding. Unfortunately, these cells failed to grow in the media used 
by the RLH Cytogenetics Lab pre-staining, and therefore G banding analysis was not possible 
for this sample.   
4.4.3.5 Poor risk AML Samples 
Of ten patients with poor risk disease, nine sorted sufficient CD34+38-ALDHhighCLL1- cells to 
make amplification of cells by LTC viable. Sorting of sample 10147 yielded only 8 cells after two 
hours of processing. Therefore sort efficiency could not be verified, and LTC was not 
attempted.  
Of the nine remaining samples, three yielded colonies after 7 weeks LTC, and the results of 
their analysis are shown in Table 4-8. In two cases (9584 and 7820), all growth in the assay, 
including positive controls failed (see Section 4.4.2.2.2). In an additional four samples, the 
sorted CD34+38-ALDHhighCLL1- cells did not yield colonies in LTC. This finding is discussed in 
more detail in Sections 4.4.4 and 8.2.2.  
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Samples 8791 and 9963 were analysed by appropriate FISH probes, and the colonies derived 
from LTC were found to be clear of the AML-associated karyotypic abnormality.  
Sample 9717 represents an unusual clinical case, where a 21 year old with no previous 
chemotherapy exposure presented with an AML associated with both deletion 7 and trisomy 
21. Tests for Fanconi’s anaemia were negative. Analysis of the cells derived from 7 week 
culture of sorted CD34+38-ALDHhighCLL1- cells showed 21/100 of these cells contained the 
deletion 7 associated with the AML. FISH on unsorted cells at the time of diagnosis suggested 
that 10/10 cells examined carried the chromosomal abnormalities, suggesting at least that the 
CD34+38-ALDHhighCLL1- subset was enriched for normal cells.  
4.4.3.6 Summary 
In summary, we have definitive data on the purity of the CD34+38-ALDHhighCLL1- fraction sorted 
from AML cells in 26 samples (4 good risk; 19 intermediate risk; 3 poor risk).  
Of the 4 good risk samples, 4/4 of the CD34+38-ALDHhighCLL1- fractions were pure. Of the 
intermediate risk samples, in 13 of the samples, the CD34+38-ALDHhighCLL1- fraction was clear 
of the leukaemia associated mutation. In 5 of the samples, the CD34+38-ALDHhighCLL1- subset 
was “enriched” for normal cells, but the leukaemia associated mutation was detected at low 
level. In one sample, the sorting strategy demonstrably failed, with the CD34+38-ALDHhighCLL1- 
fraction containing high levels of the leukaemia associated NPM1 Mutation. In the poor risk 
samples, 2 samples when sorted for the CD34+38-ALDHhighCLL1- fraction were clear of the AML 
associated karyotypic abnormality. The CD34+38-ALDHhighCLL1- fraction of a third sample was 
“enriched” for the presence of normal cells.  
Therefore, in some 73% (19/26) AML samples, the CD34+38-ALDHhighCLL1- fraction was pure of 
the AML associated mutation. In a further 25% (6/24) of samples, the CD34+38-ALDHhighCLL1- 
fraction was “enriched’ for the presence of normal cells. These samples may contain frank 
blasts, or may contain stem cell fractions where some cells contain a pre-leukaemic mutation.   
 Does the composition and behaviour of the CD34+38-ALDHhighCLL1- cells 4.4.4
within AML samples at diagnosis have clinical significance? 
4.4.4.1 Does the absence of growth of sorted CD34+38-ALDHhighCLL1- populations have 
prognostic significance?  
20 AML samples were sorted, and the viability of their CD34+38-ALDHhighCLL1- fractions tested 
in technically successful (defined by assays where the positive controls yielded colonies) LTC 
experiments. Of these, 4 contained good risk cytogenetic mutations, 9 intermediate, and 7 
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poor. Growth of colonies from the CD34+38-ALDHhighCLL1- populations was observed in 15 
samples; of the 5 where LTC did not yield cells, 4 were sorted from poor risk samples and only 
1 from an intermediate risk AML. Does an apparent in vitro absence of functional stem cells in 
these 5 samples have a bearing on the observed clinical outcome of the patient?  





 cells within AML samples and overall survival 
Figure 4-15 A is a Kaplan-Meier plot comparing overall survival data between samples which 
showed growth from their CD34+38-ALDHhighCLL1- cells, and those that did not. There is no 
significant difference between these two groups (log rank p=0.49). 
 No growth in LTC is significantly associated with disease refractoriness to initial 4.4.4.1.2
induction chemotherapy  
Of the 20 AML samples successfully tested by LTC assay, 17 were treated at diagnosis with 
intensive induction chemotherapy. 2 patients died within 30 days of diagnosis, leaving 15 
survivors who had their response to initial chemotherapy examined by morphological review 
of bone marrow samples.  
3/5 (60%) of the samples where the CD34+38-ALDHhighCLL1- fraction failed to grow in LTC 
showed evidence of refractory leukaemia at the end of Induction. This compares to 0/10 (0%) 
of those samples in which colonies were identified at the end of 7 weeks. The association of 
lack of growth in LTC and refractory disease is statistically significant (Fisher’s Exact Test, 
p=0.022).  
Potential confounding factors which might affect the chance of disease remission are age225 
and cytogenetics225,226. In an attempt to examine this small dataset for potential confounding 
factors, the observed distribution of samples between the Growth versus No Growth of 
CD34+38-ALDHhighCLL1- cells and age categories was analysed by Fisher’s Exact Test (see Table 
4-10). Distribution of samples within these categories was not statistically different to that 
which was observed across the whole cohort (2 sided Fisher’s Exact Test, p=0.242). 
When examining the potential confounding effect of cytogenetics within these groups, a 3x2 
contingency table was constructed (see Table 4-11) and examined by the Freeman-Halton 
extension of the Fisher’s Exact Test. Although this did not reach formal statistical significance 
(2 sided test, p=0.056), a very strong skew in the distribution of these samples towards the 
poor cytogenetic risk group is very obvious.  
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 cells, and age categories  
A number of large clinical studies have examined the effect of cytogenetics on the chance of 
remission induction. A retrospective review of patients treated in CALGB trials between 1985 
and 2006, using the European Leukaemia Net Cytogenetics guidelines to risk-stratify patients97, 
showed within those with poor risk cytogenetics, patients aged under 60 had an overall CR 
rate of 50% (n=818), and aged over 60 a CR rate of 39% (n=732)225. These figures are 
comparable to those observed in the No Growth in LTC group, which suggests the difference 
may simply reflect these patients’ underlying cytogenetic abnormality. Further investigation is 
warranted.  








 cells, and cytogenetic risk categories 
 An absence of growth in LTC does not preclude normal haematopoietic recovery if 4.4.4.1.3
remission is achieved  
An absence of colony growth from the sorted CD34+38-ALDHhighCLL1- populations of cells in 7 
week culture would imply an absence of normally functioning haematopoietic stem cells 
within the bone marrow, if this in vitro assay is an model predictive for in vivo behaviour. 
Therefore, one could hypothesise these patients might exhibit delayed recovery of normal 
haematopoiesis after induction chemotherapy, or indeed post-chemotherapy aplasia.  
Of the five samples where the CD34+38-ALDHhighCLL1- fraction failed to produce colonies in LTC, 
three did not regain normal blood counts after induction, but in all of these cases, this was also 
in the context of refractory leukaemia. However, in the two cases (patients 10147 and 9583) 
where there was no evidence of residual disease, count recovery occurred within the normal 
 
AGE CATEGORY 
<60 >60 TOTAL 
BEHAVIOUR IN LTC 
NO GROWTH 3 2 5 
GROWTH 9 1 10 
TOTAL 12 3 15 
 
CYTOGENETIC RISK CATEGORY 
GOOD INTERMEDIATE POOR TOTAL 
BEHAVIOUR IN LTC 
NO GROWTH 0 1 4 5 
GROWTH 3 6 1 10 
TOTAL 3 7 5 15 
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time frame (neutrophils >1.0x109/L at days 26 and 17, and platelets >100x109/L at days 25 and 
32 for Patients 10192 and 9583 respectively).  





 population (‘Mixed’ sort) have prognostic significance?   
As summarised in Section 4.4.3.6 stated above, we have definitive data on the purity of the 
sorted CD34+38-ALDHhighCLL1- population in 26 AML samples. Nineteen of these contained no 
evidence of the leukaemia-associated mutation; six contained a significantly lower proportion 
of leukaemia cells than unsorted fractions; and one contained the same frequency of mutated 
cells as the matched unsorted sample.   
Previous data series discovered a significant association between AML samples with high ALDH 
expression and poor overall survival208,209. Although my approach (using a combination of 
markers to separate out stem cells from AML rather than using ALDH expression alone) might 
reduce this impact, I had hypothesised that an AML which shared the same phenotypic 
appearance as a normal stem cell might have a worse overall outcome.  
However, in this dataset, there is no association between the presence of a leukaemia 
associated mutation within the CD34+38-ALDHhighCLL1- population and a poor clinical outcome. 
If anything, the trend appears to be in the other direction.   
 There is no significant association between overall survival and the presence of a 4.4.4.2.1









Figure 4-15 B is a Kaplan-Meier plot comparing the overall survival of patients when split into 
two groups dependant on the purity of the sorted CD34+38-ALDHhighCLL1- populations. There is 
no significant difference between the two cohorts in terms of overall survival (p=0.17).   








 populations and age categories. Fisher’s Exact Test, p=1.00  
 
AGE CATEGORY 
<60 >60 TOTAL 










MIXED 5 2 7 
PURE 14 5 19 
TOTAL 19 7 26 
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 populations and cytogenetic risk categories. Freeman-Halton extension of the Fisher’s Exact Test, 
p=0.62 
There is no obvious skewing of sample distribution between the Mixed versus Pure sort groups 
and the potential confounding factors of age and cytogenetics (see Table 4-12 and Table 4-13). 
 There is no significant association between relapse-free survival and the presence of 4.4.4.2.2








 population  
Of this set of 26 patients, 23 received chemotherapy with curative intent. 4 died in induction. 
All of the remaining 19 patients achieved remission after cycle 1 of chemotherapy, and of 
these, data are available for the assessment of relapse free survival in 18.  
Comparison of relapse-free survival for the “Mixed” (n=5) and “Pure” (n=13) CD34+38-
ALDHhighCLL1- sample groups again showed no significant difference between the two cohorts 
(see Figure 4-15 C).   








 populations and age categories. Fisher’s Exact Test, p=1.00 








 populations and cytogenetic risk categories. Freeman-Halton extension of the Fisher’s Exact Test, 
p=0.16 
 
CYTOGENETIC RISK CATEGORY 
GOOD INTER POOR TOTAL 










MIXED 0 6 1 7 
PURE 4 13 2 19 
TOTAL 4 19 3 26 
 
AGE CATEGORY 
<60 >60 TOTAL 










MIXED 4 1 5 
PURE 11 2 13 
TOTAL 15 3 18 
 
CYTOGENETIC RISK CATEGORY 











MIXED 0 4 1 5 
PURE 3 10 0 13 
TOTAL 3 14 1 18 
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As before, there is no obvious skewing of sample distribution between the “Mixed” versus 
“Pure” sort groups and the potential confounding factors of age and cytogenetics (see Table 
4-14 and Table 4-15).  
 The presence of leukaemia-associated mutation within the CD34+38-ALDHhighCLL1- 4.4.4.2.3
population might be associated with improved overall survival within the NPM1 
mutated cohort (but does not reach clinical significance)   
The results illustrated in Sections 4.4.4.2.1 and 0 seem particularly surprising given that the 
“Mixed” samples are either of Intermediate (n=6) and Poor (n=1) risk cytogenetics, and contain 
no good risk samples (although I note that this distribution of samples (see Table 4-13) is not 
sufficiently skewed to reach significance when analysed by the Freeman-Halton extension of 
the Fisher’s Exact test). Nevertheless, as all of the samples with mixed CD34+38-ALDHhighCLL1- 
populations within the Intermediate group carry the NPM1 mutation, an overall survival 
analysis was performed comparing the Mixed (n=6) versus Pure (n=10) samples which carry 
the NPM1 mutation. This is displayed graphically in Figure 4-15 D. Although the difference in 
survival between the two cohorts does not quite achieve statistical significance by log rank test 
(p=0.07), an interesting trend toward increased survival in those samples with Mixed CD34+38-
ALDHhighCLL1- populations is displayed, which is more marked than when considering all the 
cohort together. As before, analysis of the distribution of samples within these groups 
between age categories is not significantly skewed (see Table 4-16, Fisher’s Exact Test, p=1.00).  









populations and age categories for NPM1 mutated samples only 
This (non-significant) trend towards an improved overall survival with a Mixed CD34+38-
ALDHhighCLL1- population becomes more intriguing when considering the FLT3 mutational 
status of the samples in question. Unfortunately, we only have an incomplete dataset available 
(see Table 4-6). FLT3 mutational status is documented for 8 of the NPM1 mutated samples. Of 
those with data available, 3/3 of those samples with Mixed CD34+38-ALDHhighCLL1- populations 
were FLT3-ITD mutated, as opposed to 2/5 of those with Pure CD34+38-ALDHhighCLL1- sorts. It is 
well documented that the overall survival of those patients with concurrent NPM1 and FLT3-
 
AGE CATEGORY 











MIXED 4 2 6 
PURE 7 3 10 
TOTAL 11 5 16 
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ITD mutations is inferior to those with NPM1 mutations alone103,227. Further discussion of this 












 population on overall survival; 














 population within NPM1 mutated 
samples only 
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4.5 Discussion 
 General points 4.5.1
In this chapter, I describe attempts to design and validate a panel of antigenic markers, 
capable of distinguishing normal stem cells from leukaemia cells in unselected AML samples. In 
doing this, we had to overcome a number of technical hurdles. Optimising FACS sorting 
conditions to facilitate the accurate separation of tiny numbers of CD34+38-ALDHhighCLL1- cells 
(which comprised on average 0.01% of cells within AML samples); identifying methods of 
reliably assessing the genetic makeup of very small numbers of sorted cells, and assessing 
stem cell functionality within the 7 week LTC assay posed the three biggest experimental 
challenges.  
As discussed in Section 2.4.5.5, sorted samples were accepted if greater than 90% of the 
sorted cells fulfilled the initial sort criteria on reanalysis. This approach is widely accepted as a 
pragmatic approach to limit repeated sorting and where possible preserve cell viability. 
Nevertheless, this also means there is an inherent acceptance that up to 10% of sorted cells 
may therefore be leukaemic in nature, simply due to failed physical separation by the FACS 
machinery. 
The panel of antigens selected to identify normal HSCs appeared to successfully mark out cells 
with a normal genotype in 73% (19/26) of the AML samples. In a further 25% (6/24) of 
samples, the CD34+38-ALDHhighCLL1- fraction appears “enriched” for normal cells, containing a 
significantly lower proportion of cells carrying the leukaemia-associated mutation than the 
unsorted population.  
Interestingly, predicting whether the panel of antibodies is able to select successfully for 
normal stem cells based solely on FACS appearances is extremely difficult. A good illustration 
of this is provided the FACS plots of ID 9717 (see Figure 4-12), where there was excellent 
demarcation of the CD34+38- gate into high, intermediate and low ALDH-expressing 
populations (with little evidence of overlap), and yet 21% of the final sorted CD34+38-
ALDHhighCLL1- population carried a leukaemia-associated mutation.     
However, the evidence would suggest that this panel can reliably separate normal stem cells 
from patients with good risk cytogenetic abnormalities (4/4 samples tested). In intermediate 
risk samples tested, 69% (13/19) of samples successfully separated; 26% (5/19) were enriched 
for the leukaemia associated mutation, and in 5% the technique failed (1/19). Analysis of the 
panel’s efficacy in separating normal stem cells from AML cells in poor risk samples was much 
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more limited, as an inability to amplify several samples in LTC meant only three samples grew 
sufficiently to be analysed by FISH. Of these, two samples when sorted for the CD34+38-
ALDHhighCLL1- fraction were clear of the AML associated karyotypic abnormality. The CD34+38-
ALDHhighCLL1- fraction of a third sample was “enriched” for the presence of normal cells.      
 Further experimental applications of the panel  4.5.2
This panel has subsequently been used for the majority of the experimental work on normal 
stem cells in the context of AML documented in the rest of this thesis. It is key to the work 
detailed in Chapter 5, where stem cell numbers at diagnosis were calculated in a range of 
sample karyotypes. Without its use, any study would be limited to the cohort of CD34low AMLs 
we have described already.  
However, as documented above, it is almost impossible to predict from the FACS based 
appearances of samples whether they would sort pure or not using this approach. Therefore, 
wherever possible, the results of each sort are validated by testing the extracted cells for the 
presence of a leukaemia-specific mutation. For key experiments, where I was generally unable 
to sort sufficient cells to both perform the experiment and validate the population purity, I 
relied on using samples where the CD34+38-ALDHhighCLL1- cells are almost certainly clear of the 
leukaemia-associated mutation: namely those with good risk cytogenetic abnormalities and 
CD34low samples. These AMLs therefore represent the study groups used in Chapters 6 and 7.  
 Why is there a difference in the panel’s ability to separate from different 4.5.3
cytogenetic risk groups? 
It is interesting to hypothesise why there are differences in this panel’s ability to separate out 
normal HSCs from different AML samples.  
The most obvious explanation is that good risk cytogenetic AML samples do not share the 
phenotypic appearance of normal stem cells as defined by this panel. Indeed, Gerber et al 
showed that ALDH expression patterns alone were sufficient to separate out normal and 
leukaemia cells from CBF-mutated samples207. The cell of origin of the leukaemia might play a 
part: those leukaemias derived from mutations occurring in the HSC compartment might be 
more likely to have an overlapping phenotype than those evolving from a partially committed 
progenitor228. 
Alternatively, does the varying sensitivity of the analysis techniques contribute to the 
differences in separation ability seen?  5/6 of the samples which failed to sort pure carry NPM1 
Chapter 4: Identification of normal HSCs 
168 
mutations. Does the high sensitivity of this assay make it more likely to detect the presence of 
contaminating leukaemia cells than FISH?  
Or finally, is purity (for those samples analysed after LTC), more a reflection of the ability of the 
AML itself to survive in LTC culture, than the composition of the initial CD34+38-ALDHhighCLL1- 
population? More discussion of this possibility is to be found in Section 4.5.7.  
 What is the definition of a normal HSC anyway? The issue of pre-leukaemic 4.5.4
stem cells 
Evidence for the existence of pre-leukaemic stem cells in AML samples was first published in 
2012, after the start of work towards this thesis. The key initial papers described whole 
genome sequencing of sorted single cells of HSC phenotype from selected AML 
samples107,118,151. Analysis of these cells led to a hypothesis of the accumulation of sequential 
mutations within the HSC fraction, which eventually results in transformation to cells of the 
leukaemia blast phenotype. If chemotherapy proves effective against the leukaemic clone and 
remission is achieved, any residual pre-leukaemic HSCs may either persist in remission, or 
alternatively begin the process of accumulation of further mutations which may result in 
eventual relapse.  
This field brings a new dimension to the study of “normal stem cells” in AML. These pre-
leukaemic stem cells may retain the ability to survive long-term in the bone marrow and 
differentiate into mature cells, but the mutations they carry might confer a competitive 
growth advantage over other, non-mutated HSCs107. Key unanswered questions include the 
following. Are pre-leukaemic stem cells to be found universally in all AML samples? What 
proportion of the “normal” HSC fraction is made up of pre-leukaemic stem cells? Do these cells 
ever differ phenotypically from the normal HSC fraction?   
Acquisition of the NPM1 mutation is thought to represent a key step in the transformation to 
AML, as it normally detected in all leukaemic cells within samples which contain the mutation; 
is an accurate MRD marker, and is normally retained at clinical relapse111. However, as 
discussed in Sections 1.4.5.4.1 and 1.5.4, the key early papers in the field suggest that the 
NPM1 mutation is largely missing from the pre-leukaemic HSC population, where mutations in 
genes such as DNMT3A are more commonly found107,108. It therefore seems unlikely that the 
detection of low levels of NPM1 mutated cells within the HSC fraction (as seen in samples 
9850, 7912, 7777, 9878 and 9717) represents the presence of pre-leukaemic stem cells rather 
than true leukaemia cells, but this remains a question worth asking. Experimentally, one could 
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approach this question by transplanting these “Mixed” CD34+38-ALDHhighCLL1- populations into 
a permissive xenograft model, and examining the resultant CD45+ cells both morphologically 
and by flow for the presence of leukaemic blasts, although the inefficiencies of the xenograft 
transplant model might limit the usefulness of such an approach229.  
 Is there a clinical association between dirty and pure sorts? 4.5.5
As the results presented in Section 4.4.4.2 shows, there were no statistically significant 
correlations found between clinical outcome (as measured by overall survival and relapse-free 
survival) and the composition of the CD34+38-ALDHhighCLL1- cell population. However, there did 
appear to be a trend when considering NPM1 mutated samples (albeit one which did not reach 
overall significance on log rank testing) towards improved outcome, when the CD34+38-
ALDHhighCLL1- cells contained the leukaemia associated mutation   
This finding is surprising, given that high ALDH expression in AML samples (and so presumably 
an increased chance of a “Mixed” population of CD34+38-ALDHhighCLL1- cells) has been 
associated with poor clinical outcome in at least two independent datasets208,209. 
It is important to stress that any conclusions are limited by the very small size of this dataset. 
Although treatment pathways have not changed dramatically during the period of sample 
acquisition (2008 to 2014), the structure of the AML-17 trial (into which many of the later 
patients were recruited) favours an increased frequency of early allogeneic transplant in first 
remission230. Five of the seven samples where the CD34+38-ALDHhighCLL1- cell populations 
contained a leukaemia-associated mutation received an allogeneic transplant, of which four 
were in first remission. This trend for early transplantation might have an effect on the overall 
survival, which might be a significant confounder in this small dataset.   
 What is the significance of the failure of cells to grow in culture?  4.5.6
One striking result from analysis of the poor risk cytogenetic samples is that a significant 
number of the samples sorted and then grown in LTC, showed no colony development from 
their CD34+38-ALDHhighCLL1- populations. In contrast, in all of the four good risk AMLs studied, 
the wells plated with CD34+38-ALDHhighCLL1- cells grew colonies. Similarly, in eight of the nine 
intermediate risk AML samples, colonies were observed within the wells plated with CD34+38-
ALDHhighCLL1- cells. Could it be that in this group of patients, the residual ability for normal 
haematopoiesis is substantially reduced, even at presentation? This clearly has profound 
implications, as it suggests, even in the presence of chemosensitive disease, that these 
patients might struggle to recover normal haematopoiesis without transplantation.  
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Why would these cells fail to develop colonies? Once the technical difficulties with the MS5 
feeder lines described in Section 4.4.2.2.2 had been resolved, the assay appeared to be 
extremely sensitive, generating reproducible results with CD34+38-ALDHhighCLL1- cell inputs as 
low as two per well (see Section 6.4.2).  
There are a number of possible explanations for this observation. Poor risk patients, who often 
present with a disease with a slower tempo of evolution226, might simply contain no “normal” 
stem cells at the point of presentation. This could either be because these stem cells have 
themselves accumulated inactivating genetic mutations, or that their interaction with AML 
cells has rendered them functionally useless. We know that recovery with incomplete counts is 
more common in patients with poor risk cytogenetics231. However, this clearly does not 
entirely model the in vivo behaviour of these AMLS (see section 4.4.4.1.3), as the two cases 
that achieved leukaemic remission after induction, recovered normal blood counts briskly.  
Alternatively, poor risk AML may be a more powerful inhibitor of normal haematopoietic stem 
cells than good or intermediate risk samples, inducing such a degree of quiescence within the 
HSC compartment, that the cells within it are incapable of regeneration over the 7 week LTC 
period.  
A final explanation could be that within these poor risk samples, the sorted CD34+38-
ALDHhighCLL1- population contains a significant proportion of leukaemic blasts alongside the 
normal HSC fraction. During the 7 week LTC, the presence of blasts might impede recovery of 
normal haematopoietic function. However, several lines of evidence make this theory less 
likely. In two of the four samples where the CD34+38-ALDHhighCLL1- cells failed to produce 
colonies, wells of unsorted AML cells plated at the same time produced colonies. If the AML 
itself is capable of surviving the culture period, why do contaminating AML cells not similarly 
produce colonies in the wells plated with CD34+38-ALDHhighCLL1- cells? Secondarily, I have 
already described 7 samples where the CD34+38-ALDHhighCLL1- cells generated mixed 
populations of normal and leukaemia-associated cells in culture, suggesting that in these 
samples, AML cells and normal HSCs can co-exist in vitro.  
In the absence of the ability to amplify the sorted CD34+38-ALDHhighCLL1- cells of these samples 
by LTC, it is difficult to address the question as to whether these cells contain leukaemia-
associated mutations. Poor risk samples often provide the most challenging samples to analyse 
due to the complexity of the cytogenetic rearrangements seen. If amplification of sorted cells 
to facilitate standard cytogenetic analysis or FISH is not possible, alternative approaches need 
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to be explored. One possibility is single cell sorting of the CD34+38-ALDHhighCLL1- population, 
and subsequent whole genome sequencing. Alternatively, PCR-based analysis (analogous to 
the method used for the NPM1 mutated samples) could be used if an appropriate mutation 
was identified for this cohort. One candidate is the p53 gene, which is commonly mutated in 
patients with poor risk cytogenetics. One study of de novo AML patients reported the 
incidence of p53 mutations to be 7% across all subtypes, but rising to 59% in those with 
complex karyotypes. However, unlike the NPM1 mutation, mutations in the p53 gene can 
occur along the length of the gene, and so each sample would have to be individually 
sequenced before appropriate primers could be identified. In addition, serial sample analysis 
suggests p53 mutations are frequently lost on relapse, suggesting unlike the NPM1 mutation, 
this may represent a clonal marker, rather than a primary mutational event. This has 
implications for the sensitivity of such an assay232.    
If more sophisticated analysis of the CD34+38-ALDHhighCLL1- populations in these cases did 
show evidence that a significant number of cells contained the leukaemia-associated mutation 
(suggesting this panel was not able to separate normal stem cells from AML in this cohort), one 
could reapproach the design of the panel very specifically for poor risk cytogenetic samples. 
Most of the reported markers in Section 4.1.3 were identified using panels of AMLs 
representing normal or good risk disease. One approach would be to mimic the work of 
Kikushige et al198 by exploring differential gene expression between sorted normal CD34+38- 
cells and the CD34+38- fraction in a range of poor risk AMLs. Such an experiment could then 
screen for differentially expressed surface markers that might be more appropriate for this 
cohort of samples.   
 Concerns over the validity of the experimental design: LTC appears to 4.5.7
preferentially select the growth of normal haematopoietic stem cells over AML 
cells, and the strength of this selection may differ between samples  
In this chapter, the use of the 7 week LTC assay was key to the experimental set up: enabling 
not just assessment of the functionality of the sorted CD34+38-ALDHhighCLL1- cells, but also 
facilitating the amplification of sorted cells prior to genetic analysis. A key assumption was that 
if a population of sorted CD34+38-ALDHhighCLL1-cells contained a mixture of normal and 
leukaemia cells, both populations would amplify in LTC and be detectable at the end of 7 
weeks. However, close analysis of the results in Table 4-7, Table 4-8 and Table 4-9 shows that 
the LTC system appears to preferentially support the growth of normal haematopoietic stem 
cells over their leukaemic counterparts. This was an unexpected finding.  
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In the assay design for the LTC, at the time of plating sorted CD34+38-ALDHhighCLL1-cells, two to 
four wells of unsorted cells (containing approximately 50,000 cells per well) from the same 
sample were also added. This enabled us to observe if each AML sample was capable of 
survival in the LTC assay. The absence of cell growth in these wells at the end of the 7 week 
period would therefore raise concerns that assessment of the colonies from the sorted 
CD34+38-ALDHhighCLL1- cells might be unrepresentative of the purity of the initial sorted 
population.  
In addition, for the majority of samples characterised by a karyotypic abnormality detectable 
by FISH analysis, slides were made of the unsorted sample at the start of the experiment for 
use as a positive control during FISH staining. These slides were stored at 4oC for 7 weeks until 
the LTC was completed, and then analysed alongside the slides from colonies derived from the 
relevant population of sorted CD34+38-ALDHhighCLL1- cells. This was done to ensure there was a 
slide available for a positive control in each case, even if the unsorted cells failed to yield 
colonies in LTC.  
Therefore, the majority of samples had two potential slides for use as a positive control: a slide 
made at the start of the experiment from unsorted cells, and one made at the end from the 
colonies derived from unsorted cells. However, because of cost limitations around the staining 
of slides with FISH probes (and because I was unaware of the potential issue of preferential 
growth of normal cells over AML colonies), for the majority of these samples, I only used the 
slides made at the start of the experiment as positive controls.  
Samples 10139 and 10212 (both of which represent APML) had slides both made from 
unsorted cells at the start of the experiment, and also from the colonies grown from unsorted 
cells. In these cases, both slides were analysed alongside the colonies derived from the 
CD34+38-ALDHhighCLL1- cells. In both cases, the proportion of cells within the colonies grown 
from sorted AML cells which contained the leukaemia-specific mutation was markedly lower 
than on the slides made at the start of the experiment (Sample 10139: 5% from 95%; Sample 
10212: 3% from 100%).  
It is also noteworthy in the case of sample 9717 (a sample with complex cytogenetics which 
included del(7) and +21), that there was no growth observed in any wells plated with unsorted 
cells (as discussed in Section 4.4.3.5). This raises the concern that cells carrying the leukaemic 
mutation lack the ability to survive in vivo culture, seriously impacting the validity of any purity 
assessment of this sample. Interestingly however, assessment of the colonies derived from 
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CD34+38-ALDHhighCLL1- cells showed 21% of these cells to carry the leukaemia-associated 
del(7q). Quite why these cells proved able to survive in these conditions and not in others is 
unclear. In this patient, could this mutation mark a population of cells of pre-leukaemia status?    
Similar patterns of selection for normality are also observed in the cohort of intermediate risk 
samples tested for the presence of NPM1 or FLT3 mutations after LTC. In all of these cases, 
DNA was extracted from unsorted cells at the start of the LTC, as well as from colonies derived 
after 7 weeks.  
In the case of sample 9713, an AML with an associated FLT3-TKD mutation, visual examination 
of the PCR gel shown in Figure 4-14 shows a much stronger slow band (indicative of FLT3-TKD 
mutated PCR product) in Well 2 (DNA from unsorted AML cells processed immediately) than in 
Well 3 (DNA from unsorted AML cells after 7 week culture).     
NPM1-mutated AMLs behave similarly. In the case of samples 7793 and 9962, assessment of 
the sorted CD34+38-ALDHhighCLL1- colonies at the end of culture suggested these were entirely 
free of the leukaemia-associated mutation, which was present in 100% of the cells analysed 
before sorting. However, the unsorted AML cells failed to grow in culture. It is unclear if this 
absence of detectable mutated NPM1 in the colonies derived from sorted CD34+38-
ALDHhighCLL1- cells is because initial sorting was successful, or simply due to the inability of the 
AML to grow in culture. Samples 7968 and 9850 sorted sufficient CD34+38-ALDHhighCLL1- cells 
at the start of the experiment to allow immediate analysis, as well as LTC followed by analysis 
of the derived colonies. In both cases, the estimated percentages of leukaemia cells within the 
CD34+38-ALDHhighCLL1- populations were significantly higher in the cells analysed immediately 
post-sorting (for samples 7968: 81 versus 35%; for sample 9850: 18 versus 6%).      
4.5.7.1 Preferential ability of different subtypes of AML to survive in vivo culture in mice has 
also been documented  
Is there an alternative experimental design which could remove these sources of potential 
error? I had utilised an in vitro method of HSC amplification largely due to cost and sensitivity 
issues, but review of the literature would suggest that permissive murine xenograft models 
may well exhibit a similar bias.  
Pearce et al explored the causes of the observed variability of AML sample engraftment into 
NOD/SCID mice. 59 primary samples, representing a range of karyotypic abnormalities, were 
transplanted into xenograft models at the same cell dose. Engraftment was assessed at 6 
weeks by both morphological and flow based analysis of the murine bone marrow. The 
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cytogenetic risk group of the samples had a marked effect on the success of AML 
transplantation: 0/11 good risk karyotype samples engrafted, as compared to 18/36 
intermediate samples and 5/5 poor risk samples. Interestingly, in 7 of the samples where the 
AML failed to engraft, there was evidence of normal human haematopoietic development 
instead (the co-existence of CD45+33+ myeloid and CD45+19+ lymphoid colonies). The authors 
do not comment on whether there was evidence of low level normal haematopoietic activity 
seen in those 23 samples where AML engraftment was successful229. By contrast, normal 
haematopoietic tissue consistently engrafts NOD/SCID mice233.   
 Further experiments  4.5.8
I have envisaged a number of experiments which might address unanswered questions from 
this work.  
Primarily, it would be vital to increase the size of the AML sample cohort studied. The sample 
size in this chapter was largely limited by the expense of lengthy sorting and LTC; however, to 
determine if either the final composition of the CD34+38-ALDHhighCLL1- population, or its ability 
to survive in LTC, have clinical relevance, a much larger study cohort is required.  
Increasing funds would also enable study of a large group of AML samples which have to date 
remained elusive: those with a normal karyotype, and no associated NPM1 or FLT3 mutation. 
The advent of high-throughput screening means targeted sequencing of the most commonly 
mutated genes in AML can now be performed in a relatively cost-effective manner. Such a 
panel might screen for changes within the mutational hotspots of genes such as ASXL1, CBL, 
CEBPA, DNMT3A, ETV6/TEL, EZH2, GATA2, IDH1&2, KDM6A, KIT, KRAS, NRAS, RUNX1, SF3B1, 
SRSF2, STAG2, TET2, TP53, U2AF1 and ZRSR. Detection of a mutation would then lead to design 
of primers capable of detecting the leukaemia-specific mutation within the sorted stem cell 
population.  
One of the most interesting findings within this chapter is the apparent absence of normal 
stem cell function shown by a significant proportion of poor risk samples. If this finding were 
replicated in a wider cohort of samples, it raises key questions about how important residual 
stem cell functionality is in prognosis and whether such knowledge should modulate our 
decision making around treatment.   
However, I feel it is important to stress some of my anxieties with this data. It is very difficult 
to explain the normal recovery of blood counts in two patients post-successful remission 
induction, if the in vitro data truly reflect the in vivo situation. It would be interesting to repeat 
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the culture of sorted CD34+38-ALDHhighCLL1- cells from these AML samples, but using a 
xenograft model rather than an in vitro assay, to see if the same patterns are observed.    
As already discussed in Section 4.5.6, it has proved difficult to determine the composition of 
the CD34+38-ALDHhighCLL1- populations as these cells failed to amplify. Either the development 
of a PCR based assay for assessment of a pooled population of cells (for any of the genes 
detailed above found to be mutated within the AML blasts), or the adoption of single cell 
sorting and whole genome sequencing might help to answer this question.    
Finally, to try and answer if the in vivo model is a good model for assessing stem cell 
functionality in vivo, I would be interested in specifically investigating the small cohort of 
patients which have been rendered hypoplastic or aplastic (but with blast clearance) after 
chemotherapy. It would be fascinating to identify their pre-chemotherapy stem cell 
populations, and document their behaviour in vivo, to see if the resultant aplasia could have 
been predicted. 
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Chapter 5 Enumerating Stem Cells in Primary Diagnostic Bone 
Marrow samples from Patients Presenting with Acute Myeloid 
Leukaemia  
5.1 Introduction 
Our group is interested in the effect of acute myeloid leukaemia (AML) on the behaviour of 
normal HSCs in bone marrow, and how this interaction modulates downstream 
haematopoiesis. One hypothesis for the trilineage haematopoietic failure often observed in 
AML is that competition between AML leukaemia stem cells (LSCs) and normal HSCs might lead 
to death of the healthy cells, or disruption of their normal function. However, prior 
experimental work by our group using both mouse xenograft models and human primary 
diagnostic AML samples, has led us to the conclusion that HSC numbers are (at least initially) 
preserved, but that the proportion of cells in cycle is reduced.  
The group’s work on human diagnostic AML samples was limited to 16 CD34low AML biopsies, 
which, as described in Section 1.5.2.2, are ideal for this purpose, as their blast populations are 
solely found in the CD34low cell fraction. This phenotypic appearance is commonly associated 
with normal karyotype, NPM1 mutated samples. However, AMLs with this mutation pattern 
are associated with distinct clinical103, cytogenetic234, molecular235, and immunologic 
features236. As a result, they are now included as a separate entity within the WHO 
classification of haematological malignancies112. These 16 patients represent a highly selected, 
homogenous group of patients, which may not represent the diversity of behaviour across 
AML subtypes.   
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5.2 Aims and Objectives  
The primary aim of this chapter was to utilize the techniques described and validated in 
Chapter 4 to enumerate HSC numbers across a wide variety of AML subtypes at diagnosis. This 
was to enable us to see if the observations we had previously made concerning stem cell 
preservation and quiescence in leukaemia samples with low CD34 expression were applicable 
to a greater range of AML samples1.  
A secondary aim was to investigate if there was any correlation between stem cell numbers at 
diagnosis and clinical outcome, as measured by time to haematopoietic recovery and overall 
survival.     
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5.3 Specific methods  
 Processing of Fresh Samples 5.3.1
5.3.1.1 Sample Extraction 
In an attempt to limit the haemodilution which occurs with extensive BM removal, a standard 
operating procedure was used to ensure that the BM samples used for stem cell enumeration 
were obtained from the first pull of the aspirate, and in a small volume (less than 0.5ml) to 
reduce haemodilution for quantification of normal progenitors and HSCs. All patients 
presenting to St Bartholomew’s Hospital with a possible diagnosis of acute leukaemia, and all 
patients undergoing staging bone marrows for lymphomas were requested to have a sample 
taken. Samples were decanted into Eppendorfs containing 100µl Anticoagulant Citrate 
Dextrose Solution (Haemonetics, Cat: 426C).  
5.3.1.2 Sample Processing 
Samples were in general analysed the same day as they were taken, and always within 24 
hours. Between sample extraction and analysis, samples were kept at 4oC. Any sample with a 
visible clot at the time of analysis was discarded. 
200µl of fresh BM was mixed with 4ml ammonium chloride solution (Stem Cell Technologies, 
Cat: 07850), and incubated at 4oC for 10 minutes to induce red cell lysis. 1ml FBS was added 
and the sample pelleted (1500rpm, 5 minutes). The cells were resuspended in 50µl 2% HAG, 
mixed well and incubated for 20 minutes at 4oC. 5µl of CD34-PerCP (BD, Cat: 345803 (clone 
8G12)) and CD38-Pecy7 (BD, Cat: 335825 (clone HB7)) were added, and the sample incubated 
for 30 minutes at 4oC. The sample was then washed in 4ml 2% PBS, and resuspended in 300µl 
2% PBS/DAPI/DNase. Cell counting was facilitated by the addition of 50µl CountBright™ 
Absolute Counting Beads (Life Technologies, Cat: C36950). Analysis was performed using a BD 
Biosciences LSR.  
5.3.1.3 Confirmation of Clinical Details and Appropriateness for Further Investigation 
As samples were often taken before a firm diagnosis of AML were made, and control samples 
taken as part of lymphoma staging, no further analysis was undertaken until cross-referencing 
with the St Bartholomew’s Hospital Diagnostic Database was undertaken. Only those samples 
from patients with a confirmed diagnosis of AML, or those from newly diagnosed Stage I-III 
lymphoma patients with a full blood count within normal parameters with an unaffected bone 
marrow as confirmed by aspirate, flow cytometry and trephine histopathology were analyzed 
further. This represented approximately 50% of the samples initially received.  
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5.3.1.4 Analysis of the Initial Sample 
Cell numbers within a sample of known volume were calculated using the CountBright System 
(Molecular Probes). A known volume of a calibrated suspension of fluorescent microspheres 
was added to a defined volume of test sample, therefore producing a known sample volume to 
microsphere ratio. The volume of the sample analysed can therefore be calculated by using the 
recorded numbers of microsphere events.   
Sample analysis on the flow cytometer was followed by bead counting on a plot depicting Side 
scatter on a log scale versus R670/14 on a linear scale. Gating was then performed to 
enumerate the number of live, single CD34+ cells present in the sample, by the gating strategy 
illustrated in Figure 5-1 A.  
The concentration of CD34+ cells present in the original sample was then calculated by the 
following formula:  







Where a: number of cell events, b: number of bead events, c: assigned bead count of the 
individual CountBright batch (beads/50μl) and d: volume of the sample used (μl)  
 Subsequent Stem Cell Identification of Stored, Frozen BM Samples  5.3.2
5.3.2.1 Sample processing 
At a later date, previously stored bone marrow samples, taken at the same time as the 
samples analysed fresh in Section 5.3.1.4, were accessed. Samples were processed, stained for 
CD34, CD38, ALDH and CLL1 expression and analysed as described in Section 4.3.2.2. 
5.3.2.2 Analysis of the frozen sample 
HSC numbers (the CD34+CD38-ALDHhighCLL1- population) in the frozen sample were determined 
by the sequential gating strategy shown in Figure 5-1 B. CD34+ cell numbers in the same 
sample were calculated by the sequential gating shown in the same figure.  
The original concentration of CD34+CD38-ALDHhighCLL1- cells (cells/µl) at diagnosis was 
calculated as shown below. 
[                     ]      
[          ]                   {
                           
           
}                    
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5.3.2.3 Validating the purity of the identified CD34+38-ALDHhighCLL1-population 
As described in Chapter 4, a clear population of CD34+38-ALDHhighCLL1- cells (predicted to be 
stem cells, free of the leukemic clone) can be identified in the majority of patients with AML. 
However, as discussed in Section 4.5.1, even in those samples in which a clear, separate, 
population of CD34+38-ALDHhighCLL1- cells can be identified, those cells are not always 
karyotypically normal. To be able to confidently count residual stem cell numbers in diagnostic 
bone marrow samples, it is vital to be able to confirm the sorted cells are genuinely pure of the 
leukaemia-associated mutation. Therefore, in all cases possible, an attempt was made to 
establish the purity of the CD34+38-ALDHhighCLL1- sorted cells from the leukaemic clone, by the 
most appropriate method. Techniques utilized were conventional cytogenetic analysis, FISH 
and PCR specific for mutations within the NPM1 or FLT3 genes. 
 Clinical Outcome Data 5.3.3
Treatment details, time to count recovery and clinical outcome data were obtained by 
reference to hospital records. Final censoring of patients took place in April 2016.    
 Statistical analysis of data  5.3.4
The majority of statistical analysis was performed using the Prism software package. All data 
sets were tested for normality of distribution by the D’Agostino & Pearson omnibus normality 
test. If data were not normally distributed, a Mann-Whitney t-test was applied in the 
determination of statistical significance. 
Clinical outcome data analysis was performed using the SPSS statistical package. Overall 
survival and relapse free survival data were displayed graphically using Kaplan-Meier curves, 
and differences in outcome analysed by the log-rank assay. Due to small sample size, 
multivariate analysis of clinical outcome data was not undertaken. The distribution of samples 
within categories of variables of known significance was analysed by the Fisher’s Exact Test (for 
2x2 contingency table), or the Freeman-Halton extension of the Fisher’s Exact Test (for 3x2 




Figure 5-1 illustrating the sequential gating strategy used to analyse fresh and frozen AML samples. Sample shown is ID 10139, an APML BM. Plot A illustrates the gating strategy used on fresh 
samples to identify the initial [CD34
+
]. CountBeads are visible on the first plot shown; Plot B illustrates the gates used on analysis of frozen samples to identify both the numbers of CD34
+









 cells in the sample 
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5.4 Results 
 Samples processed for fresh BM analysis 5.4.1
Between June 2012 and August 2015, 71 fresh Eppendorf BM samples from patients were 
received and processed to determine the concentration of CD34+ cells at diagnosis. 
Subsequent examination of the St Bartholomew’s Integrated Diagnostic Pathology Reports 
revealed that 34 of these patients had been newly diagnosed with AML, and 16 represented 
true controls (see Table 5-1 and Table 5-2). 
A further 60 AML samples and 20 control samples had previously been processed and analysed 
by Dr F Miraki-Moud between 2007 and 2012 (clinical details not shown). 
5.4.1.1 Criteria for selection of samples for further analysis  
Interrogation of the tissue bank data base suggested that 73 of these 94 AML patients had a 
further sample of diagnostic BM available for further evaluation. Of these, 45 were thawed, 
stained for the panel of markers detailed in Section 5.3.2.1 and analysed in conjunction with 
the data stored from their fresh samples to calculate the concentration of CD34+34-
ALDHhighCLL1- cells present at diagnosis. In parallel, 24 control samples were analysed.  
Numbers were limited due to the expense and the time consuming nature of these 
experiments. The AML samples chosen represented the full range of observed cytogenetic risk 
groups and phenotypic appearances. Therefore sample selection was not random: those AML 
samples which had an identifiable karyotype or genetic mutation, which would enable 
assessment of the CD34+38-ALDHhighCLL1- cell population for a leukaemia-associated mutation, 
were preferentially processed.   
Table 5-3 and Table 5-4 summarise patient demographics and presenting FBC for the 45 AML 
and 24 control samples analysed. Table 5-3 also highlights the results for those AML samples 
where the CD34+34-ALDHhighCLL1- population was not just quantified, but also sorted and 
interrogated for the presence of a leukaemia-associated mutation. Table 5-5 details the 
treatment and clinical outcome for all 45 AML patients. 
5.4.1.2 CD34+38-ALDHhighCLL1- cell concentrations for all AML and control samples 
processed  
Table 5-6 summarises the concentration of CD34+38-ALDHhighCLL1- cells at diagnosis for the 45 
AML samples assayed. Table 5-7 illustrates the same information for the 24 control samples 
assayed.  
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Table 5-1 Control bone marrows analysed fresh for [CD34
+
 cell] between 2012 and 2015 
 
SAMPLE ID PATIENT DETAILS PRESENTATION BLOOD COUNT 





TEMP2027 10146 62 F DLBCL 8.0 14.1 661 
TEMP1950 10115 50 M DLBCL 15.0 12.6 294 
TEMP2011 10145 28 M MEDIASTINAL T CELL LYMPHOMA 12.9 16.0 517 
TEMP1954 10089 80 M MALT 11.2 8.1 312 
TEMP1935 10114 44 M DLBCL 10.3 3.5 177 
TEMP1862 9974 39 M DLBCL 11.6 14.9 417 
TEMP1831 9979 70 M FL 15.0 4.9 167 
TEMP1823 
 
30 F HD 11.9 8.5 395 
TEMP1821 9968 74 F DLBCL 12.5 6.0 229 
TEMP1735 
 
30 M REACTIVE 14.6 12.7 252 
TEMP1728 
 
75 F DLBCL 12.4 11.8 341 
TEMP1693 9760 64 F FL 13.9 7.0 360 
TEMP1692 9806 54 M BURKITTS 11.2 7.6 301 
TEMP1605 
 
88 M DLBCL 11.4 8.1 191 
TEMP1449 
 
26 F HD 12.3 12.3 280 
TEMP1503 9516 74 M DLBCL 12.0 10.5 313 
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Table 5-2 Newly diagnosed AML cases processed fresh for [CD34
+
 cell] at diagnosis between 2012 and 2014 
SAMPLE INFO PATIENT DETAILS AML DETAILS PRESENTATION BLOOD COUNT 





TEMP2467 10782 48 M AML-M0 NORMAL WT WT 8.2 2.2 32 
TEMP2028 10212 30 F AML-M3 t(15;17) WT MUT 10.7 9.8 52 
TEMP2010 10203 67 M AML-M5b NORMAL MUT MUT 7.8 99.0 27 
TEMP2009 10192 57 M AML-M5b DEL(11p) MUT MUT 7.0 56.0 121 
TEMP1987 10147 36 F AML-M6 COMPLEX INC DEL 5q 
  
5.4 2.3 54 
TEMP1982 10032 74 M MIXED PHENOTYPE AML/ALL HYPERDIPLOID WT WT 8.6 1.3 121 
TEMP1949 10139 22 M AML-M3 t(15;17) WT MUT 8.1 10.5 23 
TEMP1867 9900 61 F AML-M6 
 
WT WT 9.7 1.0 239 
TEMP1853 9892 56 M AML-M5b NORMAL WT MUT 8.3 134.0 30 
TEMP1848 9891 61 M AML-M2 NORMAL WT WT 10.5 1.0 60 
TEMP1842 9964 24 M AML-M2 NORMAL MUT MUT 13.9 77.0 70 
TEMP1810 9963 70 F AML WITH MDS COMPLEX INC DEL7q WT WT 10.8 5.0 57 
TEMP1811 9962 67 F AML-M4 NORMAL 
  
7.2 178.0 29 
TEMP1794 9879 58 M AML-PLASMABLASTIC SUBTYPE COMPLEX 
  
9.8 5.2 204 
TEMP1754 9850 59 M AML-M4 NORMAL MUT MUT 7.5 49.0 70 
TEMP1727 NA 24 F AML-M4 NORMAL MUT WT 8.2 0.9 26 
TEMP1724 9878 49 M AML-M5b NORMAL MUT MUT 11.8 73.0 47 
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SAMPLE INFO PATIENT DETAILS AML DETAILS PRESENTATION BLOOD COUNT 





TEMP1689 9786 69 M AML-Mo t(2;19), t(8;11) 
  
10.9 0.9 88 
TEMP1687 9653 53 M AML-M4 
 
WT WT 9.7 28.0 13 
TEMP1677 9815 43 M AML-M4 NORMAL WT WT 7.7 3.9 80 
TEMP1667 9716 70 M AML-M4 NORMAL WT WT 7.9 13.2 135 
TEMP1553 9668 62 F AML-M1 NORMAL 
  
10.3 17.0 54 
TEMP1565 9713 38 M AML-M0 NORMAL 
  
5.5 19.4 100 
TEMP1649 9717 24 F AML WITH MDS DEL(7) &  ADD(21) 
  
9.5 2.5 38 
TEMP1627 9725 73 F AML WITH MDS NORMAL 
  
10.4 4.7 CLUMPS 
TEMP1637 9718 56 F AML-M1 
   
5.4 7.5 173 
TEMP1619 9672 62 M SECONDARY AML DEL(7q) 
  
8.0 37.0 21 
TEMP1623 9719 62 M AML-M2 NORMAL MUT MUT 8.9 6.1 123 
TEMP1611 9669 42 M AML-M4 Eo INV(16) WT WT 11.1 12.2 70 
TEMP1552 9655 64 M AML-M0 NORMAL WT WT 7.7 0.8 23 
TEMP1542 9583 44 M 
  
WT WT 
   
TEMP1537 9584 84 F AML-M5a WITH MDS DEL(5q), HYPERDIPLOID WT WT 5.5 1.9 71 
TEMP1457 9467 87 M AML-M0 
   
9.0 1.0 38 
TEMP1510 9554 39 M AML-M4 NORMAL WT MUT 8.6 85.2 60 
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7774 62 M 8.1 0 37 NORMAL Y-TCTG 
 
PURE 
7777 39 M 8.9 15 83 NORMAL Y-TCTG 
 
MIXED 
7793 56 F 11.1 4 10 ADD 13 Y-TCTG 
 
PURE 
7820 66 M 12.6 9 52 t(9;22) 
  
 
7829 22 M 11.1 5 82 ADD 13; t(3/14) Y-TCTG 
 
 
7882 46 M 9.9 2 69 INV(16) 
  
 
7912 72 F 7.3 3 19 NORMAL Y-TCTG 
 
MIXED 
7916 62 F 6.3 38 76 NORMAL WT 
 
 
7955 61 M 9.3 14 19 NORMAL WT 
 
 
7967 67 F 10.0 2 18 NORMAL Y-CCTG 
 
 
7968 51 F 12.0 13 180 ADD 13 Y-TCTG 
 
MIXED 
8169 27 F 9.7 0 110 t(11;19) WT 
 
 
8199 45 F 6.6 22 41 NORMAL Y-TCTG 
 
PURE 
8361 38 F 9.5 41 53 t(6;9) WT FLT3-ITD PURE 
8429 48 M 6.1 3 39 NORMAL Y-TCTG FLT3-TKD PURE 
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8452 27 M 8.6 6 75 t(11;17) WT WT  
8458 49 F 11.2 ? 35 NORMAL Y-TCTG FLT3-TKD PURE 





8751 62 M 10.6 4 57 t(8;21) WT WT  
8791 59 M 7.4 31 43 COMPLEX 
  
 
8932 43 M 7.2 3 54 t(8;21) WT WT PURE 
8993 83 M 6.5 45 25 TRISOMY 11 
  
PURE 
9066 59 F 6.8 12 84 DEL 5 WT WT  
9067 67 M 7.4 142.6 172 NORMAL Y-CTTG WT PURE 
9154 63 M 10.3 4 129 COMPLEX WT WT  
9583 44 M 8.3 7.6 9 HYPERDIPLOID WT WT  
9584 84 F 5.5 1.9 71 DEL5Q;HYPERDIP WT WT  
9669 41 M 11.1 12 70 INV(16) WT WT PURE 
9672 61 M 6.9 45 20 DEL 7q WT 
 
 
9713 36 M 5.5 19 100 NORMAL WT FLT3-TKD PURE 
























9719 61 M 8.9 6 123 NORMAL Y-TCTG FLT3-ITD MIXED 
9815 42 M 7.7 5 105 NORMAL WT WT  
9850 59 M 8.3 56 101 NORMAL Y-TCTG FLT3-ITD MIXED 
9878 48 M 11.8 73 47 NORMAL Y-TCTG FLT3-ITD MIXED 
9900 60 F 9.1 1 239 NORMAL WT WT  
9962 66 F 7.0 230 40 NORMAL Y-TCTG 
 
PURE 
9963 69 F 10.8 5 57 DIF CLONES INC. DEL 7Q AND 11 WT WT PURE 
9964 24 M 13.9 77 80 NORMAL Y-TCTG FLT3-ITD PURE 
10139 22 M 8.1 10.5 23 t(15;17) WT FLT3-ITD PURE 
10147 36 F 5.4 2.3 54 COMPLEX WITH 5Q 
  
 
10192 57 M 7.0 56 121 DEL 11P Y-TCTG FLT3-ITD PURE 
10203 67 M 7.8 99 27 NORMAL WT FLT3-ITD & TKD  
10212 30 F 10.7 9.8 52 t(15;17) WT FLT3-ITD PURE 
10782 48 M 8.2 2.2 32 NORMAL WT WT  
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] at diagnosis by co analysis of 
fresh and frozen samples 
PATIENT INFO CLINICAL DETAILS PRESENTATION BLOOD COUNT 










7865 41 M HD 15.5 5.3 265 
 
7926 42 M HD 11.2 14.3 527 
 
7957 63 M DLBCL 12.5 5.2 295 
 
7958 22 F HD 10.5 6.2 479 
 
8066 27 F HD 13.5 7.5 316 
 8113 53 M DLBCL 13.2 8.1 432 
 
8115 42 M HD 16.5 8.1 318 
 8126 61 M MALT 13.7 6.2 250 
 8215 72 F MALT 12.7 7.2 110 
 
8245 45 M HD 12.9 7.8 316 
TEMP 0484 8445 62 M FL/DLBCL 15.1 7 252 
TEMP 0487 8510 21 F T CELL LYMPHOMA 13.1 7.4 587 
TEMP 1503 9516 74 M DLBCL 12.0 10.5 313 
TEMP 1693 9760 64 F FL 13.9 7.0 360 
TEMP 1692 9806 54 M BURKITTS 11.2 7.6 301 
TEMP 1605 9903 88 M GREY ZONE LYMPHOMA 11.4 8.1 191 
TEMP 1728 NA 75 F DLBCL 12.4 11.8 341 
TEMP 1735 NA 30 M REACTIVE 14.6 12.7 252 
TEMP 1821 9968 74 F DLBCL 12.5 6.0 229 
TEMP 1823 9975 30 F HD 11.9 8.5 395 
TEMP 1831 9979 70 M FL 15.0 4.9 71 
TEMP 1954 10089 80 M MALT 11.2 8.1 312 
TEMP 1950 10115 50 M DLBCL 15.0 12.6 294 
TEMP 2011 10145 28 M 
MEDIASTINAL T CELL 
LYMPHOMA 
12.9 16.0 517 
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7774 DA REFRACTORY 
  
HD ARAC YES 78 YES 
 
148 DEAD 244 
 
7777 AML 15-DA CR N/A N/A 
 
YES N/A YES ALLO N/A ALIVE 
 
3219 
7793 AML 15-DA 
DIED IN 
INDUCTION 
- - - - - - - - DEAD 22 
 
7820 GLIVEC N/A - - 
 
NO - - - - DEAD 139 
 
7829 GMALL CR - - 
IMMEDIATE 
ALLO 
YES 24 NO - - ALIVE 
 
3000 
7882 DA CR N/A N/A 
 
YES 34 YES ALLO 277 ALIVE 
 
3015 
7912 AML 16- DClo 
DIED IN 
INDUCTION 
- - - - - - - - DEAD 21 
 
7916 SUPPORTIVE N/A - - - - - - - - DEAD 2 
 
7955 DA CR N/A N/A 
 
YES N/A NO - - ALIVE 
 
35 
7967 AML 16-DClo CR N/A N/A 
 
YES 32 YES AZA 449 DEAD 584 
 
7968 AML 15-DA CR N/A N/A 
 
YES 28 YES 
 
170 DEAD 321 
 
8169 DA CR 18 26 - YES 26 YES ALLO 1466 ALIVE 
 
2756 
8199 AML 15-? CR 31 49 
 
YES 49 NO - - DEAD 105 
 
8361 DA CR 23 22 ALLO YES 23 YES 
 
245 DEAD 358 
 
8429 DA & GO CR 23 32 
 
YES 32 YES 
 





CR 28 38 
 









































CR 24 26 
 
YES 26 YES 
 
266 DEAD 391 
 
8618 DA CR 21 30 
 




AML 16-DA & 
GO 
CR 21 32 
 
YES 32 YES 
 
233 DEAD 327 
 
8791 AZA REFRACTORY 
   
NO - - 
 





CR 23 22 
 
YES 23 NO - - ALIVE 
 
509 
8993 SUPPORTIVE N/A 
   
NO - - 
 
- DEAD 472 
 









- - - - - - - - DEAD 2 
 
9154 






YES 66 YES 
 
140 DEAD 389 
 
9583 DA CR 17 32 
 
YES 32 YES 
 
1 DEAD 113 
 
9584 SUPPORTIVE N/A 
   
NO - - 
 
- DEAD 28 
 
9669 DA CR 22 28 
 
YES 28 NO - - ALIVE 
 
1219 
9672 AML 17-DA REFRACTORY 
  
LD ARAC NO - - 
 
- DEAD 338 
 
9713 AML 17-DA CR 28 64 
IMMEDIATE 
ALLO 
YES 64 NO - - ALIVE 
 
1211 
9717 DA CR 26 31 
IMMEDIATE 
ALLO 
YES 31 YES 
 












































9815 AML 17-DA CR 24 23 ALLO YES 24 NO - - ALIVE 
 
1148 
9850 AML 17-DA CR 35 35 ALLO YES 35 NO - - ALIVE 
 
1087 
9878 AML 17-DA CR 22 26 ALLO YES 26 NO - - ALIVE 
 
1015 
9900 DA CR 29 30 ALLO YES 30 NO - - ALIVE 
 
929 
9962 DA CR 29 30 
 
YES 30 YES 
 
191 DEAD 239 
 
9963 RAAVA REFRACTORY 
   
NO - - 
 
- DEAD 331 
 
9964 DA CR 21 28 ALLO YES 28 YES 
 





CR 36 29 
 
YES 36 NO - - ALIVE 
 
881 
10147 DA CR 30 30 ALLO YES 30 NO - - DEAD 158 
 
10192 AML 17-DA CR 26 25 ALO YES 26 NO - - ALIVE 
 
798 
10203 DA CR 21 28 
 
YES 28 YES 
 







- - - - 
 
- - - DEAD 24 
 













 stem cell concentrations for the 45 AML samples enumerated 
PAT ID 





































7774 15573 100 51800 286 9.5 118021 993 0.08 
7777 3511 100 51800 36 5.3 205865 512 0.01 
7793 22204 100 51800 672 15.7 2025286 1165 0.01 
7820 33870 100 51800 379954 5810.9 44468 15 1.96 
7829 20904 200 51800 720810 8930.8 96217 31 2.88 
7882 707 150 51800 89441 43687.4 13234278 25089 82.82 
7912 2931 50 51800 48 17.0 3216 90 0.47 
7916 35242 50 51800 614 18.0 23279 5500 4.26 
7955 26653 200 51800 302919 2943.6 1429399 4037 8.31 
7967 12237 200 51800 15520 328.5 192887 1210 2.06 
7968 16372 200 51800 249912 3953.5 679 3 17.47 
8169 2311 150 54000 2699 420.4 1227309 3175 1.09 
8199 3033 150 54000 268 31.8 9510 387 1.29 
8361 5772 200 54000 169064 7908.4 4212 9 16.90 
8429 1998 200 52500 153 20.1 2286 3 0.03 
8452 7969 200 52500 869 28.6 8081 2334 8.27 
8458 1991 100 52500 1691 445.9 286 0 0.00 
8618 31762 100 52000 1449 23.7 1495 5 0.08 
8751 2130 50 52500 109346 53903.0 9371014 2428 13.97 
8791 2258 150 52000 5195 797.6 37955 255 5.36 
8932 3468 40 51000 184953 67997.4 2428178 56 1.57 
8993 1851 200 52500 35128 4981.7 482919 747 7.71 









































9067 1821 200 51000 133 18.6 1200802 2339 0.04 
9154 280 200 51000 51375 46787.9 4509 1 10.38 
9583 26699 200 51500 489 4.7 15 0 0.00 
9584 17018 167 51000 65792 1180.6 13381 41 3.62 
9669 9161 200 51000 770534 21448.1 4360255 498 2.45 
9672 10791 200 51000 1508200 35640.0 2544238 172 2.41 
9713 20381 4.8 51000 182079 94921.2 44215 301 646.19 
9717 11231 200 51000 159289 3616.7 141420 2956 75.60 
9719 44341 200 51000 2444 14.1 2367 3 0.02 
9815 3432 200 49500 518138 37365.7 889768 1710 71.81 
9850 3321 200 49000 18604 1372.5 88684 537 8.31 
9878 6293 200 49000 7893 307.3 31503 130 1.27 
9900 18898 200 55000 206445 3004.1 98006 217 6.65 
9962 7231 200 49000 333743 11307.8 44193 93 23.80 
9963 15255 200 49000 1102432 17705.4 55689 54 17.17 
9964 402 200 55000 21733 14867.1 254587 115 6.72 
10139 22003 200 55000 375584 4694.2 886806 446 2.36 
10147 9666 200 55000 20511 583.5 293771 1 0.00 
10192 7920 200 55000 20714 719.2 10231 25 1.76 
10203 12346 200 55000 6601 147.0 15001 127 1.24 
10212 27333 200 55000 459817 4626.3 408141 266 3.02 
10782 20111 200 55000 410501 5613.2 365403 162 2.49 
 
195 








 stem cells for 24 control samples 
PAT ID 



































7865 12475 200 51800 19042 395.3 1250 12 3.80 
7926 12919 200 54000 2849 59.5 20633 820 2.37 
7957 32200 200 51800 196 1.6 154432 3305 0.03 
7958 25101 200 51800 10466 108.0 10797 32 0.32 
8066 19251 100 54000 5030 141.1 13630 131 1.36 
8113 18401 100 54000 18532 543.8 283737 3372 6.46 
8115 9850 100 54000 6457 354.0 42114 1642 13.80 
8126 33867 60 54000 7324 194.6 755488 33545 8.64 
8215 22217 50 54000 10980 533.8 226807 1278 3.01 
8245 14811 100 54000 9284 338.5 69628 4715 22.92 
8445 1073 200 52500 1129 276.2 27850 851 8.44 
8510 13423 100 52500 5937 232.2 106581 1408 3.07 
9516 31144 136 51000 535 6.4 91244 965 0.07 
9760 31759 200 49000 310 2.4 1483 24 0.04 
9806 20268 200 49000 6954 84.1 7952 55 0.58 
9903 25143 100 51000 1138 23.1 363274 1038 0.07 
TEMP1728 14119 200 49000 9251 160.5 34392 1065 4.97 
TEMP1735 20068 200 49000 369 4.5 13800 33 0.01 
9968 17591 200 49000 13194 183.8 688 9 2.40 
9975 4148 200 49000 3738 220.8 7248 74 2.25 
9979 24996 200 55000 9837 108.2 2766 8 0.31 
10089 20082 200 55000 31318 428.9 5320 82 6.61 
10115 6213 200 55000 30928 1368.9 19995 107 7.33 
10145 22964 200 55000 2707 32.4 923 11 0.39 
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5.4.1.3 Summary of the clinical characteristics of AML and control patients  
Table 5-8 directly compares the demographics of the patients whose samples were analysed 
for stem cell concentration at diagnosis.  
In 7 of the 45 AML samples where an attempt was made to calculate the stem cell 
concentration at diagnosis, cytogenetic or PCR based analysis of the sorted population of 
CD34+38-ALDHhighCLL1- cells showed them to be a mixture of normal and leukemic cells (see 
Table 5-3: Pat IDs 7777, 7912, 7968, 9717, 9719, 9850 and 9878). Therefore, as I am unable to 
estimate the actual normal stem cell concentrations in these samples, they are excluded from 
further analysis.   
Table 5-8 Comparison of characteristics of the patients within the AML and control cohorts 
 Summary of treatment outcomes for AML patients   5.4.2
5.4.2.1 Induction therapy 
Of the 38 AML patients analysed further, 32 (84%) underwent initial intensive induction 
therapy (the vast majority enrolled into the relevant MRC AML trial). 3/38 (8%) received low 
dose chemotherapy with palliative intent, and 3/38 (8%) received supportive therapy with 
blood products. 
5.4.2.2 Overall survival  
Kaplan-Meier curves showing the effect of cytogenetic risk group and age on overall survival in 
the cohort as a whole are shown in Figure 5-2 A and B respectively. The significant effect of 
both factors fits expected patterns, and suggests this is a representative dataset.  
SAMPLE TYPE CONTROL AML- ALL 
AML- EXCLUDING 
THOSE KNOWN TO 
SORT MIXED 
POPULATIONS 
SAMPLE NUMBER 24 45 38 
AGE 
MEDIAN 54 51 54 
RANGE 22-88 22-84 22-84 
SEX 
MALE 67% (16) 62% (28) 63% (24) 
FEMALE 33% (8) 38% (17) 37% (14) 
CYTOGENETIC 
RISK 
GOOD - 13% (6) 16% (6) 
INTERMEDIATE - 62% (28) 58% (22) 
POOR - 24% (11) 26% (10) 
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5.4.2.3 Remission Induction 
Of the 32 patients who received high dose induction therapy with curative intent, 25/32 (78%) 
achieved CR after Cycle 1. 4/32 (13%) had refractory disease, and 3/32 (9%) died within 30 
days of diagnosis. 3/4 (75%) of those with initially refractory disease achieved remission with 
salvage chemotherapy and/or allogeneic transplantation.    
5.4.2.4 Relapse free survival  
Of the 28 patients who did achieve remission, clinical data were obtainable for 26/28 (93%) to 
permit the calculation of relapse free survival. Figure 5-2 C and D show the effects of 
cytogenetics and age on relapse-free survival across the whole cohort. As with the data 
pertaining to overall survival, these figures suggest this cohort is a representative sample.  
5.4.2.5 Time to Count Recovery after Induction chemotherapy  
Of the 25 patients who achieved remission after initial induction therapy, data were obtainable 
for 21/25 (84%), to allow the calculation of time to count recovery after initiation of therapy. 
The median time for neutrophil recovery (using the MRC trial definition of neutrophils greater 
than 1.0x109/L) was 24 days (range 17 to 36 days). The median time for platelet recovery 
(using the MRC criteria of platelets greater than 100x109/L) was 30 days (range 22 to 64 days). 
 Comparison of normal stem cell concentrations between AML and control 5.4.3
samples     
Calculated HSC (as defined by CD34+38-ALDHhighCLL1- cells) concentrations at diagnosis are 
shown in Table 5-6 for all individual AML samples and Table 5-7 for controls.  
5.4.3.1 Stem cell numbers appear to be preserved between AML samples and controls 
Figure 5-3 A is a bar chart comparing stem cell concentrations at diagnosis between AML 
samples and controls. There is no statistically significant difference between the concentration 
of stem cells within control samples (n=24; median 2.4 cells/µl), and the diagnostic AML 
samples (n=45; median 2.5 cells/µl). When the AML samples are subclassified to either exclude 
those samples where the CD34+38-ALDHhighCLL1- population contains the leukaemia-associated 
mutation (“dirty” sort)(n=38; median 2.7 cells/µl) or only include those samples where the 
CD34+38-ALDHhighCLL1- population is known to be free of the AML associated mutation 
(“proven pure” sort) (n=17; median 2.4 cells/µl), there are still no significant differences to be 
found between any AML subpopulation and the control group. 
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 Subanalysis of AML samples  5.4.4
5.4.4.1 There is no association between stem cell number at diagnosis and the age of the 
patient, or cytogenetic karyotype of the AML 
The 38 AML samples were further analysed for factors which we hypothesised might have an 
effect on stem cell concentration at diagnosis. There was no significant difference observed 
between the stem cell concentration and patient sex (male, n=24, median CD34+38-
ALDHhighCLL1- concentration 2.5 cells/µl; female, n=14, median CD34+38-ALDHhighCLL1- 
concentration 3.1 cells/µl), as illustrated in Figure 5-3 B.  
Age does not appear to have a significant effect on stem cell concentration this cohort. This is 
the case when age is defined as a categorical variable (see Figure 5-3 C) (<60, n= 23, median 
2.5 cells/µl; >60, n=15, median 4.3 cells/µl, p=0.23 by Mann Whitney t-test), as well as when 
expressed as a quantitative variable (non-significant Spearman rank coefficient of 0.17 
(p=0.33)). 
Finally, there is also no significant association between CD34+38-ALDHhighCLL1- concentration at 
diagnosis and karyotype (good risk, n=6, median 2.7 cells/µl; intermediate risk, n=22, median 
2.3 cells/µl; poor risk, n=10, median 3.4 cells/µl) (Figure 5-3 D).  
























 population was 








 population to be free of leukaemia-associated mutations. Medians and IQRs are displayed; 
B: Bar chart comparing stem cell concentrations of 38 AML samples between male and female patients. Medians and IQRs are displayed. Mann-Whitney t-test shows no significant difference between 
male and female groups; C: Bar chart showing the relationship between stem cell concentration of 38 AML samples and age. Median and IQRs are displayed; D: Bar chart showing the relationship 
between stem cell concentration of 38 AML samples and cytogenetic risk group. Medians and IQRs are shown. There are no significant differences between groups by Kruskal-Wallis testing.
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5.4.4.2 Effect of stem cell concentration on clinical outcome  
 Low stem cell concentration at diagnosis is significantly associated with reduced 5.4.4.2.1
overall survival 
There is a significant range of concentrations of CD34+38-ALDHhighCLL1- cells at diagnosis within 
the 38 samples studied, ranging from 0 to 646 cells/µl, as shown in Table 5-6. There appears to 
be a cluster of samples (n=8) with a low stem cell concentration (ranging 0 to 0.1 cells/µl), with 
the remaining 30 samples having concentrations which range from 1 cell/µl upwards (with the 
majority 1 to 10 cells/µl). For the purpose of further analysis, stem cell concentration has been 
expressed as a categorical variable (low stem cells= [CD34+38-ALDHhighCLL1-] <0.1 cells/µl; high 
stem cells= [CD34+38-ALDHhighCLL1-] >0.1 cells/µl). 
Figure 5-4 A is a Kaplan-Meier survival plot illustrating a significant difference in overall survival 
between those with low and high stem cells, with those patients with less than 0.1 cells/µl at 
diagnosis having a significantly lower overall survival (log rank test, p=0.01) than those with 
higher levels at diagnosis.   
In order to validate this cut-point between the two groups, it would be appropriate to use the 
same parameters to analyse a second, independent sample cohort.  
This cohort of samples is too small to allow for multivariate analysis to determine if stem cell 
number at diagnosis is a truly independent variable from the other factors shown to have a 
significant effect on overall survival (age and cytogenetic analysis). In an attempt to examine 
the data for potential confounding factors, the observed distribution of samples between age 
and stem cell concentration groups was analysed by Fisher’s Exact Test (see Table 5-9). 
Distribution of samples within these categories was not statistically different to that which was 
observed across the whole cohort (2 sided Fisher’s Exact Test, p=0.440).  
Table 5-9 Cross tabulation for comparison of sample distribution within diagnostic HSC concentration and age 
categories 
A similar method was employed to investigate the observed distribution of samples between 
cytogenetic risk and HSC concentration groups. A 2 by 3 contingency table was constructed 
 
AGE CATEGORY 
<60 >60 TOTAL 
[STEM CELL] 
<0.1 CELLS/µl 6 2 8 
>0.1 CELLS/µl 17 13 30 
TOTAL 23 15 38 
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(see Table 5-10), and analysis was performed using the Freeman-Halton extension of the 
Fisher’s Exact Test (2 sided probability, p=0.47).   
Table 5-10 Cross tabulation for comparison of sample distribution within diagnostic HSC concentration and 
Cytogenetic Risk categories  
This provisional analysis (limited due to the size of the sample, and the number of factors 
known to be potential confounders) would suggest that the distribution of samples within the 
low and high stem cell groups within the age and cytogenetic stratification categories reflects 
that seen in the cohort as a whole. This is highly suggestive that stem cell concentration is an 
independent variable impacting overall survival.   
 There is no associated between low stem cell number at diagnosis and increased 30 5.4.4.2.2
day mortality 
When all 38 AML patients were considered together (irrespective of initial therapy), low stem 
cell concentration at diagnosis is associated with a worse outcome in terms of an increased 30-
day mortality. Of those 8 with a low HSC concentration at diagnosis (<0.1 cells/µl), the 30 day 
mortality rate was 25% (2/8), as opposed to 10% (3/30) for those with high HSC concentration 
at diagnosis (>0.1 cells/µl). However, this effect does not reach statistical significance (Fisher’s 
Exact Test, p=0.246).  
This association is more pronounced when only the 32 patients deemed fit to receive intensive 
induction therapy, are included in analysis. The 30 day mortality for those with low stem cells 
remains 25% (2/8), as opposed to 4% (1/24) for the high stem cell concentration cohort. Again, 
however this effect does not reach statistical significance (Fisher’s Exact Test, p=0.139).     
 There is no association between stem cell number at diagnosis and leukaemia 5.4.4.2.3
resistance to induction chemotherapy 
Only 4 of the 32 patients who received intensive induction therapy were refractory to initial 
treatment. 1/8 (13%) of those with a low stem cell concentration at diagnosis had refractory 
disease; 3/24 (also 13%) of the high stem cell concentration cohort responded similarly.  
 
CYTOGENETIC RISK CATEGORY 
GOOD INTER POOR TOTAL 
[STEM CELL] 
<0.1 CELLS/µl 0 6 2 8 
>0.1 CELLS/µl 6 16 8 30 
TOTAL 6 22 10 38 
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 Low stem cell number at diagnosis is significantly associated with reduced relapse 5.4.4.2.4
free survival.   
Of the 32 patients who received intensive chemotherapy at diagnosis, 25 entered an 
immediate remission. 3 of the 4 patients with initially refractory disease obtained remission 
after further salvage chemotherapy. Of this group of 28 patients, data were obtainable on 
relapse free survival for 26. Figure 5-4 B is a Kaplan-Meier plot illustrating the differential 
relapse free survival for the low stem cell (n=6) and high stem cell (n=20) cohorts. Relapse free 
survival was significantly lower in the cohort with low stem cell numbers at diagnosis (p=0.02, 
log rank test).   
As discussed in Section 5.4.4.2.1, this sample group is too small to facilitate multivariate 
analysis. As before, a Fisher’s Exact Test was used to analyse the observed distribution of the 
26 samples between age and stem cell concentration groups (see Table 5-11). Distribution of 
samples was not different to that observed across the whole cohort (p=1.00).   
Table 5-11 Cross tabulation for comparison of sample distribution between HSC concentration and age categories  
Table 5-12 Cross tabulation for comparison of sample distribution between HSC concentration and cytogenetic risk 
categories 
A similar method was employed to investigate the observed distribution of samples within 
stem cell concentration and cytogenetic risk groups. A 2 by 3 contingency table was 
constructed (see Table 5-12), and analysis was performed using the Freeman-Halton extension 
of the Fisher’s Exact Test (2 sided probability, p=0.369).   
As with overall survival, this analysis (albeit even more limited due to the smaller sample 
numbers) suggests that stem cell concentration at diagnosis is an independent variable 
predicative of relapse-free survival.  
 
AGE CATEGORY 
<60 >60 TOTAL 
[STEM CELL] 
<0.1 CELLS/µl 5 1 6 
>0.1 CELLS/µl 14 6 20 
TOTAL 19 7 26 
 
CYTOGENETIC RISK CATEGORY 
GOOD INTER POOR TOTAL 
[STEM CELL] 
<0.1 CELLS/µl 0 4 2 6 
>0.1 CELLS/µl 5 12 3 20 
TOTAL 5 16 5 26 
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 There is no significant association between stem cell concentration at diagnosis and 5.4.4.2.5
time to count recovery 
Of the 38 AML patients studied, 32 received intensive chemotherapy with a realistic aim of 
inducing remission. Of these, 25 entered CR after Cycle 1, and of these, serial blood count data 
were available for 21/25.  
Using the same categorisation of samples into low and high stem cells at diagnosis, there 
appears to be no association between stem cell number and time to neutrophil recovery (using 
the MRC criteria of neutrophil count greater than 1.0x109/L) from the start of induction 
therapy (low stem cells, n=5, median days to neutrophil recovery 23; high stem cells, n=16, 
median days to neutrophil recovery 24; p=0.45 by Mann Whitney t-test) (Figure 5-4 C). 
Similarly, there is no association between stem cell number and time to platelet recovery 
(using the MRC criteria of platelets greater than 100x109/L) from the start of induction (low 
stem cells, median days to platelet recovery 30; high stem cells, median days to platelet 
recovery 28.5; p=0.40 by Mann Whitney t-test) (Figure 5-4 D).  
It is worth noting time to count recovery is a highly complex variable. Within this cohort of 
patients, a variety of induction chemotherapy regimens were used (details are listed for 
individual patients in Table 5-5). These have been shown to vary in the degree of 
myelosuppression induced. In addition, those patients who developed severe sepsis may well 
have prolonged time to count recovery. G-CSF use to promote neutrophil recovery is now 
widespread in clinical practise, but was not subject to standardised use during the whole of the 
period these patients were treated. In a cohort of this size, it is not possible to control for all of 





Figure 5-4 A: Kaplan-Meier Plot showing effect of HSC concentration at diagnosis on overall survival; B: Kaplan-Meier plot showing effect of HSC concentration on relapse free survival; C: Bar chart 
showing association between HSC number at diagnosis and days from induction start to neutrophil recovery. Samples are divided into those with [stem cell] < 0.1 cells/µl (n=5) and [stem cell]> 0.1 
cells/µl (n=16). Median and interquartile range for each group are shown; D: Bar chart showing association between HSC number at diagnosis and days from induction start to platelet recovery. 
Samples are divided into those with [stem cell]<0.1 cells/µl (n=5) and [stem cell]>0.1 cells/µl (n=16). Median and interquartile range for each group are shown
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 Control Sample Subanalysis  5.4.5
One of the most striking and unexpected findings from this analysis is the considerable 
variation in the concentration of CD34+38-ALDHhighCLL1- cells present at diagnosis within the 
control cohort. In these 24 supposedly normal samples, there is an observed three log fold 
variation in stem cell concentration, from 0.01 to 23 HSCs/µl (as shown in Table 5-7).  
Further analysis was performed to investigate factors that potentially could contribute to 
variation in stem cell concentration at diagnosis.  
5.4.5.1 There is no significant effect of age or gender on stem cell concentration within the 
control cohort.  
There is no significant difference between the stem cell concentration for men and women 
(men, n=16, median 3.18 cells/µl; women, n=8, median 2.3 cells/µl) (see Figure 5-5 A). There is 
also no significant effect of age on stem cell concentration. This appears to be the case when 
age is defined as a categorical variable (see Figure 5-5 B (age<60, n= 13, median 2.4 cells/µl; 
age>60, n=11, median 2.4 cells/µl)), as well as when expressed as a quantitative variable (non 
significant Spearman rank coefficient of -0.03 (p=0.89)).  
 
Figure 5-5 Bar charts showing the effect on HSC concentration in control patients of A: gender and B: age. Medians 
and interquartile range are plotted. Assessment of statistical significance between groups was performed by Mann-
Whitney t-test  
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5.5 Discussion 
 Potential Clinical Applications 5.5.1
This study of a cohort of AML patients which represents a range of cytogenetic and genetic 
abnormalities, appears to confirm the earlier finding of our group in a more selected patient 
population, that normal HSC numbers are preserved at diagnosis1. 
In addition, calculation of HSC concentration at diagnosis with AML may have prognostic 
benefit for newly diagnosed patients. Analysis of 38 AML patients revealed this population 
appeared to separate into two biological groups- one cohort with a low CD34+38-ALDHhighCLL1- 
cell concentration at diagnosis (<0.1 cells/µl), and one with a higher concentrations (>0.1 
cell/µl). Comparative analysis of these two groups revealed that low stem cell concentration at 
diagnosis was significantly associated with reduced overall survival and relapse free survival. 
There was a non-significant trend toward increased 30 day mortality within the patients with a 
low stem cell concentration at diagnosis. There was no significant association found between 
the stem cell concentration at diagnosis, and induction failure due to refractory disease, or 
time to count recovery from the start of induction.   
Ideally, these findings would be validated in a larger, independent cohort. However, if further 
study did corroborate the findings, how might this information be put to clinical use, most 
importantly to improve patient outcomes? It is difficult to see how one might improve the 
survival to 30 days with standard therapy, where patients are normally closely monitored, 
sepsis treated aggressively and G-CSF support is now used widely. However, this cohort also 
displayed a reduced relapse-free survival: therefore knowledge of stem cell number at 
diagnosis might potentially be a factor for influencing the decision to transplant in first 
remission; or indeed selecting an induction regimen such as FLAG-IDA associated with a 
reduced relapse risk. Such information might be particularly relevant in stratifying risk and 
treatment decisions in those patients with intermediate risk disease by cytogenetics. Indeed, it 
is this intermediate risk cohort of patients where the association between initial stem cell 
concentration and overall survival appears the most marked (see Figure 5-6). 
However, there are certain limitations with this dataset, which restrict the strength of any 
conclusions drawn from its analysis. As discussed at length in Chapter 4, the panel of 
antibodies selected to identify and separate normal stem cells from AML cells does not work 
for every AML sample. The data illustrated in that chapter suggest that in 71% (17/24) of AML 
samples, the CD34+38-ALDHhighCLL1- fraction retains stem cell functionality and is free of  
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Figure 5-6 Kaplan-Meier plots showing the effect of stem cell concentration for those patients with intermediate 
risk cytogenetics on A: overall survival and B: relapse free survival 
the AML-associated mutation. In a further 25% (6/24) of samples, the CD34+38-ALDHhighCLL1- 
fraction is “enriched’ for the presence of normal cells (less than 25% of all cells contain the 
leukaemia-associated mutation). Therefore, accurate enumeration of normal HSC populations 
using this methodology is not possible for all samples.  
Of my initial cohort of 45 patients with enumerated cells, analysis of the genetics of the 
CD34+38-ALDHhighCLL1- cells was attempted in 35 (78%) of the samples. 5/45 (11%) had no 
karyotypic or identified genetic abnormality which would facilitate separation of normal cells 
from AML; and the remaining 5 (11%) did have karyotypic abnormalities, but the sorted cells 
were used for other purposes (such as RNA extraction) which meant immediate cytogenetic 
analysis was not possible. 
Seven of those AML samples where the CD34+38-ALDHhighCLL1- populations were successfully 
analysed were shown to be a mixture of AML cells and normal cells, although these cells were 
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clearly enriched for residual normal cells, as the proportion of AML to normal cells was below 
25% in all but one case. Nevertheless, all of these samples were excluded from further analysis 
in this chapter. The remaining analysed cohort of 38 samples is therefore comprised of 
samples where the CD34+38-ALDHhighCLL1- population has been shown to be clear of the AML-
associated mutation (n=17), but also includes those samples where it was impossible to 
determine the origin of cells, due to a lack of identifiable leukaemia-associated mutation, as 
well as those samples where purity analysis was technically unsuccessful.  
It is interesting that when these different groups are compared (see Figure 5-3 A), there are no 
significant differences between their median stem cell concentrations. This is reassuring, in 
that the inadvertent inclusion of a “dirty” stem cell sample (for example one of the normal 
karyotype AMLs, with no NPM1 or FLT3 mutation) is unlikely to have a significant impact on 
the overall findings.  
I chose to do the bulk of analysis using the 38 AML samples which represented the entire 
cohort minus the seven samples known to sort dirty (rather than only the 17 samples known to 
sort pure) for two reasons. Firstly, when attempting to draw correlations between stem cell 
numbers and clinical outcomes, the larger the cohort, the more useful any conclusions will be. 
Secondarily, there is a clear bias within the pure cohort to patients with good risk disease (as 
these have easily identifiable cytogenetic abnormalities) and therefore clinical correlations 
within this sample group would be limited, even if it were a larger size.     
 Variation of stem cell concentrations 5.5.2
One of the interesting and somewhat unexpected findings of this work was the substantial 
variation in stem cell concentrations observed within the control cohort of samples, which 
spanned three log folds between individuals. Why might this be? Is this a real finding, or a 
reflection of the limitations of the experimental method employed? Some potential 
explanations are discussed below.  
5.5.2.1 Potential biological causes of variability in stem cell numbers within the control 
cohort  
 Variation between individuals  5.5.2.1.1
Experimental information on absolute stem cell number in the bone marrow in humans is 
surprisingly limited. No previous papers exist where attempts have been made to quantify 
calculate the HSC concentration in fresh BM samples as we have attempted here. We know 
that the process of normal haematopoiesis is an extremely tightly controlled homeostatic 
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pathway, and between healthy individuals, the numbers of mature blood cells (erythrocytes, 
platelets, neutrophils etc.) are kept within relatively narrow normal distributions. One might 
therefore extrapolate that the same should be true of the number of HSCs, but this does not 
appear to be the case from the data shown above.  
Alternatively, it is possible that individuals do have widely varying numbers of stem cells 
maintained throughout life, and yet due to redundancy within the system, still retain the 
ability to maintain a normal blood count.  
In in-bred mice, several quantitative trait loci have been identified which can control stem cell 
numbers, suggesting a genetic link between stem cell numbers and specific genes237. It is 
possible that genetic factors account for similar variation within a healthy human population.  
 Age 5.5.2.1.2
One might assume the number of functional HSCs in the bone marrow might decrease with 
age for the following reasons. Clinically, we observe that haematopoiesis becomes restricted 
to smaller areas of the bone marrow with increasing age. We know that with age comes 
reduced bone marrow cellularity238. We know age is associated with increased incidence of 
diseases associated with dysfunctional haematopoiesis, such as anaemia and MDS239. Younger 
donors for bone marrow transplant procedures will be preferentially selected over older 
donors240, although the reasons for this are complex and not solely related to an increased 
chance of successful engraftment.  
Pang et al published a study looking at the effect of age on human HSC populations. HSCs 
(identified as a Lin-CD34+38-90+45RA- population) were quantified as a proportion of the CD34+ 
cells (as opposed to all cells) within previously frozen BM samples. Samples from young (aged 
20 to 35) healthy donors (n=13), and older (age >65) healthy donors (n=11) were compared. 
Flow characterisation suggested the ratio of Lin-CD34+38-90+45RA- to CD34+ cells increased 
with age, as the proportion of quiescent HSCs fell. In vivo xenograft culture experiments 
suggested that the older stem cells were myeloid skewed, in terms of the progeny they 
generated241. Whilst it is easy to question whether expressing HSCs as a proportion of total 
CD34+ cells (which may themselves vary in number with age) is a valid approach, these findings 
have also been mirrored in murine studies242.  
In our similar sized cohort of patients, we found no statistical association between age and 
stem cell number within the control cohort.  
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It is worth remembering that the actual functional volume of bone marrow which is able to 
perform haematopoiesis is increasingly restricted with age. Therefore, irrespective of the 
absolute stem cell concentration within the areas sampled, the actual overall number of stem 
cells present in the body must therefore fall with age, even if their concentration with active 
haematopoietic areas remains constant.  
 Do stem cell numbers vary over time within a healthy individual? 5.5.2.1.3
No studies exist, in either animal models or human subjects, which track the number of HSCs 
in an individual’s bone marrow over time. One assumes their numbers are under tight 
homeostatic regulation, whilst being able to respond to the challenge of illness, blood loss, 
pregnancy etc. which might require the increased production of blood cells.  
Within healthy individuals, it is interesting to hypothesise that stem cell numbers might 
fluctuate even on a more frequent basis. A number of studies of both human and mice 
progenitor cell production suggests this process follows circadian rhythms, both in terms of 
production and release from the BM243. Clinically, we use this knowledge to try and optimise 
stem cell collections from BM donors by morning apheresis procedures. Although the same 
patterns may well not be observed for the more immature HSC fraction of cells, the timing of 
extraction of bone marrow samples (whilst for the vast majority being between 9am and 5pm) 
was not standardised.  
 Are these samples really controls?  5.5.2.1.4
An important consideration, and a possible cause for the variation in HSC concentration seen 
within the control cohort, is that these patients are not “normal”. As stated in Section 5.3.1.3, 
control samples were only included in further analysis if they came from patients with Stage I 
to III lymphoma (the vast majority I and II), with no prior treatment. Examination of both 
aspirate and trephine by morphology, flow, cytogenetics and immunohistochemistry had to 
exclude any suggestion of infiltration; and blood counts at the time of biopsy had to fall within 
the normal range.  
However, these remain patients recently diagnosed with cancer, and therefore their bone 
marrow might reflect changes indicative of a reactive process.     
We do not have access at Bart’s Hospital to bone marrow samples from entirely healthy 
volunteers, although to answer this question fully, it would be appropriate to consider 
applying for ethical and financial approval to recruit volunteers for sample collection. This 
would clearly have the advantage of being able to standardise the procedure (see Section 
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5.5.2.2). Ideally, bone marrows would be taken by an appropriately trained single operator, at 
a standardised time of day. This would also enable a reduction in the time to sample 
processing within the laboratory.  
5.5.2.2 Sources of Potential Experimentally introduced variation   
 Bone marrow extraction  5.5.2.2.1
All samples were taken and processed according to an SOP set up within the Haematology 
Department at Bart’s Hospital (see Sections 5.3.1.1 and 5.3.1.2). The close proximity between 
hospital and research laboratory, as well as the excellent service provided by the Tissue Bank 
at Bart’s meant this process is as well standardised as possible for collection of clinical 
samples. However, there are clearly some potential variables within this process. These are 
discussed in detail below.   
5.5.2.2.1.1 Operator Variation  
Any clinician with experience of taking bone marrow samples knows that two different 
operators can take widely different quality of samples on the same patient at the same time 
dependent on a combination of experience and luck. Haemodilute, aparticulate draws of bone 
marrow can occur, even with the most experienced operators, and one would imagine that 
such a sample would generate a much lower stem cell concentration on analysis.    
Such haemodilute draws can be attributable not just to the operator, but also to the biological 
state of the bone marrow (such as myelofibrosis or infiltration with a non-haematological 
malignancy).  
5.5.2.2.1.2 Location of stem cells within the bone marrow  
All samples processed were aspirates taken from the right or left iliac crest (as opposed to the 
sternum). However, we believe that that stem cells are not distributed uniformly throughout 
the bone marrow, and therefore potentially small differences in the position of the aspiration 
needle might significantly affect the concentration of CD34+38-ALDHhighCLL1- cells within the 
material obtained.  
5.5.2.2.1.3 Order of aspirate draw 
The SOP requests that on taking a bone marrow sample for research, the very first 200µl 
drawn is immediately placed into an eppendorf tube for further analysis. Subsequent samples 
for morphological analysis, flow, cytogenetic, molecular genetics and further research samples 
should then be obtained from the same needle position. However, one can imagine that busy 
doctors, who should prioritise the diagnostic value of a bone marrow procedure to the patient, 
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might use the first pull for clinical purposes, and only use subsequent marrow for research 
processes.  
Clearly, the order that samples are taken is vital, as with each repeated pull on a positioned 
needle, the extracted sample becomes visibly more haemodilute. 
All Registrars responsible for taking bone marrows are made familiar with the research SOPs 
on induction, but anecdotal discussion suggests these protocols were not always rigorously 
undertaken, possibly in part because the full significance of changes in technique would only 
be apparent to those analysing the data.   
5.5.2.2.1.4 Variable dilution with EDTA  
The aspirated bone marrow was immediately placed into an eppendorf prefilled with 100µl 
EDTA for anticoagulation. Although the SOP requested the collection of 200µl only, it was clear 
when processing samples that the received volume of bone marrow varied between 200µl to 
1ml. Therefore, the relative degree of dilution due to the additional EDTA will vary between 
samples, which might impact on observed stem cell concentration.  
 Time to processing  5.5.2.2.2
All samples included in analysis were processed within 24 hours of removal from BM 
extraction. However, one would imagine that cell viability could fall within this window, within 
increasing time of processing, even if the sample was kept at 4oC.   
 Two-step analysis  5.5.2.2.3
As described in Sections 5.3.1.2 and 5.3.2, identification and subsequent enumeration of the 
CD34+38-ALDHhighCLL1- population within these samples was a two-step process. Initial 
processing of the fresh sample with CountBeads enabled quantification of the CD34+ 
concentration. Subsequent staining of a frozen sample allowed enumeration of the CD34+38-
ALDHhighCLL1- populations. Calculation of the concentration of CD34+38-ALDHhighCLL1- cells in 
the fresh sample makes the assumption that these cells survive the processing, freezing and 
thawing process in exactly the proportion as the CD34+ cells within the same sample.  
This process was necessarily split for two reasons. Primarily, it was vital to accrue sufficient 
samples to study. Approximately 30 to 40 new cases of AML present to Bart’s each year, but 
for a variety of reasons (patient consent, technical difficulties in bone marrow sampling, delays 
in sample transport, time of sampling etc. to name a few), by no means all of these provide 
suitable research samples. At the start of my PhD, I started analysis of all new AML and control 
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samples for their CD34+ cell concentration. It was only after 24 months of concurrent work that 
I had constructed and validated the panel of antibodies which I felt had the optimal chance of 
distinguishing normal HSCs from AML, and hence enumerate stem cells.   
Secondarily, this approach enabled me to utilise the samples previously processed between 
2007 and 2012 by Dr Miraki-Moud, all of which had been quantified for CD34+ cell 
concentration at diagnosis.  
The potential variation introduced by two-step processing of samples was tested by the 
analysis when fresh of the last AML sample received (Pat ID 10782), with the entire panel of 
antibodies (CD34, CD38, ALDH and CLL1), along with Count Beads; followed by the staining of a 
frozen sample at a later date for the same markers. Using this technique, when stained fresh, 
the concentration of CD34+38-ALDHhighCLL1- cells was calculated as 1.4 cells/µl. When the 
concentration of the same group of cells was calculated using the method detailed in Sections 
5.3.1.2 and 5.3.2, it was calculated as 2.5 cells/µl. Ideally, this comparison would be performed 
on more than one sample, but I was somewhat reassured that the differences in stem cell 
concentrations given by these two methods certainly could not explain the log fold changes in 
stem cell concentrations observed between different samples!  
5.5.2.3 Is very accurate flow based quantification of stem cell concentration the best way of 
determining the functional capacity of the bone marrow for regeneration?  
It is well documented that not all of the cells with long term reconstitutive potential reside in 
the CD34+38- compartment within normal bone marrow, but that these markers determine a 
population significantly enriched for stem cell function75. ALDH and CLL1 expression pattern 
have been independently shown to mark cells with stem cell-like behaviour, but it remains an 
assumption that the concentration of CD34+38-ALDHhighCLL1- cells reflects the concentration of 
cells with true functional repopulating potential within the bone marrow. It may be, for 
example, that the proportion of functional stem cells within the CD34+38-ALDHhighCLL1- 
compartment of AMLs and control samples may significantly differ.   
In Chapter 6, a number of AML and control BMs were sorted and placed into a 7 week long 
limiting dilution analysis to determine their functional stem cell numbers. Four of the control 
samples utilised in this experiment also had been quantified for their CD34+38-ALDHhighCLL1- 
cell concentration at diagnosis by flow based analysis. Table 5-13 summarises the comparison 
between the calculated stem cell concentration at diagnosis, and the concentration of cells 
capable of colony generation in a 7 week long culture assay within this population. It is clear 
from even these four samples that the concentration of functional long term culture 
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generating cells within this relatively tightly described phenotypic group varies significantly 
(between 1 in every 15 cells to 1 in every 161 cells).    
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Similarly, the results summarised in Chapter 4 raise the possibility that within the AML samples 
with poor risk cytogenetics, there exists a cohort of samples where CD34+38-ALDHhighCLL1- cells 
exist phenotypically, but appear unable to grow in the conditions of LTC, suggesting that these 
cells have impaired stem cell function.   
 Issues specific to AML samples  5.5.3
5.5.3.1 Sampling bias 
There is also an inherent (and I would argue) unavoidable bias in the samples which were 
processed and enumerated, due to their biological nature.  
Any sample with visible clot in it at the time of processing was excluded from further analysis. 
Coagulation of BM samples from APML patients is more likely to occur, due the susceptibility 
of these patients to DIC. This data series contains two APML samples within 45 samples, a 
relative under-representation from the expected 10%. Similarly, all samples successfully 
enumerated for their CD34+38-ALDHhighCLL1- population concentration at diagnosis had to have 
had both an eppendorf and an EDTA BM sample sent for research purposes. This requirement 
for relatively abundant BM effectively excludes those patients with difficult BM aspirates to 
obtain (i.e. those with AML M7).   
5.5.3.2  Patchy infiltration with disease 
It is generally assumed that the acute leukaemias, in contrast to other haematological 
malignancies such as myeloma or lymphoma, present with diffuse intramedullary involvement, 
and as a result, discrepant results from bilateral iliac biopsies are rare94. This assumption is 
corroborated by MRI appearances which show diffuse changes at diagnosis throughout the 
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BM attempts from a variety of sites are required to obtain a final diagnosis245. Thus it remains 
a possibility that some of these patients might yield very different results between technical 
replicates if bone marrow aspiration was attempted from multiple sites.   
5.5.3.3 Might the development of AML change the phenotypic expression of surface markers 
on normal stem cells?   
As discussed in Section 1.3.5.1, not all cells with long term repopulating ability reside within 
the CD34+38-ALDHhighCLL1- fraction. For example, we know very immature cells may be 
localised within the CD34- population75. Although this distribution of cells with different 
phenotypic appearances exists in health, it is possible that this pattern of distribution may 
become more marked with the development of a disease such as AML. Changing patterns of 
HSC surface antigen expression with AML have not been described to date. However, in 
Chapter 6 of this thesis, we demonstrate that levels of CD33 expression within the CD34+38-
ALDHhigh population of bone marrow drop significantly on development of AML. It is possible, 
albeit a very difficult question to address experimentally, that the expression levels of the 
other markers associated with long term repopulating cells might similarly fluctuate, and thus 
might make comparative enumeration of AML and control samples impossible.    
 Further experiments  5.5.4
The most pressing experiment to be undertaken would be the validation of this study on an 
independent cohort of patients, ideally from a different centre. I would place a particular 
emphasis on validating the conclusions drawn by comparison between the low and high stem 
cell groups within the AML, and the effect this appeared to have on overall survival, relapse-
free survival, and 30 day survival.  
Having now designed the appropriate test panel to identify stem cells in the majority of 
samples as detailed in Chapter 4, it would be desirable to process samples immediately for  
CD34, CD38, ALDH and CLL1 expression patterns in the presence of Count Beads, to reduce the 
potential error involved in the sequential processing of fresh and then frozen samples.  
Increasing the sample size would clearly be advantageous to increase the confidence in any 
clinical correlations drawn from the data, which are somewhat limited with an AML sample 
size of 45, given the heterogeneous nature of the disease and treatment.   
To investigate further whether the variability observed within the control cohort was a true 
biological phenomenon, and not due to technical and sampling issues, the study of biological 
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replicates (i.e. samples taken from simultaneously from the right and left iliac crest) from a 
limited number of patients with suitable consent would be desirable. 
I have been partially able to explore the question of variability between technical replicates for 
a few selected patient samples. For all of the AML and control patients studied, we received 
only one Eppendorf for immediate processing, and therefore there is no possibility of exploring 
the effects of technical replicates for this step of the process. However, the additional samples 
which were stored in the Tissue Bank (See Section 2.2.2) were commonly divided into multiple 
vials at the time of processing dependent on the cell number received. For two of the samples 
studied, I have extracted multiple vials of the same sample for different experiments over 
different days, and stained them with the same panel of antibodies. Comparison of these 
results enables a snapshot view of the potential variability in results between technical 
replicates (see Table 5-14).  
















] at diagnosis   
I remain intrigued that there appeared to be no obvious relationship between HSC number at 
diagnosis and time to count recovery. However, it is interesting that in this cohort, there were 
no patients who obtained remission from leukaemia after their Induction chemotherapy, but 
with significantly prolonged count recovery. One patient (9713) had prolonged time to platelet 
recovery (64 days), but this was in the context of severe abdominal sepsis. None of the 
patients who survived induction chemotherapy were rendered persistently hypoplastic or 
aplastic. It would be interesting to specifically identify patients who showed a marked delay in 
count recovery after induction, despite achieving remission from leukaemic infiltration, and 
quantify their stem cells at diagnosis, to see if this cohort had abnormal presentation HSC 
concentrations. However, in an analogous situation, not all studies show a relationship 
between CD34 dose and time to haematopoietic recovery after BMT, and therefore, factors 
other than a received dose of haematopoietic progenitors are likely to play a role246.  
Finally, I remain intrigued by the observed significant variation in HSC numbers within control 
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finding is reproduced in a totally normal cohort. I think it would also be fascinating (with a 
willing donor!) to perform serial BMs over time in one individual, to identify the degree of 
fluctuation in HSC concentration over time. 
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Chapter 6 Exploring the effect of AML on CD33 expression on 
normal stem cells  
6.1 Introduction 
 CD33 expression patterns  6.1.1
6.1.1.1 In normal haematopoiesis 
CD33 (also known as sialic acid binding Ig-like lectin 3 or Siglec-3), is a transmembrane 
receptor frequently, but not exclusively, expressed on myeloid cells. It is a member of the sialic 
acid binding family of receptors: other members of which include CD22 (Siglec-2), CD169 
(Siglec-1) and MAG (Siglec-4). These receptors are thought to mediate cell-cell interactions and 
intercellular signalling through binding to sialic acid.  
In addition, there exists a large subfamily of CD33-related Siglec receptors, which share 
significant structural homology. These receptors appear to have evolved rapidly and recently: 
comparisons between species have revealed little homology between mammals such as mice, 
monkeys and humans. This has obvious ramifications for the utility of animal models in 
investigating the role of these receptors in normal cell functioning247.  
The members of the CD33-related Siglec family are expressed mainly on the mature cells of the 
innate immune system, such as neutrophils and eosinophils248,249. In contrast, CD33 itself tends 
to be expressed earlier in development at the progenitor phase. To date, reported roles for 
this family of receptors include inhibition of cellular proliferation250, apoptosis induction251, 
inhibition of cell activation210 and induction of pro-inflammatory cytokine secretion252. 
However, it is unknown at present how much overlap in function exists between structurally 
similar receptors.    
How do CD33 and related Siglecs mediate the effects described above? Structural studies have 
revealed all these receptors to contain an amino-terminal V set immunoglobulin domain, 
capable of sialic-acid recognition. Avidity for different sialic residues appears to vary between 
family members. Interestingly, sialic acids are found abundantly in the membrane-region of 
most human cells, and therefore it is assumed that for many of these receptors, their binding 
sites may be occupied by cis, rather than trans, ligands247.   
The intracellular section of these proteins contains immunoreceptor tyrosine-based inhibitory 
motifs that are implicated in inhibition of cellular activity. On phosphorylation of these motifs 
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by SRC tyrosine kinases, the receptors recruit SRC homolog 2 (SH2)-domain containing 
proteins, including SHP1 and 2, or SOCS 3210. 
The current prevailing consensus in published literature is that CD33 is absent from the most 
immature HSCs, with expression occurring only at the progenitor stage onwards in 
development212,253-255. However, several groups, including our own, have reported the 
expression of CD33 on cells with a stem phenotype256-258. Taussig et al provided functional data 
which suggest that the CD33+ fraction of sorted human CD34+38- stem cells is capable of 
preferential engraftment (when compared to the CD33- fraction) in a NOD-SCID murine 
xenograft model214. 
6.1.1.2 In AML  
CD33 expression in AML is highly ubiquitous, with 90 to 95% of clinical samples showing some 
level of antigen expression211,212. Levels of antigen expression vary significantly between 
patients259,260, although the average antigen density on a typical blast cell is relatively sparse at 
104 molecules per cell260. Mimicking the patterns seen in normal haematopoietic development, 
antigen expression is lower in the fraction traditionally though to contain LSCs (CD34+38-
CD123+ or CD34+38-). Antigen expression appears to vary predictably with disease genetics: 
APML is associated with high CD33 expression261, in contrast to the other core-binding factor 
leukaemias, where low CD33 levels are classically observed259. Similarly, high levels of CD33 
expression are also associated with NPM1 and FLT3-ITD mutations262.  
 Anti CD33 therapy in AML 6.1.2
The backbone of standard chemotherapy in AML (daunorubicin and cytarabine) has not 
changed in 40 years. Such intensive, untargeted cytotoxic therapy is associated with significant 
side effects, including marked myelosuppression, which can limit its use in older patients. As 
detailed in Section 1.4, even when administered at full dosage, current therapy frequently fails 
to cure patients, with only half surviving to five years after diagnosis. There is an absolute 
consensus amongst clinicians that new effective therapies are urgently required.  
Interest in the development of targeted molecular therapies for haematological malignancies, 
combined with knowledge of the ubiquitous expression of CD33 in AML, resulted in focussed 
attempts to develop an anti-CD33 antibody therapy. Despite challenges with CD33 as a target 
for therapy (due to its relatively low abundance of expression, and slow conjugate 
internalisation)260, cross linking of the receptor with antibodies was shown to cause significant 
apoptosis in AML samples over ten years ago213.  
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Today, a number of related therapies are either in use or development, and their details are 
summarised below.  
6.1.2.1 Gemtuzumab Ozogamicin (GO) 
The first developed, and most widely studied anti-CD33 antibody in clinical practise is 
Gemtuzumab Ozogamicin (GO) (marketed in the UK as Mylotarg by Wyeth): a monoclonal 
humanised IgG4 antibody against CD33 (hP67.6), conjugated to calicheamicin263. The 
unconjugated antibody is not directly toxic to cells, but binding to the CD33 receptor facilitates 
internalisation of the conjugate. Subsequent lysosomal degradation results in a calicheamicin 
derivative capable of causing single and double stranded DNA breaks. These in turn lead to cell 
cycle arrest, and either DNA repair or cellular apoptosis. The central role of DNA damage in 
GO-induced cytotoxicity is supported by the observation that cell lines defective in DNA repair 
are highly sensitive to calicheamicins264.  
In vitro and in vivo resistance to GO can be mediated via increased drug efflux caused by 
members of the ATP binding cassette protein family, such as P-glycoprotein (ABCB1) and 
multidrug resistance-associated protein 1 (ABCC1)265-268. 
GO gained accelerated FDA approval for use in AML therapy following one non-randomised 
study, which revealed a benefit with the administration of single agent GO to patients over the 
age of 60 with relapsed AML269. Since then, the efficacy of GO has been tested in several large 
international trials, in a range of age groups and dosing schedules, but mainly in newly 
diagnosed patients in combination with standard chemotherapy.   
Concerns about its potential toxicity in treatment (chiefly the development of veno-occlusive 
disease, but also reports of prolonged cytopenias270,271), had been raised since the FDA licence 
was approved. However, in 2010, the drug was voluntarily withdrawn in the USA, following the 
Phase III SWOG S0106 trial, which showed an increase in toxicity-associated mortality in those 
patients who received GO, without a matched benefit in terms of disease control272. However, 
in the last three years, the results of several other collaborative studies have been published, 
refuting these findings3,4. Experts remain divided over its clinical benefit273. 
 The UK Experience 6.1.2.1.1
The two largest studies investigating the efficacy of GO with standard chemotherapy in 
treating newly diagnosed AML patients have been the MRC-sponsored AML 15 and 16 trials. 
The AML 15 trial, which ran between 2002 and 2006, randomised 1113 patients 
(predominantly aged under 60) to receive GO in induction and/or consolidation, in 
Chapter 6: The effect of AML on CD33 expression on normal HSCs 
222 
combination with a variety of standard chemotherapy regimens. 557 patients were 
randomised to receive GO at induction, and follow-up revealed no differences in overall 
survival, response rate or 30-day all-cause mortality between the two treatment arms. 
However, subgroup analysis revealed that those patients with a favourable risk karyotype 
(inv(16) and t(8;21)) showed a significant improvement in overall survival if they received GO 
at induction (79% versus 51%)3. This finding was replicated in the SWOG SO106 trial272.  
Interestingly, in those patients who received GO at a dose of 3g/m2, the AML 15 study did not 
reveal significantly increased haematopoietic suppression. Those receiving GO treatment at 
induction did require significantly more platelet transfusions (18.9 versus 13.7 units, p<0.001) 
during course 1, and more days of antibiotics (20.4 versus 19 days, p=0.02). However, the time 
to haematopoietic recovery was similar between the 2 groups (time to neutrophil recovery 20 
versus 21 days (p=0.3), and to platelet recovery 20 versus 19 days (p=0.2)). A similar effect was 
observed in AML 16, which used GO in an older patient cohort4. 
These promising data, showing an improvement in overall survival, without the significant 
toxicity reported in the SWOG trial, has led to the inclusion of GO within the protocol for both 
current UK based AML trials (AML 18 and 19)122,126. In these, all eligible patients should receive 
either one or two doses of GO during their induction therapy.  
6.1.2.2 Vadastuximab talirine (SGN-CD33A) 
Although GO remains the most widely studied anti-CD33 agent, difficulties with access and 
concerns over toxicity have led to the development of a number of competitors. These include 
Vadastuximab talirine (SGN-CD33A), marketed by Seattle Genetics. Vadastuximab is a 
conjugate of an anti-CD33 antibody, attached to a pyrrolobenzodiazepine dimer of the drug 
SGD-1882 (a DNA binding agent). Preliminary data from phase I trials demonstrating 
tolerability have been reported274,275, and a Phase II clinical trial involving its use in 
combination with demethylating agents, to treat older patients newly diagnosed with AML, is 
planned to open this year.  
6.1.2.3 AMG 330 
AMG 330 is a bispecific T-cell engaging (BiTE) antibody, which has specificity for CD33 and CD3 
antigens. In a mechanism analogous to the more well-known Blinatumomab (which binds to 
CD3 and CD19)276, the design of the BiTE antibody brings CD3+ cytotoxic T cells into contact 
with cells expressing CD33, resulting in cell destruction. One potential advantage in its design is 
that, as internalisation of the drug is not required for its mechanism of action, resistance to its 
effects cannot develop via drug efflux mechanisms129,266.  
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In vitro experimental work has shown AMG 330 to be capable of lysis of AML blasts277. 
Recruitment for a Phase I clinical trial is currently underway.  
6.1.2.4 Does anti-CD33 therapy affect normal haematopoiesis?  
As discussed above in Section 6.1.1.1, the classical understanding of CD33 expression patterns 
during haematopoietic development describes antigen expression beginning only as cells enter 
the progenitor stage of differentiation212,253-255. However, several other groups, including our 
own, have shown cells capable of long term reconstitution to express CD33, suggesting it can 
be found on the most primitive of HSCs214,256-258. 
Whether HSCs express CD33 has clinical relevance for those patients receiving anti-CD33 
therapy, as elimination of cells with long term reconstituting potential could lead to prolonged 
cytopenias (and delays in subsequent consolidation chemotherapy), or indeed permanent 
aplasia.  
Interestingly, in the early days of GO therapy, there were several reports of its usage being 
associated with prolonged cytopenia in remission270,271. However, it is noteworthy that the 
data available on count recovery from the much larger cohort of patients in the AML 15 and 16 
trials do not support these early concerns (see Section 6.1.2.1.1). 
 Data from our group showing CD33 expression patterns within the normal HSC 6.1.3
population of CD34
low
 AML samples  
Why do we not observe more prolonged haematopoietic suppression with the use of GO 
clinically, given that we and others have demonstrated normal stem cells do express CD33?  
In Section 1.5.2.2, we describe a cohort of AML samples defined by low CD34 expression. In 
these samples, it has been demonstrated that the CD34+38- compartment retains normal stem 
cell activity, with no evidence of the leukaemia-associated mutation130. These samples are 
therefore ideal to use in the investigation of the effect of AML on normal HSCs1. 
Previous unpublished work from our group has shown that the CD33 expression (the 
percentage of CD33 positive cells, as defined by FMO) in the CD34+38- normal stem cell 
fraction within these CD34low AML samples is significantly lower than the same compartment 
within control samples. Median percentage CD33 positivity within 15 CD34low AML samples 
was 18%, versus 82% within 20 control samples (p <0.0001 by Mann-Whitney test) (see Figure 
6-1).    
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 AML and controls. Median and 
interquartile range are plotted for both groups. Median CD33 expression was 18% (AML) v 82% (controls) 
This is a novel finding, and I believe the first demonstration of normal HSCs illustrating an 
altered surface phenotype in response to exposure to AML. This led us to ask whether this 
altered expression pattern is limited solely to the normal HSCs found within CD34low AMLs, or 
is a more universal finding. Secondarily, given increasing interest in anti-CD33 therapy, it also 
raises the question as to whether these changes in expression of CD33 have clinical impact in 
terms of altered sensitivity to antigen-targeted therapy.  
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6.2 Aims and Objectives  
The primary aim of the work in this chapter was to study the CD33 expression pattern within 
the normal HSC compartment of a range of AML subtypes, to identify if the reduced expression 
observed on normal HSCs from CD34low AMLs is a universal finding.  
The first objective was therefore to study CD33 expression patterns within the CD34+38-
ALDHhigh compartment of CBF leukaemias. Previous work from Gerber207, as well as results 
detailed in Section 4.4.3.3, had shown we could confidently separate normal HSCs from AML 
cells in this cohort of samples using this antigen panel, without the need to validate the purity 
of the sort. This enabled the testing of multiple samples quickly. In addition, previous trial data 
suggest it is this particular group of patients who gain the most clinical benefit from GO 
therapy3, and therefore are the most likely to receive it if the drug becomes widely available in 
the future.   
The secondary objective was to see if any changes in CD33 expression are reversible on 
remission. This was achieved by identifying remission samples from CBF AML patients, where 
available, and simultaneously assaying them with diagnosis samples. 
The secondary aim of this chapter was to identify if a change in CD33 expression has an impact 
on HSC sensitivity to GO therapy. Does lower CD33 expression reduce susceptibility to the 
drug, and therefore have a protective effect for the normal HSC population at diagnosis with 
AML, when compared to controls? 
Thus the final objective was to test the effect of GO on normal HSCs using an in vitro LTC assay. 
Sorted normal HSCs from AML samples were briefly exposed to GO, prior to assessment of 
residual stem cell function by a 7 week LTC assay. The effect of the drug on stem cell frequency 
was compared to control samples treated in the same fashion.   
Chapter 6: The effect of AML on CD33 expression on normal HSCs 
226 
6.3 Chapter Specific Methods 
 Patient Samples 6.3.1
Diagnostic bone marrow from patients diagnosed with CBF mutated AML and CD34low AML 
along with control samples were obtained from the Bart’s Tissue Bank with prior patient 
consent.  
 CD33 Expression Analysis  6.3.2
6.3.2.1 Staining 
Bone marrow samples were thawed, washed and cell counted as previously described.   
4x106 cells (or the total contents of the bone marrow vial if lower) were stained with activated 
AldefluorTM reagent as described. HAG staining was followed by staining with CD34-PerCP, 
CD38-Pecy7 and CD33-APC (BD, Cat: 551378 (Clone WM53)) antibodies at a concentration of 
5µl/1x106 cells.  
6.3.2.2 Flow Data Analysis 
Samples were all processed on a BD Biosciences LSR Fortessa. Subsequent analysis was 
performed using the FlowJo Program. The number of CD34+CD38-ALDHhigh normal stem cells in 
each sample was quantified, and the proportion of CD33+ cells (as defined by the Fluorescence 
Minus One CD33 control for each sample) recorded. For those patients with paired diagnostic 
and remission/relapse samples, all samples were processed on the same day to aid inter-
sample comparison.  
6.3.2.3 Statistical analysis  
The majority of statistical analysis was performed using the Prism software package. All 
datasets were tested for normality of distribution by the D’Agostino & Pearson omnibus 
normality test. If data were normally distributed, means are quoted, and a t-test was used for 
analysis. If data were not normally distributed, medians are quoted, and a Mann-Whitney t-
test was applied in the determination of statistical significance.   
 GO Exposure Experiment  6.3.3
This experiment was performed at three different times, dependent on the availability of GO. 
As we were unable to access GO directly from Wyeth for this work, we instead utilised the 
excess from vials reconstituted for patients within the AML-19 trial. In all cases, the GO was 
used within 72 hours of reconstitution, and before use, was kept in the dark at 4oC.  
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In total, 7 AML and 7 control samples were used: the numbers were limited by the costs of the 
experiment, as well as the substantial time taken to sort sufficient HSCs from each sample.    
6.3.3.1 Sorting of HSCs 
Two slightly different sorting techniques were utilised, dependent on the subtype of AML 
being investigated. In the first experiment, HSCs were extracted from three CD34low AML 
samples and three matched controls, and, in an attempt to maximise the stem cell yield prior 
to LTC, HSCs were extracted based on a CD34+38- phenotype only. In the subsequent two 
experiments, for CBF AMLs and matched controls were sorted, and as described in Chapter 4, a 
CD34+38-ALDHhighCLL1- criteria was required for separation of HSCs from AML cells in these 
cases.   
The three CD34low AML and three matched control bone marrow samples were thawed, 
washed and cell counted as previously described. HAG staining was followed by staining with 
CD34-PerCP and CD38-PeCy7 at a concentration of 5µl/1.5x106 cells. A further aliquot of 0.5 
million cells was stained with HAG and then CD34-PerCP, CD38-PeCy7 and CD33 APC, and 
analysed separately to assess CD33 expression. Cells were resuspended in 2% PBS/DNase/DAPI 
and the CD34+38- population sorted into 2% PBS.  Purity was checked, and cells resorted if 
purity fell below 90% as previously described.  
The four CBF AMLs (one t(8;21) and three inv(16)) and four control bone marrow samples were 
thawed, washed and cell counted as previously described. Samples were stained for ALDH 
expression as previously described. Staining with HAG dissolved in ALDH buffer was followed 
with staining for CD34-PerCP, CD38-PeCy7 and CLL1-PE at a concentration of 5µl/1.5x106 cells. 
A further aliquot of 0.5 million cells was stained for ALDH expression, followed by HAG and 
finally stained with CD34-PerCP, CD38-PeCy7, CLL1 PE and CD33 APC, and analysed separately 
for CD33 expression. Cells for sorting were resuspended into ALDH/DNase/DAPI and the 
CD34+38-ALDHhighCLL1- cells sorted into ALDH buffer as previously described. Sort purity was 
checked, and cells resorted if purity fell below 90%.  
6.3.3.2 Drug Exposure  
In both experiments, the exact number of cells sorted for each samples was recorded. 
Subsequent to sorting, the sample was gently mixed by pipetting and then divided into 2 tubes 
of equal volume. Tubes were spun (1500rpm, 10 minutes), and the cells resuspended in 1ml 
H5100 MyelocultTM with and without the addition of GO at a concentration of 3µg/ml for 2 
hours at 37oC. Samples were then washed with 3ml H5100 MyelocultTM, and centrifuged 
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(1500rpm, 10 minutes). The supernatant was aspirated using a Gilson pipette, and cells 
resuspended in 100µl H5100 MyelocultTM.  
6.3.3.3 LTC set up and maintenance 
Cells were then plated in serial dilutions of between 2 to 800 cells per well, on plates set up for 
LTC conditions with collagen and MS5 as previously described. A maximum additional fluid 
volume of 10µl per well was added. 4 to 20 replicates for each cell dilution were added, 
dependant on the cell numbers available for plating.  
Cells were incubated at 37oC, 5% CO2 for five weeks, with weekly changes of H5100 media 
(65µl supernatant extracted and replaced with 75µl fresh H5100 MyelocultTM, pre-warmed to 
37oC). After 5 weeks in culture, the supernatant was aspirated from each well using a Gilson 
aspirator, leaving a residual volume of 10 to 20 µl. 100µl of methylcellulose was added to each 
well and the plates cultured at 37oC in an incubator for a further 2 weeks. Wells were then 
examined for the presence of colonies and recorded as either positive or negative.  
6.3.3.4 Data analysis 
An LTC-IC concentration was calculated for each condition using the Extreme Limiting Dilution 
Analysis software package278,279. Statistical analysis comparing the relative effect of GO 
treatment on HSCs from control and AML samples was performed using the Wilcoxon signed 
rank test.  
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6.4 Results 
 CD33 expression patterns within CD34+38-ALDHhigh stem cells of CBF AML 6.4.1
samples   
All available patient samples from patients with core binding factor mutations were tested. A 
total of 53 samples of diagnostic, first remission and relapse bone marrow samples from 21 
patients diagnosed with CBF leukaemia were obtained from the Bart’s Tissue Bank with prior 
patient consent. These were compared to 9 normal bone marrows.  
6.4.1.1 Patient Details 
Analysis of the Bart's Patient Registry identified 37 patients diagnosed with CBF leukaemias 
between 1997 and 2012. 13 patients had inv(16) AML and 24 t(8;21) AML. Of these, diagnosis 
BMs were obtainable for 22 patients (14 from t(8;21) and 8 from inv(16) patients).  
The vast majority of these patients achieved a remission with standard induction therapy. 
Remission BMs were obtainable for 17 of these patients (10 with t(8;21) and 7 with inv(16)). 
Despite the relatively favourable prognosis of the CBF leukaemia subgroup, a proportion of 
these patients relapsed. Of the 22 patients with obtainable diagnosis BMs, 4 patients had 
relapse BM samples stored in the Tissue Bank (all 4 patients had t(8;21) mutated AML). Sample 
availability and clinical information is summarised in Table 6-1.  
6.4.1.2 CD33 expression on normal stem cells in CBF AMLs is downregulated at diagnosis in 
comparison to controls  
22 diagnosis BM samples for patients with CBF leukaemias and 9 controls were analysed for 
the CD33 expression of their normal stem cell populations. Normal stem cells were identified 
as CD34+38-ALDHhigh cells. CD33-expressing stem cells were defined as those with a higher 
intensity of CD33 expression than the FMO control, and are expressed as a percentage of all 
CD34+38-ALDHhigh cells The mean percentage of CD33+ normal stem cells found within the bone 
marrow of CBF AML samples is significantly lower than that of control bone marrow (means 
17% versus 58%; p=0.005, unpaired t-test with Welch correction) (see Figure 6-2 A). 
CD33 expression is lower in HSCs in the 8 samples with inv(16) than the 14 samples with 
t(8;21) (median 2% versus 13%, p=0.03 by Mann Whitney t test). However, allowing for 
multiple testing, this difference does not achieve statistical significance. When compared 
independently to the control samples, the stem cells from each favourable-risk cytogenetic 
group do display statistically significant reduced CD33 expression (inv(16) 2% versus controls 
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67%, p=0.001 by Mann-Whitney t-test; t(8;21) 13% versus controls 67%, p=0.01 also by Mann-
Whitney -test). These results are illustrated graphically in Figure 6-2 B.  
6.4.1.3 CD33 expression on normal stem cells in CBF AML increases towards baseline when 
patients obtain morphological remission    
Of the 22 AML patients whom a diagnosis BM was obtainable, 16 also had a BM sample 
available which was taken at clinical remission (7 with inv(16) and 9 with t(8;21)). Of these 
samples, fifteen were obtained after induction chemotherapy, and one dated from 6 months 
post completion of chemotherapy. The percentage of CD33+ normal stem cells was compared 
between paired diagnosis and remission samples.  
The mean percentage of CD33+ normal stem cells across all CBF samples at diagnosis was 13%; 
at remission, this figure rose to 55%. The mean average increase of CD33+ stem cells was 42%. 
Paired two-tailed t-testing suggests this change is highly significant (p<0.0001). This result is 
illustrated graphically in Figure 6-2 C. This increase in CD33 expression remained statistically 
significant when the two cytogenetic groups were considered independently. The seven 
patients with inv(16) AML exhibited an average increase in CD33 positivity within their stem 
cell populations of 33% from 2 to 35% (p=0.03); the nine patients with t(8;21) AML similarly 
showed a slightly greater increase of 48% from 22 to 70% (p=0.002).      
6.4.1.4 CD33 expression on normal stem cells in CBF AML does not fall in the same manner 
at relapse  
Of all patients with CBF treated at Bart’s, four of those who subsequently relapsed had a BM 
taken at that time available for analysis. All of these patients had AML associated with t(8;21).  
The results of parallel analysis of diagnosis, remission (available for three of the four), and 
relapse samples for the CD33 expression in the HSC sunset are shown in Figure 6-2 D.  
The median percentage of HSCs which are CD33 positive at diagnosis is 23%; at remission this 
figure rises to 91%, and falls again at relapse to 59%. These results do not reach statistical 
significance when analysed by Friedman’s test, but in this case, the very small sample size may 




Table 6-1 Clinical characteristics and sample availability of CBF AMLs 
CLINICAL CHARACTERISTICS SAMPLE AVAILABILITY 
ID KARYOTYPE SEX AGE 
PRESENTATION 
WCC 
REMISSION SAMPLE? RELAPSE SAMPLE? CLINICAL OUTCOME 
3206 INV(16) F 59 38 Y 
 
REMISSION 
3229 INV(16) F 30 34 Y 
 
REMISSION 
3230 t(8;21) F 44 5.3 Y Y RELAPSE @ 2 YEARS 
4400 t(8;21) M 49 14 Y 
 
RELAPSE @ 5 MONTHS 
5904 t(8;21) M 34 16 N 
 
REMISSION 
6252 t(8;21) M 53 28 Y 
 
RELAPSE @ 2 YEARS 
6434 t(8;21) F 18 4.9 Y Y RELAPSE @ 1 YEAR 
6461 t(8;21) F 34 28 N 
 
REMISSION 
6527 t(8;21) F 49 5.9 Y 
 
REMISSION 
6550 t(8;21) M 68 6 Y 
 
REMISSION 
6555 t(8;21) F 22 70 N 
 
REMISSION 
6720 INV(16) F 68 127 Y 
 
RELAPSE @ 7 MONTHS 
6734 t(8;21) M 51 6 Y Y RELAPSE @ 3 MONTHS 
6755 INV(16) M 65 113 Y 
 
REMISSION 
6988 INV(16) M 55 7.2 Y 
 
REMISSION 
7013 INV(16) F 59 61 Y 
 
RELAPSE @ 2 YEARS 
7849 t(8;21) F 57 9.4 Y 
 
REMISSION 
7882 INV(16) M 46 33 N 
 
RELAPSE @ 1 YEAR 
8750 t(8;21) F 39 6.1 Y 
 
REMISSION 
8751 t(8;21) M 62 22 N Y RELAPSE @ 7 MONTHS 
9220 t(8;21) F 55 41 Y 
 
REMISSION 
9445 INV(16) F 52 95 Y 
 
REMISSION 
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Figure 6-2 A: CD33 expression within the HSCs of CBF AML samples (n=22) versus controls (n=9). Means and SD are shown; B: CD33 expression within the HSCs of inv(16) AMLs (n=8), t(8;21) AMLs 
(n=14) and controls (n=9). Median and IQR are displayed for all samples; C: changing pattern of CD33 expression on normal HSCs between diagnosis and remission for 16 CBF AML patients; D: CD33 
expression within the HSC compartment of 4 t(8;21) AML patients at diagnosis, first remission and relapse 
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 The effect of CD33 expression of HSCs on susceptibility to GO therapy  6.4.2
In 3 separate experiments, a total of 7 AML and 7 control samples underwent sorting for HSCs. 
Extracted HSCs were exposed to GO at a concentration of 3µg/ml for 2 hours, prior to 7 week 
LTC. At the end of this period, stem cell concentration was calculated using the Extreme 
Limiting Dilution Analysis software package as described in Section 6.3.3.4.  
In the first experiment, stem cells from 3 CD34low AMLs were extracted by selection of the 
CD34+38- cells. 3 matched controls were sorted in the same way. Previous data had shown 
these antibodies to be capable of selecting out normal stem cells from these AMLs, and my 
initial concerns about sorting sufficient stem cells to perform parallel limiting dilutions analyses 
meant I had selected staining by this method, rather than also including ALDH and CLL1. In 
retrospect, I acknowledge that using the same panel of antibodies for all samples processed 
would have been preferable to enable comparison between different AML subtypes.   
In the two subsequent experiments, HSCs from 4 CBF AMLs (3 with inv(16) and 1 with t(8;21)) 
were separated with an additional 4 controls by selection of CD34+38-ALDHhighCLL1- cells. In all 
experiments, samples were split into two groups, exposed to 0 and 3µg/µl GO in H5100 
respectively. Whilst all other experimental details remained unchanged, in the final 
experiment, knowledge of the likely frequency of stem cells within the samples meant that 
care was taken to plate multiple (20 wells) at the extreme low ranges of the dilution (2,5,10 
cells per well) to ensure sufficient statistical power to detect any discrepancies between 
groups.  
Clinical details of all samples and number of cells sorted are listed in Table 6-2. Final estimation 
of stem cell frequencies generated by the limiting dilution assays are shown in Table 6-3. 
6.4.2.1 GO does not appear to have a significant effect on functional HSC numbers in either 
AML or control samples 
In only three of these fourteen samples, did there appear to be a significant difference in the 
stem cell frequencies generated between the untreated and treated samples (7882, 8126 and 
8215). One of these was an AML sample, and two were controls. In two of these cases, the 
stem cell frequency was greater in the untreated sample (as we had hypothesised). But in one 
(8215), the reverse was true. This is very difficult to explain. Further discussion as to why this 
might be the case is found below in Section 6.5.3.  
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6.4.2.2 Comparison of the relative effect of GO on HSCs from AML and control samples  
Whole group analysis on the relative effect of GO on HSCs from AML and controls was 
performed using the Wilcoxon signed rank test. There was no statistically significant difference 
found either between estimated stem cell frequencies before and after GO treatment in the 
seven AML HSC samples (p=0.47), or between stem cell frequencies before and after GO 
treatment in the seven control HSC samples (p=0.22).  
For completeness, the same analysis was performed looking solely at the CD34low AML samples 
and controls sorted for CD34+38- cells. There was no significant difference in estimated stem 
cell frequencies before and after GO treatment in the three AML samples (p=1.0), or three 
controls (p=0.5). We also analysed the CBF AML samples and matched controls sorted for 
CD34+38-ALDHhighCLL1- cells. Unsurprisingly, there was no significant difference found in 
estimated stem cell frequencies before and after GO treatment in the four AML samples 
(p=0.25), or four controls (p=0.63). 
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Table 6-2 Details of AML (CD34
low
 and CBF) and control samples sorted for stem cell populations and subsequently exposed to GO 
SAMPLE INFORMATION STEM CELL SORTING 
PAT ID TIME TYPE KARYOTYPE FLOW SORT CRITERIA CELLS SORTED CELLS PER CONDITION 






 5809 2905 






 4960 2480 






 9283 4642 






 2893 1447 






 2898 1449 






 18768 9384 








 8999 4499 








 3997 1998 








 14376 3594 








 3179 1589 










 1968 984 










 28276 4713 










 1146 573 










 3598 1794 
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Table 6-3 illustrating results for all samples from ELDA Hall analysis of stem cell frequency and pairwise analysis of results 
PATIENT DETAILS EXPERIMENT DETAILS RESULTS 
ID SAMPLE KARYOTYPE SORT CRITERIA 
GO DOSE 
µg/ml 
1/STEM CELL FREQUENCY PAIRWISE ANALYSIS TREATED V UNTREATED 
ESTIMATE LOWER CI HIGHER CI CHISQ PROB (>CHISQ) 





0 10.1 22.5 4.5 
0.225 0.635 
3 12.9 25.2 6.6 





0 12.4 24.7 6.2 
3.39 0.0657 
3 4.4 9.9 1.9 





0 4.4 9.1 2.1 
0.328 0.567 
3 5.9 11.6 2.9 





0 25.4 47.7 13.5 
0.154 0.695 
3 29.9 55.7 16.1 





0 12.5 21.9 7.1 
3.41 0.0646 
3 25.1 43.2 14.6 





0 13.2 27.0 6.5 
0.000216 0.988 
3 13.1 26.8 6.4 









0 9.3 12.6 6.9 
0.864 0.353 
3 7.6 10.3 5.6 









0 7.9 16.4 3.8 
2.87 0.0902 
3 18.0 34.8 9.3 









0 7.4 10.1 5.4 
7.96 0.00479 
3 14.0 18.9 10.3 









0 5.0 11.1 2.3 
1.35 0.244 
3 9.3 19.1 4.6 









0 89.2 188.0 42.3 
0.352 0.553 
3 124.8 287.0 54.3 









0 54.4 78.5 37.6 
10.8 0.00099 
3 148.4 244.1 90.2 









0 160.8 506.0 51.1 
5.2 0.0226 
3 39.6 76.9 20.4 









0 14.8 29.1 7.5 
1.56 0.211 
3 26.5 49.5 14.2 
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6.5 Discussion 
 General points  6.5.1
Flow based analysis of CD33 expression on clinical samples from 22 patients with CBF 
leukaemias detailed in Section 6.4.1, suggests that CD33 expression is significantly lower on 
normal HSCs exposed to AML, but increases significantly once remission is obtained. This 
mirrors an effect previously found by my group when studying the CD33 expression of the HSC 
compartment of CD34low AMLs. We chose to study CBF leukaemias partly because there exists 
a validated means of identifying and separating out stem cells from the malignant clone in 
these samples207, and partly because the interaction between CBF AMLs and GO is of current 
interest, as it is these patients that derive the most clinical benefit from GO therapy3.  
 Why might CD33 expression show variable patterns on normal HSCs in the 6.5.2
context of AML? Is this a cause or an effect? 
Why do normal HSCs show reduced CD33 expression in this context of leukaemia 
presentation? As the exact function of the CD33 receptor on HSCs is unknown, this is a difficult 
question to answer.  
Increased expression of CD33 is associated with a more mature phenotype, as cells develop 
towards the progenitor CD34+38+ subtype. If (as we speculate in Section 1.5.2) normal stem 
cells in the context of AML are induced to remain quiescent and undifferentiated, it may be 
that a greater proportion of the cells in the CD34+38- gate of these samples are immature, and 
therefore have lower CD33 expression. A more appealing, alternative hypothesis is that an 
induced change in CD33 expression on normal HSCs, by either the surrounding AML cells or 
stroma, results in a change in signalling which drives the observed stem cell quiescence and 
differentiation block.   
One way of attempting to investigate this further is to attempt to manipulate CD33 expression 
experimentally (either by inducing transient gene overexpression, or knockdown) and 
investigate how this affects stem cell behaviour and differentiation in vitro.  
This is another area where a functional in vitro model of the interplay between AML and 
normal HSCs would be invaluable (see Section 8.2.3.6). It would be interesting to compare the 
CD33 expression phenotype of HSCs exposed to AML in vitro, and see if the same patterns are 
replicated as we have documented in human samples. Such an experiment would not answer 
whether such changes are due to the influence of the AML directly on CD33, or simply reflect 
induced quiescence and immaturity of the normal HSC subset. However, subsequently 
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inducing forced over-expression of CD33 on normal HSCs, and seeing if this negated the effect 
of the AML on their behaviour might be more illuminating.     
One of the potential difficulties in exploring the functional role of CD33 in HSC development is 
the observed inter-species differences, mentioned in Section 6.1.1.1. As there is no direct 
homolog between CD33 in humans and mice, investigating the effects of gene deletion in 
xenograft experiments is not possible. However, it is interesting that in the gene expression 
profiling experiment previously performed by our group using AML samples transplanted into 
a murine xenograft model (see Section 7.1.2.1 for experimental detail), one of the genes most 
markedly downregulated in normal murine HSCs exposed to AML was Sialic acid binding Ig-like 
lectin E (Siglec E), a member of the CD33 related gene family (log fold reduction in gene 
expression 2.32 AML versus controls, p=0.00077, Adjusted p value 0.134). 
 Does the differential expression pattern of CD33 on HSCs have a clinical 6.5.3
consequence?   
Does the reduced CD33 expression on normal HSCs in the context of AML presentation have a 
protective effect for these cells against the effect of GO? The results illustrated in Section 6.4.2 
would suggest that this is not the case.  
6.5.3.1 Clinical trial data suggest that CD33 expression level is not predictive for cytotoxicity   
It is logical, in today’s era of precision medicine, to hypothesise that the level of antigen 
expression on a cell would be predictive for the cytotoxic effect of a therapy targeted to that 
antigen. However, in the case of CD33 and GO, it is worth noting that the clinical data from the 
MRC-AML trials involving GO suggest this is not the case.  
When considering the effect of GO on normal HSCs, it is worth comparing the time to count 
recovery after chemotherapy, or incidence of cytopenias observed, between the patients who 
received GO therapy in induction and later in Consolidation 3. As discussed in detail in Section 
6.1.2.1.1, those receiving GO at Induction had no significant difference in time to count 
recovery compared to those who did not. However, the same pattern was also seen in those 
who were randomised to receive chemotherapy in consolidation 3. If the patterns described in 
Section 6.4.1.3 with respect to HSC CD33 expression increasing to baseline at remission in 
patients with CBF mutated AML are replicated across a cohort of wider karyotypic 
abnormalities, this would imply that HSCs appear unaffected by GO, despite fluctuating levels 
of CD33 expression.  
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Secondary evidence comes from the more widely studied effect of GO on AML blasts 
themselves. Possibly counter-intuitively, the same trial shows no correlation between the level 
of CD33 expression on blasts and the clinical effectiveness of GO therapy 3,280.  
6.5.3.2 Why might HSCs be immune to the effect of GO? 
The data illustrated in Section 6.4.2 suggest that at least in this in vitro model, normal HSCs 
(from AML samples and controls) are not significantly affected by the presence of GO. There 
exist a number of explanations for this observation, which might either represent a true 
biological finding, or reflect an inadequacy of the in vitro system used in this experiment.    
 Normal HSC expression of CD33 is significantly lower than on blast cells  6.5.3.2.1
A lack of clinical effect of GO on the behaviour of normal HSCs (compared to its effects on AML 
blast cells) might in part be explained by the significantly lower CD33 expression seen on 
normal HSCs. Figure 6-3 shows the median fluorescence intensity (MFI) of CD33 expression 
calculated for the 22 AML samples and 9 controls studied in Section 6.4.1. When the MFI is 
calculated for the subsets of CD34+38-ALDHhigh cells from both AML and control samples, it is 

















































































































































Figure 6-3 Bar chart illustrating the Median Florescence Intensity of CD33 expression of unselected AML cells 













from normal BM. Median Fluorescence Intensity and interquartile range are displayed  
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expression for unselected AML is 2362; HSCs from AML samples is 513, and HSCs from control 
samples is 1028). Kruskal-Wallis testing suggests the observed differences between these 
results are highly significant (p value <0.0001). Subsequent pair-wise analysis, using Dunn’s 
multiple comparison test, suggests that the difference in MFI between unselected AML blasts 
and HSCs from AML is highly significant (p<0.0001), and between control and unselected AML 
p=0.028 (which when correcting for multiple testing is just above the level of significance 
(p<0.025)).  
Are these differences significant enough to explain the observed lack of effect of GO on the 
normal HSCs?  
 Are other aspects of normal HSC biology more important than CD33 expression for 6.5.3.2.2
protection against the effects of GO?   
GO, once internalised by cells after CD33 binding, exerts its cytotoxicity by inducing DNA 
strand breaks in cycling cells264. In vitro and in vivo resistance to GO can occur by increased 
drug efflux by members of the ATP binding cassette protein family, including P-glycoprotein 
(ABCB1) and multidrug resistance-associated protein1 (ABCC1)265-268. Thus stem cells, which 
cycle relatively infrequently281, have unique DNA repair mechanisms282 and reduced apoptotic 
responses to DNA damage283, and active drug efflux pathways284,285, may be extremely well 
adapted to resist such agents when administered in isolation.  
However, new potential strategies to increase the effectiveness of GO by giving it in 
combination with ABC transporter blockade, might potentially increase its cytotoxicity.     
 How could the in vitro experimental model be improved?  6.5.3.2.3
Despite the fact that the results from the in vitro experiments, showing resistance of normal 
HSCs to the effects of GO, do replicate what is observed clinically, it is worth pointing out that 
the model used could benefit from significant optimisation to be truly confident of any 
conclusions drawn.  
Key to this is the limited availability of GO, which only became available for our use in the last 
4 months of this PhD, when the AML-19 trial opened locally. As we were using excess 
reconstituted GO designed for patient use, experiments (which under normal circumstances 
would be planned well in advance to allow for growth of sufficient MS5 feeder cells, irradiation 
access and sorter bookings) were performed at short notice and thus sample numbers were 
limited. Secondarily, the method of obtaining GO meant there was often a delay between 
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reconstitution and in vitro use (although this was limited to a maximum of 72 hours). In clinical 
usage, drug stability is not guaranteed from 24 hours after reconstitution.        
Because we only had access to GO three times in total, lengthy optimisation of experimental 
conditions was not possible. The only published paper involving GO and a LTC assay involved a 
two hour exposure of unselected cells from the bone marrow of a patient with CML to GO at a 
dose of 5µg/ml, prior to washing and plating in LTC for 5 weeks. At this dose and with this 
exposure method, GO significantly reduced the number of CFU-GM cells when compared to 
untreated controls286. I used an exposure dose of 3µg/ml for two hours to pre-sorted cells, as 
this replicated the mean Cmax of plasma hP67.6 antibody levels observed in Phase II trials
263 
(with GO being administered at a dose of 9mg/m2, three times higher than that now used in 
AML-19126). However, it could certainly be argued that a two hour exposure time before cell 
plating (although reflecting the time taken to reach Cmax clinically) is not sufficient to illustrate 
the potential effects on slowly cycling HSCs. Pharmacokinetic studies suggests the plasma t1/2 is 
in fact 62 hours. Secondarily, whether the plasma Cmax is necessarily good guide to the levels of 
GO in the bone marrow, where stem cells normally reside, is clearly debatable. 
Therefore, ideally, a range of concentrations of GO would ideally be assayed for their effect on 
HSC viability. Secondarily, the effectiveness of the GO (given concerns about reducing stability 
from reconstitution) should be assayed in parallel with each experiment by testing its ability to 
reduce the viability of AML blast cells, either from primary samples, or an AML cell line known 
to be sensitive to is effects. 
We had chosen to measure HSC numbers functionally by a 7 week LTC assay, as opposed to 
purely phenotypically by flow based appearances. An alternative approach, which would allow 
for a more prolonged drug exposure period, would be to place cells in culture with GO for 48 
hours, and then assess cell viability by a flow based assay at the end of this period. Using this 
approach to assess GO sensitivity in LSCs, Jawad et al found normal CD34+38- HSCs were 
insensitive to the effects of GO (albeit at a much lower concentration of 10ng/ml)287.  
 Potential further experimental work  6.5.4
This work has raised a number of unanswered questions, which would be worth exploring with 
further experimental effort.  
We have illustrated that CD33 expression is downregulated on normal HSCs in the context of 
AML development for both CD34low samples and CBF leukaemias. We have also demonstrated 
for the CD34low cohort that this change reflects a downregulation in CD33 gene expression; 
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ideally we would also explore gene expression patterns within the CBF AML cohort to see if the 
same pattern is observed.      
As discussed in Section 6.5.2, it is unclear if the changes we have described in CD33 expression 
patterns on normal HSCs are directly induced by exposure to AML cells, or whether they simply 
reflect an increase in the proportion of more immature, quiescent HSCs within the CD34+38-
ALDHhigh population. One way of addressing this would be to explore the effect of transient 
CD33 over or underexpression on HSCs. Not only would it be interesting to observe the effect 
this had on HSC division kinetics and repopulation ability, but I would also be keen to study if 
modified cells were still influenced in the same fashion (in terms of induced quiescence) by the 
presence of AML.  
Despite the observed changes in CD33 expression on normal HSCs in the context of AML 
development, the clinical evidence from recent AML trials, as well as our in vitro experimental 
data would suggest that HSCs from both normal and AML bone marrows are relatively 
insensitive to the effects of GO. However, as anti-CD33 therapy in AML undergoes a current 
resurgence in interest, it will be interesting to see if new, emerging therapies are associated 
with prolonged cytopenias and delayed count recovery. In particular, proposed trials looking at 
GO therapy administered in combination with drug efflux inhibitors might render normal HSCs 
more susceptible to its effects. As AMG 330 (by nature of its design as a BiTE antibody) is not 
reliant on cell cycle status, DNA repair mechanisms or drug transporters, it may prove to be 
more toxic to normal HSCs than GO. Our data suggest the time of greatest differential of CD33 
expression between normal HSCs and AML is at diagnosis, and therefore is supportive of the 
use of anti-CD33 therapies at induction rather than consolidation. Clinical trial data are 
supportive of this288,289. 
. 
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Chapter 7 Using RNA-Seq to compare the transcriptomes of 
normal HSCs from AML and control bone marrow samples  
7.1 Introduction 
As discussed in Section 1.5.2, previous work from our group using both primary human 
samples and a xenograft transplant model of AML, suggested that whilst the concentration of 
HSCs in the bone marrow at diagnosis with AML is preserved, the cells themselves appear to 
enter a state of quiescence. We have hypothesised that this may be responsible for the 
corresponding fall in progenitor numbers and observed downstream failure of 
haematopoiesis1.  
The mechanism by which this occurs is not known. Observational work published over thirty 
years ago suggests cell-cell contact between AML cells and HSCs is not required290,291. Blasts 
might either affect the cycling behaviour of normal HSCs through a direct signalling pathway, 
or indirectly by modulating the activity of the stromal cells normally responsible for niche 
formation140-143.  
The almost universal observation of bone marrow failure associated with the development of 
AML, despite the known diversity of genetic aberrations in leukaemic populations, would 
suggest to me that these changes are most likely the result of the modulation of a signalling or 
homeostatic feedback pathway which is normally involved in the control of HSC behaviour, 
rather than a new acquired signalling route. Could it be possible that the proliferating blasts 
are resistant to inhibitory feedback mechanisms that under normal circumstances should 
prevent their further growth, but might concurrently inhibit normal HSC development? 
Hunting for the pathway or pathways responsible for HSC quiescence in this setting has 
become the holy grail of my PhD over the last three years. Identification of even one of the 
important factors in this process might reveal a pharmacological target, through which we 
could reverse this process. Clinically, whilst the prevention of haematopoietic failure in this 
setting might not provide a long-term cure, it might result in effective disease palliation and a 
reduced need for transfusional support.   
 Difficulties with HSC work  7.1.1
A key consideration when planning experimental work in this area is the small number of HSCs 
available. This is particularly an issue when working with primary human samples, when ethical 
considerations limit the amount of bone marrow it is possible to extract from each patient. 
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Personal experience has shown it is possible to extract between 500 and 2000 HSCs from most 
bone marrow samples stored in the Bart’s Tissue Bank. Using techniques modified for low cell 
numbers, it is possible to study both the DNA and RNA content of these cells. However, this is 
far less than the minimum material required for proteomic analysis via Western blotting, ELIZA 
or mass spectrometry. Any attempted amplification of the HSC population after sorting would, 
by definition, require a reversal of the quiescence we are attempting to study.   
7.1.1.1 Experimental models of the AML-normal HSC interaction 
In the past, as detailed in Section 1.5.2.1, we have utilised a xenograft transplant model of 
AML development, where NSG mice act as permissive recipients of primary human AML 
samples. This approach was used both in our recent publication on HSC numbers at AML 
diagnosis1, as well as to date unpublished work involving the analysis of AML-exposed normal 
murine HSCs by gene expression array (see Section 7.1.2.1). The alternative approach of Cheng 
et al, who, rather than transplanting primary human AML samples into mice, developed an 
AML murine model by introduction of the MLL-AF9 gene into Ly B6-Ly5.2 mice, avoids many of 
the concerns that the observed changes in HSC behaviour might be due to the transplantion 
process per se136.  
To date, we have been unable to develop an in vitro model of the interaction between normal 
HSCs, stromal cells and AML blasts. Over several years, our group in collaboration with 
members of Dr Bonnet’s lab at the LRI, have made strenuous attempts to develop such an 
assay, but without reproducible success. Further discussion of these attempts is found in 
Section 8.2.3.6, and the relevant experimental protocols listed in Appendix 2.  
Given these limitations, one method of screening for the activation of potentially important 
signalling pathways, is the study of the comparative transcriptomes of HSCs within AML 
samples and controls. Such an approach has been attempted by my group and others when 
studying murine HSCs, but not to date, with primary human samples.    
 Previous work assessing the HSC transcriptome in the context of AML 7.1.2
development 
7.1.2.1 Within a murine xenograft model  
Unpublished work from my group using a murine xenograft model of AML-induced bone 
marrow failure has revealed differential gene expression linked to metabolic control and TGF β 
signalling within the normal HSC subset, when compared to controls.  
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Seven unirradiated NSG (Nod/Scid/il2-Gamma chain receptor null) mice were transplanted 
with one primary sample of AML. Once the mice had reached the midphase of AML bone 
marrow engraftment1, they were sacrificed along with six untransplanted controls. Murine 
HSCs were extracted from bone marrow by FACS sorting using CD48, CD150, CD117 and 
mCD45. Subsequent RNA extraction and whole RNA genome amplification was undertaken, 
prior to genomic expression analysis using the Affymetrix array platform. 
Significant changes in gene expression were detected in over 200 genes, with subsequent 
pathway enrichment analysis suggestive that many of these were involved in the control of cell 
metabolism (in particular the PPAR pathway) and the TGF β signalling pathway.  
The data from this model clearly have some limitations when translating its relevance to the 
interaction between human HSCs and AML. Firstly, the cells under investigation are murine, 
not human HSCs, and there are well documented differences between the mechanisms that 
control their behaviour. Secondarily, this is an interspecies xenograft transplant model, and 
some of the induced changes in behaviour may well be due to the transplantation process, 
rather than an effect solely due to the AML per se (controls were untransplanted mice, rather 
than mice transplanted with normal human haematopoietic tissue). Finally, these mice were 
all transplanted with the same sample of AML, previously documented to be capable of 
causing engraftment within the NSG murine model. Therefore, it is impossible to say if any 
observed differences in behaviour are due to a common effect from all AML samples, or are 
specific to this particular sample. There is no representation of disease diversity. 
The alternative approach of Cheng et al mentioned above, and in Section 1.5.2.3, involved the 
generation of a murine model of AML-induced BM failure, with the retroviral-driven 
introduction of the MLL-AF9 gene into Ly B6-Ly5.2 mice. Subsequent transplant of murine AML 
cells into a Ly B6-Ly5.1 murine recipient allows the development of leukaemia without 
concerns of immune rejection, but provides a means of easy flow-based identification of 
normal HSCs from leukaemic blasts. 
The authors of this paper also performed microarray analysis of the normal HSC populations of 
these mice, and identified relative upregulation of a number of genes associated with cell 
quiescence signalling, including Egr3. In a number of subsequent experiments, a role for Egr3 
in mediating AML-induced HSC quiescence was mapped out. Retrovirally induced 
overexpression of Egr3 in murine stem cells led to a quiescent phenotype both in vitro and in a 
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murine transplant model. The reverse effects were observed when Egr3 expression was 
reduced in murine stem cells by shRNA knock-down.  
7.1.2.2 My own work on primary human samples using targeted pathway analysis  
Targeted pathway analysis was used to compare the expression of genes within the PPAR and 
TGFβ pathways between AML-exposed HSCs and controls. In the interests of brevity, I have 
chosen to summarise these experiments here, rather than in their own, individual chapter.  
These experiments were performed using normal HSCs extracted from primary human AML 
and control bone marrow samples. In their completion, I gained experience in the accurate 
sorting of HSCs from BM samples, as well as subsequent efficient RNA extraction from limited 
material. Knowledge of the observed inter-sample heterogeneity amongst both the HSCs from 
controls, as well as different AML subtypes, was invaluable for planning the subsequent RNA-
Seq work which comprises the bulk of this chapter.   
 Rationale for studying the expression of genes within the TGFβ and PPAR 7.1.2.2.1
signalling pathways  
The results from the murine xenograft work detailed in Section 7.1.2.1 highlighted the 
differential expression of a number of genes which contributed to two pathways: the 
Peroxisome Proliferator Activator Receptor (PPAR) pathway and the TGFβ signalling pathway.  
Peroxisome proliferator-activated receptors are a group of nuclear receptor transcription 
factors that regulate the expression of genes which control cellular differentiation, 
development and metabolism. Three PPAR isoforms exist with differential expression across 
the body: α, β and γ292. Activated receptors heterodimerize with the retinoic acid receptor 
(RXR) in the nucleus, before binding to specific peroxisome proliferator hormone response 
elements within DNA. PPAR activity can be modulated by a number of coactivators and 
repressors293, and in addition, a variety of drug modulators. In humans, hereditary loss of 
function disorders of all of the PPAR receptors has been reported, largely resulting in 
metabolic deregulation leading to lipodystrophy, or insulin resistance, rather than loss of bone 
marrow function294.   
Ito et al assigned a key role for the PPAR β/δ pathway in the maintenance of normal HSC 
quiescence and differentiation in mice. Conditional deletion of the PPAR δ gene resulted in 
reduced long term repopulating ability of stem cells; whereas exposure to PPAR δ agonists 
(GW-501516) increased cobblestoning activity of HSC and progenitor cells. Downstream 
inhibition of mitochondrial fatty acid oxidation (by the drug etoxomir) reduced the numbers of 
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HSCs and their ability to repopulate lethally irradiated mice; similarly, the addition of etoxomir 
to cells negated the effect of the PPAR agonist GW-501516. These data together suggest a key 
role for PPAR β/δ, modulated downstream by the fatty acid oxidation pathways, in regulating 
stem cell division and differentiation decisions62.  
TGFβ signalling is known to have a key, multifactorial role in the control of cell proliferation, 
differentiation and cell death, both under conditions of health, and in the context of cancer. 
TGFβ is a secreted protein that exists in at least three isoforms295. In normal cells, TGFβ 
signalling results in G1 stage arrest, leading to the cessation in proliferation, differentiation 
induction, or promotion of apoptosis296. Cancer cells can acquire mutations in the TGFβ 
signalling pathway, leading to insensitivity to its effects297.  
Through analysis of cell lysates from AML samples using western blotting techniques, our 
group has shown a consistent increase in TGFβ production from AML samples when compared 
to GMPB (D Taussig, personal communication).  
TGFβ signalling has been shown to affect normal HSC behaviour within patients with multiple 
myeloma. Bruns et al used Affymetrix gene expression profiling on HSC fractions derived from 
multiple myeloma patients to show prominent changes in expression of genes within the TGFβ 
signalling pathway, when compared to HSCs from normal controls. Whilst Ki67 staining 
revealed reduced cycling within stem cell progenitors in patients with myeloma, this effect was 
reversed by the addition of SD-208, an inhibitor of Smad-2 phosphorylation298. 
The role of the TGFβ pathway in affecting HSC behaviour in patients with AML has not been 
defined, but it remains an attractive target for further investigation, as it is widely understood, 
and several pharmacological modifiers of both receptors and downstream signalling targets 
are available299.    
 Summary of experimental method  7.1.2.2.2
Five CD34low, NPM1 mutated AML BM samples and four controls were sorted for CD34+38- HSC 
populations. Four CBF AML BM samples and four controls were sorted for CD34+38-ALDHhigh 
HSC populations. Cells were sorted as previously described, and processed following the 
method detailed  within the Qiagen RT2 Profiler PCR assay kit.  
These assays facilitate the simultaneous qPCR based analysis of expression of 84 genes within 
a particular pathway. The incorporation of a pre-PCR amplification step allows the analysis of 
very small initial RNA quantities.   
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RNA extraction from sorted cells was performed as per Section 2.8.2.  For analysis of TGFβ 
pathway expression, the RT² Profiler™ PCR Array Human TGFβ Signalling Targets (Qiagen, Cat: 
PAHS-235Z) was used. For analysis of PPAR target expression, the RT² Profiler™ PCR Array 
Human PPAR Targets (Qiagen, Cat: PAHS-149Z) was used. After cDNA synthesis, samples 
underwent pre-amplification for the cDNA target templates, followed by loading onto 384 well 
plates prefilled with the appropriate primers for all 84 gene targets.  
Analysis of the resultant qPCR data was performed as per Section 2.8.4.5.4.   
 Summary of results  7.1.2.2.3
7.1.2.2.3.1 PPAR Pathway analysis  
Initially, the data from all 8 AML samples and 8 controls were analysed together. Of the 84 
genes within the PPAR pathway, 10 showed upregulation (relative expression greater than 
two) in those HSCs sorted from AML samples when compared to those from control samples, 
and 12 showed downregulation (relative expression less than 0.5). However, the variability in 
expression between individual samples meant that only one of these results obtained 
statistical significance: the expression of malonyl CoA decarboxylase, which was 
downregulated in stem cells derived from AML samples as compared to controls.  
Gene expression within the HSCs from CBF leukaemias (n=4) was then compared 
independently to matched controls (n=4). Four genes showed statistically significant 
alterations in expression: Cytochrome p450, 3-hydroxy-3methylglutaryl-CoA synthase 2 
(HMGCS2), Peroxisome Proliferator Activated Receptor Alpha (PPARA) and Retinoid X Receptor 
Gamma.  
By comparison, when the gene expression within the HSCs derived from CD34low leukaemias 
(n=4) was compared independently to matched controls (n=4), two genes were significantly 
downregulated in AML-exposed HSCs: Enoyl CoA hydratase/3hydroxyacyl CoA dehydrogenase 
and E1A binding protein p300. 
7.1.2.2.3.2 TGFβ Signalling Pathway analysis  
When all AML samples and controls were analysed together as a single cohort, 20 genes 
showed upregulation (relative expression greater than two) in AML exposed HSCs, and 7 
showed down regulation (relative expression less than 0.5). However, as before, the 
intersample variability in results meant that only four of these changes obtained statistical 
significance: Epithelial membrane protein 1 (EMP1), FBJ murine osteosarcoma viral oncogene 
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homolog (Fos), Ras Homolog member A (RhoA) and Ras homolog member B (RhoB) all showed 
statistically significant upregulation when compared to control samples.   
Gene expression within the HSCs from CBF leukaemias (n=4) was then compared 
independently to matched controls (n=4). Expression of the Aryl Hydrocarbon receptor 
interacting protein-like 1 (AIPL1), plasminogen (PLG) and EMP-1 were significantly increased in 
AML-exposed HSCs, and expression of Inhibitor of DNA binding 1 (ID1) significantly 
downregulated in AML-exposed HSCs.  
Subgroup analysis of mRNA extracted from stem cells from AMLs of the CD34low phenotype 
(n=4) also showed a small but significant rise in expression of the cyclin dependent kinase 
inhibitor 1B (p27). 
 Validation attempts  7.1.2.2.4
I subsequently attempted to validate the changes observed and selected one of the five genes 
shown to be differentially expressed when both subtypes of AML were analysed together-
RhoA. This was partly a pragmatic decision based on the availability of commercial antibodies 
of proven validity, and partly because of a recent publication from the Bonnet lab had 
suggested that RhoA upregulation in a lentiviral transfection model led to cord stem cell 
quiescence300.  
Two methods of assessment of protein expression in HSCs were attempted. Sorted HSCs (both 
CD34+38- cells from CD34low AMLs and CD34+38-ALDHhigh cells from CBF AMLs) were placed on 
slides, fixed and stained for RhoA expression using an anti RhoA mouse-derived IgG1 antibody 
(AbCam, Cat: ab54835).  
Secondarily, RhoA expression was studied using the same antibody to stain fixed cells from 
unsorted bone marrow samples, prior to flow cytometric based analysis. Samples were 
analysed for the proportion of CD34+38- cells that were positive for RhoA. 
This work proved technically challenging, as it required intracellular staining with 
unconjugated, primary anti-RhoA antibody, followed by secondary staining with a Goat Anti-
Mouse antibody, conjugated to PE (BD, Cat: 550589). The necessity for cell fixation prior to 
staining for intracellular RhoA expression precluded the use of CBF AML samples, where the 
vital stain ALDH is necessary for accurate distinguishing of normal cells from the leukaemia 
clone.  

































 HSCs of AMLs and controls. Median percentage of RhoA 
positive cells and interquartile ranges are plotted.  
Having optimised this flow-based technique, I then assessed RhoA expression patterns on 
seven CD34low AML bone marrows and five controls. Populations were analysed for the 
percentage of CD34+38- cells which were RhoA positive, based on isotype-stained controls. 
These data are illustrated graphically in Figure 7-1. The median percentage of RhoA positive 
cells within the CD34+38- HSC population of CD34low AML samples was 81% (IQR 55 to 96%, 
n=7); for controls, this figure was 98% (IQR 50-99%, n=5). There is no significant difference 
between these values, as determined by Mann-Whitney t-test (p=0.22).  
 Summary  7.1.2.2.5
 The experience of these experiments taught me several things of relevance to the RNA-Seq 
work that followed.  
One of the strengths of this work is that it is performed on primary human samples, 
representing a variety of different AML subtypes. This avoids all of the inherent concerns with 
using a murine xenograft model summarised in Section 7.1.2.1.  
However, one of the difficulties with the use of primary samples is the significant inter-sample 
heterogeneity in gene expression, which resulted in few genes reaching statistical significance 
in terms of differential expression. This was apparent even within the control samples used. 
Interestingly, it also appeared that there were differences between the patterns of gene 
expression observed between the HSCs from CBF and CD34low AMLs. Although the observed 
changes might not have any demonstrable effect of stem cell quiescence or differentiation, 
this was an unexpected result. The obvious response to such inter-sample variability is to 
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substantially increase the number of samples studied, but we were limited both by cost 
implications and tissue availability within the Bart’s Tissue Bank.  
In retrospect, the experiments would have been better designed if I had adopted a consistent 
approach to sorting HSCs across all the AML subtypes tested. CD34 and CD38 expression are 
sufficient to separate out normal HSCs from CD34low AML cells, but the more rigorous CD34+38-
ALDHhigh selection is required when analysing CBF mutated samples. Although the HSCs from 
both types of AMLs were analysed against control samples sorted by identical criteria, it is 
certainly possible that some of the differences in gene expression observed between the HSCs 
from the AML subtypes could be due to the slightly different sorting strategies employed, 
rather than an inherent biological distinction.    
Finally, despite the limitations detailed above, the results of this experiment did highlight the 
lack of parallels between results generated by a murine xenograft model and primary human 
samples. As we believe the use of actual human samples is far more likely to represent 
relevant translational biology, this reinforced my desire to continue to work with these in 
further experiments.  
 RNA-Seq  7.1.3
7.1.3.1 Background 
 The technique of RNA-Seq (also known as WTSS or Whole Transcriptome Shotgun Sequencing) 
harnesses the ability of Next Generation Sequencing platforms to detect the RNA present 
within cells. It is most commonly used to study the mRNA transcripts within cells, but 
experimental techniques can be modified to focus on non-coding RNA such as miRNA301 and 
tRNA302. Its sensitivity is such that it can be used to study a huge dynamic range of starting 
material- from single cells, to millions of pooled cells.  
7.1.3.2 RNA-Seq versus Microarray 
The dominant technology until recently for whole transcriptome analysis of cells involved the 
use of microarrays, which allowed the simultaneous detection of multiple gene transcripts. 
Microarray chips are coated with thousands of probes specific for particular genes, in tightly 
specified locations. A test sample of cDNA is pre-treated with chemoluminescent dyes that 
bind to the cDNA, and emit light on hybridisation. On probe binding to complementary cDNA, 
hybridisation is detected by a chemoluminescent signal, which is proportional in intensity to 
the degree of binding, and therefore the amount of the target within the sample. After 
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washing of the chip to remove non-specifically bound targets, the fluorescence of the chip is 
read.  
In recent years, RNA-Seq based approaches have largely superseded microarrays as the 
technique of choice for parallel sequencing analysis. The technology behind RNA-Seq offers a 
number of improvements on previously available methods. Microarrays require detailed prior 
knowledge of the genome, so that primers can be produced for all known genes under 
investigation. By contrast, RNA-Seq requires no prior knowledge of the genome, making it 
ideal for the studies of rare species. This also enables the detection of novel genes, mutated 
transcripts (particularly of relevance for cancer work), rare allelic variants and splice variants. 
Finally, as the detection of transcripts is not dependant on chemoluminescence, RNA-Seq 
offers a wider dynamic range, in the absence of significant background signal303.       
7.1.3.3 RNA-Seq experimental design for small cell inputs 
 RNA extraction and cDNA synthesis  7.1.3.3.1
At the time of experimental design, several commercial kits optimised for the extraction of 
RNA and cDNA synthesis from small numbers of cells prior to library preparation were 
available. 
The SmartSeq v4 Ultralow RNA Kit for Sequencing (Clontech, Cat 634889) is marketed for the 
production of cDNA from RNA or cells, for inputs of between 1 and 1000 cells. mRNA is 
selected by the use of primers specific for the PolyA tail of transcripts. The subsequent use of 
SMART® technology, which relies on the template switching activity of reverse transcriptases, 
enriches for full-length cDNAs and adds PCR adapters directly to both ends of the first-strand 
cDNA304. This ensures the final cDNA libraries contain the 5’ end of the mRNA, and hopefully 
maintains a true representation of the original mRNA transcripts. This process is illustrated in 
Figure 7-2.  
Market competitors include the Ovation V.2 RNA-Seq kit (Nugen, Cat 7109), which also offers 
cDNA synthesis and amplification from small RNA inputs (500pg upwards). In this case, the 
manufacture of cDNA involves the use of primers both specific to the PolyA tail of mRNA 
transcripts as well as random sequences, and therefore allows for production of transcripts 
from both polyadenylated and non-polyadenylated RNA. 
Our final choice of the Clontech SmartSeq kit was based on discussions with other users in 
Oxford, UCL and BCI, who all had experience of using this kit in experiments with limited cell 
numbers.    
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Figure 7-2 The method of mRNA selection and cDNA synthesis involved with use of the Clontech SmartSeq kit
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 Library Preparation Options 7.1.3.3.2
Library preparation prior to NGS involves the fragmentation of DNA, followed by the fusion of 
the resultant fragments to adaptors capable of immobilising the strands onto a solid surface 
during sequencing. Initial fragmentation of DNA strands can be performed either by 
mechanical shearing, or enzymatic breakdown of cDNA306.  
Commonly, libraries are amplified by PCR, and undergo size selection of fragment strands prior 
to sequencing.  
The Nextera XT DNA library preparation kit (Illumina, Cat FC 131-1024) is specifically designed 
for efficient library preparation from very small DNA or cDNA inputs (1ng per sample). 
Efficiency is increased by the use of an engineered transposome to simultaneously fragment 
and tag the input DNA in random places with adapter sequences. Subsequent PCR uses the 
adapter sequences to amplify the insert DNA. The PCR reaction also adds index sequences on 
both ends of the DNA. This process is illustrated in Figure 7-3.    
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Figure 7-3 The process of DNA library production utilising the Nextera XT kit
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7.1.3.4 Next Generation Sequencing  
The process of NGS sequencing is briefly described here. In the first step of cluster generation, 
the DNA library is added to the Sequencer, where the fragments bind to a cell lined with 
sequences complementary to their adapters. Each fragment is amplified, and distinct clonal 
clusters produced.  
Subsequent sequencing involves the incorporation of fluorescently labelled dNTPS by DNA 
polymerase to a single strand of template DNA in sequential cycles. The binding of each dNTP 
releases a fluorescent signal which can be detected. Simultaneous sequencing of multiple 
strands in parallel allows collection of huge data sets for analysis308. Data regarding sequence 
are stored and then analysed via a Bioinformatics pathway.  
In planning a sequencing experiment, a number of choices have to be made. Key decisions 
include the depth and length of reads required, as well as a choice of single or paired end 
reads. Allowing for a greater number of reads per sample comes at a higher cost, but allows 
for the detection of infrequently expressed genes, as well as mutations within transcripts.  The 
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choice of read length is often defined by the provider of the sequencing platform, but the 
advantage of longer reads is an increased ease of unambiguous mapping to a specific position 
within the genome. The advent of paired end sequencing allowed sequencing from both ends 
of a DNA strand, and the automatic association of the data generated. This approach facilitates 
better read alignment, which is of particular value in repetitive regions of the genome.   
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7.2 Aims and Objectives  
The work described in this chapter aimed to use transcriptome analysis to identify key 
regulators responsible for the observed quiescence of HSCs exposed to AML. In doing so, I 
hoped to identify potential therapeutic targets with the aim of reversing this process.  
This first objective of this chapter was to sort HSCs from human primary CD34low AML BM 
samples and matched controls by the techniques already described in this thesis, and study to 
their transcriptomes via RNA-Seq analysis. This required the generation of cDNA from the RNA 
of sorted cells, followed by the production of DNA libraries.  
A first experimental attempt generated poor quality data, with a significant number of 
sequencing reads mapping to non-coding DNA regions. As a result, the entire experiment was 
repeated with some substantial methodological changes.   
The secondary objective was to validate the expression changes of genes of interest either by 
qPCR, or by flow-based assessment of protein expression where possible.  
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7.3 Attempt 1: Library Preparation involving cDNA synthesis directly 
from cell lysate 
 Specific Methods  7.3.1
7.3.1.1 Samples 
Six CD34low and six control samples were chosen for transcriptome analysis. The decision to 
study only CD34low AMLs samples was based on the previous work on targeted pathway 
analysis summarised in Section 7.1.2.2, which suggested there may exist differences in gene 
expression patterns between the HSCs from different AML subtypes. As budget limitations 
meant the number of samples to be sequenced was relatively restricted, we decided to 
sequence the HSCs within a hopefully homogenous group of AMLs. Control BM numbers were 
matched, as the same previous work suggested these also exhibited relatively heterogeneous 
gene expression profiles.  
Sample details for the six AML samples are shown in Table 7-2. As in previous work, control 
samples came from patients with no prior chemotherapy exposure, blood counts within 
normal limits and a normal BM appearance by morphology, flow and immunohistochemistry. 
7.3.1.2 Sorting 
Samples were thawed, washed and cell counted.  
As CD34low AML samples had been chosen for this experiment, we could have separated 
normal HSCs on the basis of a CD34+38- signature alone. Instead, we chose to use the selection 
criteria for normal HSCs described in Chapter 4: namely CD34+38-ALDHhighCLL1-. Despite the 
increased experimental costs this incurred, using this more rigorous phenotype for the 
selection of HSCs meant that if any findings were to be validated in a different subgroup of 
AML samples (such as the CBF leukaemias), their HSCs could be separated in the same fashion.  
Samples were stained for ALDH expression as previously described. Staining with HAG 
dissolved in ALDH buffer was followed with staining for CD34-PerCP, CD38 PeCy7 and CLL1-PE 
at a concentration of 5µl/1.5x106 cells. Cells were resuspended into ALDH/DNase/DAPI, and 
the CD34+38-ALDHhighCLL1- cells sorted into ALDH buffer. 1100 cells were sorted for each 
sample, and 100 cells utilised for a purity check at the end of sorting. Cells underwent resorting 
if purity fell below 90%.  
Sorted cells underwent cell lysis and immediate cDNA synthesis, followed by amplification and 
clean-up, utilising the SmartSeq v4 UltraLow Input RNA Kit (Clontech, Cat 634889). The full 
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protocol is listed in the associated manual, but the completeness, details of the protocol are 
given below. Given low cell numbers, all sample processing was performed under a flow hood 
to reduce the possibility of contamination.  
Sorted cells in a FACS tube were spun (3000rpm, 10 minutes, 4oC) and the supernatant 
aspirated using a Gilson machine. The pellet was resuspended by flicking the tube, and the 
residual contents transferred to a 200µl eppendorf tube (MicroAmp Reaction Tube and Cap, 
AB, N801-0612). 100µl PBS was added to the FACS tube, vortexed and the liquid then 
transferred to the eppendorf, to transfer any residual cells and remove any residual ALDH 
buffer which might impede subsequent cell lysis.  
7.3.1.3 RNA prep and cDNA synthesis  
 Cell Lysis and Direct RNA to cDNA synthesis  7.3.1.3.1
The 200µl eppendorf was spun in a microcentrifuge (3000rpm, 10 minutes, 4oC), and the 
supernatant carefully fully removed using a Gilson aspirator loaded with a 10µl pipette tip. 
9.5µl nuclease-free water was then added, and the tube vortexed to resuspend the pellet.  
Cell lysis was then performed as follows. A stock solution of 10x Reaction Buffer was made by 
mixing 19µl 10x Lysis buffer with 1µl RNase Inhibitor to a total volume of 20µl. 1µl of Reaction 
buffer was added to each test sample, which was briefly vortexed, and then incubated at room 
temperature for 5 minutes. A negative control of 1µl Reaction Buffer and 9.5µl nuclease-free 
water was processed simultaneously.  
Samples were placed on ice, and 2µl 3’SMART-Seq CDS Primer IIA added to each. Samples 
were briefly vortexed, and spun down, and then incubated at 72oC for 3 minutes in a 
preheated thermal cycler. Samples were then placed immediately on ice for 2 minutes.  
cDNA synthesis master mix was then made up in the following proportions: 4µl 5x Ultralow 
First Strand Buffer; 1µl SmartSeq v4 Oligonucleotide and 0.5µl RNase Inhibitor. 2µl per sample 
of Reverse Transcriptase was added to the master mix immediately before use.  
The master mix was gently vortexed, and 7.5µl added to each reaction tube, which was then 
gently mixed, spun down and placed in a PTC-225 Peltier Thermal Cycler for the following PCR 
regime:  42oC for 90 mins; 70oC for 10 minutes, followed by holding at 4oC.   
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 cDNA Amplification by LD PCR 7.3.1.3.2
The resultant cDNA was amplified by the following methodology, optimised for the quantity of 
cDNA produced from these cells.  
PCR master mix was prepared in the following proportions: 25µl 2xSeqAmp PCR Buffer; 1µl 
PCR Primer IIA; 1µl SeqAMP DNA Polymerase and 3µl Nuclease Free Water.  
The master mix was briefly vortexed and spun down. 30µl of PCR master mix was then added 
to each tube containing 20µl first strand cDNA product. The samples were vortexed briefly, 
spun down and then placed on a PTC-225 Peltier Thermal Cycler set to the following program: 
95oC for 1 minute; 98oC for 10 seconds, 65oC 30 seconds, 68oC 3 minutes for a total of 10 
cycles; 72oC for 10 minutes; hold at  4oC.  
 Purification of Amplified cDNA using the Agencourt AMPure XP Kit  7.3.1.3.3
PCR products were transferred to a 1.5ml eppendorf tube. 1µl 10x Lysis Buffer was added to 
each sample. AMPure XP beads (Agencourt AMPure XP, A63881) (having been allowed to 
equilibrate to room temperature for 30 minutes before the start of the experiment) were then 
vortexed for 30 seconds to ensure even distribution of beads, before adding 50µl beads to 
each sample. Sample and beads were then mixed carefully by pipetting up and down at least 
10 times. Samples were incubated for eight minutes at room temperature to allow cDNA to 
bind to the beads. Tubes were briefly spun down, before placing on a magnetic separation 
device (DynamagTM2/Magnetic Particle Concentrator, Invitrogen) for five minutes until the 
supernatant was completely clear. Leaving the tube on the magnet, the supernatant was 
removed using a pipette, and 200µl of freshly made 80% ethanol was added without disturbing 
the beads. After 30 seconds, the supernatant was removed, and the process repeated once. 
Samples were briefly spun down, and then replaced on the magnet for 30 seconds. Any 
residual traces of ethanol were removed by pipette.  
Eppendorf tubes were left with their lids open for 2.5 minutes, to allow samples to dry. 17µl of 
elution buffer was then added to the pellet, which was gently pipetted to resuspend fully. The 
sample was then incubated at room temperature for two minutes to thoroughly rehydrate. 
Samples were briefly spun, and then replaced on the magnet for one minute until the 
supernatant was completely clean. The clean supernatant was then removed by pipette, and 
stored at -20oC.    
 Sample QC and quantification  7.3.1.3.4
Sample quality control was performed at the Genome Centre, Bart’s Cancer Institute.  
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Successful cDNA synthesis and amplification is predicted to yield no product in the negative 
control, and a distinct peak spanning 400bp to 10000bp, peaking at 2500bp in the positive 
control and yielding between 3.4-17ng of cDNA. The optimal methodology for assessing a 
sample’s suitability for further processing would involve the use of the Agilent 2100 
BioAnalyser, combined with Agilent’s High Sensitivity DNA Kit (Agilent, 5067-4626). This is of 
the appropriate sensitivity for the predicted yield of cDNA, and covers the expected sample 
size range. Unfortunately, this was not available in the Institute, and therefore on the advice of 
staff in the Genome centre, the DNA D1000 Tape Station High Sensitivity (35 to 1000bp, 
sensitive to 5pg/µl), loaded onto an Agilent 4200 Tape Station, was used to assess samples 
(Agilent 5067-5584). “Successfully” processed samples were identified by visualisation of the 
start of the cDNA peak visible between 500 and 1000bp (see Figure 7-4 Aii). In retrospect, 
given the difficulties with the quality of the data generated with the first RNA-Seq experiment, 
this approximation may have been significant. It meant we were unable to make any 
assessment of the quality of the cDNA generated, as we could only see the smallest strands 
generated. In theory, a significantly degraded sample might generate some cDNA of under 
1000bp length, but no peak in the 1000 to 10,000 range where full length mRNA transcripts 
would be expected to lie.  
Since the first experiment was completed, Agilent have produced the HS D5000 DNA 
ScreenTape (Agilent 5067-5592), which is much more appropriate for assessment of the cDNA 
libraries generated by the SmartSeq kit. It covers a size range of 100 to 5000bp, and is also 
sensitive to a concentration of 5pg/µl. This was used in for QC of samples generated in the 
second RNA-Seq attempt (see Section 7.4.1.3.4). 
7.3.1.3.4.1 Quantification using the Qubit dsDNA HS Assay Kit  
Quantification of cDNA libraries generated by the SmartSeq kit was performed using the Qubit 
HS DNA reagent kit (ThermoFisher Q32851), which offers a sensitivity range of 0.2-100ng/µl.  
A working solution of a 1:200 dilution of Qubit dsDNA HS Reagent with dsDNA HS Buffer was 
prepared fresh, and mixed well. 190µl of working solution was added to two plastic analysis 
tubes (provided with kit), and 10µl of kit DNA Standards 1 and 2 were added to each 
respectively. For each test sample, 1µl cDNA was added to 199µl of working solution in a fresh 
tube, prior to vortexing for three seconds. All samples and standards were left to equilibrate 
for 3 minutes at room temperature before analysis. 
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Analysis was performed using the Qubit 3.0 fluorometer. Calibration was first performed by 
analysis of the two standards diluted in working solution, followed by analysis of the samples.  
 Secondary Clean-Up 7.3.1.3.5
All test samples on initial analysis contained a small cDNA peak of 60bp size, thought to 
represent excess adaptor (see Figure 7-5). This was removed prior to further analysis by repeat 
cleaning of the cDNA sample, using a modified version of the above method with AMPure XP 
Beads. The residual sample (15µl) and AMPure XP beads were mixed in a 1:1 volume ratio (this 
ratio is optimal to remove DNA strands of less than 100bp length). Samples were then 
processed, washed with ethanol and eluted in 17µl of buffer as already described. 
Quantification using the high sensitivity Qubit test was repeated, as was visualisation by HS 
D1000 DNA ScreenTape. 
The clean supernatant was then removed by pipette, and stored at -20oC. 
7.3.1.4 DNA Library Preparation  
DNA Libraries were prepared using the Nextera XT DNA Library Preparation Kit (Illumina, FC-
131-1024). The protocol is summarised below. All reagents are included within the kit, unless 
where specifically stated.    
With each batch of processed samples, a negative control (compromising of the negative 
control processed through the SmartSeq cDNA synthesis process) also underwent the same 
library preparation process.  
 Index Selection  7.3.1.4.1
As 12 libraries were to be pooled together and sequenced simultaneously, the Illumina Low 
Plex Pooling Guidelines were followed when choosing compatible Index 1 (i7) and Index 2 (i5) 
adapters. Index sequences need to be complementary to ensure appropriate registration of 
samples during the sequencing process: as the sequencer uses a green laser to sequence G and 
T bases, and a red laser to sequence A and C bases, at each cycle at least one of two 
nucleotides for each colour channel needs to be read.  
From within the 24 sample Nextera XT DNA Library Preparation Index kit (FC131-1001), a 
combination of N701 to 706 (Index 1 (i7)) and S503 to 504 (Index 2 (i5)) were identified as 
compatible with the pooling and simultaneous analysis of 12 samples.  
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 Tagmentation of Input DNA 7.3.1.4.2
10µl Tagment DNA buffer was added to a 200µl eppendorf tube, followed by 5µl of the 
amplified cDNA (prediluted to a concentration of 0.2ng/µl). Samples were gently mixed by 
pipetting. 5µl of Amplicon Tagment Mix was then added to each eppendorf, and samples again 
mixed by pipetting. Tubes were then centrifuged (280g, 1 minute, 20oC), and placed on a PTC-
225 Peltier Thermal Cycler for the following program: 55oC for 5 minutes, followed by 10oC 
forever.  
As soon as the samples reached 10oC, the transposome was immediately neutralised by the 
addition of 5µl Neutralise Tagment Buffer to each well. Samples were mixed by pipette and 
centrifuged (280g, 1 minute, 20oC), prior to incubation at room temperature for five minutes.  
 PCR Amplification  7.3.1.4.3
Tagmented DNA was subsequently amplified by limited PCR. Simultaneously, indexes were 
added to barcode each sample before pooling for sequencing.  
15µl Nextera PCR master mix was added to each reaction well. 5µl of the appropriate i2 primer 
was added to each sample, followed by 5µl the appropriate i1 primer. Samples were mixed by 
pipetting. Tubes were centrifuged (280g, 1 minute, 20oC), and then placed on the PTC-225 
Peltier Thermal Cycler for the following program: 72oC for 3 minutes; 95oC for 30 seconds; 95oC 
for 10 seconds, 55oC for 30 seconds, 72oC for 30 seconds for a total of 12 cycles; 72oC for 5 
minutes;  hold at 10oC.  
 PCR clean up 7.3.1.4.4
PCR clean-up of the library was then performed, using a bead to sample ratio designed to 
remove excess short fragments, which are preferentially read during the sequencing process.  
Tubes were centrifuged (280g, 1 minute, 20oC), and samples transferred to 1.5ml eppendorf 
tubes. 90µl Agencourt AMPure XP beads (having been brought to room temp for 30 minutes 
and resuspended by thorough vortexing) were added to each sample, and mixed by pipetting 
10 times. Tubes were incubated for five minutes at room temperature to allow DNA binding to 
beads. The tubes were placed on a magnetic stand for two minutes until the supernatant had 
cleared. With the tube remaining on the stand, the supernatant was removed by pipette and 
the sample washed with freshly made 80% ethanol as follows. 200µl 80% ethanol was added 
to the tube on the magnetic stand, left for 30 seconds, and then removed by pipette. This 
process was repeated a second time. The sample was then left to air-dry on the stand for 15 
minutes. The tubes were then removed from the magnet, and 52.5µl Resuspension Buffer 
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added to each tube before resuspension by gentle repeated pipetting. The resuspended beads 
were then incubated at room temperature for two minutes to allow for DNA elution, before 
placing back on the magnet for a further two minutes until the supernatant had cleared. 50µl 
of supernatant was then removed and stored at -20oC until further notice.  
QC of the resultant DNA library was performed by repeat analysis on the HS D1000 DNA 
Screen Tape, and the resultant DNA concentration of the library confirmed by Qubit analysis. 
Optimal libraries should contain a range of fragment sizes between 250 and 1000 bp. 
 Quantification  7.3.1.4.5
7.3.1.4.5.1 Using Cubit and HS D1000 DNA Screen Tape  
Quantification of the DNA concentration of the library was performed as follows. The average 
size of the fragments contained within the library was determined by integration under the 
trace generated by the HS D1000 DNA ScreenTape. Library concentration was then calculated 
using the following formula: 
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7.3.1.4.5.2 Using Kappa Primers  
Individual libraries were also quantified using the KAPA Library Quantification Kit for Illumina® 
platforms (KAPA Biosystems, KK 4824). This contains primers designed to target the Illumina 
P5 and P7 flow cell oligo sequences, and therefore, when used in combination with DNA 
standards, provides an absolute quantification of the amount of DNA tagged for sequencing.  
7.3.1.4.5.2.1 Library Dilution and Generation of a Standard Curve  
Six DNA standards were provided with a range of concentrations between 0.0001pM and 
20pM. 
Libraries were pre-diluted to fall within the dynamic range of the assay. To reduce potential 
error associated with pipetting errors, two independent dilutions into 10mM Tris-HCl, pH 8.0 
(to concentrations of 1/10000 and 1/20000) were made for each library. Each dilution was 
made in two serial steps (1/10000: 1µl undiluted library into 99µl buffer, followed by a 
separate dilution of 1µl into 99µl (1/10,000); 1/20000: 1µl into 99µl, followed by 1µl into 
199µl). Samples were thoroughly vortexed between each dilution. Diluted libraries were kept 
on ice to increase their stability.  
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7.3.1.4.5.2.2 Reaction Set Up 
6µl KAPA SYBR®FAST and Primer Premix and 2µl H20 per sample were combined to make PCR 
master mix. 8mcl of PCR master mix was added to each well, followed by 2µl of DNA library or 
DNA standard, to a total well volume of 10µl. Each concentration was assayed in triplicate. 384 
well, clear white wells (BioRad HSP 3805) were used and sealed with compatible seals 
(Microseal B Seals, BioRad MSB1001). After sealing, the plate was centrifuged (1500rpm, 1 
min). 
The following analysis cycle was run on the BioRad C1000 Touch Thermal Cycler: 95oC for 5 
minutes; 95oC for 30 seconds, 60oC for 45 seconds for a total of 35 cycles; melt curve 65oC to 
95oC, with 0.5oC increments every 5 seconds.  
7.3.1.4.5.2.3 Data Analysis 
A standard curve was calculated using the results generated from the DNA standards. This was 
used to convert the average Cq score for each dilution of each library to an average 
concentration (pM). The average size-adjusted concentration for each dilution was calculated 
as follows: 
                                        
                                       
                            
                                       
 
The size adjusted concentration was then multiplied by the dilution factor to calculate the final 
concentration of the undiluted library. As for each library, two dilutions were assayed; the 
average of these was taken to calculate the working concentration used for subsequent 
pooling.   
 Library Pooling 7.3.1.4.6
The Library Normalisation step, utilising beads as described in the Nextera XT handbook, was 
not used. This decision was taken after discussion with the Oxford Genomics Centre and 
Illumina, who felt that the concentration yielded by the Bead Normalisation approach would 
not be sufficient for samples being sequenced on the HiSeq 4000. Therefore Library 
normalisation was undertaken manually using library concentrations generated by Kappa 
analysis.  
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7.3.1.5 Sequencing  
Library sequencing was undertaken at the High Throughput Genomic Centre at Oxford. The 
pooled library was run over two lanes of an Illumina HiSeq 4000, with paired end reads of 
75bp. This was calculated to give an average read depth of 40 million reads per sample.  
7.3.1.6 Bioinformatic Analysis 
Sequencing reads were aligned to the human genome build hg38/GRCh38 with the HISAT2 
aligner. Transcript quantification was performed with HTSeqt part of the HTSeq package 
(version 0.6.1p1)309, using GENCODE v23 human gene annotation (Ensembl release 81). 
The read count data were filtered to keep genes that achieve at least one read count per 
million (cpm) in at least three samples.    
Reads per kilobase per million mapped reads (RPKM) values were calculated with the 
conditional quantile normalisation (cqn) counting for gene length and gc content in the R 
statistical environment via Bioconductor packages310.  
Expression data were analysed using LIMMA 
(http://bioconductor.org/packages/release/bioc/html/limma.html) to fit a linear model to the 
expression data for each gene to detect differentially expressed genes between two groups 
(AML versus control samples). Differential expressed genes were gauged using LIMMA 
empirical Bayes statistics module. The differentially expressed genes are selected when p-
value is less than 0.05 and the absolute value of log fold change is more than 1.  
7.3.1.7 Validation Techniques  
 qPCR based validation 7.3.1.7.1
7.3.1.7.1.1 Sample selection  
Excess sorted HSCs for both AML and control samples used for RNA-Seq underwent immediate 
RNA extraction using the Qiagen MicroColumn method detailed in Section 2.8.2, prior to 
storage at -70oC. In several cases, insufficient HSCs were extracted to allow for both RNA-Seq 
analysis, and separate RNA extraction, and no further vials from the same patient were stored 
in the Tissue Bank. Therefore, an additional five control samples were sorted at a later date, 
using the same sorting and extraction methodology. Table 7-9 shows details of the samples 
used for qPCR based validation of the RNA-Seq data. 
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7.3.1.7.1.2 cDNA synthesis 
First strand cDNA synthesis from RNA was performed using the Superscript®VILOTM cDNA 
synthesis kit (Thermofisher, Cat 11754050), supposedly optimised for maximising efficiency of 
RNA conversion.       
cDNA synthesis was performed as follows. Into a single eppendorf tube the following reagents 
were mixed: 4µl 5xVILOTM Reaction mix; 2µl 10xSuperscript Enzyme mix; RNA 1 to 14µl as 
required; H2O to a total volume of 20µl. The tube was gently pipetted and placed on a thermal 
cycler for the following PCR reaction: 25°C for 10 minutes; 42°C for 120 minutes; 85°C for 5 
minutes; hold at 4oC. 
 For Taqman based probes  7.3.1.7.2
Master mix was made up in the following proportions for each sample: 1µl 20xProbe/Primer 
set; 10µl Taqman 2xPCR Master mix (Thermofisher, Cat: 4304437); 2µl cDNA; 7µl H2O. Each 
sample was set up in triplicate, along with appropriate negative controls. Plates were sealed 
and centrifuged at 1500rpm for one minute.   
Samples were run on a AB StepOne Plus analyser on the following cycle: 50oC for 2 minutes; 
95oC for 10 minutes;  95oC for 15 seconds, 60oC for 1 minute, for a total of 40 cycles.  
The following probe-primers were used, both tagged to FAM detectors: for CD33 
Hs01076281_m1 Taqman CD33 (Thermofisher, Cat 4331182); and for U2AF1 Hs01597465_g1 
Taqman U2AF1 assay (Thermofisher, Cat 4351372). A GAPDH probe in VIC-TAMRA 
(Thermofisher, Cat 4310884E) was used as a housekeeping gene.   
7.3.1.7.2.1 For SYBR gene based probes 
7.3.1.7.2.1.1 Primer design  
Ten genes were selected for validation by qPCR using the SYBR green system. No Taqman 
probes were commercially available for these genes.  
For eight of these genes, primer pairs from previous publications were selected from the 
Primer Bank website website311. Published primers were checked for suitability and specificity 
against the human genome using the BLAST website312.   
For the final two genes of interest, no published primer pairs were available. I am very grateful 
for the assistance of Dr Emily Saunderson with primer design for qPCR for the HIST1H2BC and 
HIST1H2AH genes.  
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Primer pairs were ordered from Sigma at a concentration of 100µM, using their custom qPCR 
probe service. Ordered sequences are detailed in Table 7-1. Primers were diluted in nuclease-
free H2O to a concentration of 10μM before use.   
Table 7-1 Primer Pair sequences for SYBR Green qPCR 
7.3.1.7.2.1.2 SYBR green qPCR 
Primer specificity and efficiency were first tested on two samples of stock cDNA from normal 
bone marrows. Melt-curves were inspected for the presence of multiple amplicons.   
A master mix was made to a total volume of 9μl per well as follows: 6μl Sso Advanced 
Universal SYBR Green Supermix (Biorad, Cat: 7725274); 0.125μl F primer (10μM); 0.125μl R 
primer (10μM); 2.75μl H2O. 9μl of master mix was added to each well, followed by 1μl of 
cDNA, to a total well volume of 10μl. Reactions were set up in triplicate, along with 
appropriate negative controls. 384 well, clear white wells (BioRad HSP 3805) were used and 
sealed with compatible seals (Microseal B Seals, BioRad MSB1001). After sealing, the plate was 
centrifuged (1500rpm, 1 min).  
The following analysis cycle was run on the BioRad C1000 Touch Thermal Cycler: 95oC for 2 
minutes; 95oC for 5 seconds, 60oC for 30 seconds for a total of 40 cycles; melt curve 65oC to 
95oC, with 0.5oC increments every 5 seconds.  
All ordered primers yielded single amplicons. 
Gene Name 
Primer Sequence (5' - 3') 
Forward Reverse 
GNA15 CCAGGACCCCTATAAAGTGACC GCTGAATCGAGCAGGTGGAAT 
HIST1H2BC ACACAGAGTAACTCTCCTTGCG AAGAAGGCAGTGACCAAAGC 
HIST1H2AH CAAGCAAGGCGGTAAAGCTC AACCCGCTCGGCATAATTAC 
IDH1 TGTGGTAGAGATGCAAGGAGA TTGGTGACTTGGTCGTTGGTG 
KLF9 GCCGCCTACATGGACTTCG GGATGGGTCGGTACTTGTTCA 
LILRA2 AGCCCCAGGAAAGAACGTG GCTGAGTGAGCTGTAGCATCT 
NFIL3 AAAATGCAGACCGTCAAAAAGGA TGACACTTCCGTTAAAGCAGAAT 
NXF3 GGACACACTACGGGTCACAC ACAGGTTCAGACCTACTGCTAAA 
RGS1 TCTTCTCTGCTAACCCAAAGGA TGCTTTACAGGGCAAAAGATCAG 
S100A10 GGCTACTTAACAAAGGAGGACC GAGGCCCGCAATTAGGGAAA 
TRAF4 TATTGGGCCTGCCTATCCG CAAAACTCGCACTTGAGGCG 
ZKSCAN4 TCAAGGGTCTCAAAGTAGCCA CTATCGTGTAAGGGCTGGGAT 
GAPDH GATTTGGTCGTATTGGGCGC TTCCCGTTCTCAGCCTTGAC 
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7.3.1.7.2.2 Analysis 
qPCR results were analysed as described in Section 2.8.4.4.  
The distribution of calculated fold changes in gene expression seen for individual samples 
within the AML-exposed and control HSC groups was examined for normality by the 
D’Agostino-Pearson normality test. Non-parametric datasets were analysed for significance by 
the Mann-Whitney t-test, using a cut-off value for statistical significance of <0.05. 
 Flow based analysis 7.3.1.7.3
BM samples of CD34low AML and controls were thawed, washed and counted as previously 
described. Samples were stained with ALDH, followed by HAG (dissolved in ALDH buffer). 
Samples were then stained with the following dyes at a concentration of 5µl/1.5x106 cells: 
CD34-PerCP, CD38-Pecy7, CLL1-PE and CD85g-APC (BD, Cat 562355). A second batch of the 
samples was stained with CD34-PerCP, CD38-PeCy7, CLL1-Alexaflour 647 (BD, Cat 562568) and 
Anti-TWEAK PE (BD, Cat 565731). Analysis of all samples was performed on a BD Aria II.  
Analysis was performed using the FlowJo v10 package. Staining of samples was expressed as 
the percentage of CD34+38-ALDHhighCLL1- HSCs which were positive (as defined by matched 
FMOs) for either CD85g or TWEAK expression.     
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 Results 7.3.2
7.3.2.1 Optimisation of SmartSeq Kit 
Knowledge of likely yields of CD34+38-ALDHhighCLL1- cells from bone marrow samples stored in 
the Bart’s Tissue Bank suggested that the majority should yield a minimum of 1000 HSCs on 
sorting. Therefore, all samples were sorted until exactly 1100 cells had been collected. Excess 
HSCs were sorted into a separate tube, to undergo RNA extraction for later qPCR validation.   
 Optimal input material: the use of cells rather than RNA appeared to offer more 7.3.2.1.1
efficient cDNA production  
The SmartSeq v4 kit allows for cDNA synthesis starting either from intact cells or previously 
extracted RNA. I first compared the efficiency of these two approaches, using the Qiagen 
MicroColumn method for RNA extraction.   
One sample (Pat ID 10146) of normal control BM was sorted as described for CD34+38-
ALDHhighCLL- cells. 1000 cells were collected into two separate FACS sorting test tubes. One 
underwent RNA extraction, producing an eluate of 14µl volume. 9.5µl of this was transferred 
to a 200µl eppendorf. The second FACS tube was processed as described above (Section 
7.3.1.3), with cells undergoing washing, transfer to a 200µl eppendorf and resuspension in H2O 
to a volume of 9.5 ml.   
1µl of a 10x Reaction buffer was added (19µl 10xLysis Buffer, 1µl RNase Inhibitor) to both 
tubes (of RNA and intact cells), after which the tubes were vortexed, and then incubated for 5 
minutes at room temperature to promote cell lysis.  
All downstream processing of the samples was identical (see Section 7.3.1.3.1). Analysis of the 
resultant cDNA on a HS 1000 Screentape appeared to suggest a larger yield when direct cell 
lysis was used, rather than formal RNA extraction (see Figure 7-4 A). As a result, sorted intact 
cells were used in preference to pre-extracted RNA.  
 Optimal amplification cycles of cDNA: 10 PCR cycles appeared to offer consistent 7.3.2.1.2
detection of cDNA  
Optimisation of the number of PCR cycles used in cDNA amplification within the SmartSeq v4 
kit was performed. Yields of cDNA can vary dependant on the input number of cells and 
relative size of their transcriptomes, as well as the performance of the thermal cycler used. 
Too few PCR cycles can lead to small yields of cDNA; too many cycles leads to a less 
representative library. 
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Sorting 1000 cells from a control BM and amplifying the cDNA with 8 PCR cycles generated no 
visible cDNA on HS ScreenTape. The experiment was then repeated using 9, 10 and 12 cycles 
on 1000 cells sorted from the same cycle. cDNA was visible at both 9 and 10 cycles (see Figure 
7-4 B).  
A final choice of 10 PCR cycles per sample was taken on the basis that the sorting process and 
the SmartSeq kit were both costly, and sample availability was limited. Less wastage would 
occur with the use of 10, rather than 9, cycles. We took some reassurance that the cDNA was 
not over amplified, as the output concentration of cDNA as assessed by HS Qubit after clean-
up was at the lower end of the expected range (3.4 to 17 ng cDNA). 
 Optimal cleaning: at the end of the SmartSeq process, an additional 1:1 clean up step 7.3.2.1.3
of cDNA was required 
On analysis of all samples using the HS1000 Screentape at the end of processing, there was a 
consistent peak of DNA of 60bp size, thought to represent adaptor dimer. If left in situ, this 
was further amplified during library preparation, a process which might reduce the efficiency 
of sequencing.  
Two different time points for repeat clean-up were compared. Repeat cleaning of the cDNA 
after PCR amplification using a 1:1 bead ratio effectively removed the adapter-dimer peak, but 
also removed some of the cDNA of larger size (and therefore overall concentration). This 
method was compared with using a 1:1 bead ratio to remove the same peak after the sample 
had undergone library preparation using the Nextera XT kit. In the illustrated case, cleaning 
resulted in fall in library concentration from 1.1 to 0.6ng/µl, but more importantly, incomplete 
removal of the unwanted peak.  
Therefore, in order to ensure complete removal of adaptor dimer, the additional 1:1 bead: 
sample clean up step was performed after cDNA production, and before library preparation. 
These results are summarised in Figure 7-5. Repeat cleaning of the cDNA sample at this stage 
often resulted in a fall in sample concentration to below the 0.2ng/µl sensitivity of the HS 
Qubit assay. However, despite this, it was still possible of generate libraries of apparently 




Figure 7-4 HS 1000 DNA ScreenTape traces showing A: yield of cDNA from SmartSeq kit from 1000 cells when (i) immediate RNA extraction and subsequent processing through SmartSeq protocol 
(ii)cells lysed direct cDNA synthesis performed without prior RNA extraction. Traces shows size of strand on x axis, Intensity/amount on y axis. Upper and lower markers are labelled; B: comparing the 




Figure 7-5 showing the effect of clean-up at different stages of library preparation. Four HS DNA ScreenTape 1000 traces are shown where A. cDNA trace after SmartSeq preparation showing a small 
peak of adapter present at 60bp; B: library appearance after Nextera XT prep with no additional clean up C: library after 1:1 clean up D: library appearance if an additional 1:1 clean-up is performed 
on cDNA pre-library formation
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7.3.2.2 Sample Information  
Sample information in terms of patient details, blood counts at presentation and genetic 
mutational status is given in Table 7-2.  
Table 7-2 Clinical information for 6 CD34
low
 AML and 6 controls which underwent sorting for HSCs prior to RNA-Seq 
based transcriptome profiling  
7.3.2.3 Library Preparation  
 Sorting and cDNA synthesis  7.3.2.3.1
All samples listed yielded a minimum of 1100 cells after staining and sorting for HSCs as 
described above.  
A typical screen tape trace at the end of SmartSeq cDNA synthesis is shown in Figure 7-4 Biii. 
All samples at this point were assessed for DNA concentration by the Qubit HS DNA assay. 
After an additional 1:1 cleaning step to remove excess adaptor, all concentrations were re-
assayed, and sample composition re-analysed by HS D1000 screen tape. Results are shown in 
Table 7-3. 
In all cases, the secondary 1:1 cleaning step to remove excess adaptor resulted in a fall in the 
dsDNA concentration as measured by HS Qubit below the level of detection of the assay. 
Nevertheless, these cDNA samples remained capable of producing DNA libraries of adequate  
ID SAMPLE SEX AGE 













7793 AML F 56 11.1 4 10 +13 NPM A 
9002 AML M 68 8.9 0 41 NORMAL WT 
9067 AML M 67 7.4 142 172 NORMAL NPM A 
8169 AML F 27 9.7 0 110 t(11;19) WT 
8452 AML M 27 8.6 6 75 t(11;17) WT 
7774 AML M 62 8.1 0 37 NORMAL NPM A 
8245 CONTROL M 45 12.9 7.8 316 NORMAL 
 
7926 CONTROL M 42 11.2 14.3 527 NORMAL 
 
10115 CONTROL M 50 15 12.6 294 NORMAL 
 
8445 CONTROL M 62 15.1 7 252 NORMAL 
 
TEMP 1728 CONTROL F 70 12.4 11.8 341 NORMAL 
 
9903 CONTROL M 88 11.4 8.1 191 NORMAL 
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Table 7-3 Qubit concentrations of cDNA library pre and post 1:1 cleaning 
concentration for sequencing. Given that the additional cleaning step was so effective at 
reducing the adaptor  presence, and optimisation experiments had suggested cleaning BEFORE 
library prep was preferable to afterwards,we proceeded on this basis. A disadvantage of this 
approach is that an approximation had to be made as to the amount of cDNA added to each 
library preparation. As detailed in Section 7.3.1.4.2, 1ng cDNA (at a concentration of 0.2ng/µl) 
is required for input into the Nextera XT kit. Given that the secondary cleaning step appeared 
to reduce the DNA concentrations by a minimum of a third, I estimated that adding between 7 
and 8 µl of cDNA would be appropriate for library preparation. This appeared to me to be one 
of the potential sources of inaccuracy between individual libraries in the protocol, but there 
was no obvious alternative.    
 Library Prep 7.3.2.3.2
After library preparation, libraries were QCed by analysis by HS ScreenTape. An example trace 
is shown in Figure 7-5 D. The average BP size of the resultant library was calculated using the 
Integration analysis package on the HS Screen tape. This varied between 289 and 445 bp. 
Interestingly, (despite the same initial DNA input), the final library concentration varied quite 
considerably. Individual Qubit concentrations and average BP size of the library are given in 
Table 7-4. Indexes added are also logged. Individual libraries were also QCed with the use of 
the Kappa qPCR kit. Average concentrations based on these dilutions are shown in Table 7-5. 
SAMPLE ID PAT ID 
PRE-CLEAN [] 
ng/µl 
POST 1:1 CLEAN [] 
ng/µl 
VOLUME IN LIBRARY 
PREP µl 
1 7793 0.218 <0.2 8 
2 9067 0.26 <0.2 7 
3 8445 0.294 <0.2 7 
4 7926 0.3 <0.2 8* 
5 8452 0.318 <0.2 7 
6 7774 0.308 <0.2 7 
7 10115 0.218 <0.2 8 
8 8169 0.188 <0.2 8 
9 8245 0.274 <0.2 7 
10 TEMP 1728 0.246 <0.2 7 
11 9002 0.272 <0.2 7 
12 9903 ND <0.2 7 
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Table 7-4 showing Library concentrations as estimated by Qubit 
Table 7-5 Library Concentrations as estimated by qPCR 
 Library Normalisation and pooling 7.3.2.3.3
Library normalisation was performed based on the library concentrations generated by Kappa 
based analysis. Pooling ratios are shown in Table 7-6.  
A library concentration minimum of 2nM was required for sequencing on the HiSeq4000. The 
final pooled library underwent HS D1000 Screentape analysis, and was found to have an 
average length of 360bp. HS Qubit measured a final concentration of 1.41ng/μl, which equates 
ID SAMPLE INDEX 1 (i7) INDEX 2 (i5) 
AVERAGE 






7793 AML N701 S503 302 0.96 4.9 
9067 AML N702 S503 325 2.98 14.1 
8445 CONTROL N703 S503 445 6.8 23.5 
7926 CONTROL N704 S503 320 0.984 4.7 
8452 AML N705 S503 271 5.66 32.1 
7774 AML N706 S503 302 1.57 8.0 
10115 CONTROL N701 S504 289 4.52 24.1 
8169 AML N702 S504 345 1.2 5.4 
8245 CONTROL N703 S504 342 3.34 15.0 
TEMP 1728 CONTROL N704 S504 306 1.15 5.8 
9002 AML N705 S504 294 1.07 5.6 













7793 AML 302 2.76 4.07 3.42 4.89 
9067 AML 325 17.76 21.99 19.88 14.11 
8445 CONTROL 445 26.74 29.11 27.93 23.51 
7926 CONTROL 320 6.82 7.41 7.12 4.73 
8452 AML 271 33.71 38.52 36.12 32.13 
7774 AML 302 11.95 13.75 12.85 8.00 
10115 CONTROL 289 23.73 29.33 26.53 24.06 
8169 AML 345 5.24 6.50 5.87 5.35 
8245 CONTROL 342 18.13 15.92 17.02 15.02 
TEMP 1728 CONTROL 306 7.31 6.24 6.77 5.78 
9002 AML 294 9.25 7.32 8.29 5.60 
9903 CONTROL 334 21.27 23.05 22.16 14.83 
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to 6nM. The final concentration was also calculated independently using Kappa primers (on 
library dilutions of 1/10,000, 1/20000 and 1/40000), which generated a mean concentration of 
6.74nM. 
Table 7-6 Volumes used in final library pooling to ensure equal representation of all 12 libraries in sequencing 
7.3.2.4 Sequencing data  
 A high proportion of reads map to intronic and intergenic regions, highly suggestive 7.3.2.4.1
of gDNA contamination  
After successful sequencing at the Oxford High Throughput Genome, the resultant data were 
analysed by the BCI Bioinformatics Team.  
Analysis of the data revealed that a large proportion of reads mapped to non-coding regions of 
the genome. Although this occurred in all samples, the proportion of total reads mapping to 
coding regions varied significantly from sample to sample. These data are shown in Table 7-7.  
Potential explanations for this rather unexpected and disappointing result are detailed in 
length in Section 7.5.1. In brief, external contamination appeared an unlikely explanation given 
the consistent success of negative controls at all stages in processing.  
The SmartSeq kit design is dependent upon the selection of polyadenylated RNA only for cDNA 
synthesis and subsequent amplification. As we had chosen to use cells as our starting material 
(rather than pre-extracted total RNA), the specificity of this selection process is vital to exclude 
the amplification of non-polyadenylated RNA or DNA, which will also be present in the cell 
PAT ID SAMPLE LIBRARY [] BY qPCR (nM) RELATIVE CONCENTRATION VOLUME ADDED (µl) 
7793 AML 3.42 1.00 20.00 
9067 AML 19.88 5.82 3.44 
8445 CONTROL 27.93 8.18 2.45 
7926 CONTROL 7.12 2.08 9.60 
8452 AML 36.12 10.58 1.89 
7774 AML 12.85 3.76 5.32 
10115 CONTROL 26.53 7.77 2.57 
8169 AML 5.87 1.72 11.64 
8245 CONTROL 17.02 4.98 4.01 
TEMP 1728 CONTROL 6.77 1.98 10.09 
9002 AML 8.29 2.43 8.24 
9903 CONTROL 22.16 6.49 3.08 
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lysate. Thus inadvertent amplification of internal gDNA might be one explanation of the 
received results.   
Table 7-7 Number of reads mapped to coding and non-coding regions for all 12 samples  
Clontech have published QC data examining the efficiency with which their kit produces 
sequencing data mapping to coding regions of DNA. They have explored the effect of different 
starting amounts of material, as well as the quality of data generated from cells versus RNA. 
When 1000 HeLa cells were used as starting material for direct cDNA synthesis and library 
generation, 75% of eventual reads mapped to the coding regions of the genome. However, it is 
interesting to note that this specificity is significantly less than observed when cell input 
numbers are smaller. When the kit is used for single cell processing, an impressive 97% of 
reads map to coding regions. The reasons for this deterioration in performance are not 
expanded upon in the company literature306. 
We hypothesised that as the concentration of DNA and RNA within the reaction increases, as 
would be expected as cell input numbers rise, the efficiency of selection for polyadenylated 
RNA might fall. It is also interesting to hypothesise whether the relative amount of RNA per 
input cell might have a bearing on the quality of data generated. It would seem reasonable 
that the transcriptome of a quiescent HSC is likely to be significantly smaller than that of a 
metabolically active HeLa cell, and therefore the ratio of DNA to RNA within this cell type is 
likely to be considerably higher (see Section 7.5.1.2).  
ID SAMPLE 
READS MAPPED TO 
CODING REGIONS 
READS MAPPED TO 
INTRONIC REGIONS 
Intronic/coding+Intronic 
7793 AML 3515643 24869043 0.876 
9067 AML 13988713 17771459 0.600 
8452 AML 12592268 12553038 0.499 
7774 AML 13060130 12446822 0.488 
8169 AML 4154727 30407212 0.880 
9002 AML 10515967 11655531 0.526 
8445 CONTROL 3169227 43637766 0.932 
7926 CONTROL 3983312 26909355 0.871 
10115 CONTROL 17746555 13054093 0.424 
8245 CONTROL 14750523 17906626 0.548 
TEMP 
1728 
CONTROL 5886733 22759573 0.795 
9903 CONTROL 10954671 19330724 0.638 
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 Internal QC of sort purity  7.3.2.4.2
We have previously shown that CD34+38- cells sorted from CD34low AMLs generate normal 
haematopoietic colonies, both in in vitro and murine transplant work. We have also 
independently sorted the CD34+38- cell populations from NPM1 mutated CD34low AML 
samples, and shown the leukaemia-associated mutation to be absent in these cells by 
immediate qPCR-based analysis.  
Because cell numbers in this experiment were highly limited, and all sorted CD34+38-
ALDHhighCLL1- cells were either used for immediate cDNA synthesis or extraction of RNA for 
subsequent validation, DNA-based analysis to confirm the presumed normal genotype of the 
sorted cells was not performed at the time of sorting.  
Nevertheless, an internal QC of sorting efficiency was performed by looking in detail at three 
of the AML samples known to have a NPM1 Type A mutation (Patients 7793, 9067 and 7774). 
Examination of the reads which mapped to Exon 12 of the NPM1 gene for each of these 
samples showed normal sequences, with no evidence of the leukaemia associated mutation.  
 Differential gene expression  7.3.2.4.3
Even allowing for the high proportion of reads which mapped to intronic regions, the read 
depth per sample was high enough for a reasonable number of reads for each sample to have 
mapped to coding regions (between 3.5 to 17 million reads per sample). Although we do not 
presume that all of these reads relate to cDNA made from polyadenylated RNA, if one assumes 
that the genomic contamination was random, and therefore evenly distributed throughout the 
genome, genes which appear to be differentially represented between the two sample cohorts 
are certainly worthy of further investigation. 
Filtering revealed differential expression of 18025 genes. Of these, 525 showed differential 
expression between the two subgroups with fold changes of greater than two, and a calculated 
p-value of less than 0.05. No gene changes achieved an adjusted p value of significance of 
<0.05 (calculated using the Benjamini–Hochberg procedure). Tables showing details of the top 
differentially expressed genes are located in Appendix 3 of this thesis.  
7.3.2.5 Validation of RNA-Seq Data  
 Choice of genes for validation  7.3.2.5.1
The choice of genes for attempted validation was based on a number of filters. Interest was 
focussed on those genes which exhibited a difference in expression between HSCs from AML 
Chapter 7: RNA-Seq 
279 
and control samples of greater than two, and ideally where the p-value of the observed 
changes was calculated to be less than 0.001.  
Any genes with previous reported roles in cell cycle regulation, HSC maintenance or AML 
development or normal haematopoietic development were noted with interest. 
Comparison was also made between the datasets generated by this work in primary human 
samples, and that previously produced by the group in the murine xenograft experiment 
detailed in Section 7.1.2.1. Within the top 200 differentially regulated genes from both 
datasets, seven appeared in both groups. Of these, only three exhibited changes in gene 
expression in the same direction in both datasets. Expression of the DMD (Dystrophin) and 
SEMA7A (Semaphorin 7A) genes was increased in AML-exposed HSCs compared to controls; 
ST3GAL5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) expression was relatively lower in 
the same cohorts. However, given none of these genes had described roles in the regulation of 
cell cycle or differentiation within either normal HSC or AML biology, none were selected for 
further validation.  
 Selection of Validation Methods  7.3.2.5.2
7.3.2.5.2.1 By qPCR 
Given our concerns with regard to the quality of the RNA-Seq data detailed in Section 
7.3.2.4.1, we felt it was reasonable to attempt validation by qPCR for a number of genes of 
interest.  
At the end of sorting, we had extracted RNA from any excess HSCs not required for SmartSeq 
processing. As a result of the small number of available cells, this RNA was assumed to be 
extremely dilute (certainly below the lower level of sensitivity of HS Qubit RNA assay). To try 
and maximise the cDNA yield from the small quantity of RNA available, we used the 
Superscript®VILOTM cDNA synthesis kit (Thermofisher, Cat 11754050), with a prolonged 
incubation time designed to promote maximum cDNA synthesis.  
Despite this step, the number of genes which we could attempt to validate expression levels 
on was limited. Samples were sufficiently dilute that on qPCR, even highly expressed house-
keeping genes were detected relatively late (with an average Ct of 30 to 32). Therefore, highly 
expressed genes (as defined by RPKM values from the RNA-Seq data) were preferentially 
selected for validation, in the hope that levels for all samples would fall within the sensitivity of 
40 cycle qPCR.  
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7.3.2.5.2.2 By protein expression levels 
Protein-level validation of changes in gene expression was also attempted where possible. 
Previous work had shown that simultaneous staining of samples for HSC markers and the 
protein of interest, followed by flow-based analysis, was the most efficient way of approaching 
this question. Many of the differentially expressed genes of interest coded for nuclear-located 
proteins such as transcription factors. However, the experience of intracellular staining for 
RhoA expression during the flow cytometry assessment detailed in Section 7.1.2.2.4 had 
highlighted some of the difficulties of this approach for protein based validation, especially in 
the absence of a validated, fluorochrome-conjugated antibody. However, three genes of 
interest coded for cell surface proteins, with commercially available flow antibodies to assess 
their expression levels.  
 Validation targets  7.3.2.5.3
Table 7-8 shows the chosen targets and methods for validation, along with observed fold 
changes in gene expression between the two cohorts and statistical significance of these 
changes. Pre-existing experimental evidence for these genes having a potential role of interest 
in HSCs, AML development or cell cycle control is detailed below in Sections 7.3.2.5.3.1 and 
7.3.2.5.3.2.   
Table 7-8 Genes selected for Validation by qPCR and flow-based assessment 
 



































leukocyte immunoglobulin-like receptor, 
subfamily A (with TM domain), member 2 
2.87 0.0027 FLOW 
IDH1 
isocitrate dehydrogenase 1 (NADP+), 
soluble 
























U2AF1 U2 small nuclear RNA auxiliary factor 1 3.42 0.0018 
TAQMAN 
qPCR 
HIST1H2BC histone cluster 1, H2bc 3.37 0.0122 SYBR qPCR 
S100A10 S100 calcium binding protein A10 2.61 0.0015 SYBR qPCR 
TNFRSF12A 
tumor necrosis factor receptor 
superfamily, member 12A 
2.18 0.0232 FLOW 
TRAF4 TNF receptor-associated factor 4 2.13 0.0168 SYBR qPCR 
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7.3.2.5.3.1 Genes relatively downregulated in HSCs exposed to AML compared to controls 
7.3.2.5.3.1.1 CD33 
The role of CD33 in HSC behaviour, and its pattern of expression on normal and AML-exposed 
HSCs are discussed at length in Chapter 6 of this thesis.  
As a cell surface marker, protein based expression is readily quantified by flow cytometry, but 
a specific Taqman probe/primer pair is also commercially available to assay gene expression 
levels.  
7.3.2.5.3.1.2 LILRA2 (Leucocyte Immunoglobulin-Like Receptor, subfamily A (with TM 
domain), member 2 (CD85H)  
The Leucocyte Immunoglobulin-Like Receptors are expressed on monocytes and B cells. There 
exist two subfamilies: subfamily A receptors are thought to have stimulatory functions, whilst 
subfamily B receptors facilitate inhibitory signalling. LILRA2 has recently been implicated as 
holding an important role within the innate immune system. Signalling through the receptor 
appears vital in the recognition of pathogen-cleaved immunoglobulin molecules, and the 
myeloid cell activation that follows313.  
Whilst members of the LILRB subfamily have been shown to have functions within the normal 
HSCs of both mice and humans, and to be capable to causing HSC proliferation314, the LILRA 
subfamily have no documented roles in stem cell populations or in cancer development to 
date. 
As a cell surface protein, protein expression is quantifiable by flow cytometry.  
7.3.2.5.3.1.3 IDH1 (Isocitrate Dehydrogenase 1) 
 The IDH 1 and 2 genes have been identified as recurrent mutation targets in a variety of 
cancers. Their significance was first described in gliomas315, and shortly afterwards in AML316. 
Current estimates suggest that 15 to 20% of AMLs carry mutations in one of these genes, with 
an increased incidence in AMLs of normal karyotype.  
Under normal circumstances, IDH1 and 2 play key roles in the regulation of metabolism, 
converting isocitrate into α-ketoglutarate (αKG). As well as being a component of the Krebs 
cycle, αKG is required for the normal functioning of a number of dioxygenase enzymes, such as 
TET2 and histone demethylases.  
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Mutations in these genes have a dual effect: not only do they reduce the activity of the normal 
enzyme, but when present in the heterozygous form, the mutant enzyme can also catalyse the 
conversion of existing αKG into an alternative “oncometabolite” R-2-hydroxyglutarate (2HG). 
2HG is a competitive inhibitor of a number of dioxygeneases317. As a result, such mutations 
results in a change in cellular metabolism, epigenetic reprogramming318, and a block in cell 
differentiation. However, as patients rarely present with AML characterised solely with 
mutations in IDH1 or 2, the accumulation of further mutations is thought to be required for 
transformation.  
In murine models, knock-in of mutated IDH1 into myeloid cells resulted in abnormal 
haematopoiesis, with increased numbers of early haematopoietic progenitors and the 
development of extramedullary haematopoiesis319.  
There is little available literature on the effect of over- or under- expression of the wild-type 
IDH1 gene in humans. However, interesting recent work using zebrafish showed that 
knockdown of wildtype IDH1 resulted in a blockade of normal myeloid differentiation320.  
Primers were designed for use with the SYBR green system for qPCR based gene expression 
analysis. 
7.3.2.5.3.2 Genes relatively upregulated in HSCs exposed to AML 
7.3.2.5.3.2.1 U2AF1 (U2 small nuclear RNA auxiliary factor 1) 
U2AF1 represents the small subunit of the U2 small ribo-nuclear protein, an auxiliary factor 
involved in pre mRNA splicing. Mutations in spliceosome-coding genes have caused significant 
interest in the field of cancer evolution, as a number have recently been reported in both solid 
and haematological malignancies. Affected genes include SF3B1, SRSF2, U2AF1 and ZRSR2321.   
Spliceosome mutations have been identified in at least 50% of patients with MDS322. U2AF1 
mutations are found in around 9% of MDS patients, and are associated with an increased risk 
of transformation to AML323. The mutations of interest affect the Ser34 amino acid, which 
forms part of the zinc binding domain of the protein, and is normally highly conserved.  
Functionally, mutations in the U2AF1 protein result in enhanced splicing and exon skipping323. 
In a conditional murine model with inducible expression of the mutant gene, changes in 
haematopoiesis were observed when the mutant allele was expressed. Murine leucocyte 
levels dropped (whilst red cells and platelet levels were maintained). Interestingly, after a 
month of mutant gene expression, CD150+cKit+Lin- stem cell proliferation (as evidenced by 
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BRDU incorporation and Ki67 staining) increased. However, in vitro assays of stem cell 
repopulating ability showed these HSCs to be at a competitive disadvantage to unmutated 
forms322.  
Identified targets of downstream missplicing in this setting include genes involved in DNA 
damage repair (ataxia telangiectasia and Rad3 related (ATR)), epigenetic regulation (H2A 
histone family Y (H2AFY)) and apoptosis (caspase 8)324,325.     
To date, all experimental interest has focussed on the effect of mutation on the activity and 
function of the U2AF1 protein. There is no literature to date which comments on the potential 
effects of increased expression of wild type U2AF1 on HSC behaviour or myelopoiesis.  
Taqman based probe-primer sets are commercially available for gene expression validation.  
7.3.2.5.3.2.2 Histone factors HIST1H2AL and HISTH2AH 
One of the most striking features of this dataset is the marked enrichment within the AML 
exposed HSCs for expression of members of the histone family. Ten of the top thirty genes 
overexpressed in AML-exposed HSCs compared to controls code for histones. 
Interestingly, the fact these genes appear at all within the RNA-Seq dataset is a puzzle, and 
possibly indicative of the failure of PolyA selection of mRNAs. Most of these gene transcripts 
are not polyadenylated, but instead contain a palindromic termination element, and therefore 
theoretically should not have undergone amplification within the SmartSeq kit.  
Histones are basic proteins, responsible for the formation of the nucleosomes around which 
chromosomes are wrapped. Nucleosomes are comprised of two of each of the four core 
histones (H2A, H2B, H3 and H4). H1 is a linker histone, which binds to DNA between 
nucleosomes and is responsible for chromosome compaction.  
Histones are thought to be vital in the regulation of gene expression: genes bound to histones 
are less transcriptionally active326. However, most research has focussed on how post-
translational modifications of histones such as acetylation or methylation affect their repressor 
activity. There are limited published data on whether differential expression of specific histone 
genes are associated with different cell behaviours, and the mechanisms which control their 
transcription are poorly understood.   
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Of relevance, increased expression of H2A histone genes has been associated with cell 
senescence327. Could an increase in histone expression be associated with a state of acquired 
HSC quiescence as well?  
Primers were specifically designed to assay gene expression within the SYBR green qPCR 
system.  
7.3.2.5.3.2.3 S100A10 
S100A10 (also known as p11) is part of the S100 family of proteins. S100 proteins have been 
reported to play roles in cell cycle progression and differentiation.  
The structure of S100A10 allows it to bind internally to annexin I and II, whilst facilitating 
interactions with a variety of cell surface-based proteins. It has a role in shuttling protein 
channels to the cell surface, and therefore in the maintenance of cell polarity. Its role in 
neuronal development has been the most studied, where it assists in the transport of 
neurotransmitters to the cell surface328.  
It can also be found embedded in the cell surface membrane, where it functions as a receptor 
for plasminogen, mediating the conversion of plasminogen to plasmin329. Murine knock-outs of 
the S100A10 gene have led to a subsequent reduction in neutrophil-plasmin generation, and 
thus impeded migration due to a reduced ability to degrade the extracellular matrix. A similar 
role for S100A10 in mediating invasive behaviour has been proposed for cancer cells330. To 
date, S100A10 has not been reported to have a defined role either in normal HSC, or AML 
development.  
Primers were specifically designed to assay gene expression within the SYBR green qPCR 
system.  
7.3.2.5.3.2.4 TNFSF12A (Tumor necrosis family receptor superfamily, member 12A)  
The gene TNFRSF12a, also known fibroblast growth factor-inducible 14 (Fn14), codes for a cell 
surface receptor belonging to the TNF receptor family, known as TWEAKR or CD266. Its ligand 
is TNF-like weak inducer of apoptosis (TWEAK or TNFSF12), a member of the TNF ligand 
family331.  
TWEAKR is fairly ubiquitously expressed during development, before becoming more restricted 
in adulthood to the heart, kidney, liver and placenta332,333. Under normal conditions, 
expression levels of TWEAKR are thought to be modulated by a range of cytokines330. 
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Abnormal TWEAKR expression has been reported in a number of solid organ malignancies, 
including pancreatic tumours334. AML cells have been reported to downregulate the receptor 
to promote their survival335.  
The receptor ligand, TWEAK, has been reported to be cytotoxic both in cancer lines and 
healthy monocytes336. However, in contrast to other members of the TNF ligand family, TWEAK 
seems to require the co-activation of additional signalling pathways to result in cell death. In 
vascular endothelial cells, TWEAK has been reported to be responsible for cell proliferation337, 
as well as directing cell migration338. 
It is assumed, because of structural homology with other TNF-receptor family members, that 
TWEAKR signalling utilises TRAFs338. Downstream of this, TWEAK-R activation is thought to 
result in NF-κB activation, as forced overexpression of the receptor results in NF-κB 
activation339.   
Of interest for further validation work, there already exists a specific antibody capable of 
blocking the TWEAK-TWEAKR interaction340, which has been trialled in mice models and shown 
to reduce intestinal damage in intestinal GvHD341.   
As a cell surface antigen, protein based expression analysis is possible by flow cytometry.   
7.3.2.5.3.2.5 TRAF4 (TNF receptor-associated factor 4) 
TNF receptor-associated factor 4 is a member of the TRAF family of scaffold proteins, which 
interact with TNF and IL1R/Toll receptors, facilitating downstream signalling into the NF-κB and 
MAP kinase pathways.  
Despite its name, and structural similarities with other TRAF family members, there are to date 
no documented interactions with TRAF4 and the TNF receptor342. However, it has been shown 
to block p75, the neurotropin receptor, an action which leads to NF-κB mediated cell death343.  
Overexpression of TRF4 has been reported in a number of carcinomas, but not to date in AML.   
Primers were specifically designed to assay gene expression within the SYBR green qPCR 
system.  
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 Validation results 7.3.2.5.4
7.3.2.5.4.1 Protein based assessment  
7.3.2.5.4.1.1 CD33 is significantly downregulated in AML-exposed HSCs compared to 
controls 
As detailed in Section 6.1.3, previous unpublished work from our group has shown that the 
CD33 expression (percentage of CD33 positive cells, as defined by FMO) in the CD34+38- HSC 
fraction within CD34low AML samples is significantly lower than the same compartment within 
control samples. Median percentage CD33 positivity within 15 CD34low AML samples was 18%, 
versus 82% within 20 control samples (p <0.0001 by Mann-Whitney test) (see Figure 7-6 A). 
7.3.2.5.4.1.2 CD85g/LILRA protein expression is not significantly different between AML-
exposed HSCs and controls 
A total of 6 CD34low AML samples and 8 controls were assessed for LILRA expression by flow 
cytometry staining for surface CD85g. Results were expressed as the percentage of CD34+38-
ALDHhighCLL1- HSCs which were positive (as defined by matched FMOs) for CD85g. There is no 
significant difference between expression in AML-exposed HSCs (0%) versus control-exposed 
HSCs (0.02%) (p=0.54 by Mann-Whitney test)(see Figure 7-6 B).  
7.3.2.5.4.1.3 TNFSF12A/TWEAKR/CD266 protein expression is not significantly different 
between AML-exposed HSCs and controls 
A total of 6 CD34low AML samples and 9 controls were assessed for TWEAKR expression by flow 
cytometry staining for surface CD266. Results were expressed as the percentage of CD34+38-
ALDHhighCLL1- HSCs which were positive (as defined by matched FMOs) for TWEAKR expression 
There is no significant difference between expression in AML-exposed HSCs (10.7%) versus 
control-exposed HSCs (3.5%) (p=0.26 by Mann-Whitney test)(see Figure 7-6 C).  
7.3.2.5.4.2 qPCR based gene expression validation  
7.3.2.5.4.2.1 Sample details 
Samples which underwent sorting and subsequent RNA extraction of their CD34+CD38-
ALDHhighCLL1- populations for use in qPCR based validation are summarised in Table 7-9. All six 
CD34low AML samples are the same as those used in the original RNA-Seq experiment. Two of 
the controls (8245 and 7926) yielded sufficient HSCs for both RNA-Seq processing and separate 
RNA extraction. The other four control samples used for RNA-Seq work had no further vials 
available in the Tissue Bank, and hence a further four control samples were selected solely for 
RNA extraction for gene validation.  
Extracted RNA was converted to cDNA as described in Section 7.3.1.7.1.2., prior to qPCR.  
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Table 7-9 showing sample details for the 6 AML samples and 6 controls used in this experiment for sorting of HSC 
populations and RNA extraction. Those samples marked *had RNA extracted from them at the same time as the 
same original sort for RNA-Seq cells. Those marked ** underwent repeat sorting from a duplicate vial at a later date 
for RNA extraction. Those unmarked were control samples not used in the original experiment 
7.3.2.5.4.2.2 Low RNA Concentration meant several genes could not be validated due to 
failure to detect expression after 40 cycles of qPCR 
As discussed in Section 7.3.2.5.2.1, we had deliberately selected genes with relatively high 
expression levels in all samples in the RNA-Seq dataset (as defined by RPKM), in order to 
maximise the possibility of detectable gene expression levels during a 40 cycle qPCR 
experiment.  
Despite this, of the four genes selected for validation of gene expression levels by qPCR using 
the SYBR Green system and specifically designed primers, expression of three (S100A10, IDH1 
and TRAF4) were not detected in 8 of the 10 samples. As a result, interpretation of relative 
expression of these genes within the AML-exposed and control-exposed HSCs was not valid. 
Further discussion of this issue is located in Section 7.5.2.3.  
ID SAMPLE SEX AGE 













7793** AML F 56 11.1 4 10 add13 NPM A 
9002* AML M 68 8.9 0 41 Normal WT 
9067** AML M 67 7.4 142 172 Normal NPM A 
8169** AML F 27 9.7 0 110 t(11;19) WT 
8452* AML M 27 8.6 6 75 t(11;17) WT 
7774* AML M 62 8.1 0 37 Normal NPM A 
8245* CONTROL M 45 12.9 7.8 316 Normal 
 
7926** CONTROL M 42 11.2 14.3 527 Normal 
 
8508 CONTROL M 22 14.3 3.9 197 Normal 
 
8749 CONTROL F 70 13.9 7.8 193 Normal 
 
8984 CONTROL M 42 16.5 6.2 198 Normal 
 
10030 CONTROL F 68 12.3 7.8 228 Normal  
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7.3.2.5.4.2.3 CD33 gene expression is not significantly different between AML-exposed HSCs 
and controls 
Relative gene expression of CD33 is lower in AML-exposed HSCs than control-exposed HSCs (RE 
0.56 versus 2.00), but this change does not reach statistical significance (p=0.22, Mann 
Whitney t test) (see Figure 7-6 D). 
7.3.2.5.4.2.4 U2AF1 gene expression is not significantly different between AML-exposed HSCs 
and controls 
Relative gene expression of U2AF1 is lower in AML-exposed HSCs than control-exposed HSCs 
(RE 0.20 versus 1.27), but this change does not reach statistical significance (p=0.15, Mann 
Whitney t test) (see Figure 7-6 E).  
7.3.2.5.4.2.5 HIST1H2BC gene expression is not significantly different between AML-exposed 
HSCs and controls 
Relative gene expression of HIST1H2BC is lower in AML-exposed HSCs than control-exposed 
HSCs (RE 1.75 versus 1.23), but this change does not reach statistical significance (p=0.55, 




Figure 7-6 Scatter plots illustrating results of validation experiments. Graphs A-C show results from flow-based protein expression assessment; Graphs D-F show results from PCR based gene 
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7.4 Attempt 2: Using RNA as input material 
As detailed in the Discussion section of this chapter (Section 7.5), we were disappointed with 
the quality of the data generated by our first RNA-Seq experiment comparing the 
transcriptomes of HSCs from AML samples and controls. Sequencing data contained a high 
proportion of reads mapping to non coding regions of the genome, pointing to a potential 
failure in mRNA selection prior to cDNA synthesis and subsequent amplification.  
We still felt the approach of using RNA-Seq to identify differentially expressed genes in primary 
human samples was a valid one. Moreover, given the positive feedback regarding the 
SmartSeq kit from other groups working in the same area, we were keen to continue working 
with the same kit, using a modified methodology, to see if cleaner data could be produced.  
We decided to repeat the experiment using RNA extracted from sorted HSCs by traditional 
methods, rather than relying on cDNA synthesis directly from lysed cells.  
Considerable attention was paid to the selection of the optimal method to extract high quality 
RNA reproducibly from small cell numbers. Below are detailed the methods for the three 
different techniques of RNA extraction compared, and in the Results section that follows, the 
QC steps taken to compare the quantity and quality of the different yields. Also detailed is the 
SmartSeq technique used to produce cDNA from the RNA, which was slightly modified from 
that described in Section 7.3.1.3, as well as sample details and eventual library concentrations.  
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 Methods 7.4.1
7.4.1.1 Optimisation of RNA extraction methods  
To reduce the possibility of sample contamination, all sampling handling was performed under 
a flow hood. RNA degradation was limited by the use of RNAseZap (ThermoFisher, Cat 
AM9780) to clean all surfaces and pipettes prior to handling. Fresh filter pipette tips were used 
for all stages.  
 Trizol extraction of RNA from limited cell numbers 7.4.1.1.1
The classical method of RNA extraction, with slight modification to optimise yields from small 
cell numbers, is described below.    
7.4.1.1.1.1 Homogenizing Cells  
Sorted cells in FACS tunes were spun down (3000rpm, 10 minutes, 4oC), and the supernatant 
removed with a Gilson aspirator. Cells were resuspended by flicking the tube, prior to the 
addition of 0.9ml Trizol (ThermoFisher Cat 15596-026) and vortexing. The contents of the tube 
were then transferred to a clean 2ml eppendorf tube, and left to incubate at room 
temperature for five to ten minutes.  
7.4.1.1.1.2 Phase separation  
200µl chloroform (Sigma, Cat C2432) was added to the eppendorf tube, which was then 
vortexed. The tube was then incubated for three minutes at room temperature, before 
centrifugation (12000g, 15 minutes, 4oC). Phase separation of phenol and chloroform layers 
was then visible, with DNA at the interface between the two liquids. The top layer, which 
contains the RNA, was removed by pipetting (avoiding disturbing the DNA) and placed into a 
fresh 1.5ml eppendorf tube.   
7.4.1.1.1.3 RNA Isolation   
RNA isolation was optimised by the use of GenElute LPA carrier (Sigma Cat 56575). In a 
separate tube, LPA was prediluted to 2.5mg/ml by the addition of 10µl LPA to 90µl nuclease 
free water. 4µl (10µg) was then added to the RNA aqueous layer, and vortexed. 0.5ml 100% 
isopropanolol (Sigma, Cat 278475) was then added, vortexed briefly and left to incubate for 10 
minutes at room temperature. The tube was then centrifuged (12000g, 10 minutes, 4oC)  
7.4.1.1.1.4 RNA Washing 
After centrifugation, the supernatant was gently removed by pipetting, leaving only the 
residual pellet behind. This was washed with the addition of 0.9ml 70% ethanol, followed by 
vortexing and centrifugation (7500g, 5 minutes, 4oC). The residual liquid was carefully removed 
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using a pipette, leaving only the pellet. A repeat wash of 0.9ml 70% ethanol was added, and 
the pellet resuspended by vortexing. However, this time, the eppendorf was placed at -20oC 
overnight to improve RNA yield (personal communication, Dr J. Brown, UCL).  
The following day, the eppendorf was centrifuged as before (7500g, 5 minutes, 4oC), and all 
traces of residual ethanol removed, leaving the pellet as dry as possible. The tube was left 
open to air-dry at room temperature for 10 minutes.     
7.4.1.1.1.5 RNA resuspension   
The pellet was resuspended with the addition of 5µl RNase-free water. The eppendorf was 
then incubated at 55 to 60oC for 10 minutes. The resultant RNA was stored at -70oC.   
 DirectZol method  7.4.1.1.2
This column-based method of RNA extraction uses the DirectZolTM RNA MicroPrep with 
TriReagent kit (Zymo, Cat R2061).  
7.4.1.1.2.1 Cell homogenisation 
Sorted cells in FACS tubes were spun down (3000 rpm, 10 minutes, 4oC), and the supernatant 
removed with a Gilson aspirator. Cells were resuspended by flicking the tube, prior to the 
addition of 150µl TriReagent and vortexing. The tube was then incubated at room temperature 
for 5 minutes.  
7.4.1.1.2.2 RNA purification 
150µl 100% ethanol was then added to the tube, followed by vortexing. The contents of the 
tube were pipetted into a Zymo-Spin™ IC spin column in a collection tube and spun down 
(16,000g, 30 seconds, room temp).  The column was then transferred to a new collection tube, 
and flow-through discarded.  
7.4.1.1.2.3 On-column DNA digestion  
400µl RNA wash buffer was added to the column and centrifuged (16,000rpm, 30 seconds, 
4oC). In a separate eppendorf tube, 5µl DNase I (6U/µl) and 35µl DNA digestion buffer were 
mixed, before adding to the top of the column. This was left to incubate at room temperature 
for 15 minutes. 400µl DirectZol™ RNA PreWash was added to the column and centrifuged. The 
flow through was discarded, and the process repeated.  
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7.4.1.1.2.4 RNA Elution  
700µl RNA wash buffer was added to the column, and centrifuged (16000rpm, 2 minutes, 4oC) 
to dryness. The column was transferred to an RNase free tube and 6µl nuclease free water was 
added to the column and left for two to three minutes before centrifugation.  
 Qiagen Microcolumn method 7.4.1.1.3
This column-based RNA extraction method, involving an on-column DNA digestion step, is 
described in full in Section 2.8.2.   
7.4.1.2 RNA Quality assessment  
The quantity and quality of RNA extracted from small cell numbers by these three methods 
was compared over a series of experiments. Using cord blood as a source of cells, aliquots of 
1000 and 10,000 live (DAPI negative) cells were sorted using the Aria II FACS sorter into tubes. 
RNA extraction using the methods detailed above was performed in parallel.  
 RNA quality assessment using the RNA 6000 Pico Kit  7.4.1.2.1
Assessment of RNA yield was performed in the BCI Genome Centre, using the RNA 6000 Pico 
Kit (Agilent, Cat 5067-1513) and the Agilent 2100 Bioanalyser. In brief, 1µl per sample was 
loaded onto a chip, along with a RNA ladder. The RNA molecules separate on the basis of size 
as they run through a polymer matrix across an applied voltage. Dye molecules intercalate 
with the RNA as it runs across the chip, and are detected as they pass through a fluorescence 
detector.  
The RNA 6000 Pico Kit offers a qualitative range of 250-5000 pg/µl. Based on the assumptions 
that one cell contains 10pg total RNA and extraction was 100% efficient, one could expect to 
detect RNA from 125 cells using a Phenol based method and 250 cells with the Qiagen kits.   
 RNA Quantification using the HS Cubit RNA Assay 7.4.1.2.2
RNA quantification was attempted using the HS Cubit RNA assay (Thermofisher Q32852). This 
assay is sensitive in the range of 250pg/µl to 100ng/µl. In brief, the kit contains a dye which 
fluoresces on binding with RNA. This fluorescence is proportional to the amount of RNA 
present within the test sample, and is detected by the analyser which calculates an RNA 
concentration relative to known standards.  
 RNA Quantification using qPCR 7.4.1.2.3
As the RNA concentration of the extracted samples was below the accuracy of even the HS 
Cubit analyser, relative assessment of RNA concentrations extracted from the 12 CD34+38-
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ALDHhighCLL1- samples was performed by qPCR, to ensure the same amount of starting 
material was used for all samples before processing using the SmartSeq kit.   
cDNA was generated from 1µl aliquots of the RNA from each sample, using the methodology 
described in Section 7.3.1.7.1.2. qPCR for relative expression of GAPDH was performed, as 
described in Section 7.3.1.7.2. All samples were run in triplicate, and a mean Ct for each 
sample calculated.  
Relative cDNA concentrations (and assuming a linear reverse transcriptase reaction, relative 
RNA concentrations) were calculated as follows:  
                                                                           
7.4.1.3 cDNA synthesis using SMART-Seq kit  
The same protocol was followed as for when handling intact cells as listed in Section 7.3.1.3, 
with the following exceptions.  
 First strand synthesis  7.4.1.3.1
The relative concentrations of the 12 RNA samples were calculated as described in Section 
7.4.1.2.3. 9.5µl of the most dilute sample was added to an eppendorf for further processing, 
and the appropriate volumes of RNA from the other samples were used to attempt the same 
input of RNA for each sample. Samples were made up to 10.5µl with nuclease free water. 1µl 
of Reaction buffer was added to each test sample, which was briefly vortexed. Samples were 
placed on ice, and 1µl 3’SMART-Seq CDS Primer IIA added to each. Further steps in cDNA 
synthesis are as already described.  
 cDNA Amplification  7.4.1.3.2
Amplification of the cDNA was performed as described in Section 7.3.1.3.2, with the exception 
that 18 PCR cycles, rather than the previous 10, were utilised.  
 cDNA clean up  7.4.1.3.3
cDNA clean up using AmpPure beads was performed as described in Section 7.3.1.3.3.  
 Sample QC  7.4.1.3.4
After sample clean up, samples were run on the HS D5000 DNA ScreenTape (Agilent 5067-
5592). As discussed in Section 7.3.1.3.4, this kit is much more appropriate for assessment of 
the libraries generated by the SmartSeq kit. It covers a size range of 100 to 5000bp, and is also 
sensitive to a concentration of 5pg/µl. As illustrated by the example traces shown in Figure 
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App 4.3, a small peak at 60bp, thought to be related to excess primer, was not seen in these 
samples. Therefore the additional 1:1 clean up step was not performed. 
Quantification of cDNA library concentration was performed using the Qubit HS DNA 
Quantification kit as described in Section 7.3.1.3.4.1 
7.4.1.4 Further processing 
All further library preparation, QC, quantification and pooling was performed in the fashion as 
the first attempt at RNA-Seq, detailed in Section 7.3.1.4 onwards. 
7.4.1.5 Data analysis 
Sequencing and bioinformatic analysis of data was performed as described in sections 7.3.1.5 
and 7.3.1.6 
Gene enrichment analysis was performed using David .Version 6.8 
(https://david.ncifcrf.gov)344,345. Enrichment analysis of specific biological pathways was 
performed using the KEGG Pathway tool integral to David346.   
The dataset analysed within David contained all genes which exhibited differential expression 
between the two test groups with a fold change of greater than 2, and an individual p value of 
<0.05. Of 1013 genes that fulfilled these criteria, 810 were recognised by the software and 
therefore used for downstream analysis.   
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 Results 7.4.2
7.4.2.1 Assessment of optimal RNA extraction technique for small cell numbers  
Three different techniques for RNA extraction from small number of cells were rigorously 
compared for the efficiency and quality of the RNA yielded from 1000 cells. From experience, 
1000 cells is a reasonable achievable yield of CD34+38-ALDHhighCLL1- cells from one vial of bone 
marrow of AML or control samples stored in the Tissue Bank.  
 The importance of RNA quality in RNA-Seq Experiments  7.4.2.1.1
The absolute efficiency of RNA extraction was deemed less important in this experiment than 
the quality of the RNA generated. This was because the SmartSeq kit is sufficiently sensitive to 
allow for inputs as low as one cell, and therefore low yields of RNA could be adjusted for by 
increasing the number of PCR cycles used for amplification of cDNA.    
RNA quality measurements assess the integrity of an RNA sample, assigning it a score based on 
the likelihood of degradation. As polyadenylated mRNA is often the first component of total 
RNA to undergo degradation, maintaining RNA quality is thought to be key to ensuring the 
quality of data generated by RNA-Seq.  
The RNA integrity number (RIN) is an algorithm applied to analyse an electrophorectic trace. It 
is based on a number of characteristics of the trace including the relative areas under the 
peaks of the 18S and 28S RNA peaks, compared to the total area under the graph. Secondarily, 
the height of the 28S peak is important, as it is the most prominent species and is also first 
degraded. 
Although there are no absolute cut offs for the RNA quality required for sequencing, a 
consensus opinion appears to be a RIN of over 9.0 for each sample is deemed ideal to ensure 
good quality data. However, it is also accepted that as the quantity of available RNA falls, so 
does the maximum achievable RIN.  
Quality assessment of RNA of low concentration is challenging, and to date, our group has not 
attempted it, believing the sensitivity of available assays to be insufficient to base 
experimental decisions upon. However other labs working with small cell numbers and 
performing RNA-Seq routinely assess the quality of their RNA samples using the Agilent 2100 
system with an RNA 6000 Pico chip (personal communication, J Brown, UCL).  
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 At 1000 cell input, Qiagen columns provide optimal reliability and reproducibility. 7.4.2.1.2
Phenol based extraction techniques appear to offer the best quality RNA, but are 
highly irreproducible between technical replicates.   
Cord blood cells were thawed, washed and resuspended in DAPI to a concentration of 8x106 
cells/ml as previously described. Live cells were selected on the basis of FSC and SSC and DAPI 
negativity, and sorted into polypropylene tubes containing 2ml 2% PBS. Tubes containing 1000 
cells and 10000 cells were sorted.  
RNA extractions using the three methods detailed above (Qiagen Microkit; DirectZol and 
traditional Phenol separation) were performed in parallel, and the quality of the yields 
generated compared by assessment of RIN on the Agilent Pico Kit 6000.  
In summary, at an input of 10,000 cells, the RNA quality (as measured by RIN) yielded by all 
three kits appeared equivalent (mean RIN for Qiagen MicroColumn method 8.8, n=2; mean RIN 
for DirectZol Column method 8.4, n=1; mean RIN for Trizol 9.1, n=4). In addition, with 10,000 
cell input, the reproducibility for all three methods is excellent.  
In contrast, when cell inputs are reduced to 1000 cells, both the quality and importantly, the 
reproducibility of RNA yields, varied enormously between replicates (mean RIN for Qiagen 
method 6.6, n=3; mean RIN for DirectZol 0, n=2; mean RIN for Trizol 3.7, n=12). The results for 
Trizol-based extraction in particular proved frustratingly variable: six of the twelve extraction 
attempts generated detectable RNA, and in these samples, the mean RIN calculated was 7.5. 
However, a further six attempts generated no detectable RNA at all. Unfortunately, the 
reproducibility of this technique did not improve with repeated extraction attempts and 
increased operator experience. Small modifications to the technique (the use of increased LPA 
and the use of 1-Bromo-3-chloropropane in place of chloroform) made no difference to the 
observed reproducibility.  
We concluded that the quality of RNA yielded by phase separation with Phenol might be 
marginally better than with the column-based techniques, but that its reduced sensitivity 
rendered it impossible to use on samples as difficult and costly to extract as the ones we were 
dealing with. An additional benefit of the use of Qiagen columns is that this technique includes 
an on-column DNA digestion step, which reduced concerns about genomic DNA contamination 
in the sequencing data.  
I remain sceptical with regard to the utility of RIN based assessment of RNA quality at low 
levels. Whilst it is possible that the quality of RNA yielded from MicroColumns does fall as 
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input numbers fall (as we observe a significant fall in mean RIN between 10,000 and 1000 cell 
input with the Qiagen columns), it is also possible that the effect of a lower RNA concentration 
at the limit of detection sensitivity of the Agilent Pico 6000 chip, might result in difficulties in 
accurate assessment of RNA quality. 
7.4.2.2 Sample Information  
Clinical details pertaining to the 6 CD34low AML and 6 control samples which underwent RNA 
extraction and subsequent processing are shown in Table 7-10. All of the AML samples, and 
two of the controls were the same as those utilised in the first experiment. Due to lack of 
further BM availability in the tissue bank, a further 4 new controls were selected for use.  
Table 7-10 Sample information for the 6 CD34
low
 AML and 6 control samples used for RNA extraction in the repeat 
RNA-Seq experiment 
7.4.2.3 Library Preparation  
 Sorting and cDNA synthesis  7.4.2.3.1
All samples underwent sorting for CD34+38-ALDHhighCLL1- populations as previously described. 
In contrast to the first experiment however, rather than sorting a consistent 1100 cells into 
each FACS tube, all available HSCs for each sample were sorted into a single tube. This was 
done to try and maximise cell yield prior to RNA extraction, on the basis that RNA quality as 
assessed by RIN appeared better when starting from a higher number of cells. The number of 
cells sorted per sample is shown in Table 7-11.  
ID SAMPLE SEX AGE 
PRESENTATION BLOOD COUNT 
KARYOTYPE 
NPM1 










7793 AML F 56 11.1 4 10 +13 NPM A 
9002 AML M 68 8.9 0 41 NORMAL WT 
9067 AML M 67 7.4 142 172 NORMAL NPM A 
8169 AML F 27 9.7 0 110 t(11;19) WT 
8452 AML M 27 8.6 6 75 t(11;17) WT 
7774 AML M 62 8.1 0 37 NORMAL NPM A 
8508 CONTROL M 22 14.3 3.9 197  
 
8245 CONTROL M 45 12.9 7.8 316  
 
7926 CONTROL M 42 11.2 14.3 527  
 
8749 CONTROL F 70 13.9 7.8 193  
 
8984 CONTROL M 42 16.5 6.2 198  
 
10030 CONTROL F 68 12.3 7.8 228  
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Before commencing SmartSeq cDNA processing, I needed to quantify the RNA concentration 
for each sample, to ensure equal inputs to the SmartSeq kit. We felt that as RNA extraction 
efficiency was likely to vary significantly between samples, normalising inputs solely to the 
basis of the number of cells which underwent RNA extraction was unlikely to be accurate. The 
RNA concentration of extracted cells was below the sensitivity of the HS RNA Qubit. As a 
result, the relative concentration of RNA of each sample was calculated by qPCR as detailed in 
Section 7.4.1.2.3. The results of qPCR quantification are also shown in Table 7-11.  
Table 7-11 showing sorted number of cells, relative quantification of RNA by qPCR and volumes added for each 
sample to SmartSeq experiment 
 The amount of RNA per HSC cell is significantly lower for HSCs exposed to AML 7.4.2.3.2
than from controls 
Comparison of the yields of RNA per input cell for the 6 AML and 6 control samples was 
extremely interesting. As shown in Figure 7-7, the yield of RNA per AML-exposed HSC is 
significantly lower than that from a control HSC (relative yield 1.3 versus 3.4, p=0.02 by Mann-
Whitney t-testing).  
The significance of this result is briefly discussed in in Section 7.5.1.3, but the implication that 
the total amount of RNA per cell might be lower in AML-exposed HSCs would certainly fit with 
our hypothesis of induced HSC quiescence. It would be reasonable to hypothesise that a 
quiescent non-dividing cell would have a smaller transcriptome than one more involved in the 
process of differentiation. 
ID SAMPLE CELLS SORTED MEAN Ct FOR GAPDH 




YIELD PER CELL 
7793 AML 2919 33.9 4.8 1.1 
9002 AML 1870 34.0 5.2 1.6 
9067 AML 1100 34.9 9.5 1.5 
8169 AML 3159 33.7 4.1 1.2 
8452 AML 4539 33.4 3.4 1.0 
7774 AML 1776 34.1 5.7 1.5 
8508 CONTROL 2971 32.1 1.4 3.8 
8245 CONTROL 9843 30.6 0.5 3.1 
7926 CONTROL 1297 33.0 2.7 4.5 
8749 CONTROL 5401 30.9 0.6 4.6 
8984 CONTROL 5903 32.7 2.1 1.3 
10030 CONTROL 2213 33.5 3.8 1.9 







































Figure 7-7 Scatter plot comparing the RNA quantities extracted per cell for all 12 samples, expressed relative to 
lowest value in the group. Medians are AML 1.3 versus 3.4 for control group (n=6 for both). Median and IQR plotted 
for each group. Statistical significance between the two groups was calculated by Mann-Whitney testing (p=0.02).  
 Optimising the number of PCR cycles 7.4.2.3.3
In the first experimental attempt using 1100 cells as input to the SmartSeq kit, optimisation 
work suggested that 10 PCR cycles would be appropriate for amplification of the product of 
first strand cDNA synthesis before further processing (see Section 7.3.2.1.2 and Figure 7-4). 
However, as discussed at length in Chapter 7, QC of the resultant amplified cDNA was 
comprimised by the fact that we did not at that time possess a kit capable of detecting cDNA 
of lengths above 1000bp.  
At the time of this second repeat, QC was able to be carried out using the HS Screentape 5000, 
which allowed detection of cDNA strands up to 5000 bp long.  
RNA extracted in the same fashion as the test samples, and quantified by qPCR assessment of 
GAPDH, was used for optimising experiments testing the relative appearances and sizes of 
cDNA libraries generated by 12 (not shown), 14, 16 and 18 cycles of PCR amplification. The 
results of these optimisation experiments are shown in Figure 7-8. With this sample, the use of 
18 PCR cycles appeared to produce a cDNA library of the expected size and within the 
expected concentration yield (0.8ng/µl).  
 Normalising input RNA amounts to GAPDH expression led to overcycling in some 7.4.2.3.4
samples   
As discussed in Section 7.4.1.2.3, the relative concentration of each of the 12 RNA samples was 
determined by qPCR for GAPDH expression. The volume of input RNA into the SmartSeq kit 
was based on these normalised values, in an attempt to ensure equal RNA input.  
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The RNA used for experiments optimising the number of PCR cycles required (as detailed in 
Section 7.4.1.3.2, and results in Figure 7-8), had been quantified and normalised in the same 
fashion.  
It is interesting therefore, that despite what was deemed to be an equivalent RNA input to the 
SmartSeq prep, that different samples outputted different size libraries (shown in Table 7-12). 
This is also illustrated in the corresponding HS TapeStation 5000 traces analysing the samples 
(Figure 7-9 shows an appropriately sized library, and B shows an overcycled library). As a 
result, several libraries appeared to be overcycled, with end yields in excess of the upper end 
of the expected range. As we were keen to avoid overcycling of cDNA where possible to gain a 
representative library, for those samples which had an end DNA yield significantly above that 
expected (17ng, corresponding to a concentration of greater than 1.0ng/μl), and where there 
was sufficient residual RNA available (n=4), SmartSeq preparations were remade, using a 
smaller input of RNA but the same cycle number. The concentrations of these repeat cDNA 
libraries are also given in Table 7-12. 
 DNA Library Preparation using the Nextera XT Kit 7.4.2.3.5
After processing of the cDNA libraries using the Nextera XT kit to fragment, tag with adapters 
and subsequently amplify the DNA, the resultant DNA libraries were analysed for both average 
fragment size by HS ScreenTape 1000 and concentration by HS Qubit. Results are shown in 
Table 7-13. As in Chapter 7, the libraries were also quantified by Kappa PCR, designed to 
specifically detect DNA appropriately tagged for sequencing. These results are shown in Table 
7-14. There was good correspondence between the two methods, but as before, the results 
generated by Kappa qPCR were used to assign relative concentrations to each library, prior to 
final pooling (see Table 7-15).  
After pooling of equivalent quantities of DNA for each of the 12 libraries, the final library 
concentration pre-sequencing was estimated by HS Qubit assay at 11.1ng/μl. The average 
fragment size of the library was also calculated by HS Screentape 1000, and was found to be 
452 base pairs. This gives a calculated library concentration (using the formula in Section 




Figure 7-8 Optimisation of the number of PCR cycles used for cDNA amplification after first strand synthesis. Equal inputs of RNA (extracted from DAPI negative cells from cord blood, extracted 






Figure 7-9 SmartSeq appearances of 2 test samples and positive and negative controls, all cycled at 18 cycles. A: successful trace ID 7793 with an end [] of 0.853ng/µl; B: Possibly overcycled sample ID 
10030 with an end [] of 1.8ng/µl (above expected range); C: Positive control; D: Negative control 
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Table 7-12 Concentrations of cDNA libraries post SmartSeq preparation, as estimated by Qubit  
Table 7-13 Concentrations of final DNA libraries post Nextera XT processing, as estimated by Qubit 
  
SAMPLE ID PAT ID 
POST-CLEAN [] 
ng/µl RUN 1  
POST-CLEAN [] 
ng/µl RUN 2 
VOLUME IN LIBRARY PREP (µl) 
1 8452 1.02  0.98 
2 8169 1.45  0.69 
3 7793 0.858  1.17 
4 9002 3.02 0.668 1.5 
5 7774 1.26  0.79 
6 9067 2.48  0.4 
7 8508 1.46 0.728 1.37 
8 8245 1.12  0.89 
9 7926 2.32  0.43 
10 8749 1.05  0.95 
11 8984 4.92 0.768 1.3 
12 10030 1.8 0.504 1.98 
ID SAMPLE INDEX 1 (i7) INDEX 2 (i5) 
AVERAGE 






8452 AML N701 S503 467 7.58 25.0 
8169 AML N702 S503 413 5.82 21.7 
7793 AML N703 S503 519 8 23.7 
9002 AML N704 S503 449 7.72 26.5 
7774 AML N705 S503 511 7.88 23.7 
9067 AML N706 S503 471 8.58 28.0 
8508 CONTROL N701 S504 480 3.68 11.8 
8245 CONTROL N702 S504 447 5.94 20.4 
7926 CONTROL N703 S504 472 11 35.9 
8749 CONTROL N704 S504 445 5.28 18.3 
8984 CONTROL N705 S504 472 7.1 23.1 
10030 CONTROL N706 S504 461 5.64 18.8 
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Table 7-14 Concentrations of final DNA libraries post Nextera XT processing, as estimated by Kappa qPCR  
Table 7-15 Volumes used in final DNA library pooling to ensure equal representation of all 12 libraries in 













8452 AML 467 26.5 28.4 27.4 25.0 
8169 AML 413 26.8 22.7 24.7 21.7 
7793 AML 519 23.3 26.2 24.7 23.7 
9002 AML 449 30.7 34.8 32.7 26.5 
7774 AML 511 22.8 27.2 25.0 23.7 
9067 AML 471 45.7 47.8 46.7 28.0 
8508 CONTROL 480 12.5 13.5 13.0 11.8 
8245 CONTROL 447 20.5 29.6 25.1 20.4 
7926 CONTROL 472 39.8 43.1 41.5 35.9 
8749 CONTROL 445 27.9 28.4 28.1 18.3 
8984 CONTROL 472 27.4 32.7 30.0 23.1 
10030 CONTROL 461 26.0 33.3 29.6 18.8 
PAT ID SAMPLE LIBRARY [] BY qPCR (nM) RELATIVE CONCENTRATION VOLUME ADDED (µl) 
8452 AML 27.4 2.1 9.5 
8169 AML 24.7 1.9 10.5 
7793 AML 24.7 1.9 10.5 
9002 AML 32.7 2.5 8.0 
7774 AML 25.0 1.9 10.4 
9067 AML 46.7 3.6 5.6 
8508 CONTROL 13.0 1.0 20.0 
8245 CONTROL 25.1 1.9 10.4 
7926 CONTROL 41.5 3.2 6.3 
8749 CONTROL 28.1 2.2 9.3 
8984 CONTROL 30.0 2.3 8.7 
10030 CONTROL 29.6 2.3 8.8 
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7.4.2.4 Sequencing data  
 Proportion of reads mapping to coding regions of genes is significantly improved 7.4.2.4.1
when RNA extraction is performed prior to first strand synthesis  
In attempt 1, when cells were used directly as the source of RNA for cDNA synthesis, the 
proportion of reads mapped to non-coding regions of the genome ranged from 42 to 88% 
between samples. However, when RNA extraction was performed prior to cDNA synthesis 
using the SmartSeq kit, the proportion of reads mapping to non-coding regions dramatically 
reduced to between 7 and 34% per sample. These data are shown in Table 7-16. This compares 
favourably with the expected data from the company literature347. 
Table 7-16 Percentage of RNA-Seq reads mapping to coding and non-coding regions for each sample 
 Differentially expressed genes 7.4.2.4.2
7.4.2.4.2.1 Principal Component Analysis  
Principal component analysis of the 12 samples, performed and graphically illustrated by Ai 
Nagano (Bioinformatics Department, BCI) shows weak clustering into two groups as shown in 
Figure 7-10. 
7.4.2.4.2.2 Individual genes of interest 
Filtering revealed differential expression of 14624 genes between normal HSCs from AML 
samples and controls. Of these, 243 showed differential expression with log fold changes of  
ID SAMPLE 
TOTAL NUMBER OF 
READS 
% READS UNIQUELY 
ALIGNED TO GENOME 
% ALIGNED READS 
MAPPED TO INTRONIC 
REGIONS 
7793 AML 62261501 62 13 
9002 AML 60122953 61 34 
9067 AML 51128266 64 13 
8169 AML 58066526 57 26 
8452 AML 70935294 62 27 
7774 AML 66088268 62 8 
8508 CONTROL 63003682 58 21 
8245 CONTROL 55627489 57 7 
7926 CONTROL 58162995 61 11 
8749 CONTROL 50223437 57 13 
8984 CONTROL 54387966 60 20 




Figure 7-10 Principal Component Analysis illustrating weak clustering of the 12 samples into two groups consistent 
with their origin (analysis and graphic kindly supplied by Ai Nagano) 
greater than two, calculated p-value of less than 0.01. These are listed in Appendix 4 of this 
thesis. By comparison, only 37 genes were differentially expressed by the same criteria in the 
original experiment. 
Six genes were differentially expressed in a statistically significant fashion when allowing for 
multiple testing (an adjusted p value of <0.05 calculated using the Benjamini–Hochberg 
procedure). Of these, one gene showed significantly increased expression in control HSCs 
versus AML-exposed HSCs (GNPDA1); and five showed significantly increased expression in 
AML-exposed HSCs versus control HSCs (ADGRG3, MIAT, WDR31, RP11-244H3.1 and RXFP1). 
Reported data on these genes are summarised below. In the first experimental attempt, no 
genes were significantly differentially expressed after the Benjamini-Hochberg test had been 
applied.  
7.4.2.4.2.2.1 Genes relatively downregulated in HSCs exposed to AML compared to controls 
7.4.2.4.2.2.1.1 GNPDA1 (Glucosamine-6-phosphate deaminase 1)  
GNPDA1 (also known as oscillin) is an allosteric enzyme that catalyses the reversible 
conversion of D glucosamine-6-phosphate into D-fructose-6-phosphate and ammonium348. 
Originally identified as a sperm-derived factor responsible for calcium flux within oocytes, it is 
now known to be ubiquitously expressed and is therefore thought to have a housekeeping 
role. There are no published associations with haematopoietic development, AML or control of 
cell division.  
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7.4.2.4.2.2.2 Genes relatively upregulated in HSCs exposed to AML  
7.4.2.4.2.2.2.1 ADGRG3 (Adhesion G protein coupled receptor G3) 
ADGRG3 is an orphan receptor which acts to regulate endothelial cell migration via 
RhoGTPases and CDC42. Other members of the adhesion GPCR family function to control cell 
polarity, migration and adhesion. Up and down regulation has been noted in a variety of 
cancer types349.  
A related family member, GPR56, has a role in haematopoietic stem cell formation. Saito et al 
demonstrated high GPR56 expression in EVI1-positive AML cells. Knockdown of the gene in 
AML cells resulted in reduced cellular adhesion. In murine GPR56 knock-outs, HSC numbers 
were significantly reduced in the BM and increased in liver and spleen and blood, with 
concurrent loss of their repopulating ability350.  
7.4.2.4.2.2.2.2 MIAT (myocardial infarction associated transcript) 
MIAT (also known as RNCR2 (retinal non-coding RNA2)) is a long, non-coding RNA. These RNAs 
are postulated to play a role in gene expression regulation. Unlike many non-coding RNAs, 
MIAT is polyadenylated, and therefore would be expected to be amplified by the SmartSeq kit.  
Although most studies have focussed on an association between expression and increased 
cardiac risk351, MIAT expression has also been associated with a variety of cancers. In 
glioblastoma cases, MIAT upregulation has been linked to increased survival rates352. 
Conversely, in CLL, MIAT upregulation under the control of OCT4 is associated with more 
aggressive disease353.  
7.4.2.4.2.2.2.3 WDR31 
WDR31 is a gene encoding a member of the WD repeat protein family. These are minimally 
conserved regions of 40-odd amino acids, which facilitate formation of multiprotein 
complexes. Other family members have a variety of reported roles, including cell cycle 
progression, signal transduction and apoptosis, but to date, none have been specifically 
reported for WDR31.   
7.4.2.4.2.2.2.4 RP11-244H3.1 
RP11-244H3.1 is a non-coding long RNA with no reported functions or associations to date. 
7.4.2.4.2.2.2.5 RXFP1 
RXFP1 is a human G protein coupled receptor, which is one of the relaxin receptors. There are 
no published associations with haematopoiesis, AML or cell cycle control to date.  
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 Pathway analysis 7.4.2.4.3
Gene enrichment analysis performed using the DAVID functional annotation chart is 
summarised in Figure 7-11354. The input dataset contained all genes differentially expressed 
between HSCs from AML samples and controls, with a fold change of greater than 2, and 
individual p value of <0.05. Of 1013 genes, 810 were recognised by DAVID and used for further 
analysis.  
 
Figure 7-11 Gene enrichment analysis of differentially expressed genes from HSCs from AML samples and control, 
generated by the DAVID functional annotation chart option. Enriched categories of molecular function, cellular 
compartments, and biological processes are shown. Significance of enrichment is shown by EASE score (modified 
Fisher’s Exact Score). The illustrated figures are NOT corrected for multiple testing 
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Of particular interest are the biological processes which show enrichment within this gene set. 
As might be expected, given the previous observed quiescence of HSCs in AML samples, there 
is enrichment in genes involved in control of cell cycle, especially around key points such as the 
G1/S transition. Similarly, given the assumed lack of downstream differentiation of HSCs, it is 
interesting that genes associated with haematopoiesis and haem synthesis also strongly 
appear.   
However, it must be highlighted that none of the functions highlighted by David using this 
input set of genes are significant when correction is made for multiple testing using the 
Benjamini-Hochberg procedure. As before, one wonders if the limited number of samples 
along with the variation seen between biological samples may be responsible.  
7.4.2.4.3.1 KEGG pathway analysis  
Enrichment analysis of specific biological pathways was performed using the KEGG pathway 
analysis tool integral to David346. Table 7-17 summarises the top enhanced pathways (all with 
an individual EASE p value of <0.05). As before, none of these pathways retain statistical 
significance after the application of the Benjamini-Hochberg procedure.  
I have chosen to discuss in further depth the significance of the Tumor Necrosis Factor (TNF) 
signalling and cell cycle control pathway.  
Table 7-17 Enrichment of genes within specific biochemical pathways differentially activated between HSCs from 
AML and control samples, as generated by KEGG analysis. Significance of enrichment is shown by EASE score 




EASE SCORE P 
VALUE 
P VALUE AFTER BENJAMINI 
CORRECTION 
TNF signalling pathway 11 0.003 0.51 
Non-alcoholic fatty liver disease 
(NAFLD) 
12 0.014 0.79 
Toxoplasmosis 10 0.019 0.76 
Cell Cycle 10 0.025 0.76 
Toll-like receptor signalling 
pathway 
9 0.027 0.72 
Fanconi anaemia pathway 6 0.033 0.72 
NOD-like receptor signalling 
pathway 
6 0.038 0.72 
Sulphur relay system 3 0.043 0.72 
Viral carcinogenesis 13 0.046 0.69 
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7.4.2.4.3.1.1 TNF signalling  
11 genes within the TNF signalling pathway show significant changes in expression between 
the two subgroups of HSCs, making it the most enhanced pathway on KEGG analysis (p=0.003). 
Figure 7-12 summarises the pathway, and highlights the genes within it which show 
differential expression. Of the 11 genes, 8 show increased expression in HSCs exposed to AML. 
It is harder to plausibly explain the increased expression of three genes in the pathway 
(MAPK11 (p38), MAP2K6 and TAB1) in HSCs from control samples relative to AML.    
A relative activation of the TNF signalling pathway in HSCs exposed to AML is certainly highly 
biologically plausible, and provides a potential mechanism by which HSC quiescence could be 
induced.   
Identified over 30 years ago, TNF is produced as a type II transmembrane protein, capable of 
signalling with its cognate receptors both in membrane and soluble form when cleaved355. 
There are two receptors: TNF-R1 is ubiquitously expressed, whereas TNF-R2 is found on 
lymphoid cells356. TNF has been reported to have a wide range of roles dependant on cell type 
and activated receptor, but in general mediates pro-inflammatory behaviour, and retains 
ability to induce cellular apotosis357.  
Increased levels of TNF have been illustrated in the peripheral blood and bone marrow of 
patients with AML, and are associated with high WCC disease and poor prognosis358. Increased 
levels of TNF have been documented in patients with bone marrow failure from other causes 
(AA, MDS), leading to the suggestion it may be involved in the development of cytopenias in 
these conditions359,360.  
Murine gene knock-out studies exploring the role of TNF in HSC regulation suggested that TNF 
signalling (requiring both TNFrsf1b and Tnfrsf1a activation) had a suppressive effect on HSC 
expansion361.  
Goselink et al reported the ability of AML to inhibit the proliferation of human progenitor cells 
when culture was separated by transwells of a pore size of 0.45µm. Interestingly, the addition 
of anti-TNF α inhibitor restored normal HPC proliferation. However, the authors also noted this 
led to significantly increased proliferation of AML blasts, an observation they felt would limit 




Figure 7-12 KEGG generated figure showing key genes involved in TNF signalling. Genes differentially expressed 
between HSCs from AML and control samples (fold change >2, EASE score p value <0.05) are highlighted with a star 
 
Figure 7-13 KEGG generated figure showing key genes involved in cell cycle control. Genes differentially expressed 
between HSCs from AML and control samples (fold change >2, EASE score p value <0.05) are highlighted with a star 
Chapter 7-RNA-Seq 
313 
7.4.2.4.3.1.2 Cell Cycle Control 
As one of the key hypotheses of this thesis is that HSCs from AML samples are relatively 
quiescent when compared to those from controls, it is somewhat reassuring to see that the 
pathways of cell cycle control are highlighted as one of the key differential pathways on KEGG 
analysis. This is summarised in Figure 7-13. Of the 10 genes which exhibit significant 
differential expression, all but CDKN2D (part of the Ink4d complex) are more highly expressed 
in control cells than AML cells. This is consistent with the idea that HSCs from AML cells are 
more likely to be quiescent; as in general these genes are upregulated during the process of 
cell division. The only exception to this pattern is RBL1- its relative upregulation in HSCs from 
control samples is difficult to explain, as increased expression is normally associated with 
blockade of the G1/S check point363.  
 Comparison with other Datasets  7.4.2.4.4
7.4.2.4.4.1 There is little overlap between the datasets produced in the first and second RNA-
Seq experimental attempts 
Genes which show significant differential expression between HSCs from AML samples and 
controls in both the first and second RNA-Seq experiments are shown in Table 7-18. Only 13 
genes showed marked differences in both experiments. Of these, 10 showed changed in 
expression in a consistent direction in the two experiments.  
Potential reasons for the lack of concordance between the two datasets are further explored 
in Section 7.5.2.1.  
7.4.2.4.4.2 There is little overlap between this dataset and murine xenograft data  
Comparison was also made between the dataset generated by this experiment, and that 
detailed in Section 7.1.2.1 resultant from the transplantation of mice with one human AML 
sample (and comparison with HSCs from untransplanted mice). Seven genes appeared in the 
top 200 differentially expressed genes within both datasets. However, of these, only two 
exhibited differential expression between HSCs from AML and controls in consistent directions 
in both datasets. Expression of ANK1 was relatively increased in HSCs extracted from control 
BM; expression of TMEM53 was relatively increased in HSCs from AML samples. Whilst the 
protein product of the TMEM53 gene has no clear reported roles to date, the functions of 
ANK1 are better defined.  
The ANK1 gene codes for a protein involved in linking proteins integral to the cell membrane 
to the underlying actin cytoskeleton. Clinically, mutations in ANK1 are associated with 
hereditary spherocytosis364. In health, its expression is associated with erythroid maturation 
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from HSCs and switching365. Within AML samples, microarray studies have shown its 




Table 7-18 illustrating 13 genes which showed fold changes >2 between HSCs from AML and controls samples in BOTH RNA-Seq experiments (3 genes in italics showed marked fold changes in gene 
expression in non- consistent direction between the 2 experiments) 
 
Attempt 1 Attempt 2 











ENSG00000164120 HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 2.34 up in CTR 0.0377 
0.999
8 
4.41 up in AML 0.0035 0.4387 
ENSG00000204644 ZFP57 ZFP57 zinc finger protein 2.00 up in CTR 0.0132 
0.999
8 
6.06 up in CTR 0.0083 0.5495 
ENSG00000149257 SERPINH1 
serpin peptidase inhibitor, clade H (heat shock protein 47), 
member 1, (collagen binding protein 1) 
1.78 up in CTR 0.0050 
0.999
8 
5.89 up in CTR 0.0014 0.3252 
ENSG00000080839 RBL1 retinoblastoma-like 1 1.37 up in CTR 0.0421 
0.999
8 
5.24 up in CTR 0.0057 0.5015 
ENSG00000065054 SLC9A3R2 
solute carrier family 9, subfamily A (NHE3, cation proton 
antiporter 3), member 3 regulator 2 
1.26 up in CTR 0.0474 
0.999
8 
4.05 up in CTR 0.0046 0.4796 
ENSG00000097046 CDC7 cell division cycle 7 1.26 up in CTR 0.0285 
0.999
8 
5.67 up in CTR 0.0063 0.5197 
ENSG00000113621 TXNDC15 thioredoxin domain containing 15 1.09 up in CTR 0.0144 
0.999
8 
5.54 up in CTR 0.0014 0.3252 
ENSG00000120833 SOCS2 suppressor of cytokine signaling 2 1.47 up in AML 0.0180 
0.999
8 
1.72 up in AML 0.0089 0.5495 
ENSG00000101400 SNTA1 syntrophin, alpha 1 1.54 up in AML 0.0118 
0.999
8 
5.11 up in CTR 0.0089 0.5495 
ENSG00000197329 PELI1 pellino E3 ubiquitin protein ligase 1 2.02 up in AML 0.0056 
0.999
8 
3.80 up in AML 0.0030 0.4235 
ENSG00000180573 HIST1H2AC histone cluster 1, H2ac 2.27 up in AML 0.0400 
0.999
8 
2.28 up in AML 0.0084 0.5495 
ENSG00000146592 CREB5 cAMP responsive element binding protein 5 2.43 up in AML 0.0028 
0.999
8 
4.26 up in AML 0.0033 0.4302 
ENSG00000122824 NUDT10 
nudix (nucleoside diphosphate linked moiety X)-type motif 
10 
2.64 up in AML 0.0188 
0.999
8 
5.16 up in CTR 0.0030 0.4235 
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7.5 Discussion 
This chapter follows our attempts to identify the mechanism or mechanisms by which AML 
induces quiescence in the HSC population, by studying the comparative transcriptomes of HSCs 
sorted from primary AML and control BM samples.  
The work involved provided an excellent opportunity to learn a host of new techniques 
required for the handling of DNA and RNA in small amounts. The first experiment resulted in 
data of disappointing quality, due to heavy contamination with reads mapped to intronic DNA. 
Perhaps unsurprisingly, these results failed to be replicated in validation experiments. A repeat 
experiment, using extracted RNA as source material for subsequent library preparation, has 
yielded a very different dataset, of substantially improved quality in terms of proportion of 
reads mapped to coding regions of the genome.  
Data from the second experimental attempt were received after my PhD laboratory time was 
completed; hence, I have been unable to perform validation experiments on the genes of 
interest which have been highlighted by this work.  
 Was failure of selective amplification of polyadenylated mRNA within the 7.5.1
SmartSeq kit the cause of genomic contamination of the first experiment?   
As discussed in Section 7.3.2.4.1, our first attempt at studying the comparative transcriptomes 
of sorted HSCs from AML and control samples was frustrated by the fact that a large 
proportion of sequenced reads mapped to genomic rather than coding DNA regions.  
The reason for this is not entirely clear, but our eventual favoured hypothesis was that relying 
on selection of polyadenylated transcripts by the SmartSeq kit prior to first strand synthesis 
was not specific enough to prevent the concurrent amplification of DNA. As we used intact 
cells as the direct input material to the SmartSeq kit (as opposed to pre-extracted RNA), the 
quality of the data generated is entirely dependant on this specificity of this amplification. As 
already mentioned, external genomic DNA contamination was unlikely due to the consistent 
presence of successful negative controls at all stages of library preparation.    
Quite why the SmartSeq kit might fail in this manner remains open to conjecture. It is a widely 
used kit for handling of small numbers of cells, and its use was recommended by several 
independent groups. However, all of our contacts had used pre-extracted RNA as a starting 
material for cDNA synthesis, rather than cells.  
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7.5.1.1 QC of cDNA production with the HS Screentape D1000 was inadequate 
In retrospect, our lack of access to the appropriate kit to QC at the end of cDNA generation 
(see Section 7.3.1.3.4) almost certainly meant we failed to pick up experimental issues at the 
earliest possible stage. This situation has now been rectified with the availability of the HS 
D5000 Screentape, which was used for QC on the repeated experiment (see Section 7.4.1.3.4 
and Figure 7-8 and Figure 7-9).  
7.5.1.2 Could lengthy sorting contribute to sample apoptosis?  
Why feasibly might we have been faced with difficulties in the use of this kit that others have 
not come up against? In discussions with Clontech, the company conceded that if DNA was 
present in single stranded form in the reaction mix (for example, when released by apoptotic 
cells), it is possible that this might be amplified along with mRNA. The lengthy sorting process 
that is required to separate normal HSCs from AML samples (between one to two hours per 
sample) is significantly more than most samples would have to undergo. Although HSCs were 
DAPI negative at the point of sorting, it is possible that a proportion of them will have been 
damaged enough from the process to have begun to apoptose by the time of cDNA synthesis.  
7.5.1.3 Do quiescent HSCs contain relatively less RNA per cell than other cell types?   
We know very little about the relative size of transcriptomes between different cell types, or 
indeed between cells at different stages in the cell cycle. However, from all that we 
understand about HSC biology, it is reasonable to hypothesise that these metabolically 
inactive, quiescent cells should have a limited transcriptome. This would result in a relatively 
low RNA:DNA ratio per cell, which might increase the likelihood of contamination from DNA 
amplification within the SmartSeq kit (see Section 7.3.2.4.2).   
Two observations suggest that the RNA yield per HSC is low in comparison to other cell types. 
Clontech issue a rough guide to the expected number of PCR cycles to amplify cDNA 
dependent on the input cell number. When using either cells or RNA as input, the actual 
number of cycles used (10 and 18 respectively) were significantly in excess of that 
recommended (see Figure 7-8). Secondarily, when single HSCs from AML samples underwent 
single cell sorting and cDNA production at the Single Cell Genomics Core Facility in Cambridge, 
the team there also suggested the cDNA required amplification with an unusually high number 
of PCR cycles (22) before detection.  
It is also interesting that, as shown in Figure 7-7, the relative yields of RNA per cell from HSCs 
extracted from AML samples were statistically smaller than those extracted from control 
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samples, which is in keeping with our hypothesis of induced quiescence in the HSCs exposed to 
AML. 
 Reasons for failure of validation of selected genes of interest by flow based 7.5.2
protein assessment and qPCR based analysis 
Despite the concerns regarding the quality of the data generated by the first RNA-Seq 
experiment, I attempted to see if the observed changes in gene expression in the top target 
genes could be validated by qPCR analysis and flow based assessment of protein expression.   
Of the 8 genes selected for assessment of gene expression validation, only one (CD33) 
confirmed differential expression between the HSCs exposed to AML and normal BM that was 
statistically significant (by flow based assessment of protein expression, but not by qPCR based 
assessment of mRNA levels). 
7.5.2.1 Data quality of the first experiment is poor enough to explain lack of gene validation  
When we were attempting gene validation, we were aware of apparent significant read 
contamination with genomic DNA. We assumed this represented internal contamination, due 
to the failure of the SmartSeq kit to solely select and amplify polyadenylated mRNA. In 
attempting to analyse the data further, we made a secondary assumption that the 
amplification of any DNA would occur randomly. Therefore, if a differential number of reads 
appear to map to a gene between the two sample cohorts, this could be assumed to be due to 
pre-existing differences in mRNA levels, and therefore suggestive of a true biological 
difference. Against this argument is the observation that the level of genomic contamination 
appears to vary between samples (see Table 7-7), which given the small input number of 
samples, might be a significant factor.  
In the light of the dataset subsequently received from the repeat experiment, the lack of 
validation by independent methods of results from the first experiment seems less surprising. 
None of the 8 genes chosen for validation appeared differentially expressed in the second 
dataset. Whilst poor data quality due to genomic DNA contamination might be the primary 
reason why validation of the first dataset failed, there are several other potential contributing 
factors, discussed below. 
7.5.2.2  Are differences in gene expression between control samples sufficient to prevent 
validation of the initial RNA-Seq findings?  
Even without the concerns over the quality of the initial RNA-Seq data, it is possible that the 
fact that different control samples than those used in the primary experiment had to be sorted 
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for RNA extraction, might result in differences between the control cohorts. As shown in Table 
7-9, because insufficient further BM sample was available in the Tissue Bank for 4 of the 
control samples sorted in the original experiment, HSCs were sorted from a further 4 
independent samples.   
Previous work using primary human samples (see Section 7.1.2.2) had suggested there is 
considerable variation between the gene expression profiles of control samples. This might be 
sufficient to prevent the validation of a genuine difference between AML-exposed HSCs and 
the HSCs derived from one cohort of control samples, using another cohort for validation. 
However, the obvious counter-argument to this is that such an approach should filter out non-
biologically significant differences. Such variability certainly presents a strong argument for the 
use of larger numbers of both control and AML samples to be studied in each cohort group in 
subsequent work.    
7.5.2.3 HSC-derived RNA was dilute enough to be at the borderline of qPCR detection for 
many genes of interest 
As discussed in brief in Sections 7.3.1.7.1 and 7.3.2.5.4, the concentration of the RNA extracted 
from the available numbers of HSCs (between 1000 to 5000 per sample) was sufficiently dilute, 
that the resultant cDNA (despite the optimisation of reverse transcription described in Section 
7.3.1.7.1.2) was only detected in the final cycles of qPCR. This led to a number of problems 
during analysis.  
The cDNA concentrations of all samples were so low, that even relatively highly expressed 
house-keeping genes such as GAPDH were only detected between 28 to 35 qPCR cycles for 
most samples. Despite selecting genes for validation with apparently high expression levels (as 
defined by RPKM values from the RNA-Seq data) in anticipation of this issue, for several genes 
(S100A10, IDH1 and TRAF4), expression was not detected by 38 qPCR cycles in most cycles. The 
quality and reproducibility of data generated for genes detected beyond 35 qPCR cycles is 
widely considered to be poor, and so interpretation of differences in actual gene expression 
between samples with low expression is highly challenging.   
 Would pre-amplification of low concentration RNA before qPCR-based validation 7.5.2.3.1
have been helpful? 
One solution to the difficulty of working with RNA or cDNA of low concentration is to pre-
amplify samples before qPCR based gene expression analysis, using one of a range of 
commercially available kits. Such kits are designed to amplify the different mRNA transcripts 
within a sample equally, thus avoiding bias. In retrospect, such a step would not only avoid the 
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practical difficulties of interpreting gene expression levels of genes detected after 35 cycles of 
qPCR, but would also produce sufficient cDNA to allow for the validation of many more genes.    
However, such an approach is not without its disadvantages. The use of a pre-amplification 
step brings this qPCR-based assessment of gene expression levels very close to the 
methodology of RNA-Seq, and therefore subject to the same potential bias of unequal 
amplification of specific genes. A secondary consideration was cost- current commercial kits 
are in excess of £1000 for 12 samples, and at this stage in my thesis, and while attempting to 
validate data of questionable quality, this was deemed to be unjustifiable expenditure. 
 Using RNA as a starting material leads to better quality data  7.5.3
We made the decision to concentrate on repeating the original experiment using RNA 
extracted as the source of the starting material, rather than cells. In light of the difficulties 
described above, we were supplied with free replacement SmartSeq kit by Clontech for cDNA 
synthesis.  
Given our difficulties with using sorted cells as a starting point for the RNA-Seq experiment, 
considerable care was undertaken to optimise the best technique for extracting quality RNA 
from these small cell numbers sufficient to use in further processing.  
7.5.3.1 What was the best RNA extraction methodology?  
As detailed in Section 7.4.2.1, the use of Qiagen columns for RNA extraction appeared to 
provide a reasonable compromise of quality of material and reproducibility required for RNA 
extraction from around 1000 cells. However, questions remain over the quality of the RNA 
extracted by this methodology, which during optimising experiments using 1000 cells was 
assessed by RIN as being as low as 3 (in one of three samples).  
Other laboratories working with small cell numbers (J. Brown, UCL, personal communication) 
prefer Phenol based extraction methods, which appeared to offer a higher RNA quality as 
assessed by RIN at low cell number, but poor reproducibility. It was the poor reproducibility of 
this approach which proved crucial for me in rejecting this methodology, given the limited 
number of available samples, as well as the cost and time required to sort out stem cells.  
If this work were to continue, I would be interested in trying to optimise the Phenol extraction 
method, to see if repeated attempts could improve its reliability in my hands.  
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Whilst it appears that the proportion of reads mapping to intronic regions was significantly 
lower when prior RNA extraction was used, RNA separation from DNA is clearly not perfect, in 
that between 6 to 33% of reads still mapped to intronic regions (see Table 7-16). This is 
suggestive of a degree of ongoing DNA contamination at varying levels within the samples, 
despite the fact that the Qiagen columns did contain an on-column DNA digestion step. In 
retrospect, I should have included a QC step to check for the presence of DNA contamination 
after RNA extraction (by qPCR for a gene using primers spanning an intron)  
7.5.3.2 Second dataset contained more genes with statistically significant changes in 
expression levels between the two HSC groups, but only 6 which retained significance 
when allowing for multiple testing  
Using RNA as a starting material for library preparation also appears to have produced a more 
“uniform” dataset in that many more genes appeared to be differentially expressed between 
the normal HSCs within AML and control samples.  
However, it is interesting that only six genes retained significantly different levels of expression 
after allowance is made for multiple testing. Of these genes (and their close structural 
homologues), only three have been reported to have roles in cell cycle control and 
differentiation. Given this experiment was designed to detect genes which might be 
responsible for mediating the observed quiescence of normal HSCs from AML samples, I had 
perhaps naively assumed we might detect more changes of significance between the two 
groups. I have not been able to find published datasets from similar experiments using the 
SmartSeq kit to compare with.  
In comparison, the experiment described in Section 7.1.2.1, comparing the transcriptomes of 
HSCs from 7 mice transplanted with AML and matched controls, revealed 54 genes to be 
differentially expressed between the two groups after allowance for multiple testing. 
However, this is perhaps not a fair comparison- all 7 mice were transplanted with the same 
sample of AML, unlike the diversity of AMLs represented in our samples. Given the 
documented variability of primary human samples already noted in Section 7.1.2.2, the first 
improvement to this experiment would be to increase substantially the samples of both AML 
and controls to improve the statistical power of any results.  
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 Further experimental work  7.5.4
7.5.4.1 Exploration of the second RNA-Seq dataset 
 Gene expression validation  7.5.4.1.1
The RNA-Seq data generated by the second attempt at this experiment were received after my 
time in the laboratory had concluded. Therefore, I did not have an opportunity to attempt to 
validate the observed changes in gene expression between HSCs from AML and control 
samples, as I had done with the first experiment. This is the most pressing outstanding work 
required in this thesis. 
The obvious candidates for validation of differential expression would be the genes highlighted 
in Section 7.4.2.4.2.2. It would also be useful to perform similar analysis on the genes thought 
to be differentially regulated within the TNF signalling pathway (see Section 7.4.2.4.3.1.1), 
before embarking on further functional work in this area.  
 Functional analysis of the role of the TNF signalling pathway  7.5.4.1.2
If validation experiments did confirm differential expression of genes within the TNF signalling 
pathway, the next step would be to explore its relevance to the development of bone marrow 
failure in AML within a functional model. Given that effective biological inhibitors of TNF 
signalling already exist, one approach would be to revisit the murine transplantation model of 
AML-induced bone marrow failure detailed in Section 7.1.2.1, and explore if concurrent 
therapy with TNF inhibitors such as Etanercept or Infliximab delayed the onset of HSC 
quiescence, or the development of cytopenias, as the AML engrafts.  
 Other pathways of potential interest  7.5.4.1.3
The results of enrichment analysis of specific biological pathways using the KEGG pathway tool 
is obviously highly dependant on the criteria used for selection of input genes. As described in 
Section 7.4.1.4, in our analysis, our input data comprised all genes which exhibited differential 
expression with an individual p value of <0.05 and fold change of greater than 2. Of these 1013 
genes, 810 were recognised by DAVID and used for further analysis.  
However, reanalysis using a more discrete dataset (comprising only those genes which show 
differential expression with an individual p value of <0.01 and fold change of greater than 2; a 
total of 217 genes), highlights enrichment of just two pathways: the cell cycle pathway again 
(EASE score, p=0.02; after Benjamini-Hochberg correction, p=0.86), and interestingly, the 
Notch signalling pathway (EASE score, p=0.05; after Benjamini-Hochberg correction, 
p=0.97)(see Figure 7-14). The Notch signalling pathway has been shown to be a key player in 
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HSC development, and also potentially the maintenance of quiescence, and as such is an 
intriguing target for further investigation367-370.   
 
Figure 7-14 KEGG generated figure showing the key genes involved in Notch signalling. Genes differentially 
expressed between HSCs from AML and control samples (fold change >2, EASE score p value <0.05) are highlighted 
with a star 
7.5.4.2 Are changes in gene expression limited to HSCs from CD34low AML samples, or are 
they mirrored across AML subtypes?  
If money and samples were not limited, I would view it as crucial to repeat this work using 
another panel of AML samples of an alternative subtype (such as (t(8;21) or inv(16)); sorting 
the AML and matched control samples, undergoing RNA extraction and then qPCR for the 
relevant genes of interest to see if such changes in gene expression are found in HSCs across all 
AML subtypes or simply limited to CD34low samples.   
7.5.4.3 Would single cell sorting and analysis of HSC transcriptomes yield more useful data 
than pooled cells?  
One fundamental remaining question is whether this approach of pooling HSCs and studying 
their transcriptomes en masse can lead to biologically meaningful data. For analysis, we have 
made the assumption that all the cells within the CD34+38-ALDHhighCLL1- subset have 
homogeneous transcriptomes, but this is highly unlikely to be the case. Cells are likely to be in 
different states of cycle, may represent different stages of lineage commitment and therefore 
will most likely have very different transcriptomes. By pooling their transcriptomes together 
for analysis, some significant changes in gene expression may well be lost.  
We remain interested in the possibility of single cell sorting of these populations and the study 
of transcriptomes on an individual cell level. If, for example, we sorted 100 single HSCs from 
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AML and control BMs, would the proportion of cells marking out an immature, quiescent 
phenotype be higher in those HSCs derived from an AML-exposed sample?  
We have been fortunate to begin collaboration with the Sanger Institute-EBI Single-Cell 
Genomics Centre to explore this particular question (see Section 8.2.3.3.1 for further details). 
However, exploring the effect of AML of HSC behaviour via this approach will have some 
limitations. The expense of this work will significantly limit the number of samples that can 
feasibly be analysed. Given the biological variability that we know exists between samples, are 
any meaningful conclusions likely to be drawn from the comparison of one or two biological 
replicates? We do not know the biological variability within the HSC subset, and therefore can 
only guess at the number of cells required to gain adequate representation of the potential 
diversity within this group. As discussed in Section 7.5.1.2, experts suggest that samples 
undergoing Single Cell Sorting need to be sorted and the resultant cells frozen within 8 
minutes: a time frame which we would be unable to achieve for the majority of samples (both 
control and AML). Finally, by sorting samples directly into wells, we are unable to confirm the 
accuracy of the sorting process by a retrospective purity check. Such checks are vital for the 
validity of any work involving the sorting of a rare population of cells, and in my experience 
during this thesis, approximately 20% of all samples (both AML and control) fell short of the 
required standards.  
7.5.4.4 Could the presence of pre-leukaemic HSCs alter the transcriptomes of AML-exposed 
HSCs generated from RNA-Seq?  
Recent work exploring the presence of a pre-leukaemic population of HSCs within selected 
AML samples, which carry early mutations associated with AML development, raises further 
pertinent queries regarding the work in this chapter. Such cells presumably have altered 
transcriptome profiles when compared to normal HSCs, as a result of their acquired mutations. 
If a difference in the transcriptomes between HSCs from AML samples and normal controls had 
been detected and validated from this RNA-Seq data, it might be difficult to assess if such a 
difference is related to the reversible effect of the AML on the normal HSCs, or due to the 
presence of pre-leukaemic cells within the sorted fraction.  
However, I would hypothesise this is unlikely to be a major problem for two main reasons. 
Primarily, the proportion of cells within the HSC population which carry pre-leukaemic 
mutations is relatively low107. Secondarily, the exact pre-leukaemic mutational profile will vary 
sample to sample, and therefore the effect of any individual mutation should be negated by 
the use of multiple samples.  
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 Do the transcriptomes vary between HSCs from AML exposed samples at diagnosis 7.5.4.4.1
and remission?  
One approach which would remove any uncertainty about the effect of pre-leukaemic HSCs on 
the transcriptomes of AML-exposed stem cells would involve making a comparison between 
HSCs extracted from diagnosis and remission samples from the same patient. For a patient to 
have regained remission, their blood counts must have recovered, and therefore HSC 
quiescence must have been reversed.  
Provisional work exploring the viability of such an approach was undertaken. Interestingly the 
separation of HSCs from AML remission bone marrows proved technically extremely 
challenging. Whereas we can normally identify 1000 to 2000 normal HSCs per vial from bone 
marrow samples taken at diagnosis from the tissue bank, in the 2 AML remission samples 
where separation of HSCs was attempted, only 50 CD34+38-ALDHhighCLL1- cells were obtained.  
This was a non-quantitative experiment, and to date we have not attempted to quantify the 
concentration of HSCs in remission marrows (via the techniques described in Chapter 5). The 
scarcity of HSCs in these samples would certainly fit with the often haemodilute appearances 
of bone marrow aspirates taken in first remission. Nevertheless, despite an apparently very 
small number of HSCs being present, they are clearly sufficient to have produced normal blood 
counts. This represents another line of evidence to suggest that the normal HSCs at diagnosis 
with AML are significantly functionally impaired.  
 
 Chapter 8: Discussion 
326 
Chapter 8 Discussion 
8.1 Summary of main findings  
In this thesis, I have attempted to study the interaction between AML and normal 
haematopoietic stem cells, and how this might result in the haematopoietic failure observed 
during the development of the disease.  
Starting from the group’s previous observations that HSC numbers at diagnosis with AML (at 
least with CD34low AMLs) appear preserved when compared to controls, I developed and 
validated a method of separating normal HSCs from all primary AML samples, irrespective of 
karyotype or genetic mutational status.  
Using this technique, I then proceeded to assess HSC numbers across a variety of diagnostic 
primary samples, and found that HSC numbers are relatively preserved in these too compared 
to controls. Further analysis of the AML samples suggested that there is a subgroup with a 
particularly low stem cell concentration at diagnosis. Low stem cell number at diagnosis 
appears to be predictive for a worse overall survival, an observation that may be independent 
of other prognostic factors such as age or cytogenetics.  
During validation work for the panel of antibodies for HSC separation, we also identified 
different functional behaviour patterns in HSCs dependant on the cytogenetics of the AML 
they were extracted from. HSCs derived from poor risk cytogenetics samples exhibited 
different in vitro behaviour, with relatively impaired growth over a 7 week culture period. This 
finding was not observed in patients with good or intermediate risk AML.  
We attempted to examine a cohort of patients who did not present with trilineage bone 
marrow failure, as these represent a group of patients whose pattern of presentation is 
difficult to explain with our theory of HSC quiescence. Analysis of a large database of Bart’s 
patients suggested that patients presenting with preservation of counts are rare. We were 
unable to identify patient factors which might influence presentation platelet count or 
haemoglobin, such as age, gender or cytogenetics. In all patients examined, mature cells 
appear to be of normal genetic origin, and not evolved from the leukaemia clone.  
As a side-project of potential therapeutic importance, we examined the effect of fluctuating 
CD33 expression on normal HSCs on exposure to AML, and the potential effect this might have 
on patients who received GO as therapy. We showed that the normal HSCs appear to have 
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significantly downregulated CD33 levels at diagnosis with AML, when compared to controls, 
which rapidly return to normal on remission.  
Why these changes occur remains unclear. We had hypothesised that a fluctuating level of 
CD33 might have therapeutic importance for HSCs in avoiding the toxic effects of targeted 
chemotherapy with the anti-CD33 antibody GO. However, results from an in vitro model 
designed to test the cytotoxicity of GO on normal HSCs separated from AML and control 
samples, suggested that GO did not appear to have a significant cytotoxic effect on either 
population. Nevertheless, at the time of writing, newer anti-CD33 agents (with different 
methods of cytotoxicity) are beginning human trials, and it will be interesting to see whether 
these have a more marked effect on the process of normal haematopoiesis.  
We attempted to address the mechanism by which AML functionally inhibits HSC activity. 
Normal HSCs from human primary diagnostic AML bone marrow samples were sorted, and 
their transcriptomes compared to HSCs from controls using RNA-Seq. An initial experiment 
produced a dataset of poor quality, due to the presence of a significance proportion of reads 
mapping to intronic DNA regions. This was thought to be due to a failure of selection of 
polyadenylated mRNA for cDNA synthesis during library production. Unsurprisingly, attempts 
to validate the observed differences in expression levels of six genes between the two HSC 
subtypes, by qPCR and flow based cytometry, revealed consistent statistically significant 
changes in CD33 expression only (by flow-based assessment of protein expression).  
Repeating the RNA-Seq experiment using column-based RNA extraction of sorted cells before 
the start of library preparation yielded data of significantly better quality (in terms of the 
proportion of reads mapping to exonic regions). Six genes of interest appeared to be 
differentially expressed between the two subgroups after correction was made for multiple 
testing. Enrichment analysis suggests there is an overepresentation in this dataset of genes 
involved in the TNF signalling and cell cycle control pathways. Unfortunately, due to time 
constraints at the end of my PhD, validation of these genes of interest by independent qPCR 
was not possible.  
8.2 Key areas for further experimental effort expanding on the work 
described within this thesis 
Although this work summarised in this thesis answered some of our questions about the 
interaction between normal HSCs and AMLs, it has also raised many, as yet unanswered 
queries. Planned experiments relevant to completed work have been described in detail on a 
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chapter by chapter basis. Below, I have summarised the key areas which I think would warrant 
further experimental effort in this field.  
 Does stem cell concentration at diagnosis with AML have an independent 8.2.1
prognostic impact?  
One of the most interesting findings from this project came from the quantitative analysis of 
bone marrow samples at AML diagnosis, namely that normal HSC concentration represents an 
independent prognostic marker for overall survival. However, discussed in Section 5.4.4.2.1, 
validation of these findings in an independent cohort of samples is required. We are currently 
in discussions with the Royal Marsden to see if such a collaboration is possible.  
Sample analysis for HSC concentration performed as described in Chapter 5.3 is a laborious 
process. It requires clinical staff to reserve the first aspirate of a diagnostic bone marrow 
sample for analysis, followed by speedy transport to the laboratory to facilitate analysis within 
24 hours. Staining and flow based analysis is time-consuming, requiring three to four hours per 
sample. As such, even if HSC concentration at diagnosis did carry prognostic significance, one 
wonders about its utility as an assay in general clinical practise.  
One approach currently being considered (D Taussig, personal communication) is the analysis 
of peripheral blood taken at the time of diagnosis for HSC concentration, rather than bone 
marrow. Supplies of blood from patients at diagnosis are much more plentiful, and presumably 
do not suffer from the same issues of haemodilution as bone marrow (assuming they have 
been taken before transfusion). Normal HSCs are easily identifiable in the peripheral blood of 
patients with AML65.  
The most obvious flaw of this approach is that there is no evidence at present that the 
concentration of HSCs in peripheral blood is proportional to that seen in bone marrow. 
Intuitively, it seems more logical that if normal HSCs are excluded from their niche 
environment by AML infiltration, they might be more likely to leave the bone marrow and 
enter the peripheral circulation. 
 Do poor risk karyotype AMLs exert a different effect on normal HSCs to good 8.2.2
or intermediate disease samples, as suggested by their different behaviour in 
vitro?  
One of the most intriguing and unexpected findings of this PhD is that HSCs extracted from 
different karyotypic subtypes of AML appear to exhibit different behaviour in vitro, with a 
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failure to grow in 7 week LTC being much more likely in those from poor risk AMLs than others. 
As discussed at length in Chapter 4, there are a number of factors which might explain this 
observation, from difficulty in flow-separating HSCs from AML in this setting; to a “normal” 
HSC population which might be functionally impaired from a heavy pre-leukaemic mutation 
burden; to poor risk AMLs having a more marked inhibitory effect on normal HSCs by nature of 
differential cytokine secretion.   
This group of samples might prove technically challenging to work with in the laboratory, but 
they are derived from the very patients (with slow-growing, chemoresistant disease) who 
might have the most to gain from a therapeutic reversal of inhibition of normal 
haematopoiesis.   
It is clear that a larger cohort of samples need to be investigated to see if these findings are 
consistently reproduced. It would also be interesting to see if the failure of normal HSC growth 
in 7 week LTC is recapitulated in the gold-standard test of stem cell function, the mouse 
xenograft model.   
It is hoped that these experimental approaches might be included in a current ongoing 
multicentre funding application, targeted at improving our understanding of the biology of 
poor risk karyotype AML samples.   
 What is the mechanism of BM suppression in AML?  8.2.3
From a clinical perspective, the most important aspect of this project is the attempts to 
understand how AML induces quiescence in normal HSCs. If this process was understood, and 
a signalling pathway amenable to therapeutic modification identified, it might provide us with 
the means of rebooting normal haematopoiesis. However, this process has proven 
frustratingly elusive.   
8.2.3.1 Technical considerations with HSC work  
Working with HSCs extracted from primary samples poses significant laboratory challenges, 
which I have come to fully appreciate over the last three years! The most significant of these is 
the limited number of cells contained within each biological sample, which precludes the use 
of the majority of laboratory techniques used in signalling work, including western blotting, 
ELISAs or even mass spectrometry.   
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8.2.3.2 Considerations with the use of Primary AML diagnostic BM samples  
This project has almost entirely focussed on the use of primary human samples of diagnostic 
AML BM. The work would not have been possible without the excellent storage facilities 
provided by the Bart’s Tissue Bank.  
Whilst primary samples represent the only really valid material available for studying the 
interaction of normal haematopoietic cells with AML, their use does raise some interesting 
challenges. One key issue is marked inter-sample heterogeneity: not just between AML blasts 
of different karyotypes, but also within the normal HSC population. This is also the case within 
the control samples, where the HSC populations vary widely in both concentration and 
transcriptome analysis. Whilst recognising such biological variability is crucial, for experimental 
work to reach significant findings, this requires the analysis of a large number of samples, 
which is both time consuming and costly.  
Secondarily, we recognise there is not only heterogeneity between the HSCs of different 
samples, but also most probably, within the CD34+CD38- population of an individual sample.      
8.2.3.3 Transcriptome Analysis  
We have utilised transcriptome analysis as a surrogate marker of signalling pathway activation, 
as current techniques are sufficiently sensitive to allow study of tiny cell populations.  
Whole transcriptome analysis such as that provided by RNA-Seq is a useful approach for 
producing a selection of candidate differentially expressed genes within the HSCs from AML 
samples. The second RNA-Seq experiment comparing the transcriptomes of normal HSCs 
sorted from AML and HSC samples has revealed 6 genes of interest are significantly 
differentially expressed between the groups. KEGG pathway analysis suggested gene 
enrichment within the cell cycle and TNF signalling pathways.  
Validation of these results is required as a first step, but it would be of interest to explore 
functionally whether these genes have any effects on HSC quiescence or differentiation. As 
already mentioned in the relevant chapter, it would also be useful to explore whether the 
same genes are differentially expressed (using targeted qPCR) between HSCs extracted from 
AML samples of a different subtype (such as t(8;21) or inv(16)). 
 Single Cell Transcriptome Analysis 8.2.3.3.1
The functional, and presumably transcriptional, heterogeneity of cells within the CD34+38- 
compartment of bone marrow of both AML and normal BM samples may limit the detection of 
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genes whose expression are significantly modulated in a subset of cells. However, modern 
approaches of single cell sorting and subsequent massively parallel single cell RNA-Seq provide 
a means of addressing this issue24.  
Our group has tentatively begun exploring such approaches. The CD34+38-ALDHhighCLL1low cells 
from one poor risk AML sample (ID 7820) were sorted into two 96 well plates at the BCI Flow 
laboratory using the BD FACSAriaTM Fusion sorter. These cells underwent successful cDNA 
synthesis and amplification in Cambridge, in collaboration with the Sanger Institute-EBI Single-
Cell Genomics Centre. Amplified cDNA suitable for subsequent library preparation was 
produced in 60% of wells. Library preparation prior to sequencing is still ongoing, but it is 
hoped that comparative analysis of the transcriptomes of HSCs from AML and control cells 
might identify different cell populations present within the broader CD34+38-ALDHhighCLL1- 
gate. 
Exciting as this technique is, even this first preliminary experiment raised some technical 
challenges. In order to maintain cell integrity prior to processing, we were advised to sort cells 
only once from the stained sample. As a result, there was no opportunity to check the 
performance of the sorter, by checking the purity of the sorted population of cells before 
processing. This is key when separating out HSCs from leukemic samples, due to their relative 
rarity when compared to blasts. Secondarily, we were also advised to limit the time of sorting 
to approximately 8 minutes per 96 well plate, to maintain RNA integrity. This significantly limits 
the number of samples which could be processed in this fashion; as such a rate of sorting 
(from an AML sample) is only achievable in one with a high normal HSC concentration.   
8.2.3.4 Targeted Cytokine Analysis  
The initial findings of Broxmeyer over 30 years ago suggested that AML was capable of causing 
growth inhibition of HSCs via a diffusible factor133. Although hypoxia60, metabolite availability 
or even microRNA secretion148 might be responsible for this effect, an obvious alterative is that 
cytokines (secreted either directly from AML cells or from altered stromal cells) might be 
modulating stem cell behaviour. A number of cytokines such as thrombopoietin58 or 
angiopoietin57 have already been shown to have a role in cell cycle regulation and 
differentiation of HSCs.  
To my knowledge, systematic assessment of the cytokine milieu within samples of AML bone 
marrow in comparison to controls has not been performed, although I note a similar 
assessment has been made on peripheral blood samples371.  
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As there exists a significant number (15 to 30) cytokines of interest to study, and the available 
volume of bone marrow would be too small to facilitate more than 2 or 3 ELISA assays per 
sample, I would propose using a technique such as the BD Multiplexed Bead-Based 
Immunoassay, which enables parallel identification of specifically designed panel of proteins, 
by bead-tagged antibodies.  
For the last two years, I have been collecting the supernatant of bone marrows from newly 
diagnosed AML and control patients, which have been stored at -196oC (see Section 2.2.4). 
These would provide an excellent repository of samples to test using the kit described above.  
8.2.3.5 Mass Cytometry  
Towards the end of this PhD project, Bart’s obtained a CyTof II analyser (Fludigm), which gave 
the possibility of mass cytometry experiments. Antigens (both intra and extracellular) on cells 
are labelled with antibodies tagged to rare metals. Cells are then nebulised, and the resultant 
particles ionised by the action of an argon laser, which are subsequently analysed by a time-of-
flight mass spectrometer372.  Although similar in some ways to flow cytometric analysis of cells, 
the use of rare metals to tag antibodies rather than fluorochromes means that a comparatively 
huge number of targets (upwards of 30) can be studied simultaneously on the same sample373. 
The constraints of spectral overlap mean vastly fewer targets can be studied on HSCs via 
standard flow cytometry374.  
This approach has clear applications to this field: if appropriate antibodies were available, 
given the rarity of the HSC population, CyTof analysis might provide an efficient mechanism of 
simultaneously validating a large number of protein based targets.  
However, there are some limitations. Currently, the range of available labelled antibodies is 
relatively small (although rapidly expanding). Antibodies are expensive, and the process of 
sample analysis time consuming. Whilst flow cytometry is well established enough for there to 
have developed a consensus about where an HSC population might lie, these parameters have 
yet to be established for analysis with mass cytometry based analysis. Finally, and perhaps 
most significantly, there is no possibility of follow-on functional work after cell analysis, as by 
definition during processing, the cells are destroyed.   
8.2.3.6 Attempts to develop an in vitro model of the interaction of normal HSCs and AML 
cells  
We have been hampered in our search for the factor(s) responsible for AML-induced HSC 
quiescence by the lack of a functional in vitro model of the interaction of the two cell types.  
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As mentioned in Section 7.1.1.1, both our laboratory and Prof Bonnet's at the LRI have 
developed an in vitro model which involved the culture of AML cells and HSCs together in the 
presence of a feeder stromal line. After ten days in co-culture, the effect of AML on the HSC 
population was assessed by proxy of their incorporation of BRDU over the test period.  
Although this assay had initial promise, the replicability of results proved poor. During this 
PhD, I attempted this assay a number of times, modulating conditions such as the source of 
HSCs (cord and GMPB); the flow based selection criteria of HSCs (CD34+ versus CD34+38-); the 
type of feeder cell lines (MS5 versus HS5); normoxia versus hypoxia; degree of contact 
between cell types (transwell versus no separation), and method of assessing proliferation of 
HSCs (BRDU incorporation versus Ki67). Unfortunately none of these modifications improved 
the assay’s reliability. For completeness, a summary of the basic method is included in 
Appendix 2.   
In the last few months, I have made some tentative attempts to develop another in vitro 
model of bone marrow suppression: this time growing sorted HSCs in 7 week LTC, but exposing 
the cells on a weekly basis to AML-conditioned media to see if this impacted their colony-
forming ability. At the time of writing, this had not reproducibly recapitulated an inhibitory 
effect on normal HSCs. However, there are many possible steps to hone the original protocol 
(which is given in Appendix 2), and given time, I would consider this worth further exploration.  
8.3 New avenues for further research in the broader field of malignancy-
associated bone marrow failure 
During the writing of this thesis, a number of new avenues for further research into the effect 
of AML on the normal haematopoietic process presented themselves. I have summarised 
below the directions I would be most interested in taking in the future. 
 How does the mechanism of AML–associated bone marrow failure compare 8.3.1
with that seen in other malignancies?  
This project focussed very specifically on the interaction of AML with normal bone marrow, or 
more specifically, the HSC population within it. However, failure of haematopoiesis is not 
simply a phenomenon observed in AML: although clinical experience suggests it is synonymous 
with AML development, it also occurs with other haematological diseases such as ALL, the 
chronic leukaemias, myeloma and lymphomas (with significant bone marrow involvement), as 
well as several forms of metastatic carcinoma. 
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Historical interest in the BM failure seen in AML dates back over 30 years to the initial 
observations of Broxmeyer, who noticed an effect on normal haematopoietic colony growth by 
an apparently diffusible factor secreted by AML cells.  
The cause of haematopoietic failure in these other conditions has to date not been perfectly 
mapped out. In multiple myeloma, roles for hepcidin, BMP2375, Fas-L376, TRAIL377 and TGFβ 
signalling298 in inducing cytopenia have been described. In a Science paper, showing the ability 
of pre-B ALL to alter the stem cell niche in a manner that affected homing behaviour of normal 
HSCs, Colmone et al also described the observation of similar changes in primary human AML 
bone marrow samples378.   
It is interesting to hypothesise as to whether the mechanism of bone marrow failure seen in 
these related conditions is universal, or occurs by disease-specific pathways. Is the 
concentration of normal HSCs preserved in the same fashion as with AML?  
In some ways, investigating the effect of AML on bone marrow is potentially more complex 
than other malignancies, because of the phenotypic similarities between HSCs and myeloid 
blasts. However, if a clear (and reversible) mechanism could be identified for the BM failure 
seen in AML, this might have therapeutic possibilities that extend beyond this patient group.  
 Does AML just affect HSCs, or does it modulate other levels of normal 8.3.2
haematopoiesis?  
This project has focused very specifically on the effect of AML on HSCs, defined by flow criteria 
as either CD34+CD38- or CD34+CD38-ALDHhighCLL1- cells. In Section 5.5.2.3, I have discussed that 
this separation is a simplification, with this group containing cells at various stages of lineage 
commitment and proliferative potential.  
However, it cannot be assumed that AML directly affects normal HSCs only. Might blasts also 
directly influence the behaviour of committed progenitors, or even mature cells belonging to 
the granulocytic, erythroid and megakaryocytic lineages? Previous work suggested that the 
concentration of progenitor cells (defined by CD34+CD38+) fell significantly at diagnosis with 
AML, an observation attributed to a reduction in HSC maturation1. Investigating whether AML 
directly affects these populations is not straightforward: their concentrations in AML BMs are 
extremely small, and reliable separation from AML blasts might prove challenging (for 
example, ALDH expression patterns would not help, as normal progenitors are often ALDH 
intermediate or low expressing cells).  
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 Is the effect of AML on normal HSCs the same irrespective of AML subtype?  8.3.3
AML is extremely heterogeneous disease, characterised by a range of phenotypic appearances 
and caused by a variety of distinct, recurring cytogenetic and genetic abnormalities. 
Nevertheless all of these different subtypes of disease appear to have a similar propensity to 
cause haematopoietic failure (with the exception of APML, which is associated with more 
marked thrombocytopenia at diagnosis, as discussed in Section 3.4.1.3.4). Similarly, we have 
shown that HSC concentrations at diagnosis are preserved across disease subtypes. Therefore, 
can we assume that the mechanism which causes HSC quiescence across all AML subtypes is 
the same?  
At the time of writing, although we lack evidence, I would hypothesise that the basic 
mechanism responsible for HSC quiescence is preserved across AML subtypes. Despite the 
suggestion of transcriptome heterogeneity between HSCs extracted from different subgroups 
(see Chapter 7), such a universal effect seems unlikely to be caused by an acquired mutation or 
new signalling pathway, as there is no one genetic mutation (at least not to date) found across 
all AML subtypes102,196. I would favour the idea that the normal HSC quiescence seen is a 
subversion of the normal pathway of homeostasis: either as a result of negative feedback to 
HSCs to which they are sensitive, out-competition for niche space; relative hypoxia, or possibly 
the effect of a pro-inflammatory state in the bone marrow microenvironment.  
 Are the effects of AML limited to normal haematopoiesis precursors, or does it 8.3.4
have the ability to modulate the micro environmental stromal environment?  
In this project, we have solely investigated the effect of AML on normal haematopoietic stem 
cells, and have not investigated its effects on the stromal microenvironment. Nevertheless, 
this interaction might be key: appropriate stromal support is required for HSCs to maintain a 
state of protected quiescence in the bone marrow, and if AML is able to modulate these 
pathways, these indirect effects may well prove as important as those exerted directly on stem 
cells. Key experiments in this area are found summarised in Section 1.5.3. 
 What does “normal” mean in the context of HSCs anymore anyway? 8.3.5
One of the key developments in the field of AML biology since I started this PhD is the 
discovery via high-throughput sequencing of the existence of pre-leukaemic stem cells. These 
cells appear functionally normal, but contain early mutational events that are present within 
the associated leukaemic clone107,151. This has enabled the study of the evolutionary pathway 
of successive mutations required for leukaemia development, but also raises a key question of 
just how normal are “normal” HSCs in this context? It also has practical relevance for the work 
 Chapter 8: Discussion 
336 
summarised within this thesis, where the presence of a molecular mutation at low level within 
a sorted population of cells has been taken as a surrogate marker for leukaemia contamination 
of normal cells. This might prove to be an oversimplification if the mutation in question is also 
found as part of the pre-leukaemic clone.     
Nevertheless, I would argue strongly that the discovery of cells with early mutational events by 
no means invalidates the importance of studying normal haematopoiesis in this context. The 
papers published to date in this area reveal only a small proportion of normal HSCs within the 
bone marrow to contain mutations. For example, Shlush et al studied the HSC fraction of 12 
DNMT3A mutated AML samples for the presence of the AML-associated mutation. The 
observed mutated allele frequency varied between 0 and 69%, with 75% of samples having an 
observed allele frequency of less than 30%107. A significant proportion of patients go on to 
achieve a life-long remission after chemotherapy, suggesting either that progression of pre-
leukaemic mutations is not an inevitable process, or that they are not found in all patients. 
8.4 Final comments   
This PhD project attracted me when I was looking for research projects for a number of 
reasons. I was interested in both AML and stem cell biology. I liked the way this project 
approached AML from what seemed like an entirely new perspective: looking at the effect on 
normal haematopoietic cells, rather than solely focussing on the biology and behaviour of 
blasts.  
Research progress over the last 30 years has resulted in us understanding vastly more about 
the genetic structure of AML and its disease evolution. We can use this knowledge to offer 
patients much more sophisticated prognostics at diagnosis. However, all clinicians are in 
agreement that clinical treatment has not advanced at the same rate, and that new treatments 
(both in terms of general approach and specific targeted therapy) are desperately required to 
improve outcomes.  
The idea that in reversing the effect on normal bone marrow might somehow push the 
evolutionary pathway back a little in favour of normality is very appealing. Reversal (albeit 
probably temporary) of the cytopenias observed in AML has enormous palliative potential. It is 
hoped in the future this might be achieved. 
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Appendix 1: Stock Solutions  
Manufacturers’ Details  
4’, 6-Diamidino-2-phenyindole (DAPI)   Sigma, Cat: D9564 
Dulbecco’s Modified Eagle’s Medium (DMEM)  Sigma, Cat: D6046  
Dulbecco’s Phosphate Buffered Solution (PBS)   Sigma, Cat: D8537 
Ethanol Absolute, 200 Proof     Sigma, Cat: E7023-500 
Fetal Bovine Serum (FCS)     Gibco, Cat: 10500-064   
Iscove’s Modified Dulbecco’s Medium (IMDM)   Gibco, Cat: Z1980-032 
LymphoprepTM       Fresnius, Cat: 2015-06 
MethoCult H4435     Stem Cell Technologies, Cat: 04435 
MyeloCult H5100     Stem Cell Technologies, Cat: 05100 
Streptomycin/Penicillin     Sigma, Cat: P4333 
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Stock Solution Preparation  
Activated AldefluorTM Reagent:  50µg dry inactive AldefluorTM Reagent (Stem Cell 
Technologies, Cat: 01703) was dissolved in 25µl DMSO (Stem Cell Technologies, Cat:  01706) at 
room temperature. After 1 minute, 25µl 2N Hydrochloric acid (Stem Cell Technologies, Cat: 
01704) was added and the mixture left at room temperature for 15 minutes. 360µl AldefluorTM 
Assay Buffer was added to the vial and mixed prior to storage at -20oC.     
ALDH/DNase/DAPI: To 10ml AldefluorTM Assay Buffer, 100µl DNase and 5µl DAPI were added.  
DAPI Stock 500µg/ml: To 10mg DAPI (Sigma, Cat D9564), 400µl of water was added to make a 
primary stock of 25mg/ml. A secondary 1/50 dilution was made by adding 100 µl of primary 
stock to 4.9ml of water, to make the used stock of 500µg/ml. 500µl aliquots were stored at -
20oC.   
DNase: One vial of DNase (Sigma, Cat: D4513) was suspended with 11ml of PBS, mixed well 
and left to dissolve for 20 minutes. Resultant 500mcl aliquots were frozen at -20oC. 
2% HAG: 1g Human γ-globulins (Sigma, Cat: G4386) was mixed with 50ml PBS, and left to 
dissolve for 30 minutes at room temperature. The resultant solution was filtered through a 
0.22µm Millex GP Filter Unit to remove undissolved matter, and aliquoted into 500mcl 
aliquots. These were stored at -20oC.  
2% HAG dissolved in ALDH Buffer: As above, but 50ml PBS was replaced by 50ml AldefluorTM 
Assay Buffer (Stem Cell Technologies, Cat: 01702).      
2% PBS: One 500ml bottle of PBS (Sigma, Cat: D8537) was mixed with 10ml FBS (Gibco, Cat: 
D6046) and 5ml Streptomycin/Penicillin (Sigma, Cat:  P4333). 
2% PBS/DNase/DAPI: To 10ml 2% PBS, add 100µl DNase and 5µl DAPI.  
10mM Tris HCL: 0.788g Trizma-HCl (Sigma, Cat: T5941) diluted in 500ml Millipore water. Ph 
adjusted to 8.0 using buffers. 
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Appendix 2: Methodology for the AML-Stem Cell Co-Culture 
Assays  
App 2.1 The 10 day in vitro co-culture assay   
This is a functional assay designed to model the interaction between stem cells and AML in 
vitro. This assay was originally developed by Dr D. Taussig and Dr F. Anjos-Afonso at the LRI. 
Stem cells are grown in co-culture with AML cells, in the presence of a feeder layer of 
irradiated stem cells. After 10 days in culture, the divisional status of the stem cells (as 
measured by their incorporation of the BRDU dye) is determined, and compared to controls. 
No results from this assay are included in this thesis, but for completeness the protocol is 
included here.  
App 2.1.1 Feeder Cell Layer Preparation 
MS5 cells were plated into a 24 well plate in IMDM media, at a concentration of 40,000 cells 
per well in a total volume of 600μl. Cells were incubated at 37oC; 5% CO2. After 48 hours in 
culture, the plate was irradiated at 7.5Gy. Two hours post irradiation, the well media was 
changed to H5100 MyelocultTM (Stem Cell Technologies).   
App 2.1.2 Addition of AML cells 
The following day, primary AML samples (normally samples obtained from leucophoresis of 
AML patients at presentation, rather than BM) were thawed, washed and resuspended to a 
concentration of 12x106 cells/ml. 720,000 cells were added to each well, to give an AML cell 
concentration of 1.2x106 cells). Care was taken that the volume of the added AML cells did not 
exceed 10% of the total well volume.  
App 2.1.3 Normal Stem Cells  
App 2.1.3.1 Selection of Stem cells  
24 hours later, stem cells were added to the system. Previously lineage-depleted GMPB 
samples were thawed, washed and stained with CD34 as previously described. CD34+ cells 
were sorted as previously described under sterile conditions using the BD Aria Cell Sorter. The 
resultant cells were then stained using the CellVue Maroon cell labelling kit (eBiosciences 
880870), in a technique modified for small cell numbers described below.  
App 2.1.3.2 Stem cell Labelling  
Sorted CD34+ cells were spun (1500 rpm, 10 minutes), supernatant aspirated off and cells 
resuspended in 3ml RPMI, and spun (1500 rpm, 6 minutes). Meanwhile, a 2x working dye 
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solution was prepared by adding 1μl of dye to 250μl Diluent. The supernatant was aspirated, 
and cells resuspended in 250μl Diluent C. The cells were then added to the 2x dye solution, 
and immediately mixed by uniform pipetting. The cells were then incubated for 2 to 5 minutes 
at room temperature. Staining was stopped by the addition of 500μl FCS, and samples rested 
for 1 minute. 3ml of RPMI with 10% FCS was then added, and the sample centrifuged (6 
minutes, 1500rpm). Sample was washed 3 times with 4ml 10% RPMI. The cell were then 
resuspended in 500μl of 10% RPMI, and cell numbers counted using a haemocytometer as 
previously described.   
BRDU (BD, Cat 559619) was diluted from stock to a concentration of 1mM per ml (31μl stock 
to 1ml PBS). 6μl was added to each well to produce a working concentration of 10μM.  
Cells were then added to the wells (to a maximum of 5000 cells per well) in a small 
(approximately 10μl) volume. The plate was returned to the incubator for a further 6 days at 
37oC.  
App 2.1.4 Processing of Cells prior to Analysis 
On Day 11 of the assay, wells were visually inspected under the microscope to assess cellular 
proliferation. The contents of each well were pipetted into a new labelled test tube. Each well 
was washed with 700μl of PBS, and the contents added to the collection tube. Adherent cells 
were removed by the addition of 700μl trypsin, followed by incubation at 37oC for 15 to 20 
minutes. The contents were transferred into the appropriate tube. The wells were then 
washed again with PBS as described.  
After centrifugation, cells were resuspended in 1ml Fixed Viability Dye (Fixable Viability Dye 
eFluor 780, eBioscience 65-0865-14, APCCy7) (the dye having been prediluted to a ratio of 1μl 
dye: 1ml PBS), and incubated at 4oC for 30 minutes. Cells were washed in 3ml 2% PBS, 
centrifuged (1300 rpm, 6 minutes), and the supernatant discarded. 5µl CD45-PE (BD, 555483) 
and 1μl Sca-1-Pecy7 (BD, 558162, Clone D7) were added to each tube, and cells incubated at 
room temperature for 15 minutes. Cells were washed in 4ml 2% PBS, centrifuged (1300rpm, 6 
minutes), and supernatant discarded. 
Cells were then fixed as follows. Cells were resuspended with 100µl BD Cytofix/Cytoperm 
buffer (BD, 51-2090KZ), and incubated at room temperature for 15 minutes. Cells were then 
washed in 1ml PermWash buffer (BD 51-2091KZ), and centrifuged (1400rpm, 6 minutes). Cells 
were then resuspended in 100µl BD Cytoperm Plus buffer (BD, 51-2356KC), and incubated on 
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ice for 10 minutes. 1ml PermWash buffer was then added, and cells centrifuged (1400 rpm, 6 
minutes). Cells were then resuspended in 100µl BD Cytofix/Cytoperm buffer, and incubated at 
room temperature for 5 minutes. 1ml PermWash buffer was then added, and cells centrifuged 
(1400rpm, 6 min). Cells were then resuspended with 100µl dilute DNase (made of 300μl STOCK 
DNase and 700 µl PBS), and incubated at 37oC for 1 hour. 1ml PermWash buffer was then 
added, and cells centrifuged (1400rpm, 6 minutes). 15µl of anti-BRDU FITC antibody (BD, 
556028) was added, and the tubes incubated at room temperature for 20 minutes. 1ml 
PermWash buffer was then added, and cells centrifuged (1400rpm, 6 minutes). Cells were 
resuspended in 300μl of a 1μg/ml DAPI/2% PBS solution. Cells were then incubated at 4oC for 
at least 20 minutes prior to FACS analysis.  
App 2.2. The 7 week in vitro conditioned media assay  
App 2.2.1 Introduction 
This was an attempt to develop an in vitro method of the interaction between normal HSCs 
and AML, with a modification of the 7 week culture assay. At the time of design, I hoped it 
might reflect the effect of AML on the long-term repopulating HSCs, rather than the 10 day co-
culture assay described above, which must largely reflect the activity of the short term 
repopulating cells.  
Rather than co-culture of AML and HSCs, this assay tests the effect of media conditioned by 
AML on the growth of HSCs over 7 weeks. This approach is based on the work of Broxmeyer, 
who reported that normal HSCs were inhibited by the apparent secretion of a diffusible factor 
from AML cells, and that this interaction did not require cell-cell contact. If AML cells and HSCs 
were truly co-cultured together in a 7 week culture assay, it would be impossible to assess the 
source (normal or malignant) of any visible colonies at the end of this period. Secondarily, as 
discussed at length in Chapter 4, different AMLs grow very differently in a 7 week culture assay 
(with good risk disease patients appearing to grow less well), and therefore any inhibition 
effect might fluctuate significantly over the 7 week culture period.  
The significance of the media being conditioned by AML (rather than the same numbers of 
non-malignant cells) was tested for by the use of a control media conditioned by GMPB cells 
plated at the same concentration.   
App 2.2.2 Plate set up    
A 96 well flat bottom cell culture plate (Costar, Cat: 3598) was coated with collagen using the 
following method. 50µl of Collagen Solution (Stem Cell Technologies, Cat: 04902) was added to 
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each well, and left to dry for 2 minutes before the excess collagen was removed. The plate was 
left open under a hood to dry for at least an hour. Subsequently, each well was washed with 
100µl PBS.  
App 2.2.3 MS5 preparation  
MS-5 cells were prepared at a concentration of 1x106 cells/ml in IMDM/10% FCS, and placed in 
a 50ml Falcon Tube. The cells were irradiated at a dose of 70Gy (RadSource 2000, X-ray 
emitter). Cell viability one hour post-irradiation was assessed using a Beckmann Coulter Vicell 
XR Cell Viability Counter.  
App 2.2.3.1 MS5 plating for LTC 
Cells were pelleted, and re-suspended in MyeloCultTM H5100 (Stem Cell Technologies, Cat: 
05100) to a concentration of 125,000 cells/ml. 100µl of cell/H5100 suspension was added to 
60 wells per plate, having filled the outside wells with 100µl water.  
App 2.2.3.2 MS5 plating for AML & GMPB Culture 
At the same time, after MS5 irradiation, MS5 cells were resuspended in MyelocultTM H5100 to 
a concentration of 66,666 cells/ml. 2.4 ml of cell/H5100 suspension was added to each well of 
a 6 well plate (Costar, 6 well cell culture plate, cat 3506).  
App 2.2.4 AML and GMPB cells plated for preparation of conditioned media  
Primary cells from an AML known to grow in culture were taken and GMPB were thawed, 
washed and counted as previously described. Cells were plated into a 6 well plate, previously 
coated with MS5 cells as detailed above.  Cells were added to a concentration of 1.5x106 cells 
per well.  
Plates were then placed in a long term incubator at 37oC, 5% CO2 for 3 days. At the end of this 
period, cell growth was confirmed by visual examination of the wells. Media was removed by 
pipette and filtered through a 0.22μm diameter pore membrane to remove cells (Millex GP, 
Cat SLGV033RS). Media was snap frozen at -80oC .  
App 2.2.5 HSC sorting and plating  
The following day, CD34+38- HSCs were sorted as previously described from a GMPB sample. 
Cells were pelleted (1500rpm, 10 minutes), diluted and then plated in serial dilutions of 40, 20, 
10, 5 and 2 cells per well. A maximum additional fluid volume of 10µl per well was added. 20 
replicates for each cell dilution were added. 
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The entire experiment was set up in triplicate to allow for comparative testing of the effects of 
AML-conditioned media, GMPB-conditioned media, and unconditioned media (positive 
control) on HSC growth.  
App 2.2.6 Plate Management weeks 2 to 5 
The plates were then placed in a long term incubator at 37oC, 5% CO2. Weekly, from Week one 
to four, the media was changed as followed. Taking care to not disturb the bottom of each 
well, 65µl of media was removed from the top of each well using a multichannel pipette. This 
was replaced with 75µl of MyeloCultTM H5100, which was pre-prepared as a mastermix of 40µl 
fresh MyelocultTM 5100 and 35µl thawed conditioned (either by AML or GMPB) MyelocultTM. In 
the third set of plates, media changes were made with 75µl of unconditioned media.  
At the end of week five of culture, the media was removed from each well, using a Gilson Safe 
Aspiration Station, having taken care not to disturb the 10 to 20µl at the bottom of each well. 
Using a Gilson Distriman pipette, 100µl of MethoCult H4435 enriched Methylcellulose medium 
was added to each well, and the plates returned to the incubator. After a further two weeks 
culture at 37oC, each individual well was examined for the presence of myeloid and erythroid 
colonies and scored as positive or negative. An initial stem cell concentration was calculated 
using the ELDA limiting dilution assay analysis for each condition. 
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Appendix 3: Genes with significantly altered expression between 
AML-exposed and Control HSCs, as detected by RNA-Seq 
Attempt 1 
Table App 3-1 Genes upregulated in HSCs from Controls versus AML (Fold change >2; p<0.05) 






ENSG00000090104 RGS1 regulator of G-protein signalling 1 3.23 0.0179 1.00 
ENSG00000105383 CD33 CD33 molecule 2.98 0.0046 1.00 
ENSG00000163564 PYHIN1 pyrin and HIN domain family, member 1 2.91 0.0280 1.00 
ENSG00000187626 ZKSCAN4 zinc finger with KRAB and SCAN domains 4 2.90 0.0026 1.00 
ENSG00000239998 LILRA2 
leukocyte immunoglobulin-like receptor, 
subfamily A (with TM domain), member 2 
2.87 0.0027 1.00 
ENSG00000167920 TMEM99 transmembrane protein 99 2.86 0.0119 1.00 
ENSG00000188000 OR7D2 
olfactory receptor, family 7, subfamily D, 
member 2 
2.85 0.0256 1.00 
ENSG00000169908 TM4SF1 transmembrane 4 L six family member 1 2.85 0.0178 1.00 
ENSG00000197128 ZNF772 zinc finger protein 772 2.79 0.0090 1.00 
ENSG00000133574 GIMAP4 GTPase, IMAP family member 4 2.76 0.0069 1.00 
ENSG00000186603 HPDL 4-hydroxyphenylpyruvate dioxygenase-like 2.67 0.0005 1.00 
ENSG00000169515 CCDC8 coiled-coil domain containing 8 2.59 0.0407 1.00 
ENSG00000173114 LRRN3 leucine rich repeat neuronal 3 2.59 0.0010 1.00 
ENSG00000157542 KCNJ6 
potassium channel, inwardly rectifying 
subfamily J, member 6 
2.44 0.0311 1.00 
ENSG00000109163 GNRHR gonadotropin-releasing hormone receptor 2.42 0.0103 1.00 
ENSG00000180938 ZNF572 zinc finger protein 572 2.41 0.0046 1.00 
ENSG00000143248 RGS5 regulator of G-protein signalling 5 2.39 0.0027 1.00 
ENSG00000105374 NKG7 natural killer cell granule protein 7 2.39 0.0412 1.00 
ENSG00000133636 NTS Neurotensin 2.38 0.0076 1.00 
ENSG00000021826 CPS1 
carbamoyl-phosphate synthase 1, 
mitochondrial 
2.37 0.0239 1.00 
ENSG00000179933 C14orf119 chromosome 14 open reading frame 119 2.37 0.0006 1.00 
ENSG00000117228 GBP1 
guanylate binding protein 1, interferon-
inducible 




2.34 0.0377 1.00 
ENSG00000144339 TMEFF2 
transmembrane protein with EGF-like and 
two follistatin-like domains 2 
2.32 0.0160 1.00 
ENSG00000173452 TMEM196 transmembrane protein 196 2.29 0.0165 1.00 
ENSG00000147206 NXF3 nuclear RNA export factor 3 2.28 0.0074 1.00 
ENSG00000159640 ACE angiotensin I converting enzyme 2.20 0.0002 1.00 
ENSG00000145723 GIN1 gypsy retrotransposon integrase 1 2.20 0.0287 1.00 
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ENSG00000184730 APOBR apolipoprotein B receptor 2.18 0.0489 1.00 
ENSG00000099330 OCEL1 occludin/ELL domain containing 1 2.18 0.0146 1.00 
ENSG00000189057 FAM111B 
family with sequence similarity 111, member 
B 
2.17 0.0132 1.00 
ENSG00000238227 C9orf69 chromosome 9 open reading frame 69 2.15 0.0385 1.00 
ENSG00000119328 FAM206A 
family with sequence similarity 206, member 
A 
2.14 0.0254 1.00 
ENSG00000228623 ZNF883 zinc finger protein 883 2.13 0.0186 1.00 
ENSG00000185112 FAM43A 
family with sequence similarity 43, member 
A 
2.11 0.0079 1.00 
ENSG00000106013 ANKRD7 ankyrin repeat domain 7 2.10 0.0256 1.00 
ENSG00000108679 LGALS3BP 
lectin, galactoside-binding, soluble, 3 binding 
protein 
2.09 0.0043 1.00 
ENSG00000196290 NIF3L1 NIF3 NGG1 interacting factor 3-like 1 2.07 0.0145 1.00 
ENSG00000152782 PANK1 pantothenate kinase 1 2.06 0.0232 1.00 
ENSG00000137860 SLC28A2 
solute carrier family 28 (concentrative 
nucleoside transporter), member 2 
2.06 0.0464 1.00 
ENSG00000198128 OR2L3 
olfactory receptor, family 2, subfamily L, 
member 3 
2.06 0.0404 1.00 
ENSG00000169896 ITGAM 
integrin, alpha M (complement component 3 
receptor 3 subunit) 
2.06 0.0201 1.00 
ENSG00000135346 CGA glycoprotein hormones, alpha polypeptide 2.03 0.0384 1.00 
ENSG00000061492 WNT8A 
wingless-type MMTV integration site family, 
member 8A 
2.02 0.0277 1.00 
ENSG00000060709 RIMBP2 RIMS binding protein 2 2.02 0.0113 1.00 




2.00 0.0422 1.00 
ENSG00000166510 CCDC68 coiled-coil domain containing 68 2.00 0.0461 1.00 
ENSG00000204644 ZFP57 ZFP57 zinc finger protein 2.00 0.0132 1.00 
ENSG00000187713 TMEM203 transmembrane protein 203 1.99 0.0029 1.00 
ENSG00000171700 RGS19 regulator of G-protein signaling 19 1.97 0.0321 1.00 
ENSG00000197568 HHLA3 HERV-H LTR-associating 3 1.97 0.0451 1.00 
ENSG00000139914 FITM1 
fat storage-inducing transmembrane protein 
1 
1.96 0.0045 1.00 
ENSG00000166347 CYB5A cytochrome b5 type A (microsomal) 1.96 0.0138 1.00 
ENSG00000103343 ZNF174 zinc finger protein 174 1.95 0.0398 1.00 
ENSG00000174007 CEP19 centrosomal protein 19kDa 1.94 0.0153 1.00 
ENSG00000180257 ZNF816 zinc finger protein 816 1.92 0.0493 1.00 
ENSG00000090339 ICAM1 intercellular adhesion molecule 1 1.90 0.0122 1.00 
ENSG00000060140 STYK1 serine/threonine/tyrosine kinase 1 1.88 0.0048 1.00 
ENSG00000003056 M6PR 
mannose-6-phosphate receptor (cation 
dependent) 
1.87 0.0195 1.00 
ENSG00000049883 PTCD2 pentatricopeptide repeat domain 2 1.86 0.0355 1.00 
ENSG00000143178 TBX19 T-box 19 1.85 0.0205 1.00 




ADAM metallopeptidase with 
thrombospondin type 1 motif, 3 
1.85 0.0316 1.00 
ENSG00000150540 HNMT histamine N-methyltransferase 1.83 0.0487 1.00 
ENSG00000204442 FAM155A 
family with sequence similarity 155, member 
A 
1.83 0.0053 1.00 
ENSG00000133665 DYDC2 DPY30 domain containing 2 1.83 0.0187 1.00 
ENSG00000127903 ZNF835 zinc finger protein 835 1.83 0.0179 1.00 
ENSG00000196242 OR2C3 
olfactory receptor, family 2, subfamily C, 
member 3 
1.81 0.0381 1.00 
ENSG00000184276 DEFB108B defensin, beta 108B 1.80 0.0291 1.00 
ENSG00000125895 TMEM74B transmembrane protein 74B 1.79 0.0212 1.00 
ENSG00000116791 CRYZ crystallin, zeta (quinone reductase) 1.79 0.0113 1.00 
ENSG00000149257 SERPINH1 
serpin peptidase inhibitor, clade H (heat 
shock protein 47), member 1, (collagen 
binding protein 1) 
1.78 0.0050 1.00 
ENSG00000227507 LTB 
lymphotoxin beta (TNF superfamily, member 
3) 
1.77 0.0268 1.00 
ENSG00000167333 TRIM68 tripartite motif containing 68 1.77 0.0285 1.00 
ENSG00000186160 CYP4Z1 
cytochrome P450, family 4, subfamily Z, 
polypeptide 1 
1.76 0.0080 1.00 
ENSG00000106078 COBL cordon-bleu WH2 repeat protein 1.76 0.0497 1.00 
ENSG00000010165 METTL13 methyltransferase like 13 1.75 0.0138 1.00 
ENSG00000132763 MMACHC 
methylmalonic aciduria (cobalamin 
deficiency) cblC type, with homocystinuria 
1.74 0.0399 1.00 
ENSG00000150656 CNDP1 
carnosine dipeptidase 1 (metallopeptidase 
M20 family) 
1.72 0.0417 1.00 
ENSG00000093072 CECR1 
cat eye syndrome chromosome region, 
candidate 1 
1.71 0.0083 1.00 
ENSG00000057935 MTA3 metastasis associated 1 family, member 3 1.71 0.0326 1.00 
ENSG00000185880 TRIM69 tripartite motif containing 69 1.71 0.0104 1.00 
ENSG00000049089 COL9A2 collagen, type IX, alpha 2 1.71 0.0297 1.00 
ENSG00000197847 SLC22A20 solute carrier family 22, member 20 1.70 0.0368 1.00 
ENSG00000111261 MANSC1 MANSC domain containing 1 1.69 0.0270 1.00 
ENSG00000125630 POLR1B polymerase (RNA) I polypeptide B, 128kDa 1.69 0.0149 1.00 
ENSG00000128944 KNSTRN 
kinetochore-localized astrin/SPAG5 binding 
protein 
1.69 0.0213 1.00 
ENSG00000181392 SYNE4 
spectrin repeat containing, nuclear envelope 
family member 4 
1.69 0.0450 1.00 
ENSG00000171806 METTL18 methyltransferase like 18 1.69 0.0401 1.00 
ENSG00000107104 KANK1 KN motif and ankyrin repeat domains 1 1.68 0.0063 1.00 
ENSG00000183625 CCR3 chemokine (C-C motif) receptor 3 1.68 0.0495 1.00 
ENSG00000108797 CNTNAP1 contactin associated protein 1 1.67 0.0219 1.00 
ENSG00000114993 RTKN rhotekin 1.67 0.0043 1.00 
ENSG00000142583 SLC2A5 
solute carrier family 2 (facilitated 
glucose/fructose transporter), member 5 
1.67 0.0023 1.00 
ENSG00000076641 PAG1 
phosphoprotein membrane anchor with 
glycosphingolipid microdomains 1 
1.66 0.0495 1.00 




secreted protein, acidic, cysteine-rich 
(osteonectin) 
1.66 0.0383 1.00 
ENSG00000254685 FPGT fucose-1-phosphate guanylyltransferase 1.65 0.0267 1.00 
ENSG00000105369 CD79A 
CD79a molecule, immunoglobulin-associated 
alpha 
1.65 0.0144 1.00 
ENSG00000198743 SLC5A3 
solute carrier family 5 (sodium/myo-inositol 
cotransporter), member 3 
1.64 0.0210 1.00 
ENSG00000048028 USP28 ubiquitin specific peptidase 28 1.64 0.0326 1.00 
ENSG00000109684 CLNK 
cytokine-dependent hematopoietic cell 
linker 
1.60 0.0256 1.00 
ENSG00000180245 RRH 
retinal pigment epithelium-derived 
rhodopsin homolog 
1.59 0.0336 1.00 
ENSG00000184343 SRPK3 SRSF protein kinase 3 1.59 0.0223 1.00 




1.57 0.0259 1.00 
ENSG00000174177 CTU2 
cytosolic thiouridylase subunit 2 homolog (S. 
pombe) 
1.57 0.0265 1.00 
ENSG00000143457 GOLPH3L golgi phosphoprotein 3-like 1.57 0.0236 1.00 
ENSG00000151320 AKAP6 A kinase (PRKA) anchor protein 6 1.57 0.0361 1.00 
ENSG00000171314 PGAM1 phosphoglycerate mutase 1 (brain) 1.57 0.0244 1.00 
ENSG00000223501 VPS52 
vacuolar protein sorting 52 homolog (S. 
cerevisiae) 
1.56 0.0497 1.00 
ENSG00000101076 HNF4A hepatocyte nuclear factor 4, alpha 1.56 0.0447 1.00 
ENSG00000081853 PCDHGA2 protocadherin gamma subfamily A, 2 1.56 0.0074 1.00 
ENSG00000138413 IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 1.56 0.0072 1.00 
ENSG00000213937 CLDN9 claudin 9 1.55 0.0492 1.00 
ENSG00000183850 ZNF730 zinc finger protein 730 1.55 0.0261 1.00 
ENSG00000125484 GTF3C4 
general transcription factor IIIC, polypeptide 
4, 90kDa 
1.55 0.0069 1.00 
ENSG00000120658 ENOX1 ecto-NOX disulfide-thiol exchanger 1 1.55 0.0391 1.00 
ENSG00000185477 GPRIN3 GPRIN family member 3 1.54 0.0377 1.00 
ENSG00000214782 MS4A18 
membrane-spanning 4-domains, subfamily A, 
member 18 
1.54 0.0226 1.00 
ENSG00000166971 AKTIP AKT interacting protein 1.54 0.0288 1.00 
ENSG00000198610 AKR1C4 aldo-keto reductase family 1, member C4 1.53 0.0390 1.00 
ENSG00000184162 NR2C2AP nuclear receptor 2C2-associated protein 1.53 0.0474 1.00 
ENSG00000159618 ADGRG5 adhesion G protein-coupled receptor G5 1.53 0.0414 1.00 
ENSG00000221986 MYBPHL myosin binding protein H-like 1.53 0.0420 1.00 
ENSG00000139344 AMDHD1 amidohydrolase domain containing 1 1.53 0.0140 1.00 
ENSG00000018869 ZNF582 zinc finger protein 582 1.52 0.0055 1.00 
ENSG00000178038 ALS2CL ALS2 C-terminal like 1.51 0.0433 1.00 
ENSG00000001460 STPG1 sperm-tail PG-rich repeat containing 1 1.51 0.0139 1.00 
ENSG00000188868 ZNF563 zinc finger protein 563 1.51 0.0342 1.00 




solute carrier organic anion transporter 
family, member 4C1 
1.51 0.0426 1.00 
ENSG00000238243 OR2W3 
olfactory receptor, family 2, subfamily W, 
member 3 
1.50 0.0490 1.00 
ENSG00000179855 GIPC3 
GIPC PDZ domain containing family, member 
3 
1.50 0.0419 1.00 
ENSG00000197312 DDI2 DNA-damage inducible 1 homolog 2 1.50 0.0365 1.00 
ENSG00000175544 CABP4 calcium binding protein 4 1.50 0.0487 1.00 
ENSG00000176222 ZNF404 zinc finger protein 404 1.49 0.0398 1.00 
ENSG00000144504 ANKMY1 
ankyrin repeat and MYND domain containing 
1 
1.48 0.0235 1.00 
ENSG00000137124 ALDH1B1 
aldehyde dehydrogenase 1 family, member 
B1 
1.48 0.0285 1.00 
ENSG00000188321 ZNF559 zinc finger protein 559 1.47 0.0375 1.00 
ENSG00000173088 C10orf131 chromosome 10 open reading frame 131 1.47 0.0272 1.00 
ENSG00000244242 IFITM10 
interferon induced transmembrane protein 
10 
1.46 0.0266 1.00 
ENSG00000138459 SLC35A5 solute carrier family 35, member A5 1.46 0.0259 1.00 
ENSG00000114771 AADAC arylacetamide deacetylase 1.45 0.0489 1.00 
ENSG00000164318 EGFLAM 
EGF-like, fibronectin type III and laminin G 
domains 
1.45 0.0450 1.00 
ENSG00000160446 ZDHHC12 zinc finger, DHHC-type containing 12 1.45 0.0426 1.00 
ENSG00000100726 TELO2 telomere maintenance 2 1.44 0.0379 1.00 
ENSG00000167625 ZNF526 zinc finger protein 526 1.43 0.0406 1.00 
ENSG00000245680 ZNF585B zinc finger protein 585B 1.42 0.0081 1.00 
ENSG00000113966 ARL6 ADP-ribosylation factor-like 6 1.42 0.0460 1.00 
ENSG00000118894 EEF2KMT 
eukaryotic elongation factor 2 lysine 
methyltransferase 
1.41 0.0407 1.00 
ENSG00000124786 SLC35B3 
solute carrier family 35 (adenosine 3'-
phospho 5'-phosphosulfate transporter), 
member B3 
1.40 0.0187 1.00 
ENSG00000112578 BYSL bystin-like 1.40 0.0204 1.00 
ENSG00000168778 TCTN2 tectonic family member 2 1.40 0.0466 1.00 
ENSG00000149716 ORAOV1 oral cancer overexpressed 1 1.39 0.0197 1.00 
ENSG00000134864 GGACT gamma-glutamylamine cyclotransferase 1.39 0.0278 1.00 
ENSG00000101265 RASSF2 
Ras association (RalGDS/AF-6) domain family 
member 2 
1.39 0.0208 1.00 
ENSG00000168675 LDLRAD4 
low density lipoprotein receptor class A 
domain containing 4 
1.38 0.0199 1.00 
ENSG00000166908 PIP4K2C 
phosphatidylinositol-5-phosphate 4-kinase, 
type II, gamma 
1.38 0.0188 1.00 
ENSG00000106852 LHX6 LIM homeobox 6 1.37 0.0203 1.00 
ENSG00000080839 RBL1 retinoblastoma-like 1 1.37 0.0421 1.00 
ENSG00000133111 RFXAP regulatory factor X-associated protein 1.36 0.0316 1.00 
ENSG00000185252 ZNF74 zinc finger protein 74 1.36 0.0269 1.00 
ENSG00000178921 PFAS phosphoribosylformylglycinamidine synthase 1.33 0.0143 1.00 






1.31 0.0289 1.00 
ENSG00000215915 ATAD3C ATPase family, AAA domain containing 3C 1.31 0.0219 1.00 
ENSG00000169242 EFNA1 ephrin-A1 1.31 0.0470 1.00 
ENSG00000127423 AUNIP 
aurora kinase A and ninein interacting 
protein 
1.31 0.0306 1.00 
ENSG00000272602 ZNF595 zinc finger protein 595 1.30 0.0464 1.00 
ENSG00000197134 ZNF257 zinc finger protein 257 1.30 0.0266 1.00 
ENSG00000154114 TBCEL tubulin folding cofactor E-like 1.30 0.0167 1.00 
ENSG00000112983 BRD8 bromodomain containing 8 1.30 0.0332 1.00 
ENSG00000105409 ATP1A3 
ATPase, Na+/K+ transporting, alpha 3 
polypeptide 
1.29 0.0414 1.00 
ENSG00000167384 ZNF180 zinc finger protein 180 1.29 0.0292 1.00 
ENSG00000196418 ZNF124 zinc finger protein 124 1.28 0.0359 1.00 
ENSG00000103356 EARS2 glutamyl-tRNA synthetase 2, mitochondrial 1.28 0.0231 1.00 
ENSG00000196437 ZNF569 zinc finger protein 569 1.28 0.0147 1.00 
ENSG00000140025 EFCAB11 EF-hand calcium binding domain 11 1.28 0.0318 1.00 
ENSG00000120694 HSPH1 heat shock 105kDa/110kDa protein 1 1.27 0.0493 1.00 
ENSG00000154133 ROBO4 roundabout guidance receptor 4 1.27 0.0422 1.00 
ENSG00000121075 TBX4 T-box 4 1.27 0.0258 1.00 
ENSG00000134057 CCNB1 cyclin B1 1.27 0.0482 1.00 
ENSG00000065054 SLC9A3R2 
solute carrier family 9, subfamily A (NHE3, 
cation proton antiporter 3), member 3 
regulator 2 
1.26 0.0474 1.00 
ENSG00000262209 PCDHGB3 protocadherin gamma subfamily B, 3 1.26 0.0393 1.00 
ENSG00000097046 CDC7 cell division cycle 7 1.26 0.0285 1.00 
ENSG00000169398 PTK2 protein tyrosine kinase 2 1.26 0.0076 1.00 
ENSG00000163959 SLC51A solute carrier family 51, alpha subunit 1.26 0.0337 1.00 
ENSG00000167315 ACAA2 acetyl-CoA acyltransferase 2 1.26 0.0283 1.00 
ENSG00000204428 LY6G5C lymphocyte antigen 6 complex, locus G5C 1.26 0.0388 1.00 
ENSG00000150433 TMEM218 transmembrane protein 218 1.25 0.0270 1.00 
ENSG00000146021 KLHL3 kelch-like family member 3 1.25 0.0156 1.00 
ENSG00000230510 PPP5D1 
PPP5 tetratricopeptide repeat domain 
containing 1 
1.25 0.0397 1.00 
ENSG00000178773 CPNE7 copine VII 1.24 0.0391 1.00 
ENSG00000147789 ZNF7 zinc finger protein 7 1.24 0.0313 1.00 
ENSG00000180104 EXOC3 exocyst complex component 3 1.23 0.0334 1.00 
ENSG00000134285 FKBP11 FK506 binding protein 11, 19 kDa 1.23 0.0118 1.00 
ENSG00000133805 AMPD3 adenosine monophosphate deaminase 3 1.23 0.0124 1.00 
ENSG00000130635 COL5A1 collagen, type V, alpha 1 1.22 0.0232 1.00 





ENSG00000168564 CDKN2AIP CDKN2A interacting protein 1.21 0.0282 1.00 
ENSG00000004468 CD38 CD38 molecule 1.20 0.0393 1.00 
ENSG00000134255 CEPT1 choline/ethanolamine phosphotransferase 1 1.20 0.0147 1.00 
ENSG00000140263 SORD sorbitol dehydrogenase 1.20 0.0228 1.00 
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ENSG00000160201 U2AF1 U2 small nuclear RNA auxiliary factor 1 3.42 0.0018 1.00 
ENSG00000180596 HIST1H2BC histone cluster 1, H2bc 3.37 0.0122 1.00 
ENSG00000272196 HIST2H2AA4 histone cluster 2, H2aa4 3.14 0.0271 1.00 
ENSG00000276903 HIST1H2AL histone cluster 1, H2al 3.02 0.0063 1.00 
ENSG00000088826 SMOX spermine oxidase 2.99 0.0033 1.00 
ENSG00000235961 PNMA6A 
paraneoplastic Ma antigen family member 
6A 
2.94 0.0037 1.00 
ENSG00000180611 MB21D2 Mab-21 domain containing 2 2.88 0.0004 1.00 
ENSG00000274997 HIST1H2AH histone cluster 1, H2ah 2.69 0.0061 1.00 
ENSG00000122824 NUDT10 
nudix (nucleoside diphosphate linked 
moiety X)-type motif 10 
2.64 0.0188 1.00 
ENSG00000182195 LDOC1 leucine zipper, down-regulated in cancer 1 2.62 0.0424 1.00 
ENSG00000197747 S100A10 S100 calcium binding protein A10 2.61 0.0015 1.00 
ENSG00000276410 HIST1H2BB histone cluster 1, H2bb 2.48 0.0469 1.00 
ENSG00000119138 KLF9 Kruppel-like factor 9 2.43 0.0160 1.00 
ENSG00000165030 NFIL3 nuclear factor, interleukin 3 regulated 2.43 0.0057 1.00 
ENSG00000146592 CREB5 
cAMP responsive element binding protein 
5 
2.43 0.0028 1.00 
ENSG00000134594 RAB33A RAB33A, member RAS oncogene family 2.43 0.0294 1.00 
ENSG00000165730 STOX1 storkhead box 1 2.40 0.0063 1.00 
ENSG00000184206 GOLGA6L4 golgin A6 family-like 4 2.39 0.0147 1.00 
ENSG00000178127 NDUFV2 
NADH dehydrogenase (ubiquinone) 
flavoprotein 2, 24kDa 
2.33 0.0070 1.00 
ENSG00000111405 ENDOU endonuclease, polyU-specific 2.32 0.0114 1.00 
ENSG00000187837 HIST1H1C histone cluster 1, H1c 2.32 0.0041 1.00 
ENSG00000213977 TAX1BP3 
Tax1 (human T-cell leukemia virus type I) 
binding protein 3 
2.29 0.0180 1.00 
ENSG00000180573 HIST1H2AC histone cluster 1, H2a 2.27 0.0400 1.00 
ENSG00000170379 TCAF2 TRPM8 channel-associated factor 2 2.27 0.0002 1.00 
ENSG00000172733 PURG purine-rich element binding protein G 2.26 0.0330 1.00 
ENSG00000259511 UBE2Q2L 
ubiquitin-conjugating enzyme E2Q family 
member 2-like 
2.26 0.0081 1.00 
ENSG00000168298 HIST1H1E histone cluster 1, H1e 2.21 0.0139 1.00 
ENSG00000278588 HIST1H2BI histone cluster 1, H2bi 2.20 0.0368 1.00 
ENSG00000169429 CXCL8 chemokine (C-X-C motif) ligand 8 2.18 0.0248 1.00 
ENSG00000124575 HIST1H1D histone cluster 1, H1d 2.18 0.0199 1.00 
ENSG00000006327 TNFRSF12A 
tumor necrosis factor receptor 
superfamily, member 12A 
2.18 0.0232 1.00 
ENSG00000196368 NUDT11 
nudix (nucleoside diphosphate linked 
moiety X)-type motif 11 
2.17 0.0226 1.00 
Appendix 3: Differentially expressed genes from RNA-Seq Attempt 1 
372 
 
ENSG00000006042 TMEM98 transmembrane protein 98 2.17 0.0494 1.00 
ENSG00000076604 TRAF4 TNF receptor-associated factor 4 2.13 0.0168 1.00 
ENSG00000022267 FHL1 four and a half LIM domains 1 2.11 0.0381 1.00 
ENSG00000123095 BHLHE41 basic helix-loop-helix family, member e41 2.09 0.0246 1.00 
ENSG00000273802 HIST1H2BG histone cluster 1, H2bg 2.09 0.0091 1.00 
ENSG00000143367 TUFT1 tuftelin 1 2.08 0.0155 1.00 
ENSG00000131981 LGALS3 lectin, galactoside-binding, soluble, 3 2.07 0.0486 1.00 
ENSG00000060558 GNA15 
guanine nucleotide binding protein (G 
protein), alpha 15 (Gq class) 
2.06 0.0056 1.00 
ENSG00000196110 ZNF699 zinc finger protein 699 2.06 0.0098 1.00 
ENSG00000254122 PCDHGB7 protocadherin gamma subfamily B, 7 2.05 0.0009 1.00 
ENSG00000165389 SPTSSA 
serine palmitoyltransferase, small subunit 
A 
2.05 0.0162 1.00 
ENSG00000109686 SH3D19 SH3 domain containing 19 2.05 0.0115 1.00 
ENSG00000256188 TAS2R30 taste receptor, type 2, member 30 2.04 0.0183 1.00 
ENSG00000000003 TSPAN6 tetraspanin 6 2.03 0.0197 1.00 
ENSG00000143839 REN renin 2.03 0.0422 1.00 
ENSG00000085514 PILRA 
paired immunoglobin-like type 2 receptor 
alpha 
2.02 0.0019 1.00 
ENSG00000197329 PELI1 pellino E3 ubiquitin protein ligase 1 2.02 0.0056 1.00 
ENSG00000140478 GOLGA6D golgin A6 family, member D 2.00 0.0027 1.00 
ENSG00000172005 MAL mal, T-cell differentiation protein 2.00 0.0354 1.00 
ENSG00000197238 HIST1H4J histone cluster 1, H4j 1.99 0.0038 1.00 
ENSG00000133661 SFTPD surfactant protein D 1.99 0.0335 1.00 
ENSG00000185775 SPATA31A6 SPATA31 subfamily A, member 6 1.98 0.0187 1.00 
ENSG00000115828 QPCT glutaminyl-peptide cyclotransferase 1.97 0.0043 1.00 
ENSG00000102359 SRPX2 sushi-repeat containing protein, X-linked 2 1.97 0.0352 1.00 
ENSG00000164674 SYTL3 synaptotagmin-like 3 1.95 0.0085 1.00 
ENSG00000146072 TNFRSF21 
tumor necrosis factor receptor 
superfamily, member 21 
1.94 0.0218 1.00 
ENSG00000231824 C18orf42 chromosome 18 open reading frame 42 1.94 0.0078 1.00 
ENSG00000203907 OOEP oocyte expressed protein 1.93 0.0088 1.00 
ENSG00000173334 TRIB1 tribbles pseudokinase 1 1.92 0.0021 1.00 
ENSG00000133131 MORC4 MORC family CW-type zinc finger 4 1.92 0.0041 1.00 
ENSG00000135226 UGT2B28 
UDP glucuronosyltransferase 2 family, 
polypeptide B28 
1.91 0.0167 1.00 
ENSG00000260691 ANKRD20A1 
ankyrin repeat domain 20 family, member 
A1 
1.90 0.0425 1.00 
ENSG00000179021 C3orf38 chromosome 3 open reading frame 38 1.89 0.0245 1.00 
ENSG00000184205 TSPYL2 TSPY-like 2 1.89 0.0202 1.00 
Appendix 3: Differentially expressed genes from RNA-Seq Attempt 1 
373 
 
ENSG00000115540 MOB4 MOB family member 4, phocein 1.88 0.0146 1.00 
ENSG00000123091 RNF11 ring finger protein 11 1.87 0.0192 1.00 
ENSG00000105708 ZNF14 zinc finger protein 14 1.84 0.0080 1.00 
ENSG00000213185 FAM24B 
family with sequence similarity 24, 
member B 
1.84 0.0151 1.00 
ENSG00000198553 KCNRG potassium channel regulator 1.84 0.0353 1.00 
ENSG00000172058 SERF1A small EDRK-rich factor 1A (telomeric) 1.83 0.0387 1.00 
ENSG00000277443 MARCKS 
myristoylated alanine-rich protein kinase C 
substrate 
1.83 0.0045 1.00 
ENSG00000147180 ZNF711 zinc finger protein 711 1.82 0.0362 1.00 
ENSG00000166171 DPCD 
deleted in primary ciliary dyskinesia 
homolog (mouse) 
1.82 0.0367 1.00 
ENSG00000204538 PSORS1C2 psoriasis susceptibility 1 candidate 2 1.81 0.0015 1.00 
ENSG00000198947 DMD dystrophin 1.81 0.0052 1.00 
ENSG00000108187 PBLD 
phenazine biosynthesis-like protein domain 
containing 
1.81 0.0323 1.00 
ENSG00000174945 AMZ1 archaelysin family metallopeptidase 1 1.79 0.0350 1.00 
ENSG00000196866 HIST1H2AD histone cluster 1, H2ad 1.79 0.0372 1.00 
ENSG00000179833 SERTAD2 SERTA domain containing 2 1.78 0.0151 1.00 
ENSG00000112245 PTP4A1 
protein tyrosine phosphatase type IVA, 
member 1 
1.78 0.0037 1.00 
ENSG00000127666 TICAM1 toll-like receptor adaptor molecule 1 1.78 0.0392 1.00 
ENSG00000163734 CXCL3 chemokine (C-X-C motif) ligand 3 1.77 0.0494 1.00 
ENSG00000072133 RPS6KA6 
ribosomal protein S6 kinase, 90kDa, 
polypeptide 6 
1.77 0.0175 1.00 
ENSG00000189060 H1F0 H1 histone family, member 0 1.77 0.0147 1.00 
ENSG00000127252 HRASLS HRAS-like suppressor 1.77 0.0473 1.00 
ENSG00000184897 H1FX H1 histone family, member X 1.76 0.0093 1.00 
ENSG00000133818 RRAS2 
related RAS viral (r-ras) oncogene homolog 
2 
1.74 0.0258 1.00 
ENSG00000101470 TNNC2 troponin C type 2 (fast) 1.74 0.0412 1.00 
ENSG00000163661 PTX3 pentraxin 3, long 1.74 0.0293 1.00 
ENSG00000214274 ANG angiogenin, ribonuclease, RNase A family, 5 1.71 0.0484 1.00 
ENSG00000154734 ADAMTS1 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 1 
1.70 0.0194 1.00 
ENSG00000159212 CLIC6 chloride intracellular channel 6 1.70 0.0311 1.00 
ENSG00000171044 XKR6 
XK, Kell blood group complex subunit-
related family, member 6 
1.69 0.0340 1.00 
ENSG00000105894 PTN pleiotrophin 1.69 0.0497 1.00 
ENSG00000185272 RBM11 RNA binding motif protein 11 1.68 0.0419 1.00 
ENSG00000162599 NFIA nuclear factor I/A 1.68 0.0400 1.00 
ENSG00000187627 RGPD1 RANBP2-like and GRIP domain containing 1 1.67 0.0137 1.00 
ENSG00000205078 SYCE1L 
synaptonemal complex central element 
protein 1-like 
1.66 0.0249 1.00 






1.66 0.0368 1.00 
ENSG00000256646 PSMA2 Uncharacterized protein 1.65 0.0042 1.00 
ENSG00000196470 SIAH1 siah E3 ubiquitin protein ligase 1 1.65 0.0255 1.00 
ENSG00000274641 HIST1H2BO histone cluster 1, H2bo 1.65 0.0475 1.00 
ENSG00000198523 PLN phospholamban 1.65 0.0429 1.00 
ENSG00000075618 FSCN1 fascin actin-bundling protein 1 1.65 0.0210 1.00 
ENSG00000134463 ECHDC3 enoyl CoA hydratase domain containing 3 1.64 0.0353 1.00 
ENSG00000189129 PLAC9 placenta-specific 9 1.64 0.0379 1.00 
ENSG00000144935 TRPC1 
transient receptor potential cation 
channel, subfamily C, member 1 
1.64 0.0081 1.00 
ENSG00000069956 MAPK6 mitogen-activated protein kinase 6 1.63 0.0100 1.00 
ENSG00000047634 SCML1 sex comb on midleg-like 1 (Drosophila) 1.63 0.0172 1.00 
ENSG00000117407 ARTN artemin 1.63 0.0449 1.00 
ENSG00000251655 PRB1 proline-rich protein BstNI subfamily 1 1.63 0.0413 1.00 
ENSG00000141574 SECTM1 secreted and transmembrane 1 1.63 0.0138 1.00 
ENSG00000105327 BBC3 BCL2 binding component 3 1.63 0.0459 1.00 
ENSG00000132141 CCT6B 
chaperonin containing TCP1, subunit 6B 
(zeta 2) 
1.62 0.0171 1.00 
ENSG00000131724 IL13RA1 interleukin 13 receptor, alpha 1 1.62 0.0436 1.00 
ENSG00000178934 LGALS7B lectin, galactoside-binding, soluble, 7B 1.61 0.0158 1.00 





1.61 0.0196 1.00 
ENSG00000181588 MEX3D mex-3 RNA binding family member D 1.60 0.0180 1.00 
ENSG00000175352 NRIP3 nuclear receptor interacting protein 3 1.59 0.0454 1.00 
ENSG00000029993 HMGB3 high mobility group box 3 1.59 0.0142 1.00 
ENSG00000117479 SLC19A2 
solute carrier family 19 (thiamine 
transporter), member 2 
1.58 0.0174 1.00 
ENSG00000143845 ETNK2 ethanolamine kinase 2 1.58 0.0025 1.00 
ENSG00000104147 OIP5 Opa interacting protein 5 1.58 0.0182 1.00 
ENSG00000224186 C5orf66 chromosome 5 open reading frame 66 1.58 0.0254 1.00 
ENSG00000206549 PRSS50 protease, serine, 50 1.57 0.0051 1.00 
ENSG00000142549 IGLON5 IgLON family member 5 1.57 0.0198 1.00 
ENSG00000151364 KCTD14 
potassium channel tetramerization domain 
containing 14 




1.57 0.0110 1.00 
ENSG00000196369 SRGAP2B 
SLIT-ROBO Rho GTPase activating protein 
2B 
1.56 0.0154 1.00 
ENSG00000139725 RHOF ras homolog family member F (in filopodia) 1.56 0.0240 1.00 
ENSG00000125249 RAP2A RAP2A, member of RAS oncogene family 1.56 0.0305 1.00 
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ENSG00000184785 SMIM10 small integral membrane protein 10 1.55 0.0177 1.00 
ENSG00000173166 RAPH1 
Ras association (RalGDS/AF-6) and 
pleckstrin homology domains 1 
1.55 0.0102 1.00 
ENSG00000110108 TMEM109 transmembrane protein 109 1.55 0.0481 1.00 
ENSG00000124103 FAM209A 
family with sequence similarity 209, 
member A 
1.55 0.0385 1.00 
ENSG00000101400 SNTA1 syntrophin, alpha 1 1.54 0.0118 1.00 
ENSG00000135272 MDFIC MyoD family inhibitor domain containing 1.54 0.0470 1.00 
ENSG00000147059 SPIN2A spindlin family, member 2A 1.54 0.0429 1.00 
ENSG00000196476 C20orf96 chromosome 20 open reading frame 96 1.54 0.0193 1.00 
ENSG00000175592 FOSL1 FOS-like antigen 1 1.54 0.0222 1.00 
ENSG00000078246 TULP3 tubby like protein 3 1.54 0.0105 1.00 
ENSG00000169957 ZNF768 zinc finger protein 768 1.53 0.0180 1.00 
ENSG00000213085 CFAP45 cilia and flagella associated protein 45 1.53 0.0457 1.00 
ENSG00000108960 MMD 
monocyte to macrophage differentiation-
associated 
1.52 0.0074 1.00 
ENSG00000169991 IFFO2 intermediate filament family orphan 2 1.51 0.0156 1.00 
ENSG00000186272 ZNF17 zinc finger protein 17 1.51 0.0274 1.00 
ENSG00000268447 SSX2B synovial sarcoma, X breakpoint 2B 1.51 0.0120 1.00 
ENSG00000228741 SPATA13 spermatogenesis associated 13 1.50 0.0141 1.00 
ENSG00000232653 GOLGA8N golgin A8 family, member N 1.50 0.0370 1.00 
ENSG00000196363 WDR5 WD repeat domain 5 1.50 0.0353 1.00 
ENSG00000139433 GLTP glycolipid transfer protein 1.49 0.0060 1.00 
ENSG00000139112 GABARAPL1 GABA(A) receptor-associated protein like 1 1.49 0.0149 1.00 
ENSG00000173610 UGT2A1 
UDP glucuronosyltransferase 2 family, 
polypeptide A1, complex locus 
1.49 0.0109 1.00 
ENSG00000170899 GSTA4 glutathione S-transferase alpha 4 1.49 0.0344 1.00 
ENSG00000143971 ETAA1 Ewing tumor-associated antigen 1 1.48 0.0225 1.00 
ENSG00000276203 ANKRD20A3 
ankyrin repeat domain 20 family, member 
A3 
1.47 0.0368 1.00 
ENSG00000170262 MRAP melanocortin 2 receptor accessory protein 1.47 0.0213 1.00 
ENSG00000120833 SOCS2 suppressor of cytokine signaling 2 1.47 0.0180 1.00 
ENSG00000205572 SERF1B small EDRK-rich factor 1B (centromeric) 1.47 0.0365 1.00 
ENSG00000132879 FBXO44 F-box protein 44 1.46 0.0122 1.00 
ENSG00000079739 PGM1 phosphoglucomutase 1 1.45 0.0365 1.00 
ENSG00000102109 PCSK1N 
proprotein convertase subtilisin/kexin type 
1 inhibitor 
1.45 0.0341 1.00 




1.44 0.0406 1.00 
ENSG00000168811 IL12A interleukin 12A 1.43 0.0431 1.00 






BCL2L2-PABPN1 readthrough 1.42 0.0203 1.00 
ENSG00000164543 STK17A serine/threonine kinase 17a 1.42 0.0112 1.00 
ENSG00000215790 SLC35E2 solute carrier family 35, member E2 1.42 0.0461 1.00 
ENSG00000119280 C1orf198 chromosome 1 open reading frame 198 1.41 0.0264 1.00 
ENSG00000155918 RAET1L retinoic acid early transcript 1L 1.41 0.0172 1.00 
ENSG00000108001 EBF3 early B-cell factor 3 1.41 0.0236 1.00 
ENSG00000180354 MTURN 
maturin, neural progenitor differentiation 
regulator homolog (Xenopus) 
1.41 0.0135 1.00 
ENSG00000116035 VAX2 ventral anterior homeobox 2 1.40 0.0211 1.00 
ENSG00000271303 SRXN1 sulfiredoxin 1 1.40 0.0248 1.00 
ENSG00000179562 GCC1 GRIP and coiled-coil domain containing 1 1.40 0.0308 1.00 
ENSG00000157557 ETS2 
v-ets avian erythroblastosis virus E26 
oncogene homolog 2 
1.40 0.0277 1.00 
ENSG00000197050 ZNF420 zinc finger protein 420 1.40 0.0204 1.00 
ENSG00000273899 NOL12 nucleolar protein 12 1.39 0.0438 1.00 
ENSG00000122042 UBL3 ubiquitin-like 3 1.39 0.0448 1.00 




1.37 0.0361 1.00 
ENSG00000248333 CDK11B cyclin-dependent kinase 11B 1.37 0.0382 1.00 
ENSG00000160683 CXCR5 chemokine (C-X-C motif) receptor 5 1.37 0.0093 1.00 
ENSG00000180228 PRKRA 
protein kinase, interferon-inducible double 
stranded RNA dependent activator 
1.37 0.0264 1.00 
ENSG00000204314 PRRT1 proline-rich transmembrane protein 1 1.36 0.0434 1.00 
ENSG00000059769 DNAJC25 
DnaJ (Hsp40) homolog, subfamily C , 
member 25 
1.36 0.0487 1.00 
ENSG00000148459 PDSS1 
prenyl (decaprenyl) diphosphate synthase, 
subunit 1 
1.35 0.0129 1.00 
ENSG00000132122 SPATA6 spermatogenesis associated 6 1.34 0.0274 1.00 
ENSG00000206418 RAB12 RAB12, member RAS oncogene family 1.33 0.0452 1.00 
ENSG00000111266 DUSP16 dual specificity phosphatase 16 1.33 0.0093 1.00 
ENSG00000162496 DHRS3 
dehydrogenase/reductase (SDR family) 
member 3 
1.33 0.0427 1.00 
ENSG00000184792 OSBP2 oxysterol binding protein 2 1.33 0.0050 1.00 
ENSG00000146535 GNA12 
guanine nucleotide binding protein (G 
protein) alpha 12 
1.33 0.0363 1.00 
ENSG00000175325 PROP1 PROP paired-like homeobox 1 1.33 0.0494 1.00 
ENSG00000145365 TIFA 
TRAF-interacting protein with forkhead-
associated domain 
1.33 0.0247 1.00 
ENSG00000169297 NR0B1 
nuclear receptor subfamily 0, group B, 
member 1 
1.33 0.0486 1.00 
ENSG00000138032 PPM1B 
protein phosphatase, Mg2+/Mn2+ 
dependent, 1B 
1.32 0.0198 1.00 
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Appendix 4: Genes with significantly different expression 
between AML-exposed and Control HSCs, as detected by 
RNA-Seq Attempt 2 
Table App 4 -1 Genes upregulated in HSCs from Controls versus AML (Fold change >2, p<0.01) 
ID Gene Description logFC P.Value 
adj.P.
Val 
ENSG00000169877 AHSP alpha hemoglobin stabilizing protein 8.47 0.0002 0.17 
ENSG00000055118 KCNH2 
potassium channel, voltage gated eag 
related subfamily H, member 2 
8.20 0.0002 0.19 
ENSG00000133742 CA1 carbonic anhydrase I 8.14 0.0005 0.22 
ENSG00000158578 ALAS2 5'-aminolevulinate synthase 2 7.52 0.0007 0.26 
ENSG00000155961 RAB39B RAB39B, member RAS oncogene family  7.07 0.0001 0.11 
ENSG00000136153 LMO7 LIM domain 7  6.93 0.0001 0.12 
ENSG00000101057 MYBL2 
v-myb avian myeloblastosis viral oncogene 
homolog-like 2  
6.93 0.0008 0.27 
ENSG00000029534 ANK1 ankyrin 1 6.93 0.0008 0.27 
ENSG00000093009 CDC45 cell division cycle 45 6.90 0.0001 0.12 
ENSG00000004939 SLC4A1 
solute carrier family 4 (anion exchanger), 
member 1 (Diego blood group) 
6.57 0.0015 0.33 
ENSG00000010539 ZNF200 zinc finger protein 200 6.54 0.0003 0.20 
ENSG00000090932 DLL3 delta-like 3 (Drosophila) 6.51 0.0011 0.30 
ENSG00000216775 RP1-152L7.5 
 
6.48 0.0013 0.33 




6.45 0.0009 0.29 
ENSG00000113552 GNPDA1 glucosamine-6-phosphate deaminase 1 6.43 0.0000 0.01 
ENSG00000131747 TOP2A topoisomerase (DNA) II alpha 6.42 0.0005 0.22 
ENSG00000119599 DCAF4 DDB1 and CUL4 associated factor 4 6.36 0.0005 0.22 
ENSG00000244734 HBB hemoglobin subunit beta 6.34 0.0091 0.55 
ENSG00000156876 SASS6 SAS-6 centriolar assembly protein 6.27 0.0003 0.19 
ENSG00000168754 FAM178B 
family with sequence similarity 178 
member B 
6.22 0.0086 0.55 
ENSG00000183814 LIN9 
lin-9 DREAM MuvB core complex 
component 
6.22 0.0005 0.22 
ENSG00000178999 AURKB aurora kinase B 6.13 0.0009 0.29 
ENSG00000134690 CDCA8 cell division cycle associated 8 6.12 0.0008 0.27 
ENSG00000101412 E2F1 E2F transcription factor 1 6.12 0.0034 0.43 
ENSG00000204644 ZFP57 ZFP57 zinc finger protein 6.06 0.0083 0.55 
ENSG00000114988 LMAN2L lectin, mannose-binding 2-like 6.00 0.0068 0.53 
ENSG00000170558 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 5.95 0.0034 0.43 
ENSG00000172247 C1QTNF4 
C1q and tumor necrosis factor related 
protein 4 
5.94 0.0008 0.28 
ENSG00000137700 SLC37A4 
solute carrier family 37 (glucose-6-
phosphate transporter), member 4 
5.93 0.0017 0.35 
ENSG00000080819 CPOX coproporphyrinogen oxidase 5.92 0.0032 0.43 
ENSG00000243406 MRPS31P5 
mitochondrial ribosomal protein S31 
pseudogene 5 
5.90 0.0001 0.12 




serpin peptidase inhibitor, clade H (heat 
shock protein 47), member 1, (collagen 
binding protein 1) 
5.89 0.0014 0.33 




5.84 0.0002 0.19 
ENSG00000138600 SPPL2A signal peptide peptidase like 2A 5.83 0.0016 0.34 
ENSG00000114374 USP9Y ubiquitin specific peptidase 9, Y-linked 5.83 0.0072 0.54 
ENSG00000144647 POMGNT2 
protein O-linked mannose N-
acetylglucosaminyltransferase 2 (beta 1,4-) 
5.77 0.0027 0.42 
ENSG00000133657 ATP13A3 ATPase type 13A3 5.77 0.0026 0.42 
ENSG00000070182 SPTB spectrin, beta, erythrocytic 5.75 0.0014 0.33 
ENSG00000106351 AGFG2 ArfGAP with FG repeats 2 5.71 0.0003 0.20 
ENSG00000160172 FAM86C2P 
family with sequence similarity 86 member 
C2, pseudogene 
5.70 0.0037 0.44 
ENSG00000114315 HES1 hes family bHLH transcription factor 1 5.69 0.0029 0.42 
ENSG00000097046 CDC7 cell division cycle 7 5.67 0.0063 0.52 
ENSG00000273352 RP11-61L19.3 
 
5.66 0.0025 0.42 
ENSG00000215022 RP1-257A7.4 
 
5.65 0.0062 0.52 
ENSG00000144749 LRIG1 
leucine-rich repeats and immunoglobulin-
like domains 1 
5.64 0.0025 0.42 
ENSG00000143479 DYRK3 
dual specificity tyrosine-(Y)-
phosphorylation regulated kinase 3 
5.64 0.0099 0.56 
ENSG00000151413 NUBPL nucleotide binding protein-like 5.64 0.0027 0.42 
ENSG00000181450 ZNF678 zinc finger protein 678 5.62 0.0015 0.33 
ENSG00000206172 HBA1 hemoglobin subunit alpha 1 5.60 0.0041 0.46 
ENSG00000254837 AP001372.2 
 
5.58 0.0051 0.49 
ENSG00000113621 TXNDC15 thioredoxin domain containing 15 5.54 0.0014 0.33 
ENSG00000124279 FASTKD3 FAST kinase domains 3 5.53 0.0025 0.42 
ENSG00000196436 NPIPB15 
nuclear pore complex interacting protein 
family member B15 
5.46 0.0009 0.29 
ENSG00000114739 ACVR2B activin A receptor type IIB 5.45 0.0023 0.42 
ENSG00000207475 SNORA80E small nucleolar RNA, H/ACA box 80E 5.45 0.0002 0.19 
ENSG00000169575 VPREB1 pre-B lymphocyte 1 5.44 0.0019 0.38 
ENSG00000260018 RP11-505K9.1 
 
5.43 0.0017 0.35 
ENSG00000270885 RASL10B RAS-like family 10 member B 5.42 0.0051 0.49 
ENSG00000136514 RTP4 
receptor (chemosensory) transporter 
protein 4 
5.40 0.0076 0.54 
ENSG00000182986 ZNF320 zinc finger protein 320 5.39 0.0003 0.20 
ENSG00000148773 MKI67 marker of proliferation Ki-67 5.38 0.0068 0.53 
ENSG00000272143 FGF14-AS2 FGF14 antisense RNA 2 5.37 0.0093 0.55 
ENSG00000229666 MAST4-AS1 MAST4 antisense RNA 1 5.33 0.0030 0.42 
ENSG00000172840 PDP2 
pyruvate dehyrogenase phosphatase 
catalytic subunit 2 
5.31 0.0027 0.42 
ENSG00000135451 TROAP trophinin associated protein 5.25 0.0051 0.49 
ENSG00000080839 RBL1 retinoblastoma-like 1 5.24 0.0057 0.50 
ENSG00000182118 FAM89A 
family with sequence similarity 89 member 
A 
5.24 0.0080 0.55 
ENSG00000112077 RHAG Rh-associated glycoprotein 5.23 0.0062 0.52 
ENSG00000167513 CDT1 
chromatin licensing and DNA replication 
factor 1 
5.23 0.0066 0.53 




gem nuclear organelle associated protein 8 
pseudogene 4 
5.23 0.0093 0.55 
ENSG00000122824 NUDT10 nudix hydrolase 10 5.16 0.0030 0.42 
ENSG00000159055 MIS18A MIS18 kinetochore protein A 5.14 0.0030 0.42 
ENSG00000101400 SNTA1 syntrophin, alpha 1 5.11 0.0089 0.55 
ENSG00000245105 A2M-AS1 A2M antisense RNA 1 (head to head) 5.02 0.0074 0.54 
ENSG00000252658 RNU6-786P RNA, U6 small nuclear 786, pseudogene 5.00 0.0019 0.38 
ENSG00000233974 RP11-823P9.3 
 
4.99 0.0003 0.19 
ENSG00000086506 HBQ1 hemoglobin subunit theta 1 4.97 0.0052 0.49 
ENSG00000185010 F8 
coagulation factor VIII, procoagulant 
component 
4.92 0.0087 0.55 
ENSG00000104221 BRF2 
BRF2, RNA polymerase III transcription 
initiation factor 50 kDa subunit 




4.91 0.0097 0.56 
ENSG00000152382 TADA1 transcriptional adaptor 1 4.86 0.0042 0.46 




4.85 0.0075 0.54 
ENSG00000172167 MTBP MDM2 binding protein 4.85 0.0076 0.54 
ENSG00000137054 POLR1E polymerase (RNA) I polypeptide E 4.84 0.0059 0.50 
ENSG00000227632 AC018804.6 
 
4.78 0.0034 0.43 
ENSG00000145569 FAM105A 
family with sequence similarity 105 
member A 
4.72 0.0049 0.49 
ENSG00000163808 KIF15 kinesin family member 15 4.62 0.0088 0.55 
ENSG00000135749 PCNXL2 pecanex-like 2 (Drosophila) 4.56 0.0031 0.43 
ENSG00000165832 TRUB1 
TruB pseudouridine (psi) synthase family 
member 1 
4.53 0.0032 0.43 
ENSG00000082516 GEMIN5 gem nuclear organelle associated protein 5 4.49 0.0054 0.49 
ENSG00000280106 CTC-523E23.3 
 
4.47 0.0049 0.49 
ENSG00000166886 NAB2 
NGFI-A binding protein 2 (EGR1 binding 
protein 2) 
4.43 0.0091 0.55 
ENSG00000066651 TRMT11 tRNA methyltransferase 11 homolog 4.42 0.0054 0.49 
ENSG00000213222 AC093724.2 
 
4.31 0.0006 0.25 
ENSG00000227345 PARG poly(ADP-ribose) glycohydrolase 4.28 0.0092 0.55 
ENSG00000132964 CDK8 cyclin-dependent kinase 8 4.24 0.0085 0.55 
ENSG00000147586 MRPS28 mitochondrial ribosomal protein S28 4.18 0.0080 0.55 
ENSG00000129480 DTD2 D-tyrosyl-tRNA deacylase 2 (putative) 4.16 0.0093 0.55 
ENSG00000177051 FBXO46 F-box protein 46 4.10 0.0078 0.54 
ENSG00000065054 SLC9A3R2 
solute carrier family 9, subfamily A (NHE3, 
cation proton antiporter 3), member 3 
regulator 2 
4.05 0.0046 0.48 
ENSG00000270953 RP11-2E11.9 
 
4.04 0.0041 0.46 
ENSG00000267751 AC009005.2 
 




3.80 0.0005 0.22 
ENSG00000185386 MAPK11 mitogen-activated protein kinase 11 3.59 0.0070 0.54 
ENSG00000244921 MTCYBP18 MT-CYB pseudogene 18 3.54 0.0089 0.55 
ENSG00000235065 RPL24P2 ribosomal protein L24 pseudogene 2 2.91 0.0098 0.56 
ENSG00000233585 AC115617.2 
 
2.89 0.0048 0.49 
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ENSG00000210196 MT-TP mitochondrially encoded tRNA proline 2.80 0.0067 0.53 
ENSG00000177683 THAP5 THAP domain containing 5 2.78 0.0085 0.55 
ENSG00000140848 CPNE2 copine II 2.40 0.0095 0.55 
ENSG00000253785 CTC-308K20.3 
 
2.31 0.0030 0.42 
ENSG00000197535 MYO5A myosin VA 1.87 0.0076 0.54 
ENSG00000240616 RPS6P25 ribosomal protein S6 pseudogene 25 1.80 0.0084 0.55 
ENSG00000233225 AC004987.9 
 
1.78 0.0068 0.53 
ENSG00000277105 FP236383.10 
 
1.73 0.0072 0.54 
ENSG00000184220 CMSS1 
cms1 ribosomal small subunit homolog 
(yeast) 
1.70 0.0088 0.55 
ENSG00000151353 TMEM18 transmembrane protein 18 1.54 0.0080 0.55 
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Table App 4-2 Genes upregulated in HSCs from AML samples versus controls (Fold change >2, p<0.01)  
ID Gene Description logFC P.Value 
adj.P. 
Val 
ENSG00000182885 ADGRG3 adhesion G protein-coupled receptor G3 8.46 0.0000 0.00 
ENSG00000225783 MIAT 
myocardial infarction associated transcript 
(non-protein coding) 
7.3 0.0000 0.02 
ENSG00000148225 WDR31 WD repeat domain 31 7.04 0.0000 0.01 




  6.91 0.0000 0.04 
ENSG00000183722 LHFP lipoma HMGIC fusion partner 6.73 0.0002 0.19 
ENSG00000171509 RXFP1 relaxin/insulin-like family peptide receptor 1 6.47 0.0000 0.01 
ENSG00000185278 ZBTB37 zinc finger and BTB domain containing 37 6.41 0.0001 0.12 
ENSG00000086288 NME8 NME/NM23 family member 8 6.31 0.0006 0.24 
ENSG00000115255 REEP6 receptor accessory protein 6 6.28 0.0027 0.42 




  6.16 0.0003 0.19 
ENSG00000122861 PLAU plasminogen activator, urokinase 6.16 0.0001 0.16 
ENSG00000119917 IFIT3 
interferon induced protein with 
tetratricopeptide repeats 3 
6.11 0.0020 0.38 
ENSG00000147118 ZNF182 zinc finger protein 182 6.01 0.0050 0.49 
ENSG00000164050 PLXNB1 plexin B1 6.01 0.0012 0.31 
ENSG00000228506 RP11-98I9.4   5.97 0.0053 0.49 
ENSG00000107551 RASSF4 
Ras association (RalGDS/AF-6) domain family 
member 4 
5.93 0.0040 0.45 
ENSG00000118785 SPP1 secreted phosphoprotein 1 5.92 0.0037 0.44 
ENSG00000204116 CHIC1 cysteine rich hydrophobic domain 1 5.91 0.0007 0.26 
ENSG00000198736 MSRB1 methionine sulfoxide reductase B1 5.85 0.0010 0.30 
ENSG00000165633 VSTM4 
V-set and transmembrane domain containing 
4 
5.82 0.0011 0.30 
ENSG00000130956 HABP4 hyaluronan binding protein 4 5.81 0.0055 0.49 
ENSG00000186615 KTN1-AS1 KTN1 antisense RNA 1 5.77 0.0029 0.42 




DLGAP4 antisense RNA 1 5.74 0.0003 0.19 
ENSG00000166173 LARP6 
La ribonucleoprotein domain family member 
6 
5.68 0.0038 0.44 
ENSG00000128000 ZNF780B zinc finger protein 780B 5.65 0.0027 0.42 
ENSG00000137571 SLCO5A1 
solute carrier organic anion transporter 
family member 5A1 
5.65 0.0004 0.22 
ENSG00000005238 FAM214B 
family with sequence similarity 214 member 
B 
5.63 0.0020 0.38 
ENSG00000235750 KIAA0040 KIAA0040 5.61 0.0037 0.44 
ENSG00000113161 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 5.6 0.0044 0.47 
ENSG00000125388 GRK4 G protein-coupled receptor kinase 4 5.6 0.0001 0.12 
ENSG00000229124 VIM-AS1 VIM antisense RNA 1 5.57 0.0025 0.42 
ENSG00000064999 ANKS1A 
ankyrin repeat and sterile alpha motif 
domain containing 1A 
5.57 0.0044 0.47 
ENSG00000121577 POPDC2 popeye domain containing 2 5.53 0.0039 0.44 
ENSG00000236939 BAALC-AS2 BAALC antisense RNA 2 5.46 0.0011 0.30 
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ENSG00000101255 TRIB3 tribbles pseudokinase 3 5.46 0.0010 0.30 
ENSG00000116285 ERRFI1 ERBB receptor feedback inhibitor 1 5.44 0.0058 0.50 
ENSG00000165959 CLMN calmin (calponin-like, transmembrane) 5.43 0.0011 0.30 
ENSG00000166793 YPEL4 yippee like 4 5.42 0.0004 0.20 
ENSG00000068097 HEATR6 HEAT repeat containing 6 5.4 0.0048 0.49 
ENSG00000155636 RBM45 RNA binding motif protein 45 5.35 0.0014 0.33 
ENSG00000157483 MYO1E myosin IE 5.33 0.0036 0.44 
ENSG00000235109 ZSCAN31 zinc finger and SCAN domain containing 31 5.32 0.0068 0.53 
ENSG00000120784 ZFP30 ZFP30 zinc finger protein 5.31 0.0025 0.42 
ENSG00000159882 ZNF230 zinc finger protein 230 5.25 0.0011 0.30 
ENSG00000163472 TMEM79 transmembrane protein 79 5.2 0.0027 0.42 
ENSG00000179476 C14orf28 chromosome 14 open reading frame 28 5.2 0.0050 0.49 
ENSG00000106012 IQCE IQ motif containing E 5.19 0.0057 0.50 
ENSG00000225855 RUSC1-AS1 RUSC1 antisense RNA 1 5.18 0.0012 0.31 
ENSG00000100097 LGALS1 lectin, galactoside-binding, soluble, 1 5.17 0.0074 0.54 
ENSG00000186827 TNFRSF4 
tumor necrosis factor receptor superfamily 
member 4 
5.16 0.0032 0.43 
ENSG00000150961 SEC24D 
SEC24 homolog D, COPII coat complex 
component 
5.16 0.0064 0.52 
ENSG00000162894 FCMR Fc fragment of IgM receptor 5.15 0.0031 0.43 
ENSG00000173890 GPR160 G protein-coupled receptor 160 5.14 0.0087 0.55 




  5.13 0.0092 0.55 
ENSG00000004864 SLC25A13 
solute carrier family 25 (aspartate/glutamate 
carrier), member 13 
5.12 0.0014 0.33 
ENSG00000121207 LRAT 
lecithin retinol acyltransferase 
(phosphatidylcholine--retinol O-
acyltransferase) 
5.11 0.0045 0.47 
ENSG00000146856 AGBL3 ATP/GTP binding protein-like 3 5.11 0.0019 0.38 
ENSG00000099985 OSM oncostatin M 5.09 0.0071 0.54 
ENSG00000198720 ANKRD13B ankyrin repeat domain 13B 5.03 0.0028 0.42 
ENSG00000132881 RSG1 REM2 and RAB-like small GTPase 1 5.01 0.0036 0.44 
ENSG00000153832 FBXO36 F-box protein 36 4.99 0.0075 0.54 
ENSG00000176399 DMRTA1 DMRT-like family A1 4.98 0.004 0.45 
ENSG00000229619 MBNL1-AS1 MBNL1 antisense RNA 1 4.98 0.0032 0.43 
ENSG00000172171 TEFM 
transcription elongation factor, 
mitochondrial 
4.97 0.0027 0.42 
ENSG00000172824 CES4A carboxylesterase 4A 4.95 0.0078 0.55 
ENSG00000206417 H1FX-AS1 H1FX antisense RNA 1 4.94 0.0004 0.22 
ENSG00000170175 CHRNB1 cholinergic receptor, nicotinic beta 1 4.92 0.0053 0.49 
ENSG00000130702 LAMA5 laminin subunit alpha 5 4.88 0.0090 0.55 
ENSG00000136541 ERMN ermin 4.87 0.0037 0.44 
ENSG00000213398 LCAT lecithin-cholesterol acyltransferase 4.85 0.0092 0.55 




  4.81 0.0082 0.55 
ENSG00000250510 GPR162 G protein-coupled receptor 162 4.81 0.0025 0.42 
ENSG00000206344 HCG27 HLA complex group 27 (non-protein coding) 4.77 0.0015 0.33 
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ENSG00000196083 IL1RAP interleukin 1 receptor accessory protein 4.77 0.0044 0.47 
ENSG00000177570 SAMD12 sterile alpha motif domain containing 12 4.75 0.0089 0.55 
ENSG00000162650 ATXN7L2 ataxin 7-like 2 4.74 0.0072 0.54 
ENSG00000186174 BCL9L B-cell CLL/lymphoma 9-like 4.74 0.0036 0.44 
ENSG00000187037 GPR141 G protein-coupled receptor 141 4.73 0.0040 0.45 




  4.6 0.0098 0.56 
ENSG00000143748 NVL nuclear VCP-like 4.59 0.0063 0.52 
ENSG00000245060 LINC00847 long intergenic non-protein coding RNA 847 4.58 0.0049 0.49 
ENSG00000215045 GRID2IP 
glutamate receptor, ionotropic, delta 2 
(Grid2) interacting protein 
4.55 0.0065 0.52 




  4.52 0.0054 0.49 
ENSG00000244280 ECEL1P2 
endothelin converting enzyme-like 1, 
pseudogene 2 
4.51 0.0094 0.55 
ENSG00000137752 CASP1 caspase 1 4.5 0.0046 0.48 
ENSG00000241112 RPL29P14 ribosomal protein L29 pseudogene 14 4.49 0.0062 0.52 
ENSG00000166912 MTMR10 myotubularin related protein 10 4.48 0.0077 0.54 
ENSG00000175787 ZNF169 zinc finger protein 169 4.47 0.0077 0.54 
ENSG00000260027 HOXB7 homeobox B7 4.45 0.0086 0.55 
ENSG00000144445 KANSL1L KAT8 regulatory NSL complex subunit 1 like 4.45 0.0020 0.38 
ENSG00000177669 MBOAT4 
membrane bound O-acyltransferase domain 
containing 4 








  4.4 0.0012 0.31 
ENSG00000240225 ZNF542P zinc finger protein 542, pseudogene 4.39 0.0023 0.42 
ENSG00000237298 TTN-AS1 TTN antisense RNA 1 4.38 0.0025 0.42 
ENSG00000065717 TLE2 transducin like enhancer of split 2 4.31 0.0044 0.47 
ENSG00000106086 PLEKHA8 pleckstrin homology domain containing A8 4.29 0.0043 0.47 




  4.29 0.0091 0.55 
ENSG00000146592 CREB5 cAMP responsive element binding protein 5 4.26 0.0033 0.43 
ENSG00000159885 ZNF222 zinc finger protein 222 4.23 0.0069 0.53 
ENSG00000183484 GPR132 G protein-coupled receptor 132 4.19 0.0082 0.55 




  4.03 0.0056 0.50 
ENSG00000100196 KDELR3 
KDEL endoplasmic reticulum protein 
retention receptor 3 
3.99 0.0082 0.55 




  3.97 0.0087 0.55 




  3.87 0.0039 0.44 
ENSG00000197329 PELI1 pellino E3 ubiquitin protein ligase 1 3.8 0.003 0.42 
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ENSG00000183696 UPP1 uridine phosphorylase 1 3.73 0.0057 0.50 
ENSG00000169992 NLGN2 neuroligin 2 3.65 0.0028 0.42 








  3.32 0.0048 0.49 
ENSG00000173846 PLK3 polo-like kinase 3 3.15 0.0088 0.55 
ENSG00000129355 CDKN2D 
cyclin-dependent kinase inhibitor 2D (p19, 
inhibits CDK4) 
2.97 0.0025 0.42 
ENSG00000196214 ZNF766 zinc finger protein 766 2.45 0.0072 0.54 
ENSG00000180573 HIST1H2AC histone cluster 1, H2ac 2.28 0.0084 0.55 
ENSG00000179743 FLJ37453 uncharacterized LOC729614 2.2 0.0064 0.52 
ENSG00000256235 SMIM3 small integral membrane protein 3 2.16 0.0091 0.55 
ENSG00000102362 SYTL4 synaptotagmin like 4 2.05 0.0037 0.44 
ENSG00000154144 TBRG1 transforming growth factor beta regulator 1 1.95 0.0052 0.49 
ENSG00000138744 NAAA N-acylethanolamine acid amidase 1.82 0.0055 0.50 
ENSG00000120833 SOCS2 suppressor of cytokine signaling 2 1.72 0.0089 0.55 
ENSG00000106829 TLE4 transducin like enhancer of split 4 1.52 0.0051 0.49 
ENSG00000125844 RRBP1 ribosome binding protein 1 1.48 0.0060 0.51 
ENSG00000160190 SLC37A1 
solute carrier family 37 (glucose-6-phosphate 
transporter), member 1 
1.43 0.0074 0.54 
ENSG00000064601 CTSA cathepsin A 1.34 0.0086 0.55 
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ALDH  Aldehyde dehydrogenases 
ALL  Acute lymphoblastic leukaemia 
AML   Acute myeloid leukaemia  
ANOVA  Analysis of variance (between group means) 
APML   Acute Promyelocytic Leukaemia  
ARAC   Cytosine arabinoside 
ARIA II   High speed cell FACS based cell sorter manufactured by BD.  
ATRA  All-trans retinoic acid  
BCI  Barts’ Cancer Institute 
BM   Bone marrow 
BMP4   Bone morphogenetic protein 4 
BRDU  Bromodeoxyuridine (5-bromo-2'-deoxyuridine) 
CBF   Core binding factor 
CD   Cluster Differentiation 
cDNA   complementary deoxyribonucleic acid 
CEBPA   CCAAT/enhancer-binding protein alpha 
CISH   Chromogenic in situ hybridization  
cKit  Proto-oncogene cKit or CD117 
CLL  Chronic Lymphocytic leukaemia  
CLL-1   Human C-type lectin-like molecule-1 
CML   Chronic myeloid leukaemia  
CR   Complete remission  
CT   Cycle Threshold value 
DA   Daunorubicin  
DAPI   4’-6-diamidino-2-phenylindole 
DIC   Disseminated intravascular coagulation  
DMSO   Dimethylsulphoxide 
DNMT3A  DNA (cytosine-5)-methyltransferase 3A 
EDTA   Ethylenediamine tetra-acetate  
ELDA   Extreme limiting dilution analysis  
ELISA   Enzyme linked immunoabsorbent assay 
FACS  Fluorescence-activated cell sorting 
FCS  Fetal Calf Serum 
FDA  Food and Drug Administration (US)  
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FET  Fisher’s Exact test 
FISH  Fluorescence in situ hybridization 
FITC   Fluorescein isothiocyanate 
FLAG  Fludarabine, high dose cytosine arabinose and G-CSF in combination  
FLT3   FMS-like tyrosine kinase 3 or CD135 
FMO   Fluorescence minus one 
FSC   Forward scatter 
5-FU  5-fluorouracil 
GAPDH   Glyceraldehyde-3-phosphate dehydrogenase 
G-CSF    Granulocyte-colony stimulating factor 
GMPBSC  G-CSF-mobilized peripheral blood stem cells 
GO  Gemtuzumab Ozomycin 
Gy   Gray 
H&E   Haematoxylin and eosin stain 
Hb  Haemoglobin 
HS5   Human bone marrow derived stromal cell line  
HSC   Haematopoietic Stem Cells 
IDH1/2   Isocitrate dehydrogenase 1 
IL   Interleukin 
IREM-1   Immune receptor expressed on myeloid cells 1 or CD300 
ITIM  Immunoreceptor tyrosine-based inhibitory motifs 
IQR  Interquartile range 
Ki67   Marker of proliferation  KI-67, encoded by the MKI67 gene 
Lin   Lineage (in reference to lineage specific markers expressed on maturing cells) 
LRI  London Research Institute  
LSC  Leukaemia stem cell 
LTC-IC    Long-term culture Initiating cell (assay) 
MDS   Myelodysplastic syndrome 
MFI  Median fluorescence intensity  
MGG   May-Grünwald-Giemsa stain 
MIC2   Also known as CD99 
MLL  Mixed lineage leukaemia  
MPN  Myeloproliferative neoplasm  
MRC   Medical Research Council  
MRD   Minimal residual disease 
MS5   Murine bone marrow derived stromal cell line 
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NOD/SCID Non-obese diabetic mice with severe combined immunodeficiency disease  
NPM   Nucleophosmin 
N-RAS   Neuroblastoma RAS viral (v-ras) oncogene homolog 
NSG Non-obese diabetic/severe combined immunodeficiency/interleukin-2 
receptor γ-chain null 
OS  Overall survival  
PCR  Polymerase chain reaction 
PE   Phycoerythrin 
PeCy7    Phycoerythrin coupled to the indotricarbocyanine dye Cy7 
PerCP  Peridinin-chlorophyll-protein 
PPAR   Peroxisome proliferator-activated receptors 
qPCR   Quantitative polymerase chain reaction, also known as real time PCR 
RFS   Relapse free survival  
RIN   RNA integrity number  
RhoA   Ras homolog gene family, member A 
RhoB   Ras homolog gene family, member B 
RNA   Ribose nucleic acid  
RUNX1  Runt-related transcription factor 1  
SD  Standard deviation  
SRC   Proto-oncogene tyrosine-protein kinase Src 
Siglec 3  Sialic acid binding Ig-like lectin 3  
SH2   SRC-homolog 2  
SHP1   SH2 domain containing protein tyrosine phosphatase 1  
SOCS3   Suppressor of Cytokine signalling 3 protein 
SCT  Stem cell transplant 
SSC   Side scatter 
SYBR   Asymmetrical cyanine dye, used as a nucleic acid stain 
TGFβ   Transforming growth factor-β 
TNF  Tumor necrosis factor 
Th1  Type 1 T helper cells 
TIM3   T-cell immunoglobulin and mucin-domain containing 
WCC   White cell count  
WHO   World Health Organisation  
WT1   Wilms tumor protein 
